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Viral Regulation to Identify Candidate Antiviral      
Restriction Factors 
 
Lior Vered Soday 
 
SUMMARY 
Antiviral restriction factors (ARFs) are host proteins that play key roles in inhibiting viral 
infection.  The plasma membrane provides a critical interface between the cell and the 
virus, meaning that proteins present here are well situated to act as ARFs.  An understating 
of these ARFs and how viruses interact with them, is crucial to our knowledge of infection 
and immunity, and provides potential therapeutic targets.  In this thesis, I apply 
quantitative, multiplexed proteomic technologies to explore two characteristic features of 
ARFs: induction by interferon (IFN), and downregulation by viral infection.   
Proteomics was used to investigate cell surface changes in primary monocytes and CD4+ 
T-cells upon stimulation with IFNα, across five donors. The cell surface proteomes were 
characterised, and found to be remarkably invariant between donors, whilst the effects of 
IFN were more variable between donors.  IFN stimulation of several proteins was 
validated by flow cytometry, and TMEM123 was identified as the only protein, aside 
from MHC class I molecules and the known restriction factor Tetherin, to be consistently 
upregulated by IFN at the cell surface in all donors for both cell types. 
Additional proteomic screens investigated the effects of vaccinia virus (VACV) infection, 
quantifying ~9000 human proteins over a single replication cycle.  This revealed 
downregulation of 265 proteins including innate immune proteins, collagens and 
cadherins.  Overlap with a previous proteomic investigation of human cytomegalovirus 
(HCMV) infection demonstrated that many classes of proteins were commonly targeted, 
suggesting an important role in infection and immunity.  Of the proteins downregulated 
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by VACV, ~70 % were proteasomally degraded.  In addition to human proteins, ~80 % 
of all VACV proteins were quantified.  These were classified into four distinct temporal 
classes, which correlated well with previous literature, and with known protein functions.  
Host-virus interactions were investigated by matching temporal profiles of human and 
viral proteins.  HDAC5 was found to be targeted for proteasomal degradation by the viral 
protein C6.  Overexpression and knockdown of HDAC5 demonstrated its restriction of 
both VACV and herpes simplex virus-1 replication.      
Finally, both datasets were considered alongside published proteomic data on other viral 
infections, in particular HCMV and HIV, to identify putative ARFs.  Expression of 
endothelin converting enzyme 1 (ECE1) was stimulated by IFN at the surface of CD4+ 
T-cells and was downregulated during HCMV infection. Follow-up studies to determine 
if ECE1 restricts HCMV have thus far led to inconclusive results. 
Overall, these investigations into IFN stimulation and VACV infection have yielded very 
useful data, and provide valuable, comprehensive resources for future research.   
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CHAPTER 1:  INTRODUCTION 
 
1.1 Introduction 
Until the end of the twentieth century, infectious diseases were the biggest global cause 
of premature death.  Since then, this burden has dramatically reduced due to improved 
living conditions, astounding achievements in science, and availability of antibiotics and 
vaccines.  Scientific advances and large-scale campaigns by the World Health 
Organisation (WHO) have resulted in the eradication of smallpox, a viral disease 
responsible for 3-500 million death, near eradication of polio, and vaccination programs 
for diseases such as measles and rubella.  However, the need for novel antivirals remains.  
Globally, there are still 3-5 million cases of severe illness caused by seasonal influenza 
annually, including 290-650,000 deaths.  From 2010 to 2018 there was an impressive     
40 % decrease in mortality due to human immunodeficiency virus (HIV), however there 
were still 1.7 million new cases of HIV and 770,000 deaths.  Additionally, emerging viral 
infections present a constant threat, with recent outbreaks and pandemics including severe 
acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), swine 
flu, Ebola, Zika and most recently coronavirus disease 2019 (COVID-19).  There are very 
few antivirals available for these, and they pose a particular risk in the resource limited 
settings of developing countries.  A complete understanding of the immune response to 
viral infection, as well as characterising the viruses themselves, is therefore essential 
(Holmes et al, 2017; Madhav et al, 2017; World Health Organisation).       
The 21st century has also seen the emergence of the field of systems biology which 
emphasises the importance of taking a holistic approach to research, and integrating 
multiple sources of data to generate a comprehensive understanding of biological 
organisation.  With the development of this field has come an array of ‘omic’ 
technologies, to study the genome, transcriptome, metabolome and proteome.  Given the 
complex processes and interactions within the cell, being able to examine it as a whole is 
invaluable, but with these investigations comes ever larger datasets, and the need to 
compare, filter and analyse them in order to identify biologically interesting facets of the 
data (Kirschner, 2005; Horgan & Kenny, 2011).   
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The work presented in this thesis uses proteomic technologies to develop understanding 
of viral infection and the immune response.  Antiviral restriction factors (ARFs) offer the 
first line of defence against viral infection.  These are a diverse set of proteins, able to 
inhibit infection with different viruses at various stages of the life cycle (Duggal & 
Emerman, 2012).    
Although the exact definition of an ARF remains debated (see Introduction 1.2.1) many 
criteria have been suggested.  Here, proteomic technologies are applied to explore two 
characteristic traits of ARFs: stimulation by interferon (IFN), and downregulation by viral 
infection.  IFN stimulation is considered largely in the context of the cell surface of 
primary monocytes and T cells, whilst viral infection focuses on vaccinia virus (VACV), 
as well as investigating previously published data on human cytomegalovirus (HCMV) 
and human immunodeficiency virus (HIV refers to HIV-1 unless otherwise stated) 
(Weekes et al, 2014; Matheson et al, 2015; Greenwood et al, 2016).  From this proteomic 
screen, putative restriction factors are highlighted and further examined; in particular, 
endothelin converting enzyme (ECE1) is investigated as a candidate HCMV restriction 
factor due to being stimulated by IFN and targeted for degradation by HCMV. 
 
1.2 Aim: Identify Candidate Antiviral Restriction Factors 
1.2.1 Defining Antiviral Restriction Factors  
Restriction factors act as the first line of defence against viral infection.  There is a huge 
variety of ARFs, each acting in distinct cell types to protect against diverse viruses at  
different stages of infection.  Consequently, there is not a single unambiguous definition 
for ‘restriction factors’ and which proteins this encompasses.  Historically, the term was 
used when describing research on the Fv1 locus, which is implicated in the differing 
susceptibility of various strains of mice to murine leukemia virus (Pincus et al, 1971).  It 
has since been adopted for use more broadly.  For some, a restriction factor describes any 
protein with antiviral function, whilst other scientists apply a more stringent definition 
and have attempted to define a set of criteria.  Duggal et al describes four main criteria 
for a restriction factor (Duggal & Emerman, 2012):  
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1. Host proteins whose main function is antiviral  
2. Induced by IFN or viral infection 
3. Antagonised by viral factors 
4. Evolves under positive selection  
These four broad characteristics describe common features of restriction factors.  The 
proteins are usually IFN-stimulated, indicating their primary function is in defending 
against pathogens.  Viral antagonists use several mechanisms to overcome restriction 
factors.  These may include protein degradation, mislocalisation, or mimicry of the 
restriction factor substrate to prevent function.  Some viruses however, have mutated the 
viral target in order to escape restriction.  This mutation has led to an ‘evolutionary arms 
race’, with viruses and restriction factors under constant pressure to mutate.  This results 
in an unusually high rate of non-synonymous mutations in the restriction factor, leaving 
genetic signatures of positive selection (Duggal & Emerman, 2012). 
However, many restriction factors do not fulfil all of these criteria.  For example, the IFN-
induced transmembrane proteins (IFITMs) restrict multiple viruses but a direct viral 
antagonist has not been identified (Brass et al, 2009; Zhao et al, 2019).  Probable serine 
incorporator (SERINC) 3 and SERINC5 are specifically antagonised, but do not show 
evidence of an ‘evolutionary arms race’ by being under positive selection (Murrell et al, 
2016), and they are not IFN-stimulated (Rosa et al, 2015).  Some researchers have coined 
additional terms such as ‘resistance factors’ to describe antiviral proteins for which a viral 
antagonist has not yet been identified (Doyle et al, 2015).  
Although the exact definition of an ARF remains debated, in this thesis the term will refer 
to all proteins which limit viral infection.  The discussed criteria provide a valuable basis 
for the identification of candidate restriction factors, and this investigation examines two 
of these: stimulation by IFN and downregulation by a viral factor.  There is also a 
particular focus on the plasma membrane (PM), as proteins here are well situated to 
restrict viral entry or exit to the cell.   
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1.2.2 Known Restriction Factors 
Cell Surface Restriction Factors 
There are several important restriction factors which are known to act at cell membranes, 
preventing viral entry or exit.  Perhaps one of the best known ARFs is the IFN-induced 
protein Tetherin (bone marrow stromal cell antigen 2, BST2), which restricts multiple 
enveloped viruses (le Tortorec et al, 2011).  It was first discovered in the context of HIV 
infection, when a HIV viral protein U (Vpu) deletion virus was found to be retained within 
the cell due to Vpu being responsible for antagonising an antiviral factor.  This antiviral 
factor was determined to be BST2 (Neil et al, 2008).  Immunoelectron microscopy later 
showed BST2 physically tethering HIV particles to the cell surface and preventing viral 
exit from the cell (Hammonds et al, 2010; Fitzpatrick et al, 2010).  More recently, roles 
for BST2 have been reported in immune sensing via activation of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-B) pathway (Hotter et al, 2013).  
Several proposed mechanisms for the antagonism for BST2 by HIV suggest that Vpu and 
BST2 co-localise, and that Vpu reduces the level of BST2 at the cell surface.  
Sequestration inside the cell may be through impaired secretion, or internalisation.  Vpu 
expression also leads to reduced overall levels of BST2, and this is prevented by 
proteasome inhibitors, indicating some degradation (Malim & Bieniasz, 2012).   
IFITMs are other examples of membrane proteins that restrict a range of viruses, 
including influenza A virus, dengue virus and Ebola virus.  IFITM1, IFITM2 and IFITM3 
are the best studied, however the antiviral mechanism through which they act remains 
unclear.  IFITM1 is predominantly expressed at the cell surface, whilst IFITM2 and 
IFITM3 are largely intracellular, with IFITM3 being localised to endosomes; however, 
their specific localisation depends on the cell type and expression level.  It is thought that 
the IFITMs may alter membrane fluidity and restrict membrane fusion at various points 
during viral entry into the cell, either at the PM or in endosomes.  This may prevent certain 
viruses from entering the cytosol, instead resulting in viral lysosomal degradation.  A 
small number of enveloped viruses are resistant to the effects of IFITMs, such as Sendai 
virus which fuses at the cell surface.  However, a viral antagonist has not yet been 
identified (Perreira et al, 2013; Smith et al, 2014). 
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SERINC3 and SERINC5 prevent viral fusion, restricting infection with HIV.  The 
mechanism of this has not yet been determined, but may involve interaction with the viral 
envelope protein (Env) trimer, or modification of viral lipids to inhibit fusion.  HIV 
negative factor (Nef) antagonises SERINC5 by removing it from the PM and sequestering 
it in endosomes (Ramirez et al, 2019; Gonzalez-Enriquez et al, 2017).   
Other Restriction Factors 
There are many other restriction factors, which are diverse in their ability to restrict 
various viruses at differing stages of infection.  Some well characterised examples of 
ARFs that restrict multiple viruses are summarised in Table 1.  As discussed, some act at 
the cell surface, whilst many others function within the cell.  Sterile alpha motif domain 
and histidine-aspartic domain-containing protein 1 (SAMHD1) is expressed in 
macrophages and dendritic cells (DCs), and is another HIV restriction factor.  
Interestingly, rather than acting on a viral component, SAMHD1 hydrolyses the 
intracellular pool of the host’s own deoxynucleotide triphosphates, reducing the level to 
below that required for the viral reverse transcriptase to function (Lahouassa et al, 2013).  
HIV-2 has evolved the accessory protein viral protein x (Vpx) which results in the 
ubiquitination and degradation of SAMHD1 (Hrecka et al, 2011).  In contrast, HIV-1 
does not have Vpx and this may play a role in its limited ability to infect monocyte-
derived macrophages and DCs.  SAMHD1 may restrict replication of other DNA viruses 
similarly, including herpes simplex virus (HSV) (Kim et al, 2013).  The role of SAMHD1 
is also important in regulating the innate immune response, with mutations found in 
patients suffering from the autoimmune disease Aicardi-Goutières syndrome (Rice et al, 
2009).   
Other key HIV restriction factors include tripartite motif-containing (TRIM) 5 protein, 
which acts via binding to the viral capsid.  The mechanism has not been completely 
characterised, but is thought to involve destabilising the capsid and could be ubiquitin-
dependent.  Whilst rhesus TRIM5 is a potent restriction factor for HIV, the role of 
human TRIM5 in HIV infection is more complex and less potent (Ganser-Pornillos & 
Pornillos, 2019).  The apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3 (APOBEC3) family causes cytidine deamination of the viral genome, leading to 
mutations and reduced infectivity.  
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APOBEC3 restricts HCMV infection in a similar manner.  There are also a plethora of 
other restriction factors for HCMV (some of these are reviewed in (Biolatti et al, 2018)).  
IFI16 impairs viral DNA synthesis (Gariano et al, 2012) and is antagonised by the HCMV 
proteins UL83 and UL97.  Viperin inhibits expression of late viral genes whilst HCMV 
UL37 actually co-opts viperin to enhance viral infection.  The components of the nuclear 
domain-10 (ND10) complex restrict HCMV and are discussed further in section 1.4.2. 
 
1.2.3 Therapeutic Potential of Restriction Factors  
Identification of ARFs not only improves our understanding of a virus and the immune 
system, but could also provide targets for antivirals.  Several ways in which the potential 
of ARFs can be harnessed for therapies has been explored in the context of HIV infection 
(Colomer-Lluch et al, 2018).   
Many restriction factors are IFN-stimulated, therefore IFN treatment to upregulate ARFs 
may have therapeutic potential for HIV.  IFN therapy with pegylated-IFN2a or IFN2b, 
usually in combination with Ribavirin, is already being used to treat infection with 
hepatitis C virus (HCV).  Investigation of IFN treated patients co-infected with HCV and 
HIV identified suppression of the HIV viral load, correlating with IFN-induced 
upregulation of ARFs (Abdel-Mohsen et al, 2014).  The use of IFN2 is being 
investigated for treatment of HIV in clinical trials.  However, prolonged IFN expression 
in chronic HIV infection has been observed to be detrimental, contributing to disease 
progression;  blocking the IFN response has also been suggested to have therapeutic value 
(Wang et al, 2017).  Additionally, IFN therapies have multiple side effects, and although 
they have been used for years, they have now been largely superseded by more modern 
alternatives.  A more specific approach utilising ARFs may therefore be preferable.   
Another approach could involve disruption of the interaction between an ARF and its 
viral antagonist, enabling the cells’ own intrinsic immune system to respond specifically 
to the infection with limited side effects.  A small molecule inhibitor of the HIV viral 
infectivity factor (Vif) was found to lead to increased incorporation of APOBEC3G into 
the virions (Nathans et al, 2008).  Attempts have also been made to identify inhibitors of 
the BST2 antagonist, Vpu (Zhang et al, 2011). Challenges with this approach include 
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ensuring the inhibitor only affects the viral antagonist, particularly if it mimics a host 
protein, and not disrupting any interaction between the ARF and the virus required for 
restriction.  Additionally, mutations may allow the virus to develop resistance. 
Gene therapy is another avenue for exploiting ARFs in therapeutics. Unlike rhesus 
TRIM5, human TRIM5 does not usually potently restrict HIV.  However, mutations 
and fusions of TRIM5 that improve HIV capsid binding, can improve restriction (Yap 
et al, 2005; Neagu et al, 2009).  Additionally, it does not have a viral antagonist, and was 
therefore recognised as a potential candidate for gene therapy.  A rhesus/human chimeric 
TRIM5 was included in a combination lentiviral therapy which has shown promising 
results in a murine model and is in clinical trials (Anderson et al, 2009; Walker et al, 
2012). 
 Table 1. Summary of characteristic of a selection of well characterised antiviral restriction factors 
Information is adapted from several reviews (Duggal & Emerman, 2012; Kluge et al, 2015; Biolatti et al, 2018), with some additional examples 
and antagonists from the indicated sources.  ‘-’ indicates that this information was not available in published literature. 
Restriction 
Factor 
IFN 
Induced? 
Viruses Targeted 
Viral Lifecycle Stage 
Inhibited 
Viral Antagonists 
Under 
Positive 
Selection? 
Reference 
IFITM1-3 Yes Orthomyxo-, flavi-, 
coronaviruses 
Endosomal fusion or 
uncoating, membrane 
fluidity 
None known Some (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
SERINC3,5 No Retroviruses Membrane fusion Nef (HIV, SIV), glyco-gag (MLV) No (Kluge et al, 2015) 
Fv1 No Retroviruses (MLV) Capsid uncoating None known  (though do see 
capsid mutations) 
Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
TRIM5a and 
TRIM-CYP 
Yes Retroviruses Capsid uncoating None known (though do see 
capsid mutations) 
Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
MxB Yes Retroviruses (HIV, SIV) Uncoating, nuclear 
uptake and integration 
None known (though do see 
capside mutations) 
Yes (Kluge et al, 2015) 
MxA and Mx1 Yes Orthomyxo-, paramyxo-, 
hepadna-, rhabdo-, alpha-, 
bunya-, toga-, picornaviruses 
Nucleocapsid transport 
and another early life 
cycle step 
None known Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
APOBEC3 
family 
Some Retro-, hepadna-, herpes-, 
papillomaviruses 
(Reverse) transcription, 
causes hypermutation 
Vif (lentiviruses), Bet 
(spumaviruses), Gag 
(gammaretroviruses) 
APOBEC3DE, 
APOBEC3G, 
APOBEC3H 
(Duggal & Emerman, 2012; 
Kluge et al, 2015) 
SAMHD1 Yes Retro-, pox-, herpes-, 
arteriviruses 
(Reverse) transcription, 
hydrolyses cellular 
dNTPs  
Vpx, Vpr (some SIVs), pUL97 
(HCMV) 
Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015; Businger 
et al, 2019) 
 Restriction 
Factor 
IFN 
Induced? 
Viruses Targeted 
Viral Lifecycle Stage 
Inhibited 
Viral Antagonists 
Under 
Positive 
Selection? 
Reference 
IFI16 Yes Herpesviruses Viral transcription UL97 and UL83 (HCMV) Yes (Kluge et al, 2015; Biolatti 
et al, 2018) 
TRIM28 No Retro-, herpesviruses Transcription, induces 
latency  
vPK (KSHV) No (Kluge et al, 2015) 
ZAP Yes Retro-, filo-, alphaviruses Viral protein 
translation 
None known Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
IFIT family Yes Flavi-, bunya-, rhabdo-, 
orthomyxo-, picorna-, 
corona-, poxviruses 
Translation methylation of viral RNA (VACV, 
SARS), masking of 5' end by Vpg 
(EMCV), hairpin at 5' end (VEEV), 
C9 (VACV) 
Yes (Kluge et al, 2015; Liu et al, 
2019) 
PKR Yes Poxviruses Translation K3L and E3L (VACV), TRS1 and 
IRS1 (HCMV) and many others 
Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
SLFN11 Yes Retroviruses Translation None known Yes (Kluge et al, 2015) 
ND10 complex 
(Daxx, PML, 
Sp100) 
PML and 
Sp100 
HCMV Inhibits early viral gene 
expression 
IE1, UL82 (HCMV) - (Biolatti et al, 2018; Ashley 
et al, 2017) 
HLTF -  HCMV Inhibits early viral gene 
expression 
UL145 (HCMV) - (Nightingale et al, 2018) 
Tetherin Yes Retro-, flavi-, herpes-, 
rhabdo-, paramyxo-, 
arenaviruses 
Budding Nef (some SIVs, HIV-1), Vpu (HIV-
1), Env (HIV-2), glycoprotein 
(Ebola virus), K5 (KSHV) 
Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015) 
Viperin  Yes Orthomyxo-, flavi-, herpes-, 
alpha-, paramyxoviruses  
Budding UL37 (HCMV) Yes (Duggal & Emerman, 2012; 
Kluge et al, 2015; Biolatti et 
al, 2018) 
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1.3 Screen 1: Interferon 
The term IFN was first used in 1957 to describe a substance that interfered with viral 
infection (Isaacs & Lindenmann, 1957).  IFN has since become known as a key 
component of the innate immune system, triggering a signalling pathway that culminates 
in the production of an array of IFN-stimulated genes (ISGs) with diverse functions 
involved in protecting against pathogens.  The critical role of IFN in protecting against 
viruses in vivo has been known for some time, with IFNα/β receptor (IFNAR) knockout 
mice being more susceptible to a range of viral infections (Müller et al, 1994).  The 
importance of IFN is further emphasised by the multitude of mechanisms employed by 
viruses to evade the IFN response, often requiring a substantial part of a limited viral 
genome; some of these are discussed further in section 1.4. 
In this thesis, proteomic studies are used to investigate the IFN response at the cell 
surface, for the purpose of identifying novel candidate ARFs.  Moreover, the dataset is 
also of value more broadly; a detailed characterisation of the IFN response in a variety of 
cell types is essential for a complete understanding of the immune response, may provide 
insights into IFN-related autoimmune conditions such as systemic lupus erythematosus 
(SLE), and is critical for the safe and effective use of IFN in therapeutics.  IFN is currently 
being used for treatment of viral infections such as HCV, and is being developed for use 
in cancer therapies.  However, IFN therapy is often accompanied by severe side effects.  
These may include flu-like symptoms, nausea, fatigue, psychiatric effects and a range of 
autoimmune diseases.  These adverse effects can be dose-limiting or even prevent 
therapy.  A deeper understanding of how IFN responses vary between cell types and 
patients is necessary to enable identification of patients who are more likely to benefit 
from treatment, or more targeted therapies (Sleijfer et al, 2005).  
 
1.3.1 Types of Interferon  
IFNs fall into three broad categories: type I (in humans these include 13 subtypes of IFNα, 
as well as β, ε, κ, ω), type II (IFN), and the most recently identified type III IFNs (IFN) 
(Schneider et al, 2014). Type I IFNs are the largest class and the most extensively studied.  
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They signal through the IFNAR, which is composed of the IFNAR1 and IFNAR2 
subunits.  The type I IFN subtypes have different binding affinities for the receptor and 
varying tissue expression patterns.  IFNα and IFNβ are produced by most cells in response 
to viral infection and are the main type I IFN subtypes of interest.  There is just one gene 
for IFNβ, and 13 genes encoding different subtypes of IFNα, all on chromosome 9.  These 
IFNα subtypes all have a similar gene structure and a conserved protein sequence.  
However, they have differing biological activity and result in different patterns of ISGs 
being expressed.  These differences may be explained by a combination of different 
affinities for the IFNAR and the stability of the complex formed with the receptor, cell-
type specific responses, and variation dependent on the type of infecting virus that is 
inducing IFN expression (Gibbert et al, 2013).   
IFNγ is the only type II IFN, and it acts via the IFNγ-receptor (IFNGR).  These receptors 
are expressed on a range of cell types, so despite IFNγ being expressed largely by cells 
of the immune system, many cells can respond.  Type III IFNs are the most recently 
discovered, and encompass the four types of IFNλ.  There are four types of IFN-λ, though 
it is controversial as to how functional the most recently discovered IFNλ4 is (Hong 
MeeAe et al, 2016).  They signal through distinct receptors to the other types of IFN.  
These receptors are expressed on epithelial cells and the type III IFNs are thought to 
restrict a subset of epitheliotropic viruses (Pott et al, 2011). 
This project focusses on the effects of stimulation with IFNα2a. IFNαs have been well 
characterised and play a crucial role in the immune response to viruses.  IFN2 was one 
of the first IFNs to be cloned in the 1980s, and has since been the subject of much 
research; it is therefore one of the best characterised type I IFNs (Paul et al, 2015).  For 
this reason, and due to its clinical relevance, IFNα2a is used in this investigation.  It was 
approved in a modified form (pegylated-IFN) in 2002, by the US Food and Drug 
Administration, for use in treatment of HCV infection.  It is also being investigated for 
use in treatment of hepatitis B virus infection as well as cancers, including metastatic 
malignant melanoma (Matthews & McCoy, 2004).    
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1.3.2 Type I interferon signalling pathways  
Induction of IFN Expression 
Following detection of pathogens via pattern recognition receptors (PRRs), an antiviral 
state is induced in the infected cell and neighbouring cells by production of type I IFNs.  
PRRs include toll-like receptors (TLRs), retinoic acid-inducible gene-I (RIG-I)-like 
receptors, and nucleotide-binding and oligomerization domain (NOD)-like receptors, 
with different PRRs capable of recognising different classes of pathogen associated 
molecular patterns (PAMPs).  TLR4, for example, detects bacterial lipopolysaccharide 
(LPS) at the PM or in endosomes, whilst TLR3 detects double stranded (ds) RNA in 
endosomes.  The different PRRs utilise diverse signalling cascades upon activation.  RIG-
I and melanoma differentiation-associated gene 5 (MDA5) for example, rely on the 
adaptor mitochondrial antiviral-signalling protein (MAVS), which activates TANK-
binding kinase 1 (TBK1), leading to phosphorylation of IFN regulatory factor (IRF) 3.  
TLR3 and TLR4 use the toll/IL-1R resistance domain–containing adaptor-inducing 
IFNβ (TRIF) adaptor to activate TBK1 for IRF3 phosphorylation, whilst TLR7 and TLR9 
are predominantly expressed in plasmacytoid DCs, and signal via myeloid differentiation 
factor 88 (MYD88) to activate the IRFs.  Most of these diverse pathways culminate in the 
translocation of the transcription factor IRF3 (or sometimes IRF7) into the nucleus.  This 
triggers an initial wave of transcription, where IFNβ and IFNα4 are produced, as well as 
IRF7.   This then generates a positive feedback loop and a second wave of transcription, 
resulting in the production of other IFNα genes (McNab et al, 2015).  As well as the 
nuclear translocation of IRF3 and IRF7, signalling is also via NF-B and activator protein 
(AP)-1.  These associate with IRFs and other proteins in the nucleus to form an 
‘enhancersome’ that enables transcription of IFN (Agalioti et al, 2000; Honda et al, 
2006) (Figure 1.1).  
IFN Induced Signalling 
The IFN produced can then trigger autocrine or paracrine signalling via the heterodimeric 
type IFNAR.  This receptor is ubiquitously expressed and found on the surface of most 
cell types (De Weerd & Nguyen, 2012).  Signalling is via a diverse set of pathways, but 
the canonical signalling pathway involves the activation of Janus kinase (JAK)-1 and 
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tyrosine kinase 2 (TYK2).  These phosphorylate signal transducer and activator of 
transcription (STAT)-1 and STAT2, which heterodimerise, translocate to the nucleus and 
bind IRF9.  Together, these constitute the ISG factor 3 (ISGF3) complex, which binds 
IFN-stimulated response elements (ISREs) and triggers transcription of ISGs.  As well as 
the induction of ISGs by the STAT1/STAT2/IRF9 heterotrimer, the IFNs can signal 
through a range of other molecules.  Signalling may occur through STAT1 homodimers, 
though this is more commonly associated with IFN, through other STAT proteins, or via 
the mitogen activated protein kinase (MAPK) pathway (Figure 1.1).  This contributes to 
the diversity of pathways activated by IFN, enabling it to have a broad, and cell type 
dependent, effect on the innate and adaptive immune response (McNab et al, 2015).   
Figure 1.1 Type I IFN induction and signalling pathways  
A variety of pattern recognition receptors are able to recognise infection and generate a 
type I IFN response.  Once induced, IFN can act through a range of pathways to trigger 
the production of ISGs with antiviral functions.  Figure adapted from (McNab et al, 2015). 
 
1.3.3 Effects of Interferon 
Interferon Stimulates Genes  
IFN signalling leads to the transcription of ISGs.  These encode a diverse set of proteins 
with a multitude of functions (Schneider et al, 2014).  Some ISGs are involved regulating 
the IFN response (Ivashkiv & Donlin, 2014).  This can be positive feedback, amplifying 
Figure of IFN induction and signalling pathways removed for copyright reasons.  
Copyright holder is Springer Nature BV. 
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the IFN response; many IRFs and PRRs are IFN-stimulated.  STAT1 and IRF9 for 
example are IFN-stimulated, augmenting the response.  Often, these proteins are present 
at quite low abundance, potentially to avoid aberrant signalling, however upon detection 
of a pathogen and IFN signalling they increase in abundance and enhance the sensitivity 
of the cell for detecting infection.  Other ISGs have an opposing effect of desensitising 
the cell to IFN, for example suppressor of cytokine signalling (SOCS) proteins inhibit 
binding of STAT to JAK, and ubiquitin specific peptidase 18 (USP18) interacts with 
IFNAR2 to prevent binding of JAK.  Finally, other ISGs have direct antiviral effects.  
These include many of the ARFs discussed previously, such as IFITMs, APOBECs, 
TRIMs and BST2 (see section 1.2). 
Activation of the Immune Response 
As well as the cell intrinsic effects discussed, IFNs are able to impact the innate and 
adaptive immune response, with diverse effects dependent on context.  Type I IFNs can 
inhibit or promote the differentiation of precursor cell types into DCs, and may inhibit or 
activate DCs.  Amongst other effects on DCs, IFNs enhance expression of co-stimulatory 
molecules and migration to lymph nodes, therefore promoting T cell activation.  The 
effect of IFN stimulation on T cells is again complex and context dependent, altering 
survival, proliferation and cytokine production.  The variable effects are thought to be 
due to differential activation of STATs and signalling pathways following activation of 
the IFNAR.  Type I IFNs enhance survival and B cell help by CD4+ T cells in response 
to viral infection, but not bacterial infection.  In West Nile virus infection, IFNs control 
differentiation of regulatory CD4+ T cells.  In CD8+ T cells, type I IFNs can exert STAT1 
dependent anti-proliferative effects, inhibiting growth.  However, IFN can promote 
survival and clonal expansion of CD8+ T cells during infection; this may involve 
downregulation of STAT1.  Type I IFNs are also involved in enhancing natural killer 
(NK) and B cell responses. Though again, this may be context and timing dependent.  
Some studies found that IFN signalling enhances the antibody response of B cells, whilst 
others have observed higher viral titres at late time point in infection in IFNAR deficient 
mice compared to controls (McNab et al, 2015). 
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1.3.4 IFN Responses in Leukocytes 
Cell Type Variability 
IFN responses are well documented as being context dependent.  Different cell types have 
constitutive expression of varying components of the IFN signalling pathway, or different 
basal levels of these proteins.  In some cells, priming with other cytokines is able to 
modify the IFN response; for example priming with IFN increases the concentration of 
the ISGF3 components, and in monocytes and DCs it induces expression of STAT4.  
There are differences in activation of STAT proteins between cell types, and varying 
induction of the STAT independent signalling pathways.  Differential activation of 
STAT1, STAT3 and STAT5 was previously observed across T cells, B cells and 
monocytes by IFN.  For example, increased activation of STAT3 and STAT5 was 
observed in B cells and CD4+ T cells compared to monocytes, and very little activation 
of STAT1 was seen in B cells (van Boxel-Dezaire et al, 2006, 2010).  In NK cells, STAT4 
is initially activated, leading to production of IFN.  As levels of STAT1 increase, this 
becomes predominant, and IFN production is replaced by NK cell killing (Mack et al, 
2011). 
Primary Monocytes and CD4+ T cells 
Given the variability in IFN response between cell types, it was necessary to focus this 
investigation on particular cells, and primary monocytes and CD4+ T cells were chosen.  
These leukocytes both originate from hematopoietic stem cells in the bone marrow, which 
differentiate into myeloid or lymphoid precursors.  The myeloid precursor goes on to 
further differentiate into various cell types, including monocytes and neutrophils, whilst 
the lymphoid precursors differentiate into B cells, T cells and NK cells (Figure 1.2).   
Monocytes have several roles in the immune system, including phagocytosis of 
pathogens, antigen presentation and production of cytokines.  They can be classified into 
classical (CD14++, CD16-), intermediate (CD14++, CD16+) and non-classical (CD14+, 
CD16++) subsets, with ~85% of the population consisting of classical monocytes.  Whilst 
all subsets differentiate into macrophages, classical monocytes provide the principal 
source of monocyte-derived DCs.  They also demonstrate the greatest phagocytic activity 
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and secretion of cytokines (Ziegler-Heitbrock et al, 2010; Boyette et al, 2017; Ravenhill 
et al, 2020). 
T cells are derived from the lymphoid precursor, maturing in the thymus into CD4+ helper 
T cells, or CD8+ cytotoxic T cells.  These are activated by interaction with an antigen 
presenting cell (APC) expressing a co-stimulatory protein, and foreign antigen bound to 
major histocompatibility complex (MHC).  Activation of CD8+ T cells leads to target cell 
killing, whilst naïve CD4+ T cells go on to differentiate into further subsets of effector T 
cells, which secrete cytokines and activate other innate and adaptive immune cells.  
Helper T cells activate B cells for antibody secretion, macrophages for phagocytosis, and 
naïve CD8+ T cells to become effector cells, as well as developing into memory T cells 
(Lanzavecchia & Sallusto, 2000; Alberts, 2015). 
These cell types were chosen as they provide accessible primary cells with relevance in 
viral infection, and they respond to IFN, though there is little previous information on the 
IFN-induced effects at the cell surface.  Analysis of primary cells is important in this 
context, as not all cultured cell lines express the same restriction factors.  This is 
demonstrated by the HIV accessory proteins, which may be dispensable in cultured 
systems, but are important for in vivo replication (Malim & Emerman, 2008).  The search 
for BST2 demonstrated the effect of expression of different ARFs between cell types, 
with Vpu being required for viral release in HeLa cells, but not in in 293T and HT1080 
cells unless they had been stimulated with IFN (Neil et al, 2008).  Additionally, isolation 
from peripheral blood makes monocytes and T cells easily accessible, so it is feasible to 
investigate multiple donors.   
Monocytes and CD4+ T cells play a critical role in the immune response, and are valuable 
cell types to examine for ARFs due to their relevance in viral infection.  HCMV 
establishes a latent infection in monocytes, providing a major site of persistent infection 
in the host.  Differentiation of monocytes into macrophages or DCs promotes reactivation 
(Taylor-Wiedeman et al, 1991; Reeves & Sinclair, 2013; Poole et al, 2015).  HIV is able 
to infect both monocytes and CD4+ T cells, due to expression of CD4 and viral co-
receptors.  HIV predominantly infects CD4+ T cells, but monocytes may also play an 
important role in infection, possibly acting as a viral reservoir (Campbell et al, 2014).    
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Figure 1.2 Blood lineages derived from hematopoietic stem cells 
Multipotent stem cells differentiate into common myeloid or lymphoid precursors, and 
progenitor cells become increasingly specialised at each level of differentiation.  
Monocytes and T cells are derived from the myeloid and lymphoid lineages respectively.  
Figure is adapted from (Häggström, 2014), which was released under the Attribution-
Share Alike 3.0 Unported license. 
 
Published ‘Omics Data on IFN Stimulation of Primary Monocytes and CD4+ T Cells 
There is a wealth of previous ‘omics data regarding IFN stimulation on a variety of 
cultured and primary cell lines, however the majority of this is transcriptomic.  Much of 
this is deposited in the Interferome, a large database of IFN responsive genes, curated 
from various genome-wide microarray based studies (Rusinova et al, 2013).  It includes 
data for type I, II and III IFNs and allows filtering based on the type of IFN and the cell 
types examined amongst other parameters.  To date, it includes 40 experiments with type 
I IFNs, encompassing 107 datasets.   
Searching for IFN stimulation of primary monocytes yielded just one dataset in the 
Interferome (dataset 306) (Smiljanovic et al, 2012).   This study used microarrays to 
compare expression profiles in patients with rheumatoid arthritis (RA) or SLE with 
healthy donors.  They also looked at in vitro stimulation of primary monocytes pooled 
from a number of donors, with a range of cytokines (IFN2a, IFN and tumour necrosis 
factor (TNF)-) in order to generate profiles that could be matched to the disease 
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signatures.  They determined that gene expression in SLE patients was predominantly 
driven by IFN, whilst TNF was dominant for RA, with disease dependent responses to 
each cytokine adding further complexity.  The focus of the work was therefore on the 
disease aspects with little analysis of the IFN data, but it provides some data on IFN 
stimulation of primary monocytes.  
Another major investigation of IFN stimulation of primary leukocytes at the 
transcriptomic level was by Schlaak et al (2002).  In this study, four cell lines alongside 
primary PBMCs, T cells and DCs were stimulated with IFN2a, before analysis of the 
expression of 150 known ISGs and genes of interest on a  complementary DNA (cDNA) 
‘macroarray’.  Only seven genes were induced across all cell types in all experiments, 
and multiple genes were only substantially induced in the primary cells.  IRF7 was 
induced exclusively in the hematopoietic cells.  Three donors were used for DCs, and five 
for T cells, allowing donor specific variation to be investigated.  Multiple replicates of 
the experiment on cell lines generated similar results each time, suggesting a reproducible 
response to IFN, and a robust technique.  However, much greater variation was observed 
amongst the primary cells from different donors.  In the T cells, 45 genes were induced 
more than 2 fold in at least 1 donor, whilst just 10 genes were induced in all 5 donors.  
DCs also showed donor-specific responses, though with slightly less extreme variation 
between donors than in the T cells.  This study was limited to only investigating a 
predetermined set of genes, predominantly decided based on previous studies of IFN 
stimulation of fibrosarcoma cells.  The methodology therefore doesn’t allow 
identification of novel ISGs, and even greater differences between the cell types may be 
expected in a broader study including more immune cell specific ISGs. 
These transcriptomic studies provide valuable datasets, however  the correlation between 
transcript and protein levels is often quite poor (Haider & Pal, 2013; Liu et al, 2016), and 
proteomic investigations are likely to reveal novel data, particularly given the ability to 
examine specific subcellular compartments such as the cell surface.  One previous 
proteomic study utilised 2-dimensional gel electrophoresis (2DE) to investigate IFN 
stimulation of activated CD4+ T cells.  The technique is known to underperform in the 
detection of membrane proteins and identified a very limited number of proteins; there 
were 11 ‘spots’ of differentially expressed proteins between the IFN-stimulated and 
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unstimulated cells, corresponding to 7 proteins (Rosengren et al, 2005).  The project 
presented here therefore substantially furthers these studies.     
  
1.4 Screen 2: Systems Analyses of Viral Infection 
As well as being stimulated by IFN, candidate restriction factors should also be 
downregulated by viral infection.  In the work presented in this thesis, a new proteomic 
dataset has been generated investigating various aspect of VACV infection.  This was 
considered alongside existing proteomic data regarding HCMV and HIV infection 
(Weekes et al, 2014; Matheson et al, 2015; Greenwood et al, 2016).  These proteomic 
studies of viral infection provide a great deal of information on the ability of viruses to 
modulate host cells, as well as the kinetic profiles of expression of viral proteins, and 
have previously been used to identify novel facets of innate immunity and host-virus 
interactions.  They have also been used here to identify candidate ARFs.    
 
1.4.1 Vaccinia Virus 
Background 
VACV is a member of the orthopox genus of large dsDNA viruses (Poxviridae family, 
Chordopoxvirinae subfamily).  It is genetically related to variola virus, the causative 
agent of smallpox.  VACV infection was found to provide cross protection for smallpox, 
and was therefore used as an effective live vaccine, culminating in its eradication in 1980 
(Fenner et al, 1988).  It is unclear where VACV originated and it is believed to no longer 
exist in a natural host, but related viruses are seen circulating in cattle in Brazil (Moss et 
al, 2013).  Despite the eradication of smallpox, research on VACV continues as a model 
for host-virus interactions.  Additionally, it is being developed as a vector for vaccines, 
and as an oncolytic therapy (Verardi et al, 2012; Guo et al, 2019).  A complete 
understanding of the virus is therefore critical to ensuring safety and efficacy.    
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VACV Life cycle  
The VACV genome encodes approximately 216 proteins, and is conventionally divided 
into early (E) genes which are subdivided into E1.1 and E1.2, and post-replicative genes 
(PR).  These PR genes are expressed following DNA replication, and are further divided 
into intermediate and late categories (Yang et al, 2010, 2011, 2015).  The sequential 
expression of these is dependent on early genes encoding transcription factors for 
intermediate genes, which in turn encode transcription factors for the expression of late 
viral proteins.  This expression cascade is also reliant on rapid turnover of mRNAs due 
to decapping by viral proteins.  These decapping enzymes are additionally responsible for 
global shut down of host protein synthesis (Parrish et al, 2007; Parrish & Moss, 2007).   
Virions enter the cell by fusion at the PM, or endocytosis.  They are then transported on 
microtubules to cytoplasmic viral factories, where gene expression occurs.  The virion 
therefore contains all the machinery required for transcription of the early viral proteins.  
The mRNAs produced are capped and polyadenylated. Early genes encode proteins 
required for modulation of the host immune response, DNA replication and transcription 
of intermediate genes.  Following early gene expression, the viral core is disrupted in the 
proteasome dependent uncoating process, DNA replication occurs and intermediate genes 
are expressed.  These encode transcription factors for late viral gene expression.  The late 
genes encode virion structural proteins, and the early transcription factors which are 
packaged within the virion (Moss et al, 2013).   
VACV initially assembles into an intracellular mature virus (IMV), which is the most 
abundant infectious form of the virus, and is released by cell lysis.  Alternatively, the 
IMV may acquire an additional double membrane at the trans-golgi network or 
endosomes, forming an intracellular enveloped virus (IEV).   The IEV is transported to 
the cell surface where it fuses with the PM, exposing the enveloped virion on the cell 
surface and forming a cell-associated enveloped virus (CEV).  This may be propelled to 
surrounding cells by the formation of actin tails.  Alternatively, the virus may be released 
as an extracellular enveloped virus (EEV) for long range spread of the virus (Smith & 
Law, 2004; Moss et al, 2013) (Figure 1.3).   
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Figure 1.3 VACV life cycle 
VACV IMVs or EEVs enter the cell by direct fusion or endocytosis, before being 
transported along microtubules to viral factories, where replication occurs.  The IMV 
produced here may either be released by cell lysis, or acquire an additional membrane at 
the trans-golgi network or endosomes, forming an IEV.  This is transported to the PM 
where it fuses and is exposed as a CEV, which may be released from the cell as an EEV.  
Figures is based on descriptions by (Smith & Law, 2004; Roberts & Smith, 2008).  
 
Immunomodulation by VACV 
A large proportion of the VACV genome is dedicated to subversion of the host innate 
immune response, blocking and evading the effects of complement, cytokines, 
chemokines, IFNs, apoptosis and NK cells (Smith et al, 2013a).  Evasion of the type I 
IFN response is crucial to VACV, as replication in the cytoplasm makes VACV 
particularly susceptible to its effects.  VACV therefore encodes multiple proteins to 
22 Chapter 1 - INTRODUCTION 
 
inhibit the production and effects of type I IFN, in particular IFN, at all stages of the 
infection and the IFN response (Smith et al, 2018).   
A key initial trigger for IFN production is detection by the host of viral infection, and as 
such, VACV has several mechanisms for inhibiting this step.  VACV E3 for example 
binds the dsRNA which forms late during infection, limiting activation of PRRs (Chang 
et al, 1992), and C16 binds Ku, restricting the sensing of cytoplasmic DNA by the DNA-
dependent protein kinase (DNA-PK) complex (Peters et al, 2013).  A multitude of viral 
proteins then act to inhibit IRF3 and NF-B signalling, to limit production of IFN.  For 
example, A46 binds adaptor molecules such as MyD88, TRIF and translocating chain-
associated membrane protein (TRAM) which interact with TLRs, preventing their 
activation of MAPK signalling, NF-B and IRF3 (Smith et al, 2013a).   
As some IFN is still likely to be produced by the cell, or by activated neighbouring cells, 
several viral proteins inhibit IFNs directly. Examples include B18, which is secreted from 
infected cells and binds IFN extracellularly to prevent it binding to the receptor 
(Colamonici et al, 1995; Symons et al, 1995).  H1 dephosphorylates STAT proteins to 
block IFN signalling (Najarro et al, 2001) and C6 interacts with STAT2 to inhibit 
transcription of ISGs (Stuart et al, 2016), as well as inhibiting nuclear translocation of 
IRF3 (Unterholzner et al, 2011).  Finally, VACV encodes proteins which antagonise 
ISGs.  E3 binds ISG15 and suppresses its antiviral activity (Guerra et al, 2008), whilst 
C9 degrades the IFN-induced proteins with tetratricopeptide repeats (IFIT) proteins (Liu 
et al, 2019). 
Systems Analyses of VACV Infection 
A limited number of previous proteomic studies have been conducted which examined 
the modulation of the host proteome by VACV, often constrained by the technology 
available.  Bartel et al. utilised 2DE followed by mass spectrometry to quantify 24 human 
proteins modulated by infection, and 3 viral proteins (Bartel et al, 2011).  A further 
proteomic investigation studied human embryonic kidney (HEK293T) cells which were 
either mock treated, or infected for 20 hours in the presence or absence of cytosine 
arabinoside (AraC) (Chou et al, 2012).  As AraC is a viral DNA replication inhibitor 
which prevents expression of PR genes, these were treated as early and late points during 
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infection respectively.  Here, 136 viral proteins were quantified, and 3,798 host proteins.  
The overwhelming majority of proteins showing differential expression between the 
conditions were viral ones, with most host proteins not changing in abundance during 
infection. 
Additionally, several studies have been conducted focussing on expression of the viral 
proteins.  These were largely performed at the transcriptomic level, initially defining early 
and PR genes (Yang et al, 2010), and then further dissecting this class into the 
intermediate and late genes (Yang et al, 2011).  The temporal expression of viral genes 
was also investigated at the proteomic level by Croft et al, performing two proteomic 
experiments at various time points up to 9.5 hours post infection (hpi).  They quantified 
101 viral proteins which were classified into 4 clusters.  Of these, 47 proteins were 
quantified in both experiments and had concordant assignments to the 4 clusters (Croft et 
al, 2015).     
   
1.4.2 Human Cytomegalovirus  
Herpesviridae 
The Herpesviridae family of viruses are enveloped, dsDNA viruses which generally 
establish a lytic infection that kills the cell upon release, as well as a latent infection for 
life-long persistence in the host.  Historically, they were divided into alpha, beta and 
gamma herpesviruses based on biological characteristics, and more recently the 
classification was confirmed based on sequencing data.  Broadly, Alphaherpesvirinae 
have a variable host range, relatively short replication cycle, and establish latent 
infections predominantly in neuronal cells.  These includes HSV, and varicella-zoster 
virus (VZV), the causative agent of chickenpox.  Betaherpesvirinae, such as HCMV, tend 
to have a more restricted host range and longer replication cycles, and establish latency 
in secretory glands, leukocytes, kidneys and other tissues.  Gammaherpesvirinae include 
Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV).  These 
viruses are restricted to the family of their natural host, and usually to T or B lymphocytes, 
establishing latency in lymphoid tissues (Pellett & Roizman, 2013). 
24 Chapter 1 - INTRODUCTION 
 
Impact of Human Cytomegalovirus 
HCMV is a member of the betaherpesvirinae family.  It is an ubiquitous pathogen, with 
a global seroprevalence of 83 %, with the highest seroprevalence in the WHO Eastern 
Mediterranean region (~90 %) and lowest in the WHO European region (~66 %) (Zuhair 
et al, 2019).  For most individuals, transmission occurs during childhood, with the virus 
being acquired from contact with infected bodily secretions, and the infection is 
asymptomatic.  However, reactivation during pregnancy may lead to transplacental 
transmission.  Congenital HCMV infection can result in life-long sensorineural hearing 
loss, with ~10-15 % of babies infected showing symptoms, and others developing 
symptoms later on.  Of the symptomatic infants, fatality is estimated to be between 4-30 
% (Dollard et al, 2007).  Initial infection with the virus during pregnancy increases the 
chance of transplacental transmission from ~1 % to around ~33 %, and is linked with 
severe disease (Kenneson & Cannon, 2007).  Infection or reactivation is also damaging 
in immunocompromised individuals, particularly those undergoing organ transplants 
(Azevedo et al, 2015) or with acquired immunodeficiency disease syndrome (AIDS) 
(Emery, 2001).   
Three drugs are currently available for treatment of symptomatic individuals, and pre-
emptive therapy is sometimes employed where infection is the result of a medical 
intervention and can be predicted, such as organ transplants.  These are all inhibitors of 
the viral polymerase ((val)Ganciclovir, Cidofovir and Foscarnet).  There are a couple of 
other antivirals more commonly used for prophylaxis (Letermovir, Valacyclovir).  
However, these treatments have numerous side effects, such as leukopenia, renal 
dysfunction and ophthalmologic toxicity, as well as development of resistant viral 
infection.  Additionally teratogenic effects have been observed in animals models so they 
are not recommended for use during pregnancy (Kotton, 2019; Malm & Engman, 2007).  
As HCMV is a leading cause of congenital disease, and due to the potential severity of 
infection, a vaccine, or improved antivirals, would therefore be highly desirable.   
The Virus and its Life Cycle 
HCMV has a the largest genome of the herpesviruses, at 236 kbp (Dolan et al, 2004), and 
coding for ~170 canonical proteins.  Expression of these genes is temporally regulated, 
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and can be broadly divided into immediate early (IE), delayed early (DE) and late (L) 
viral genes (Wathen & Stinski, 1982), or into five classes (temporal profile (Tp) 1-5) by 
proteomic data (Weekes et al, 2014), and the replication cycle takes 48-72 h.  The 
structure is characteristic of herpesviruses, with the dsDNA genome being encased in an 
icosahedral capsid, within an envelope acquired from the host cell membrane.  HCMV 
tropism includes a wide range of cells such as fibroblasts, epithelial cells, endothelial 
cells, smooth muscle cells and macrophages (Sinzger et al, 1995).   
HCMV can enter cells either by fusion of the viral envelope with the cell membrane (as 
during infection of fibroblasts) or following endocytosis (as in endothelial and epithelial 
cells).  Microtubules then deliver the nucleocapsid to nuclear pore complexes where the 
viral genome enters the nucleus.  The virus may enter a lytic life cycle.  In this instance, 
IE genes regulate the transcription of host and viral genes.  Around 14 - 24 hpi in 
fibroblasts, DE genes control viral DNA replication, followed by expression of L viral 
genes.  The viral capsid assembles in the nucleus and then translocates to the cytoplasm.  
Throughout this process, it acquires a temporary envelope at the inner nuclear membrane, 
and then undergoes de-envelopment at the outer nuclear membrane.  The nucleocapsid 
acquires tegument proteins at the cytoplasmic viral assembly compartment (AC) and 
undergoes secondary envelopment at the endoplasmic reticulum – golgi intermediate 
compartment.  Finally, the virion is released from the cell by exocytosis (Fields et al, 
2013; Beltran & Cristea, 2015) (Figure 1.4).   
Alternatively, HCMV can establish a life-long latent infection.  As with other 
herpesviruses, in latent infection, no new virions are produced, and it was thought that a 
smaller subset of viral genes are expressed (Poole & Sinclair, 2015).  However, recent 
research found that gene expression during latency is similar to that of late lytic infection, 
but at lower levels, suggesting the differences between lytic and latent infection may be 
quantitative rather than qualitative (Shnayder et al, 2018).  Latency occurs in myeloid 
cells, however on differentiation to macrophages or DCs this can result in reactivation of 
the virus.  It is important to understand latency as it may provide new therapeutic avenues 
for clearing latent infection before reactivation occurs during transplant (Poole et al, 
2014). 
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Figure 1.4 HCMV life cycle  
CMV virions initiate infection by attaching to receptors at the cell surface and then fusing 
with the PM, or by endocytosis.  The tegument proteins and capsid are released to the 
cytosol.  Infectious HCMV particles enter the cell through receptor interactions, and the 
capsid and tegument proteins are delivered to the cytosol.  The capsid travels to the 
nucleus along microtubules, where the viral genome is released and the gene expression 
cascade occurs (expression of IE, DE and then L viral genes).  L gene expression triggers 
capsid assembly in the nucleus.  Nuclear egress occurs, and the virus acquires tegument 
proteins in the cytosol.  The virus is trafficked to AC where it acquires more tegument 
proteins and a viral envelope.  Infectious particles are released by exocytosis.  Figure 
reprinted from (Beltran & Cristea, 2015).     
 
HCMV and the Immune Response 
The ability of HCMV infection to remain asymptomatic in healthy individuals, whilst it 
can cause devastating disease in the immunocompromised, highlights the effectiveness 
of the immune response in controlling the infection.  HCMV has a multitude of 
mechanisms for subverting the immune response. 
Diagram of HCMV life cycle removed for copyright reasons.  Copyright holder is 
Taylor & Francis.  
1.4 Screen 2: Systems Analyses of Viral Infection 27 
HCMV infection is initially controlled in a number of ways by the intrinsic and innate 
immune response, including detection of the envelope glycoproteins B and H by TLR2, 
subsequent signalling through NF-B and production of IFN (Boehme et al, 2006).  
Additionally, NK cells play a crucial role in control of HCMV infection (Biron et al, 
1989; Gazit et al, 2004; Vivier et al, 2008).  Several restriction factors are involved in the 
immune response (see section 1.2.2), including the subnuclear structure ND10.  This is 
composed of promyelocytic leukaemia protein (PML), death domain-associated protein 
6 (Daxx) and nuclear autoantigen Sp-100 (Sp100).  Viral genomes are found in close 
proximity to the ND10 bodies, and knockdown of any of these proteins leads to enhanced 
replication of HCMV (Tavalai et al, 2008; Adler et al, 2011).  Daxx limits transcription 
of IE genes by generating a repressive chromatin structure at the viral major immediate 
early promoter (Woodhall et al, 2006).  Sp100 is an IFN-stimulated protein, and also 
limits viral transcription.  HCMV evades this restriction by delivering the viral protein 
pp71 in the virion and this targets Daxx for proteasomal degradation, stimulating 
expression of IE genes (Saffert & Kalejta, 2006); HCMV IE1 downregulates Sp100 
(Tavalai et al, 2011).  
IE proteins also disrupt the IFN mediated immune response, with IE1 preventing STAT1, 
STAT2 and IRF9 associating to form ISGF3 (Paulus et al, 2006), and IE2 blocking the 
production of IFNβ (Taylor & Bresnahan, 2005).  Other examples of HCMV proteins 
involved in immune evasion include US2, one of several HCMV proteins able to 
modulate MHC class I expression.  It also downregulates integrins and thrombomodulin, 
and can act synergistically with UL141 to downregulate the NK cell ligand CD112 (Hsu 
et al, 2015).  Alongside downregulating MHC class I,  HCMV encodes UL18, an MHC 
class I homologue which binds the inhibitory leukocyte immunoglobulin-like receptor 1 
(Lir-1) (Yang & Bjorkman, 2008).   
Adaptive immunity is also crucial in controlling infection, as evidenced by HCMV 
reactivation in immunosuppressed transplant recipients (Azevedo et al, 2015).  
Presentation of HCMV antigens on APCs leads to a large HCMV-specific T cell response, 
similar in size to that seen with HIV and larger than for most other viruses, composed of 
virus-specific CD4+ and CD8+ T cells.  The scale of the T cells response varies between 
individuals, but examination of memory T cells in seropositive individuals found ~10% 
of CD4+ and CD8+ cells were reactive to HCMV (Rosa & Diamond, 2012; Sylwester et 
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al, 2005).  Adoptive transfer of HCMV specific CD8+ T cells reduced viremia in patients, 
emphasising the importance of the T cell response in controlling infection  (Cobbold et 
al, 2005).  B cells are also important in the adaptive immune response, with antibodies 
generated against tegument, envelope and non-structural proteins (Landini et al, 1988; 
Urban et al, 1996).  
Proteomic studies of HCMV used in this thesis 
A previous study used quantitative temporal viromics to analyse the proteomic changes 
observed in the host and virus during HCMV infection (Weekes et al, 2014).  The data 
from Weekes et al. has been used here for comparison with VACV infection, and for the 
identification of ARFs.  Fibroblasts were infected with the Merlin strain of HCMV, and 
either whole cell lysate (WCL) or PM enriched samples harvested at various time points 
throughout a single viral replication cycle.  Each sample was digested and labelled with 
a different tandem mass tag (TMT), prior to analysis by triple-stage mass spectrometry 
(MS3).  This gave the relative quantitation of each protein across the samples (proteomic 
techniques are discussed further in section 1.5.  For each of the WCL and PM 
experiments, samples were harvested either at the time points described in Figure 1.5 
(WCL2 and PM2) or in duplicate at mock, 24, 48 and 72 hpi (WCL1 and PM1).  More 
than 8000 human proteins were quantified over the time-course, including ~1200 proteins 
with PM related gene ontology (GO) annotations, as well as 139 of the 171 canonical 
HCMV proteins.   
 
Figure 1.5 Schematic of HCMV time-course proteomics experiment  
Fibroblasts were infected with the Merlin strain of HCMV, and samples harvested at 
various time points throughout infection for either WCL or PM analysis (Weekes et al, 
2014).  The proteins were then digested, labelled with TMT and subjected to mass 
spectrometry analysis.  The time points displayed are those relating to the WCL2 and 
PM2 experiments. 
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Proteins downregulated by HCMV infection were identified in the data and used to 
predict those that might be important in infection.  Examination of the downregulated 
proteins identified multiple protocadherins, some of which are putative NK cell ligands, 
as well as modulation of proteins in the IFN induction and signalling pathways, and ISGs.  
Additionally, analysis of the kinetics of expression of viral proteins defined five temporal 
classes of protein expression (Tp1-5). 
This data demonstrates the power of multiplexed proteomics in large scale studies of 
infection.   It also provides a comprehensive resource which is used in this thesis to aid 
identification of candidate ARFs.  Several additional proteomic studies on HCMV have 
been conducted during my PhD in the Weekes lab.  As they are not central to this project, 
they are not discussed further, however they focus on protein degradation during HCMV 
infection, leading to the identification of HLTF as a novel ARF (Nightingale et al, 2018), 
and the generation of a global interactome of HCMV proteins (Nobre et al, 2019). 
 
1.4.3 HIV 
Background 
HIV was first discovered in the 1980s when individuals started presenting with unusual 
symptoms including lymphadenopathy, opportunistic infections, unusual cancers and a 
depletion of CD4+ T cells; this became recognised as AIDS.  HIV was isolated in 1983 
and found to be the causative agent of the disease.  Several years later a second strain was 
discovered, and these have now been designated HIV-1 and HIV-2.  The former is more 
dominant and pathogenic, and therefore the focus of much research and of the proteomic 
investigations discussed here.  HIV is part of the lentivirus genera of retroviridae.  These 
are a large family of viruses, which  have an RNA genome that is reverse transcribed and 
integrated into the host chromosomal DNA upon infection.  This then provides the 
template for production of viral RNAs for formation of new virions.  The genome encodes 
16 proteins, including structural proteins, viral enzymes, envelope proteins, regulatory 
proteins and accessory proteins.         
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It is estimated that in 2019, 37.9 million people globally were living with HIV.  In 2010, 
just 7.7 million people had access to antiviral therapies, but by 2018 this had risen to 24.5 
million.  However, there were still 770,000 AIDS related deaths (end of 2018).  It is 
estimated that in 2020, AIDS response in low and middle-income countries will cost 
$26.2 billion (UNAIDS, 2019).  Therefore, despite improved access to therapy and a 
reducing death toll, HIV still poses a great social and economic burden.  It has also been 
the subject of much ARF related research. 
HIV life cycle 
The HIV envelope glycoprotein 120 (gp120) binds CD4 to initiate cell entry.  The main 
target of HIV is CD4+ T cells, but other cells expressing CD4 can be infected, including 
monocytes and DCs.  Additional binding to a co-receptor, C-C motif chemokine receptor 
5 (CCR5) or C-X-C motif chemokine receptor 4 (CXCR4), leads to exposure of the viral 
‘fusion peptide’, part of glycoprotein 41 (gp41), which inserts into the cell membrane and 
causes membrane fusion.  The capsid partially uncoats to allow reverse transcription of 
the viral RNA, and the linear DNA is integrated into the host chromosome.  Following 
integration, the late phase of HIV replication occurs.  This includes viral gene expression 
and the assembly of virus like particles at the PM.  The particle buds through the PM and 
undergoes maturation, where the precursor Gag-Pol polyprotein is cleaved, resulting in 
the mature infectious virion (Engelman & Cherepanov, 2012; Maartens et al, 2014). 
HIV and the immune response 
The innate immune system is activated early during infection.  The predominant pathways 
for this differ between infected cell types, but include detection of ssRNA by TLR7, and 
detection of DNA by cyclic GMP-AMP synthase (cGAS) in plasmacytoid DCs and 
monocyte-derived DCs respectively, whilst DNA sensing by IFI16 is important in CD4+ 
T cells.  Even though they are not infected themselves, mucosal epithelial cells detect 
gp120 by cell surface TLR2 and TLR4, and secrete inflammatory cytokines.  These 
signalling pathways lead to IFN induction, stimulating the production of ISGs, including 
numerous ARFs (see section 1.2).  However, HIV has many mechanisms for 
downregulating the immune response, such as Vpx antagonising SAMHD1, and Vpu 
antagonising BST2.   NK cells are also activated and are thought to have roles both in 
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killing infected cells and regulating adaptive immunity (Altfeld & Gale, 2015; Silvin & 
Manel, 2015; Bergantz et al, 2019).  
There is a complex relationship between HIV infection and the pool of CD4+ T cells 
which it infects.  Following an initial infection, there is an ‘eclipse period’ where no viral 
RNA is detected.  Once the virus infected cells reach the draining lymph node and more 
CD4+ CCR5+ T cells are available for infection, peak viremia is reached.  Following this, 
the viral load decreases to its ‘set point’.  There may be a role of CD8+ T cells in this 
control of viremia.  The previously depleted CD4+ T cell levels return to normal, however 
the adaptive immune system is still activated.  It is hypothesised that the activation of 
CD4+ T cells in HIV infection may actually worsen the pathogenesis, providing more 
targets for the virus to infect (McMichael et al, 2010; Mogensen TH et al, 2010).     
Proteomic Studies of HIV Infection 
HIV has also been studied using global proteomic techniques, and a couple of key TMT-
based studies have been examined for comparison to other data in this thesis.  In one 
study, CEM-T4 cells were infected with an Env-deficient, vesicular stomatitis virus 
glycoprotein G (VSVg)-pseudotyped HIV-1 virus for a PM  proteomic time-course.  
TMT-based mass spectrometry was used to analyse samples at 0, 6, 24, 48 and 72 hpi.  A 
total of 2320 proteins were quantified, including 804 proteins with PM related GO 
annotations.  More than 100 proteins were downregulated during infection, and these 
were involved in cell adhesion, leukocyte activation and transmembrane transport 
(Matheson et al, 2015).   An identical time-course was later performed, this time 
harvesting WCL samples.  More than 6500 proteins were quantified, and many of the 
known ARFs were observed to be modulated by infection, as expected.  Additional 
experiments considered the effects both on the WCL and the phosphoproteome of 
infection with a Vif deletion virus, and identified that depletion of protein phosphatase 
2A (PP2A) during infection was Vif dependent (Greenwood et al, 2016).  Most recently, 
a time-course was performed using primary CD4+ T cells.  In this case, the cells were 
infected with a HIV reporter virus expressing a cell surface streptavidin binding tag, 
allowing infection at a multiplicity of infection (MOI) of one and separation of a pure 
population of infected cells.  WCL samples were harvested from uninfected cells (either 
resting or activated), and then at 24 and 48 hpi, identifying additional proteins regulated 
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by HIV which had not been seen in T cell lines, such as AT-rich interactive domain-
containing protein 5A (ARID5A) (Naamati et al, 2019). 
 
1.4.4 Other TMT Based Quantitative Temporal Analyses of Viral 
Infection 
Many other proteomic studies of viral infection have been performed, such as multiple 
time-courses of influenza infection (Lietzén et al, 2011; Kummer et al, 2014; Turnbull et 
al, 2016).   Alongside those already discussed, other TMT-based proteomic time-courses 
include investigations of EBV, BK polyomavirus and HSV-1.  Examination of EBV 
infection at both the whole cell and PM levels identified modulation of the cell cycle and 
innate and adaptive immune pathways.  I performed a comparison of this data with the 
HCMV proteomic time-course, identifying common downregulation of a protocadherin, 
as well as multiple neuroligins; some of these were also modulated by KSHV (Ersing et 
al, 2017).  BK polyomavirus is a small dsDNA virus.  It expresses just seven known 
proteins and establishes life-long persistent infection.  Proteomic investigation 
demonstrated the importance of the cell cycle in viral replication, and a lack of innate 
immune response (Caller et al, 2019).  Analysis of HSV-1 infection quantified 6956 
human proteins and 67 viral proteins over the course of infection.  Multiple host proteins 
were downregulated, including golgi associated PDZ and coiled-coil motif containing 
protein (GOPC), a trafficking protein.  The viral protein pUL56 was found to target 
GOPC for degradation, therefore modulating the abundance of signalling molecules at 
the cell surface (Soh et al, 2019).  These studies demonstrate the power of quantitative 
proteomic investigations of viral infection, to study host-virus interactions.   
  
1.5 Key Technology Used: Proteomics 
Many molecular biology techniques are available to study the presence, abundance and 
interaction of proteins.  Immunoblotting, immunofluorescence and flow cytometry are all 
essential in the lab, however, these methods are low throughput, investigating just a few 
proteins at a time, and are reliant on high quality reagents such as appropriate antibodies.  
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The term ‘proteomics’ was coined in 1995, following the first experiments in 1975 
(Graves & Haystead, 2002).  Since then, proteomic technologies have developed, and 
now enable an unbiased, high throughput analysis, generating quantitative data on 
thousands of proteins in a single experiment.  The use of proteomic technologies is central 
to this thesis, having been applied to investigation of both IFN stimulation and viral 
infection; the value of proteomic technology in this field is evidenced by the findings in 
various viral infections discussed previously (see section 1.4).  
 
1.5.1 Basic Methodology for Bottom-Up Proteomics 
The basic principle of proteomics involves subjecting proteins to analysis by mass 
spectrometry, in order to identify them.  In most cases (and in this thesis), a ‘bottom-up’ 
approach is used, whereby the extracted proteins are digested into peptides prior to mass 
spectrometry.  This allows the analysis and identification of peptides, rather than intact 
proteins as is required for top-down proteomics, and is less challenging and more 
routinely used.  The peptide sample is separated by liquid chromatography (LC) prior to 
analysis by mass spectrometry.  In tandem mass spectrometry, the peptides are first 
ionised, converting them into the gas-phase, and are then analysed to determine their mass 
to charge (m/z) ratio in an MS1 scan.  Selected precursor ions are then fragmented (often 
by collision induced dissociation, CID), and the m/z of these fragments is determined 
(ms/ms, or ms2), and used to create a spectrum (Zhang et al, 2013).   
This process can be further enhanced by fractionation of the peptide sample prior to LC-
mass spectrometry.  Fractionation separates the mixture of peptide mixture into multiple 
samples of reduced complexity.  This simplification of the sample reduces the co-elution 
of peptides, and allows a more comprehensive examination of the sample, with more 
peptides being quantified (Chan & Issaq, 2013). 
Following the mass spectrometry run, the data is processed computationally.  The raw 
data is converted to an appropriate format for analysis, prior to identification of the 
spectra.  Peptide identification requires a theoretical database of peptides, generated by 
in silico digestion of the protein database.  The intact mass from the MS1 scan can be 
used to identify peptides with a similar m/z, and the spectrum from the MS2 scan is 
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compared to the theoretical spectra for these peptides.  This is done using searching tools 
such as Sequest (as used here), and Mascot.  Peptide-spectrum matches require filtering 
to determine those that are most likely to have been correctly determined.  A target-decoy 
strategy can be employed whereby ‘decoy’ peptides are included in the database, in order 
to estimate the false discovery rate according to how many spectra are matched to these 
decoy peptides.  In practice, the most commonly employed approach to generate a decoy 
database is to reverse all peptide sequences.  The filtered peptides then require assembly 
into the proteins from which they originated.  This is also a complex process, as some 
peptides are redundant to multiple proteins.  Assignment therefore uses an ‘Occam’s 
razor’ approach, which aims to generate the smallest number of proteins possible to 
account for the observed peptides (Noor et al, 2020).     
 
1.5.2 Tandem Mass Tags for Quantitative Multiplexed Proteomics 
The basic proteomic methodology described has been extended to enable various 
additional information to be gained.  In this thesis, quantitative proteomics has been 
performed using TMT (Thompson et al, 2003; McAlister et al, 2012).  At the time of 
performing these experiments, there were 11 different tags, but this has since been 
extended to 16 tags (Thermo), each of which can be used to label a different sample, 
allowing them to be multiplexed.  TMTs are isobaric tags which contain an amine reactive 
group that can link to lysine residues or peptide N-termini, and a cleavable reporter.  Each 
of the cleavable reporters has a different mass due to the incorporation of heavy nitrogen 
and carbon atoms.   An additional round of tandem mass spectrometry (ms/ms/ms or ms3) 
selects the most abundant ions from the MS2 spectrum, and uses high energy CID (HCD) 
to dissociate the cleavable reporter from the isolated peptides; the signal from the reporter 
is proportional to the abundance of the labelled peptide (Ting et al, 2011; McAlister et al, 
2014).  The m/z of the reporter is used to determine which sample it came from.  The 
relative abundance of a given protein in all samples is therefore determined.   
Advantages of this approach are that multiplexing allows precise relative quantitation, 
and also reduces the running time required on the mass spectrometer.  Additionally, unlike 
the commonly used metabolic labelling technique, stable isotope labelling with amino 
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acids in cell culture (SILAC), the samples are labelled following digestion, rather than 
requiring cells to be grown in specific media.  This enables investigation of primary cells.   
Quantitative multiplexed proteomics enables the comparison of any set of conditions.  
Here, it has been used to investigate IFN stimulation of multiple donors, and to examine 
various time points during infection.  Other uses include comparison of infection of wild 
type (WT) and mutant viruses to help decipher the function of the viral proteins 
(Nightingale et al, 2018), identifying biomarkers (Whitwell et al, 2020), or other aspects 
of drug discovery (Amiri-Dashatan et al, 2018). 
Additionally, the production of the sample for labelling can be modified to consider 
different aspects of the proteome.  One example of this is enriching for PM proteins, so 
these can be specifically examined, as discussed below.  Alternatively, post translational 
modifications can be considered by enriching for phosphoproteins (Swaney & Villén, 
2016), or other modifications.  Spatial proteomics uses different speeds for centrifugation 
of the cell lysate in order to separate out the nuclear, organellar and cytoplasmic fractions, 
each of which can be labelled with a different TMT, in order to determine where in the 
cell different proteins are localised (Itzhak et al, 2017).  
 
1.5.3 Plasma Membrane Profiling 
PM proteins are of low abundance, hydrophobic and often underrepresented in proteomic 
samples.  Enrichment for these proteins prior to digestion, labelling and analysis by mass 
spectrometry enables a more detailed investigation of the cell surface, and a variety of 
methods have been developed for this purpose; these are reviewed in (Li et al, 2020) and 
briefly summarised here.  The methods can be broadly categorised into approaches that 
separate PM proteins based on biophysical characteristics, those that use interaction of 
the proteins with lectins or antibodies, or by chemically coupling a tag to an exposed 
protein and using affinity purification to extract the bound proteins.  There are some 
additional methods utilising metabolic labelling or enzymes, however metabolic labelling 
is restricted to cultured cells, and the enzyme based approaches are less well developed.   
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Separating proteins on biophysical characteristics could be based on size, charge or 
hydrophobicity.  Size and density based separation for example, has utilised 
centrifugation, though this allows relatively low resolution, and often requires a large 
amount of starting material.  The second category of methods, affinity based enrichment 
for PM proteins using antibodies, only allows enrichment of known PM proteins, and is 
further limited by the requirement for high specificity antibodies.  Affinity to lectins 
allows a more unbiased approach, particularly if multiple lectins which bind different 
glycan structures are combined, however the coverage achieved is still limited.  Finally, 
chemical labelling of amines, carboxyl groups or glycan chains has been commonly 
utilised.  These approaches generally involve a reagent with a reactive residue for binding 
to the protein, a linker, and a tag, often biotin.     
Multiple methods were previously compared, recording the number of proteins identified, 
and percentage of these which were annotated as being at the PM (Weekes et al, 2010).  
Some approaches resulted in an increased proportion of intracellular proteins being 
identified, due to cell permeability, whilst others led to high levels of streptavidin 
contamination.  Biotinylation with amino-oxy biotin, and a pull-down with high capacity 
streptavidin beads, led to the greatest number and purity of PM proteins.  PM profiling 
was therefore developed using this approach (Weekes et al, 2012, 2014).  It involves the 
oxidation of sialic acid residues on cell surface glycoproteins into aldehydes, and 
subsequent biotinylation of these with amino-oxy biotin; this reaction is catalysed by 
aniline.  The high affinity interaction between biotin and streptavidin is utilised to enrich 
for these biotinylated PM proteins (Figure 1.6).   In addition to experimentally enriching 
for cell surface proteins, the proteins quantified can be filtered to identify those with 
annotations suggesting they may be present at the PM; this is done using GO terms 
(Ashburner et al, 2000; The Gene Ontology Consortium, 2019) related to the PM.  This 
accounts for the majority of proteins quantified if the sample is not fractionated, and is 
reduced to ~60% in fractionated data, as more proteins are quantified and therefore this 
includes more abundant intracellular contaminants.  However, it is worth noting that this 
filtering approach may miss any poorly annotated PM proteins.    
1.5 Key Technology Used: Proteomics 37 
 
Figure 1.6 Plasma membrane profiling 
PM profiling is used to examine cell surface proteins by mass spectrometry.  The 
sialylated PM proteins are first biotinylated and then pulled-down using streptavidin 
beads, prior to on bead digestion of the proteins by trypsin.  Peptides from each samples 
are labelled with TMT, pooled, and analysed by mass spectrometry.  Further details can 
be found in the methods (chapter 2.9). 
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1.6 Aims of this Thesis 
The aims of this thesis were to use unbiased proteomic screens to investigate two 
characteristic features of ARFs: stimulation by IFN, and downregulation by viral 
infection, and to identify putative restriction factors on the basis of these characteristics.   
Aims:   
1) Characterise the effects of IFN stimulation at the surface of primary 
monocytes and T cells:  The first screen used PM profiling to characterise in 
depth the cell surface proteome of primary monocytes and CD4+ T cells, 
determine how IFN stimulation modulates this proteome, and examine the 
variation in protein expression between different donors.  This data is presented 
in chapter 3. 
2) Examine proteomic changes induced upon infection with VACV: The 
second screen used whole-cell based proteomics to characterise VACV-
infected cells, surveying all proteomic changes induced by the virus.  This 
allows identification of enriched groups of modulated proteins that may be 
biologically important.  Further proteomic screens were conducted to examine 
which proteins were specifically targeted for downregulation by the virus, and 
in the investigation of predicted host-pathogen interactions.  This data is 
presented in chapter 4. 
3) Use data on IFN stimulation and viral downregulation to identify 
candidate ARFs: The data from the screens presented here is examined 
alongside previously published proteomic screens on other viral infections, in 
order to identify novel putative restriction factors.  This led to the identification 
of Endothelin Converting Enzyme 1 (ECE1), which is then investigated in the 
context of HCMV infection.  This is presented in chapter 5.    
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1 Ethics Statements 
Ethical approval for the use of blood samples (as required for the proteomic screen 
investigating IFN induced changes at the surface of primary leukocytes) was granted by 
the University of Cambridge Human Biology Research Ethics Committee 
(HBREC.2016.011) and written informed consent was obtained from volunteers prior to 
blood donations.  Leukocyte enriched blood samples were obtained from the National 
Health Service Blood and Transplant service (NHSBT, Cambridge, UK).  These were 
from anonymised donors, and composed of cells remaining following clinical use of 
blood donations.   
 
2.2 Cell Culture 
2.2.1 Cell lines 
All cells were cultured at 37 ºC, 5 % CO2. 
Cultured Monocyte and T Cell Lines for IFN Screen 
THP-1 (human monocyte) cells were used for proteomic studies of IFN stimulation, and 
for validation. Jurkats and SUPT1s (human T cells) were used for validation of primary 
T cell data.  They were all maintained in RPMI-1640 medium (R8758, Sigma) 
supplemented with 10 % volume per volume (v/v) foetal bovine serum (FBS, Sigma).   
The THP-1s were kindly provided by Professor Paul Lehner (Department of Medicine, 
University of Cambridge), and the Jurkats and SUPT1s were from Dr Nick Matheson 
(Department of Medicine, University of Cambridge).   For proteomic and immunoblot 
experiments involving IFN stimulation, THP-1, Jurkats or SUPT1s were stimulated with 
1000 arbitrary units (AU)/ml IFNα2a (Reagent Proteins, BCA-309), in their regular 
culture media. 
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Cancer Cell Lines for ECE1 Antibody Validation 
Three different cancer cell lines were used to produce lysates for testing of ECE1 
antibodies.  DLD1 and SW48 cells (both human colorectal adenocarcinoma) were kindly 
provided by Dr Matthew Hoare (Cancer Research UK, Cambridge).  MDA-MB-231 
(epithelial) cells were provided by Professor Paul Lehner; these cells were transduced 
with CRISPR-associated protein 9 (Cas9) due to previous use, though not relevant to 
these investigations.  All cells were maintained in RPMI-1640 supplemented with 10 % 
FBS and 1 % penicillin / streptomycin (pen/strep) (Sigma). 
Other Cell Lines 
Human foetal foreskin fibroblasts (HFFF) were immortalised with human telomerase 
(HFFF-TERT) as described in (McSharry et al, 2001), and kindly provided by Dr Peter 
Tomasec (Cardiff University).  These were used for the VACV infection time-course and 
the HCMV restriction assays.  These cells have the same morphology and growth 
characteristics as HFFFs, and are permissive to infection with the HCMV Merlin strain.   
HEK-293Ts were used for production of lentivirus to make various HFFF-TERT cell 
lines; these were kindly supplied by Professor Paul Lehner.  Both HEK-293Ts and HFFF-
TERTs were maintained in Dulbecco’s Modified Eagle Medium (DMEM, D6429, Sigma) 
supplemented with 10 % v/v FBS.  
 
2.2.2 Cell Culture for Maintenance 
Suspension cells were split as required, by taking an aliquot of the cells and diluting into 
fresh media at a ratio between 1:3 and 1:10.  Adherent cells were washed once with 
phosphate buffered saline (PBS, Sigma), and incubated at 37 ºC with trypsin (Sigma) 
until all cells had detached from the flask.  Cells were then resuspended in fresh media to 
split at a ratio between 1:2 and 1:10 as required. 
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2.3 Primary Cell Enrichment and Culture 
Protocols are described as they were used for the proteomic screen investigating the 
effects of IFN stimulation at the surface of primary leukocytes.  Methods were scaled 
accordingly for optimisation and validation experiments. 
 
2.3.1 CD4+ T cells 
Isolation of PBMCs from Peripheral Blood 
Cells were isolated from peripheral blood for the enrichment of CD4+ T cells.  50 ml 
blood was aspirated with 4 ml 4 % citrate (4 % weight per volume (w/v) trisodium citrate 
dehydrate dissolved in H2O).  The citrated blood was diluted 1:2 in PBS/citrate (4 % 
citrate diluted 1:10 in PBS to a final concentration of 0.4 %), and 25 ml slowly layered 
onto 15 ml Ficoll (GE Healthcare) for density gradient centrifugation (x 4 tubes).  The 4 
tubes were weighed to ensure they were within 0.5 g of each other and centrifuged at 800 
g, 20 mins with the brakes off.   The layer containing the buffy coat was aspirated into 
new falcon tubes (x 2 tubes), made up to 50 ml with PBS/citrate and mixed by inverting.  
Peripheral blood mononuclear cells (PBMCs) were centrifuged (800 g, 10 mins), the 
supernatant poured off and the pellets from the two tubes resuspended and combined.  
This was again made up to 50 ml in PBS/citrate, and washed by centrifugation (400 g, 10 
mins).  Two further washes were performed (400 g, 10 mins).   
Enrichment of CD4+ T Cells by Negative Selection 
Following isolation of the PBMCs, the cells were counted and 5x105 retained for analysis 
by flow cytometry (FCM).  The remaining cells (~7x107) were enriched for CD4+ T cells 
using the ‘Dynabeads Untouched Human CD4 T Cells’ kit (Invitrogen, 11346D) 
according to the manufacturers instructions.  Approximately 1.5x107 cells were obtained 
from the negative selection. Again, 5x105 cells were kept to confirm enrichment by FCM, 
and the remainder cultured overnight with or without IFN2a.   
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Overnight Culture and IFN stimulation 
For the proteomic screen, cells were centrifuged (400 g, 5 mins) and resuspended in 10 
ml RPMI-1640 medium supplemented with 10 % human AB serum (Sigma, H4522).  5 
ml was added to each of two wells in a 6-well plate, and one well stimulated with 1000 
AU/ml IFNα2a.  The cells were maintained overnight at 37 ºC, 5 % CO2 prior to 
enrichment of PM proteins for mass spectrometry (MS) analysis.  
 
2.3.2 CD14+ and Pan- Monocytes 
Isolation of PBMCs from NHSBT leukocyte cone 
PBMCs were isolated from leukocyte cones obtained from the NHSBT, and enriched for 
CD14+ monocyte or pan-monocyte populations.  Blood was transferred from the cone 
into a falcon tube and ~40 ml PBS/citrate used to wash through the cone.  The resulting 
50 ml  blood was further diluted 1:4 PBS/citrate, and 25 ml citrated blood layered slowly 
onto 13 ml Ficoll (x 8 tubes).  The 8 tubes were weighed to ensure they were within 0.5 
g of each other and centrifuged at 800 g, 20 mins with the brakes off.  The buffy coats 
from the 8 tubes were aspirated and transferred into 6 falcon tubes, each made up to 50 
ml with PBS/citrate and centrifuged at 600 g, 8 mins.  The supernatant was poured off, 
the pellets resuspended and combined into 4 tubes, and centrifuged at 400g, 8 mins. This 
was repeated twice more, combining the pellets into two tubes and finally a single tube.  
Enrichment of CD14+ and Pan- Monocytes by Negative Selection 
Following isolation of the PBMCs, the cells were counted and 5x105 retained for analysis 
by FCM.  Approximately 6x108–1x109 cells were obtained from the leukocyte cone, and 
of these 2x108 were enriched for CD14+ monocytes (more for the pan monocytes as 
additional experiments were performed alongside this proteomic screen).  Enrichment for 
CD14+ and pan- monocytes was by negative selection, using the ‘Monocyte Isolation Kit 
II’ (Miltenyi Biotec, 130-091-153) and ‘Pan Monocyte Isolation Kit’ (Miltenyi Biotec, 
130-096-537) respectively, according to the manufacturer’s instructions.  Enrichment 
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resulted in ~6x107 CD14+ monocytes.  Of these, 5x105 were retained for validation of 
enrichment by FCM.   
Overnight Culture and IFN stimulation 
Of the cells obtained from enrichment, 3x107 cells were resuspended in 6 ml X-Vivo 15 
serum-free hematopoietic cell medium (Lonza, BE02-060F).  This was split into two U-
bottom tubes for culturing overnight.  One was left unstimulated and the other was 
stimulated with IFN2a (1600 AU/ml for CD14+ monocytes, 1000 AU/ml for pan-
monocytes).  The cells were maintained overnight at 37 ºC, 5 % CO2. 
 
2.4 Generation of Cell Lines 
All cell lines were produced in either HFFF-TERTs (ECE1 assays) or THP-1s 
(transmembrane protein 123 (TMEM123) antibody tests), as described.  The generation 
of constructs and production of cell lines is detailed below for each type of cell line each 
of the different types of cell lines. 
 
2.4.1 Overexpression Cell Line 
Production of ECE1 Overexpression Plasmid and Cell Line 
Cells overexpressing ECE1 were produced using the gateway cloning system 
(Invitrogen).  In this system an insert is transferred from an entry vector into an expression 
(or ‘destination’) vector via recombination at attL and attR sites.  ECE1 (isoform b) in the 
pENTR223 entry vector was purchased from Harvard plasmids (HsCD00399893) and 
transferred into the expression vector pHAGE-PSFFV by an ‘LR’ reaction.  The insert here 
lacked a stop codon, so produced a FLAG-HA tagged version of ECE1. 
For the LR reaction, the entry vector (pENTR223) was diluted 1:5, and 1 µl (~30 ng) was 
incubated with 0.2 µl of the destination vector (pHAGE-PSFFV), 0.4 µl TE and 0.4 µl LR 
clonase II overnight at room temperature.  The reaction was terminated by treatment with 
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0.2 µl proteinase K at 37 ºC for 10 mins.  The LR reaction mix was transformed into 
competent cells as described in section 2.4.5.  Insertion of the ECE1 sequence into the 
destination vector was confirmed by sequencing using the SFFVp forward primer and 
pHAGE-Rev reverse primer, as well as an internal primer specific to ECE1 (Table 2.3).  
Following confirmation of the insert, HFFF-TERTs were transduced with the pHAGE- 
PSFFV-ECE1 plasmid as described in section 2.4.7. 
Other Overexpression Cell Lines 
Daxx and Sp100 overexpressing HFFF-TERTs, as well as cells transduced with the 
control gateway plasmid (GAW) were kindly provided by Dr Luis Nobre and Dr Katie 
Nightingale.  In the cases of Daxx and Sp100, the plasmids were generated by a 
polymerase chain reaction (PCR) from either cDNA or purchased plasmids.  Primers were 
used for the PCR reaction that incorporated attB sites, and a gateway BP reaction could 
then be used to insert the gene into a donor vector (pDONR223), to form an attL 
containing entry vector.  This could then be used for an LR reaction as described above.   
Dr Nightingale also provided me with the GAW and Daxx plasmids for generation of the 
HFFF-TERT cell lines used in the final restriction/plaque assay.  The HCMV-US2 
overexpressing HFFF-TERT cell line was made by Dr Luis Nobre and kindly provided 
to me for this project. 
 
2.4.2 shRNA Knockdown Cell Lines 
Production of ECE1 and TMEM123 shRNA Knockdown Plasmids and Cell Lines 
Short hairpin RNA (shRNA) sequences to target the ECE1 or TMEM123 genes were 
designed and validated by Sigma (Table 2.1), with the exception of ECE1_sh3, which 
was adapted from a published siRNA sequence (Lambert et al, 2008). The target sequence 
was inserted into a template to produce a pair of partially complementary 
oligonucleotides, which included BamH1 and EcoR1 restriction sites for cloning, and a 
stem loop to form the necessary structure.  Oligonucleotide pairs were ordered from 
Sigma (Appendix Table 1).  These were cloned into the pHR-SIREN vector (a kind gift 
from Professor Paul Lehner) by digestion and ligation.  
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The pHR-SIREN vector (2 µg) was digested with BamH1 and EcoR1 restriction enzymes 
for 2 h at 37 ºC, before dephosphorylating at 30 mins at 37 ºC to prevent self-ligation.  
This was then heat inactivated for 5 mins at 70 ºC.  The digested and dephosphorylated 
vector was column purified using QIAquick PCR purification kit (Qiagen), following the 
manufacturer’s instructions. 
Table 2.1 Target sequences for shRNAs 
Name Target sequence 
Control_sh1 GTTATAGGCTCGCAAAAGG 
Control_sh2 GGCATATAACTATTTAGGTAT 
Control_sh3 CGTGATCTTCACCGACAAGAT 
Sp100_sh1 CGCTAGGAAGCCAACAAACAA 
TMEM123_sh1 CCACACAACTCCAGTGCTAAC 
TMEM123_sh2 GGGATGGTCTCAACAAATATG 
ECE1_sh1 GCAGTTCCAGACCTCTACTTT 
ECE1_sh2 GCCGATGAGAAGTTCATGGAA 
ECE1_sh3 CTTCCACAGCCCCCGGAGT 
ECE1_sh4 GCCTTAAACTTTGGTGGCATA 
ECE1_sh5 TGTCTATGTCAGTGCCGATTC 
ECE1_sh6 GATCAATGAATCCGAGCCTAT 
 
To produce the insert, the forward and reverse oligonucleotides were first diluted to 100 
µM.  1 µl of each of these was combined with 1 µl 10x T4 ligase buffer (New England 
Biolabs), 0.5 µl T4 polynucleotide kinase and made up to 10 µl total with H2O.  
Phosphorylation was for 30 mins at 37 ºC, and the oligonucleotides were then annealed 
for 10 mins at 95 ºC before slowly cooling to room temperature.   
The insert was diluted 1:10 for ligation, and 0.5 µl of this was combined with 2 µl (~50ng) 
of the dephosphorylated vector, 1 µl T4 ligase buffer, 0.5 µl T4 ligase (New England 
Biolabs)  and made up to a total of 10 µl with H2O.  The insert was ligated into the vector 
at 4 ºC overnight.   
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5 µl of the ligation product was transformed into competent cells and amplified as 
described in section 2.4.5.  The shRNA expression vector was sequenced using the U6P 
primer confirming presence of the insert (Table 2.3), and used to transduce either HFFF-
TERTs or THP-1s as described in section 2.4.7. 
Other shRNA Knockdown Cell Lines 
Control shRNA and Sp100 shRNA cell lines in HFFF-TERTs were kindly provided by 
Dr Luis Nobre and Dr Katie Nightingale (Weekes lab, Department of Medicine, 
University of Cambridge).  The plasmids were produced and the cells transduced in a 
similar manner to that described above, with the target sequences given in Table 2.1.  
They also provided the plasmids for generation of control shRNA THP-1 cell lines, and 
the HFFF-TERTs used in the final restriction and plaque assays. 
 
2.4.3 CRISPR Cell Lines  
Polyclonal CRISPR Populations 
Knockout cells were produced using the clustered regularly interspaced short palindromic 
repeat (CRISPR)/Cas9 systems as previously described (Sanjana et al, 2014; Shalem et 
al, 2014).  Five guide sequences specific to ECE1, as well as guides for the restriction 
factor Sp100 and non-targeting control guides were designed based on sequences from 
the Sabatini single guide RNA library (Table 2.2) (Wang et al, 2015).  Pairs of 
oligonucleotides for each guide RNA (gRNA) were ordered from Sigma (Appendix Table 
1).  The CRISPR cell lines were produced in collaboration with Dr Katie Nightingale and 
Dr Ben Ravenhill (Weekes lab, Department of Medicine, University of Cambridge). 
The pairs of oligonucleotides were phosphorylated and annealed as described in section 
2.4.2 and diluted 1:250; 2 µl of this was used for a digestion-ligation reaction.  The 
oligonucleotide duplex was incubated with 100 ng of the pKLV expression vector 
(pKLV-U6gRNA(BbsI)-PGKpuro2ABFP, Addgene Plasmid #50946, (Koike-Yusa et al, 
2014)), 1 µl 10x Tango buffer, 1 µl Dithiothreitol (DTT), 1 µl adenosine triphosphate, 0.5 
µl FastDigestBbsI (Fermentas), 0.25 µl T4 ligase and made up to 10 µl with H20.  This 
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was incubated in a thermocycler for 5 mins at 37 ºC followed by 5 mins at 23 ºC; this 
cycle was repeated 6 times.  The product was amplified by transformation into competent 
cells as described in 2.4.5.  Insertion of the correct guide sequence in the pKLV vector 
was confirmed by sequencing with the U6P primer (Table 2.3).  HFFF-TERTs stably 
expressing Cas9 (pSpCas9(BB)-2A-GFP (PX458), Addgene Plasmid #48138; cells 
kindly provided by Dr Katie Nightingale) were transduced with the gRNA as described 
in section 2.4.7, and subjected to puromycin selection for two days, to produce polyclonal 
CRISPR knockout populations, used for an initial HCMV restriction assay. 
In order to avoid integration of the gRNA, a second transduction was performed in the 
presence of 2 µM raltegravir.  Cells were maintained in media containing raltegravir for 
one week following selection.  Immunoblot was used to confirm knockdown of the gene 
of interest in these polyclonal populations, and cell lines expressing the two guides that 
resulted in the best knockdown were chosen for single cell cloning.    
 
Table 2.2 CRISPR guide sequences 
Name Target sequence 
Control g1 GTACAGCTAAGTTAAACTCG 
Control g2 GATGTCCGTTGTAGTCCTCG 
gSp100_1 GCAGCCTGTCATCTACACCC 
gSp100_2 TGAGATGGGGAACCCGAAGG 
gECE1_1 GGAAACCCGAAAATCAGCCA 
gECE1_2 GAACTGGGTGAAGAAGAACG 
gECE1_3 CATGGAGCTCAAGATGGAGC 
gECE1_4 GAGCTCCATGGACCCCACAG 
gECE1_5 CTGGGGAAGCTGCTGGGCGG 
 
Single Cell Cloning to Generate Monoclonal CRISPR Populations 
The chosen polyclonal cell populations were seeded at 0.5 cells/well in a 96-well plate in 
DMEM (10 % FBS, 1 % pen/strep).  As the cells grew, the media was replenished with a 
1:1 mixture of fresh DMEM (FBS, pen/strep) and conditioned media.  Conditioned media 
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was produced by filtering the media from a sub-confluent flask of WT HFFF-TERTs 
through a 0.22 µm filter.    The cells were progressively transferred to a 24-well and then 
6-well plate, before testing for a knockout monoclonal population by immunoblot.  
 
2.4.4 shRNA Knockdown and Overexpression in Two Colour System 
For the two colour HCMV restriction assay system, shRNA or overexpression plasmids 
were transduced into HFFF-TERTs already expressing either mCherry (controls) or iRFP 
(test gene).  These mCherry and iRFP cells were kindly provided by Alice Fletcher-
Etherington (Weekes Lab, Department of Medicine, University of Cambridge).  Alice 
produced these by replacing the puromycin resistance gene in the pHAGE-PSFFV vector 
with blasticidin resistance, and then cloning in either mCherry or near-infrared 
fluorescent protein (iRFP) using the gateway system.  Following transduction, the cells 
were selected using 10 µg/ml blasticidin (TOKU-E).  The mCherry or iRFP expressing 
HFFF-TERTs could then be additionally transduced with either the pHR-SIREN vector 
expressing an shRNA or the original puromycin resistant pHAGE-PSFFV plasmid 
overexpressing a gene of interest, and selected again using hygromycin or puromycin 
respectively.  The shRNA and overexpressing plasmids were as described previously. 
 
2.4.5 Transformation 
The entire LR reaction product or 5 µl of the ligated plasmid mix was added to 20 µl of 
Alpha-Select Silver Efficiency or Bronze Efficiency Competent E. coli cells (Bioline).  
This was incubated on ice for 15 mins, followed by heat shock for 45 seconds at 42 ºC.  
200 µl lysogeny broth (LB) was added and this was incubated in a shaker for 1 h at 37 
ºC, or immediately plated out onto LB agar plates containing ampicillin.  Plates were 
inverted and incubated overnight at 37 ºC.  Colonies were picked and added to 4 ml LB 
containing ampicillin, and incubated in a 37 ºC shaker overnight.  Plasmids were purified 
from 2 ml of the overnight culture using the QIAprep Spin Miniprep Kit (Qiagen) 
following the manufacturer’s instructions. 
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2.4.6 Confirmation of Insert 
Following purification of the plasmid, insertion of the correct sequence in the lentiviral 
expression vector was confirmed by sequencing using the primers described in Table 2.3. 
Table 2.3 Sequencing primers to confirm inserts in lentiviral expression vectors 
Primer Sequence Vector Use 
U6P GGGCAGGAAGAG GGCCTAT 
pHR-SIREN, 
pKLV 
shRNA knockdown, 
CRISPR 
SFFVp CGCGCCAGTCCTCCGATTG  pHAGE-PSSFV Overexpression 
pHAGE-Rev GCTTCGGCCAGTAACGTTA pHAGE-PSSFV Overexpression 
ECE1_int AACGAGAAGGTGCTGACCGG N/A ECE1 overexpression  
 
2.4.7 Stable Cell Line Production by Lentiviral Transduction 
Transfection of HEK293Ts 
HEK-293T cells were seeded at 1.5x105 cells/well in a 12-well plate, in 1 ml culture 
media; 24 h after plating, cells were 70-80 % confluent and ready to transfect.  Packaging 
plasmids used for transfection were either a four helper plasmid mix (VSVG, TAT1B, 
MGPM2, HCMV-Rev1B) or VSV-g / pCMV (using 200 ng VSV-g and 400 ng 
pCMV.DR8.91, a kind gift from Professor Paul Lehner).  The helper plasmids were mixed 
with 500 ng lentiviral expression plasmid and diluted in 100 µl of pre-warmed OptiMEM 
(Gibco), with 3 µl TransIT-293 transfection reagent (Mirus).   This mixture was incubated 
for 30 mins at room temperature before being added dropwise onto the cells.  At 24 h the 
media was carefully replaced with fresh DMEM. 
Transduction of HFFF-TERTs 
HFFF-TERTs (WT or expressing mCherry or iRFP) were seeded at 1.5x105 cells/well in 
a 12-well plate at 24 h after transfection of the HEK-293Ts.  At 48 h after transfection, 
the lentiviral supernatant was passed through a 0.22 µm filter onto the fibroblasts.   
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Transduction of THP-1 Cells 
THP-1s were seeded at 2x106 cells/well in a 24-well plate, in 0.5 ml culture media.  At 
48 h after transfection, the lentiviral supernatant from the HEK-293Ts was passed through 
a 0.22 µm filter onto the THP-1 cells, and the media pipetted up and down several times.  
Cells were rocked in an incubator (37 ºC, 5 % CO2) for 3.5 h.  The cells were then pipetted 
up and down 8-10 times, and transferred into a 6-well plate containing an additional 2 ml 
media.   
Selection 
Cells were placed in selection using either 1 ug/ml puromycin (Acros Organics) or 50 
ug/ml Hygromycin (TOKU-E) at 48–72 h after transduction, and maintained in selection 
media for between 2 days and 2 weeks as required (Table 2.4). 
 
Table 2.4 Plasmids for production of cell lines 
The vectors used to transduce various cell types are given.  The cell lines were all 
produced in either WT HFFF-TERTs (wt), HFFF-TERTs already transduced with 
mCherry of iRFP for use in the two colour restriction assays (two colour), HFFF-TERTS 
already transduced with Cas9 for production of CRISPR cells (Cas9), or THP-1 cells.  For 
the helper plasmids, ‘4 plasmid’ refers to VSVG, TAT1B, MGPM2, HCMV-Rev1B, and 
VSV-g/pCMV indicates 200 ng VSV-g and 400 ng pCMV.DR8.91 were used.  Either 1 
ug/ml puromycin (Acros Organics) or 50 ug/ml Hygromycin (TOKU-E) was applied for 
selection. 
Cell Types Vector Parent Cell Helper Plasmids Selection 
shRNA 
knockdown 
pHR-SIREN 
HFFF (wt)                    
HFFF (two colour) 
THP-1 
4 plasmid     
VSV-g/pCMV 
VSV-g/pCMV 
Hygromycin 
Overexpression pHAGE-PSFFV 
HFFF (wt)       
HFFF (two colour) 
4 plasmid         
VSV-g/pCMV 
Puromycin 
CRISPR pKLV HFFF (Cas9) VSV-g/pCMV Puromycin 
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2.5 Molecular Biology Techniques 
2.5.1 Flow Cytometry 
Cell Surface Flow Cytometry 
FCM was used to confirm enrichment and validate selected hits.  Cells were washed in 
FCM buffer (PBS and 2 % FBS), prior to blocking in Human Trustain (Biolegend, 1:20 
in FCM buffer) for 10-20 mins at room temperature.  All staining was for 30 mins at 4 ºC 
in the dark, using primary antibodies diluted in FCM buffer as indicated in Table 2.5.  All 
samples were then washed in FCM buffer (400 g, 5 mins), and if required a secondary 
antibody was applied (1 h, 4  ºC, in the dark) diluted in FCM buffer as described in  
Table 2.6, before washing again.  Samples were fixed in 4 % paraformaldehyde (10 mins, 
room temperature, Biolegend), and resuspended in PBS for analysis.    
Intracellular Flow Cytometry 
Cells were washed in FCM buffer and then fixed in 4 % paraformaldehyde for 15 mins at 
room temperature.  The samples was then centrifuged, the supernatant poured off and 
cells resuspended in MeOH prior to incubation on ice for 15 mins to permeabilise.  Cells 
were washed in FCM buffer and then blocked and stained as described for cell surface 
FCM, omitting the final fixation step. 
Flow Cytometry Data Acquisition and Analysis 
Samples were analysed on the Becton-Dickinson FACSCalibur flow cytometer 
(confirmation of enrichment of primary cells, ECE1 and TMEM123 antibody testing) or 
the Becton Dickinson LSR Fortessa (validation of other IFN stimulated proteins by 
FCM).  Data was analysed using FlowJo vX software. 
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Table 2.5 Table of primary antibodies used for flow cytometry experiments 
Target 
Conjugated 
Fluorophore 
Company 
Catalogue 
Number 
Species Clone Dilution 
CD14 PE Biolegend 301850 Mouse M5E2 1:20 
CD4 APC Biolegend 317415 Mouse OKT4 1:20 
BST2 PE Biolegend 348405 Mouse RS38E 1:20 
CD69 PE Biolegend 310905 Mouse FN50 1:20 
CD38 PE Biolegend 356603 Mouse HB-7 1:20 
CD40 PE Biolegend 334307 Mouse 5C3 1:20 
Siglec1 APC Biolegend 346007 Mouse 7-239 1:20 
CD274 PE Biolegend 329705 Mouse 29E.2A3 1:20 
SLAMF7 - Santa Cruz sc-53577 Mouse 162.1 1:50 
ECE1 - R&D Systems MAB17841 Rat 303913 1:100 
ECE1 - Invitrogen PA5-24563 Rabbit - 1:50 
ECE1 - Abcam ab71829 Rabbit - 1:50 
TMEM123 - Abcam ab81423 Rabbit - 1:50 
TMEM123 - Santa Cruz SC-377295 Mouse G-2 1:50 
TMEM123 - Novus  NB100-56371 Rabbit - 1:50 
TMEM123 AF647 R&D Systems FAB3010R Mouse 297617 1:12.5 
 
Table 2.6 Table of secondary antibodies used for flow cytometry experiments 
Target 
Conjugated 
Fluorophore 
Company 
Catalogue 
Number 
Species Dilution 
anti-Mouse AF647 Invitrogen A21236 Goat 1:1000 
anti-Rat AF647 CST 4418S Goat 1:1000 
anti-Rabbit AF647 Invitrogen A31573 Donkey 1:500 
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2.5.2 Immunoblotting 
Except where otherwise stated, the following method was used for immunoblotting.  Cells 
were lysed in radioimmunoprecipitation assay (RIPA) buffer (Cell Signalling 
Technology) containing cOmplete Mini Protease Inhibitor Cocktail (Roche; 1 tablet per 
10 ml RIPA) for 15 minutes at 4 ºC, and supernatants were then clarified by centrifugation 
at 14,000 g for 10 mins. The Pierce bicinchoninic acid (BCA) protein assay kit 
(ThermoFisher) was used to measure protein concentration according to the 
manufacturer’s instructions.  Samples were denatured and reduced with 6× protein 
loading dye (375 mM Tris pH 6.8, 12 % SDS, 30 % glycerol, 0.6 M DTT, 0.06 % 
bromophenol blue) for 5 mins at 95 ºC. 50 µg of protein was separated by sodium dodecyl 
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) using Mini-Protean TGX 
precast gels (Bio-Rad), then transferred to polyvinylidene difluoride (PVDF) membranes 
(0.45 µm pore) using the TransBlot SD Semi-Dry Transfer System (Bio-Rad).  Transfer 
was for 45 mins at 20 v.  The membrane was blocked with 5 % milk dissolved in tris-
buffered saline with 0.2 %   tween (TBST) before probing overnight at 4 ºC with the 
appropriate primary antibodies (described in Table 2.7).   The following day, the 
membrane was washed 3 times in TBST, for 5 mins each time.  It was then rocked for 1 
h at room temperature with the secondary antibodies: IRDye 680RD goat anti-mouse (LI-
COR, 925-68070), IRDye 800CW goat anti-rabbit (LI-COR, 925-32211), or IRDye 
800CW goat anti-rat (LI-COR 926-32219), all diluted 1:10,000 in TBST.  After a further 
3 x 5 min washes in TBST, fluorescent signals were detected using a LI-COR Odyssey 
CLx, and images were processed using Image Studio Lite (LI-COR). 
The protocol was modified for testing of antibodies for TMEM123 as indicated in the 
figure legends.  In some cases, lysis was in 2 % SDS (20 % SDS (Sigma) diluted in PBS), 
with Benozonase (1:50).  Lysis proceeded for 30 mins in a 37 ºC shaker, before sonicating 
for 5 mins and clarifying at 14,000 rpm for 10 mins at room temperature.  Additionally, 
samples were sometimes mixed with loading dye and then heated at either 95 ºC for 5 
mins, 60 ºC for 20 mins or 37 ºC for 30 mins, as indicated, and the stated amounts of 
proteins were run on the gel.  Where indicated, transfer to the PVDF membrane was using 
the Trans-Blot wet transfer system (Bio-Rad), at 100 v for 1 h 15 mins. 
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Table 2.7 Antibodies used for immunoblots 
Target Company Catalogue Number Species Dilution 
GAPDH R&D Systems MAB5718 Mouse 1:10,000 
ECE1 Abcam ab71829 Rabbit 1:1000 
ECE1 R&D MAB17841-SP Rat 1:500 
ECE1 Proteintech N/A (was still in testing) Rabbit 1:500 
ECE1 Invitrogen PA5-24563 Rabbit 1:1000 
TMEM123 Abcam ab81423 Rabbit 1:500 
TMEM123 Santa Cruz SC-377295 Mouse 1:500 
TMEM123 Novus Biologicals NB100-56371 Rabbit 1:250 
Sp100 GeneTex GTX131570 Rabbit 1:2000 
Daxx BioRad MCA2143 Mouse 1:1000 
Calnexin LifeSpan Bio LS-B6881 Rabbit 1:10,000 
 
2.5.3 RT-qPCR 
Synthesis of cDNA 
Reverse transcription-quantitative PCR (RT-qPCR) was used for validation of proteomic 
data. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen), following 
the manufacturers instructions.  Contaminating DNA was removed from 1 µg RNA by 
combining 5 µl 10x Turbo DNase buffer (Invitrogen), 1 µl DNase and making up to 50 
µl with H20.  This was incubated at 37 ºC for 20-30 mins, and then 5 µl of DNase 
Inactivation Reagent added.  After 5 mins at room temperature, the DNase treated RNA 
was centrifuged at 10,000 g for 1.5 mins, and the RNA transferred to a new tube for 
reverse transcription. 
cDNA was synthesised from 100 ng of the DNase treated RNA, using the GoScript 
Reverse Transcription Kit (Promega), with 1 µl oligo(dT) primer and made up to 5µl with 
water.  This was heated for 5 mins at 70  ºC, and then chilled on ice for 10 mins.  The 
reverse transcription mix (4 µl GoScript 5x reaction buffer, 2 µl 25mM MgCl2, 1 µl PCR 
nucleotide mix, 0.5 µl recombinant RNasin ribonuclease inhibitor, 1 µl GoScript reverse 
transcriptase and 6.5 µl water) was added, and annealed for 5 mins at 25 ºC prior to 
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extension for 1 h at 42  ºC.  The reverse transcriptase was inactivated by heating for 15 
mins at 70 ºC. 
qPCR Analysis 
The cDNA was diluted 1:10 and analysed using the TaqMan quantitative PCR (qPCR) 
system.  Each sample was analysed in triplicate for both the gene of interest and the 
internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  Control samples 
were included where either water or RNA prior to reverse transcription was used instead 
of the sample.  A mastermix was made up including 10 µl TaqMan gene expression 
master mix (Applied Biosystems), 1 µl of the relevant TaqMan probe (ThermoFisher) for 
either ECE1 (Hs01043735_m1), TMEM123 (Hs00920881_m1) or the internal control 
GAPDH (Hs02786624_g1),  and 7 µl H2O, for each well required.  18 µl of this mix was 
added to each well in the 96-well plate (Applied Biosystems), and 2 µl of the relevant 
sample added to the well.  Analysis was performed on the 7500 Fast and 7500 real-time 
PCR systems (Applied Biosystems).  The PCR program started with activation at 95 ºC 
for 2 min, followed by 40 cycles of denaturation at 95 ºC for 5 s and annealing/extension 
at 60 ºC for 30 s.   
 
2.6 Viruses 
The HCMV with green fluorescent protein (GFP) fused to UL36  used in the restriction 
assays was as described in Nightingale et al. (2018).  It is derived from the Merlin strain 
of the virus, which is the designated HCMV reference sequence.  This strain was 
previously cloned into a bacterial artificial chromosome (BAC), which was found to 
differ to the original clinical isolate of the virus by point mutations in RL13 and UL128.  
These mutations are acquired rapidly during passaging, and enhance replication in 
fibroblasts (Stanton et al, 2010).  The mutation in UL128 has since been corrected, 
however as expression of this impairs growth of the virus, a tetracycline (tet)-operator 
was inserted upstream of the gene to allow expansion.  The BAC clone was further 
modified for expression of GFP from a porcine teschovirus-1 2A (P2A) self-cleaving 
peptide following the UL36 open reading frame.  UL36-GFP HCMV stocks were 
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prepared by Dr Katie Nightingale and Alice Fletcher-Etherington, and kindly provided to 
me for the restriction assays.  Briefly, HFFF-Tet cells were infected at low MOI, enabling 
tet repression of UL128 for expansion, and the virally infected supernatant was collected 
and centrifuged, first to pellet cell-free virus, and then to remove debris.  For the plaque 
assay, AD169-GFP (RCMV288) was used (McSharry et al, 2001), and this was prepared 
by Dr Katie Nightingale.   
 
2.7 HCMV Restriction Assays 
2.7.1 shRNA, Overexpression and CRISPR Cell Restriction Assays 
In order to examine whether a particular gene had an impact on infection, knockdown 
(shRNA and CRISPR) and overexpressing HFFF-TERT cell lines were produced, in this 
case for ECE1.  Control cells were transduced with non-targeting shRNAs, CRISPR 
guides or a GAW plasmid, and the known restriction factors Sp100 and Daxx were used 
as positive controls.  The cell lines were generated as described in section 2.4. 
Cells were seeded at 1.5x105 cells/well in a 24-well plate, with each of the control, Sp100 
and/or Daxx, and ECE1 cell lines seeded in triplicate for each MOI to be examined (with 
the exception of the first two shRNA experiments which were performed in duplicate).  
At 24 h, cells were washed once with PBS and then infected with UL36-GFP HCMV at 
a desired low MOI (0.003 – 0.1) in 150 µl of serum free DMEM.  Infection proceeded at 
37 ºC for 2 h on a rocker, before the infection media was removed and replaced with 
DMEM supplemented with 10 % FCS.   
At 24 hpi the samples were harvested for analysis.  The media was removed and cells 
washed once in PBS.  They were then incubated with 0.2 µl trypsin (Sigma) until 
detached, then 0.2 µl of DMEM and 0.2 µl of 4 % paraformaldehyde fixation buffer 
(Biolegend) were added.  The cells were transferred to eppendorfs, and after 10 mins 
centrifuged at 500 g for 5 mins.  Cells were resuspended in 300 µl PBS and analysed on 
the Becton-Dickinson FACSCalibur flow cytometer, in order to measure the percent of 
GFP positive, and therefore infected, cells.  Data was analysed using FlowJo vX. 
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2.7.2 Two Colour Restriction Assay 
HFFF-TERTs-mCherry cells expressing either the GAW overexpression control or a 
control shRNA were mixed 1:1 with HFFF-TERTs-iRFP cells expressing the relevant 
overexpression plasmid or shRNA for testing (ECE1, Sp100 or Daxx).  The mixed 
population of cells was seeded at 1.5x105 cells/well in triplicate for each MOI to be 
examined.  The infection and harvesting of the restriction assay was performed as 
described for other restriction assays (section 2.7.1).  The % GFP+ cells in both the 
mCherry and iRFP populations in each well was measured using the Becton Dickinson 
LSR Fortessa and analysed using FlowJo vX.  The data was analysed by taking the ratio 
in a given well of: 
 % GFP+ cells in the iRFP population 
 % GFP+ cells in the mCherry population 
This was then averaged across the triplicate samples for each cell type.   
 
2.7.3 Plaque Assay 
HFFF-TERT cell lines (control, knockdown or overexpression, as appropriate) were 
seeded at 1.5x105 cells/well in a 12-well plate, in triplicate for each cell type and for each 
dilution of the virus.  After 24 h they were they were infected with AD169-GFP at an 
MOI of 0.002, 0.006, 0.02 and 0.06, in serum free DMEM, and infections were in 400 
µl/well.  Infection proceeded for 2 h on a rocker at 37 ºC.  After this time, the inoculum 
was removed and replaced with 3 ml of 1:1 Avicel (FMC BioPolymer, 2% w/v in H2O) 
and 2x DMEM (125 ml H2O, 50 ml 10x minimum essential media (MEM, Gibco), 50 ml 
FBS, 15 ml sodium bicarbonate (Gibco), 10 ml pen/strep, 5 ml glutamine (Sigma)).  After 
two weeks at 37 ºC, with care not to move the cells at all during this time, the 
Avicel/DMEM mix was removed and the cells washed carefully with PBS three times.  
The cells were fixed with 0.5 ml 4 % paraformaldehyde in each well for 15 mins.  This 
was replaced with PBS for storing the cells at 4 ºC, prior to counting the plaques.      
60 Chapter 2 – MATERIALS AND METHODS  
 
2.8 Additional Methods from Chapter 4 on VACV 
The work presented in ‘Chapter 4: Vaccinia Virus Screen’ was produced in collaboration 
with Dr Jonas Albarnaz and Dr Yongxu Lu in the laboratory of Professor Geoffrey L. 
Smith (Department of Pathology, University of Cambridge).  Viral infections for the 
proteomic time course, and whole cell lysate (WCL) harvesting were performed by them, 
as well as the immunoblots for validation and the restriction assays with VACV and HSV-
1.  All further processing of samples for proteomics, and data analysis, was performed by 
myself.  Brief methods are given here for experiments performed by members of the 
Smith Lab, and more details can be found in (Soday et al, 2019). 
 
2.8.1 Cell Culture 
HFFF-TERTs were obtained from the Weekes lab and maintained as described previously 
(section 2.2).  Histone deacetylase 5 (HDAC5) knockout and overexpression cells were 
produced in U2OS (human osteosarcoma cells), HeLa and HEK-293T cells.  VACV was 
titrated onto BS-C-1 cells (African green monkey, kidney epithelial cells). All were 
maintained in DMEM supplemented with FBS (10 % v/v) and pen/strep, at 37 ºC, 5 % 
CO2.   VACV was propagated in RK13 cells (rabbit kidney epithelial cells), which were 
maintained MEM supplemented with 10 % FBS and 1-2 % pen/strep. 
 
2.8.2 Production of Cell Lines 
HDAC5 knockout cell lines were produced by CRISPR/Cas9 in HeLa and HEK-293T 
cells.  Cells were transfected with CRISPR guides designed to target exon 3 and 4 of 
HDAC5 (Exon 3: AGGTCGGGAACCATCCTTGG, Exon 4: 
CCAGCCCTGTGGAGCTACGG).  The polyclonal cell populations were single cell 
cloned.  Two HDAC5 knockout clones were generated from HeLa parental cells with 
guides targeting either exon 4 (H5KO1) or exon 3 (H5KO2), and two HDAC5 knockout 
clones were generated from HEK-293T cells with both guides targeting exon4 (H5KO3 
and H5KO4).  Overexpression cell lines were produced in U2OS cells by lentiviral 
transduction, resulting in doxycycline inducible overexpression of HDAC5-Flag. 
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2.8.3 Viruses 
For the proteomic screen of VACV infection and for validation immunoblots, the WT 
VACV western reserve (WR) strain was used.  For the investigation of the viral C6 
protein, a derivative of the mutant lacking the C6L gene was used (Unterholzner et al, 
2011), and for restriction assays a virus with the capsid protein A5 fused to GFP was 
employed (Carter et al, 2003).  The HSV-1 virus used in the restriction assay in this 
chapter was the s17 strain, with GFP fused to viral protein 26, and this was provided to 
the Smith lab by Prashant Desai (Hollinshead et al, 2012). 
 
2.8.4 Infection 
Proteomic Experiments 
HFFF-TERTs were seeded at 1x106 cells in a 25-cm2 flask and infected at an MOI of 5.  
The time course was performed in biological triplicate, with mock and VACV infected 
samples harvested at the time points described.  Where indicated, 40 µg/ml AraC was 
added to the cells at the time of infection.    For the MG132 proteomic data, the infection 
was allowed to proceed for 2 h before the inocula was removed and replaced with medium 
with or without 10 µM MG132.  The infected samples ± MG132 were both included in 
the experiment in triplicate, alongside triplicate infection with the C6 deletion mutant; 
mock infection ± MG132 was a single replicate in order to fit within the 11-plex. 
Immunoblot 
HFFF-TERTs were seeded at 1x106 cells in a 6-well plate and infected at an MOI of 5.   
Viral Replication Assays 
For viral replication assays, 2x106 WT or knock out cells were seeded in a 6-well plate 
and infected at an MOI of 0.001 with A5-GFP VACV.  After two days, the infected cells 
and the supernatant were collected and titrated on BS-C-1 cells.  For HSV-1 assays, 
supernatants were collected at three days post infection and titrated on U2OS cells. 
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2.8.5 Immunoblots 
Immunoblots in chapter 4 (Quantitative Temporal Analysis of Vaccinia Virus Infection), 
were performed by Dr Jonas Albarnaz, in a similar manner to that described in section 
2.5.2.  In this case, lysis was performed in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 10 % glycerol, 0.5 % Triton X-100, 0.1 % NP-40, supplemented with protease 
and phosphatase inhibitor cocktails (Roche), followed by clarifying by centrifugation at 
17,000 g for 15 mins at 4 ºC.  Samples were reduced with 100 mM DTT in SDS-gel 
loading buffer for 5 min at 100 ºC, before separation on a gel and transfer using the Bio-
Rad Trans-Blot Turbo transfer system.  Primary antibodies used are as described in Table 
2.8.    Secondary antibodies used were IRDye 680RD-conjugated goat anti-rabbit IgG 
(cat. no. 926-68071), IRDye 680LT-conjugated goat anti-mouse IgG (926-68020), IRDye 
800CW-conjugated goat anti-rabbit IgG (926-32211), IRDye 800CW-conjugated goat 
anti-mouse IgG (926-32210), IRDye 680LT-conjugated goat anti-rat IgG (926-68029), 
and the membrane was imaged using an Odyssey infrared imager (LI-COR Biosciences).  
For further details see (Soday et al, 2019). 
 
Table 2.8 Antibodies used for immunoblots in chapter 4 (vaccinia virus screen) 
Immunoblots performed by Dr Jonas Albarnaz or Dr Yongxu Lu (Smith Lab, Department 
of Pathology, University of Cambridge). 
Target Company Catalogue Number Species Dilution 
COL1A2 Santa Cruz sc-376350 Mouse 1:500 
COL6A2 Santa Cruz sc-374566 Mouse 1:500 
IFIT1 Thermo PA3-848 Rabbit 1:1000 
IFITM1-3 Santa Cruz sc-374026 Mouse 1:500 
TRIM5 Santa Cruz sc-373864 Mouse 1:500 
TUBULIN Serotec MCA77G Rat 1:10,000 
HDAC5 Santa Cruz sc-133225 Mouse 1:500 
HDAC1 Santa Cruz sc-81598 Mouse 1:500 
FLAG Sigma F3165 Mouse 1:1000 
D8 Described in (Parkinson & Smith, 1994) Mouse 1:1000 
C6 Described in (Unterholzner et al, 2011) Rabbit 1:1000 
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2.9 Proteomics 
Multiplexed proteomic screens examined IFN stimulation and VACV infection (Table 
2.9).  For the IFN screens, this included samples of THP-1 cells ± IFN, as well as primary 
cells from five donors for monocytes ± IFN, and two donors of pan-monocytes ± IFN.  
In the case of CD4+ T cells, data was initially acquired on samples from three donors ± 
IFN, and this was later extended to five donors (experiments summarised in Table 2.9).    
For the VACV screens, three identical time courses of WT VACV infection were 
performed, including three mock time-points, six infection time-points and one 6 h mock 
or infection with AraC treatment.  An initial 10-plex time-course experiment was used 
for optimisation of time-points; this was performed similarly to the triplicate time-courses 
described in the methods here, but the final data was not extensively analysed and so it is 
not discussed further.  An additional 11-plex investigating the effects of MG132 
treatment, and deletion of the viral protein C6 was then conducted, which included 
triplicate WT infection, WT+MG132, and infection with a C6 deletion mutant.  There 
were single replicates for mock ± MG132 (experiments summarised in Table 2.9).   
In all cases, samples were initially examined as a 3 h (sometimes 1 h) single run, and 
some samples were then fractionated into simplified mixtures of proteins, and analysed 
in multiple 3 h runs to quantify additional proteins. 
Table 2.9 Proteomic screens performed, and MS runs analysed in final dataset 
Project Experiment 
Samples in 
Multiplex 
Number of 
Single Shots  
Number of 
Fractions 
IFN 
(Plasma 
membrane 
proteomics, 
Chapter 3) 
THP-1 2 plex 2 0 
Primary monocytes 10 plex 3 6 
Primary CD4+ T cells 6 plex 1 0 
Primary CD4+ T cells 10 plex 1 6 
Pan Monocytes 4 plex 2 0 
VACV 
(Whole cell 
proteomics, 
Chapter 4) 
Time course 1 11 plex 0 12 
Time course 2 11 plex 1 12 
Time course 3 11 plex 1 12 
MG132 and C6 mutant 11 plex 1 12 
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2.9.1 Protein Extraction 
Plasma Membrane Protein Enrichment (IFN Screens) 
PM profiling was used to enrich PM proteins in THP-1s and primary leukocytes, prior to 
analysis by mass spectrometry (MS) (data in chapter 3); this was performed as previously 
described (Weekes et al, 2010, 2012).    All spins were at 4 ºC, and PBS containing 
calcium and magnesium (D8662, Sigma) was used for the biotinylation and enrichment; 
all reagents were kept ice cold.   
The suspension cells were transferred to a 15 ml falcon tube and centrifuged to collect 
(400 g, 5 mins), then washed twice in cold PBS.  Sialic acid residues were oxidised with 
sodium meta-periodate and biotinylated with aminooxy-biotin, with the reaction 
catalysed by Aniline.  This was performed by removing the supernatant from the washed 
cells, wrapping the falcon tubes in foil and adding 3 ml of biotinylation mix to each (see 
below).  The falcon tubes were rocked at for 30 mins at 4 ºC in the dark.  The reaction 
was then quenched with 600 µl 5x glycerol solution (1M glycerol (Sigma) diluted 1:2000 
in PBS), mixed by inversion and centrifuged (400g, 5 mins).  The supernatant was 
removed and the cells washed twice in PBS, before being resuspended in 1 ml 1 % triton 
lysis buffer (see below) and transferred to an Eppendorf.  Lysis proceeded on ice for 30 
mins, and then the tube was centrifuged at 13,000 g for 5 mins and the supernatant 
transferred.  Two further spins were performed, retaining the supernatant with a minimal 
amount of debris.  The final supernatant was snap frozen in liquid nitrogen prior to pull-
down and digestion.  
Once multiple samples of biotinylated glycoproteins had been collected, they were 
enriched with high affinity streptavidin agarose beads (Thermo).  The following method 
is described for 10 samples, and volumes were adjusted according to the number of 
samples.  Streptavidin agarose beads were resuspended and 500 µl and added to a Poly-
Prep column (Bio-Rad) on a vacuum manifold.  The beads were washed 4 times with 800 
µl cold 1 % triton lysis buffer, before resuspending in 1200 µl lysis buffer.  95 µl beads 
were added to each lysate, and they were incubated on a rotor for 75 mins at 4 ºC.  Each 
sample was resuspended by pipetting several times and then transferred to an individual 
polyprep column on the vacuum manifold.  Several rounds of washing were then 
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performed.  In each case, the required volume was added to each polyprep column using 
a repeat pipettor, the wash reagent removed under vacuum and then this was repeated the 
required number of times.  Cells were first washed with 4x 1 ml lysis buffer, and then 4x 
1 ml 0.5 % SDS in PBS (diluted from 20 % SDS, Invitrogen) before incubation for 20 
mins in 500 µl 0.5 % SDS/PBS/DTT (add 550 µl 1M DTT (Sigma) to 5ml 0.5 % 
SDS/PBS) in order to denature and reduce proteins.  The samples were subsequently 
washed with 8x 1.5 ml urea solution (see below), once with 10 ml urea solution, and then 
alkylated by incubating for 20 mins in the dark with 500 µl urea solution /iodoacetamide 
(IAA) (5ml urea solution with 500 µl 500 mM IAA dissolved in urea solution).  A further 
2x 1.5 ml washes were performed with urea solution, 3x 1.5 ml washes with ultra pure 
H2O (JT Baker), and finally one 10 ml wash with H2O.    The samples were transferred 
in 2x 300 µl H2O into a screw cap column (Pierce).  The column was centrifuged to 
remove the H2O at 2000 g for 1 min, and 40 µl trypsin / HEPES solution (one vial of 
Promega trypsin dissolved in 1 ml 200 mM hepes pH 8.5) added for on-bead digestion.  
After 3 h in a 37 ºC shaker, spin columns were placed in fresh eppendorfs and centrifuged 
at 2000 g for 1 min.  The tryptic peptides were stored at -80 ºC prior to TMT labelling.   
Reagents for PMP: 
Biotinylation mix - for two samples: 25-40 mg sodium periodate (Thermo) was dissolved 
in ice-cold PBS pH 6.7 (weight in mg x 0.47 ml, to make 10 mM solution), keeping on 
ice and agitating periodically.  In a foil covered tube 6 ml PBS at pH 6.7, 6.7 µl aminooxy-
biotin (Biotium) and 6.1 µl aniline (Acros Organics) were combined, and mixed 
immediately.  660 µl of the sodium periodate was then added to this. 
500 mM IAA – The weight of IAA (Sigma) in mg was multiplied by 10.8 µl and the IAA 
was diluted in this volume of lysis buffer,  urea solution or HEPES as indicated. 
1 % Triton Lysis Buffer - For 50 ml lysis buffer, 500 µl 1M Tris-HCL (Sigma), 25 ml 2 
% Triton (Thermo, one vial 10 % Trition X-100 added to 40 ml ultrapure H2O), 1.5 ml 
5M NaCL (Sigma) and 23 ml ultra pure H2O were combined.  100 µl 500 mM IAA 
(diluted in lysis buffer), was added to 10 ml lysis buffer with one protease inhibitor tablet.  
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Urea Solution – 90 g urea was dissolved in 25 ml 1M Tris-HCL (Sigma) and 156.5 ml 
ultra pure H2O (JT Baker). 
Whole Cell Protein Extraction (VACV Screens) 
For the proteomic studies of VACV infection (chapter 4), WCL protein extractions were 
performed by Dr Jonas Albarnaz.  Briefly, cells were washed twice with PBS and then 
scraped in 250 µl guanidine lysis buffer (200mM HEPES pH 8.4 is produced from a 1M 
HEPES stock (Sigma), and 3 ml of this is added to 9 ml 8 M guanidine-HCL (Pierce), to 
make 6M guanidine / 50 mM HEPES pH 8.5 lysis buffer).  Cells were collected in 
eppendorfs, centrifuged briefly and sonicated prior to centrifugation at 21,000 g for 10 
mins to remove debris.  The supernatant was transferred, centrifuged again and the second 
supernatant snap frozen in liquid nitrogen.  These samples were then given to me for 
further processing. 
A portion of the lysate (50 µl) was digested for proteomic analysis, and the rest retained 
for immunoblot analysis where required.  Proteins were reduced and then alkylated by 
incubating for 20 mins with 2.5 µl 100 mM DTT and then for an additional 20 mins in 
the dark with 1.5 µl 10x IAA (dissolved in 200 mM HEPES).  Excess IAA was quenched 
by incubating for 15 mins with a further 2.5 µl 100 mM DTT and samples were diluted 
in 143.5 µl 200 mM HEPES to achieve a final concertation of 1.5 M guanidine.  Samples 
were then digested in 2 µl endoproteinase LysC (Wako) for 3 h at room temperature.  
They were then further diluted in 398 µl HEPES to a final concentration of 0.5 M 
guanidine, prior to adding 50 µl trypsin (Pierce), and incubating in a 37 ºC shaker 
overnight.  The next day, the reaction was quenched with 65 µl 50 % formic acid (FA, 
Sigma, diluted to 50 % in H2O) to achieve a concentration of 5 % FA, and centrifuged at 
21,000 g for 10 mins to remove undigested protein.   
Peptides were then subjected to C18 solid-phase extraction (Sep-Pak, Waters).  A 50 mg 
SepPak was activated with 2x 1 ml 100 % acetonitrile (AcN, Merck) followed by 1 ml 70 
% AcN / 1 % FA.  The column was washed with 3x 1 ml 1 % FA.   Samples were diluted 
with 300 µl 1 % FA, loaded onto the SepPak and allowed to pass through slowly. The 
SepPak was washed again with 3x 1 ml 1 % FA prior to elution of the peptides in 2x 350 
µl 70 % AcN / 1 % FA.  Samples were dried completely by vacuum centrifugation in a 
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speedvac and resuspended in 75 µl 200 mM HEPES pH 8.5.   The amount of peptides 
was quantified using a micro BCA protein assay kit (Pierce) following the manufacturer’s 
instructions. 
 
2.9.2 Peptide Labelling with Tandem Mass Tags 
TMT reagents (0.8 mg, Thermo) were dissolved in 43 µl anhydrous AcN (Acros 
Organics)  Each tag was aliquoted and stored at -80 ºC.  The general protocol for TMT 
labelling is given here, and more details are below for particular experiments; details of 
sample labelling are given in Table 2.10 and Table 2.11.  The peptide samples were 
diluted into HEPES and AcN such that the final concentration with the TMT label was 
30 % AcN (v/v).   Labelling proceeded for 1 h at room temperature, before quenching by 
adding 5 % hydroxylamine (Sigma) to a final concentration of 0.5 %.  The required 
amount of sample was combined, 1:10 vol 50 % FA added, and diluted in 1 % FA.  This 
was then desalted using a StageTip, or SepPak prior to analysis by MS or fractionation.  
In general, a small amount of the sample was analysed on the mass spectrometer as single 
run to confirm labelling efficiency and that there was an equal amount of protein in each 
channel, prior to fractionation.  
Plasma Membrane Samples (IFN Screens) 
No BCA was performed for quantitation, as the amount of protein is lower in PM enriched 
samples and is below the limit of detection.  For the THP-1 and pan-monocyte samples, 
7 µl tryptic peptides was combined with 4 µl HEPES and 5 µl TMT to make a final 
concentration of ~30 % AcN.  Following 1 h of labelling, the reaction was quenched with 
5 % hydroxylamine.  The required samples were combined in a 1:1 (THP-1) or 1:1:1:1 
(pan-monocytes) ratio and 1:10 volume 50 % FA added.  The combined samples were 
dried to < 40 µl, diluted in 200 µl 1 % FA and subjected to desalting by StageTip 
(Rappsilber et al, 2007).  The StageTip was made by punching 2x 3 layers of C18 material 
and compacting it in a 200 µl pipette tip.  The tip was conditioned by applying 50 µl 
methanol and centrifuging at 1800 g for ~1 min (or until all the liquid had gone through).  
The StageTip was rinsed with 50 µl 70 % AcN/1 % FA followed by 50 µl 1 % FA.  The 
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~200 µl peptide was loaded and the liquid spun through over several minutes. The C18 
with the peptide bound was again rinsed with 2x 50 µl 1 % FA, and then the peptide eluted 
in 50 µl 70 % AcN/1 % FA.  The desalted sample was dried completely, resuspended in 
10 µl MS buffer (86 µl H2O, 10 µl 50  % FA, 4 µl 100 % AcN), and analysed on the mass 
spectrometer, initially for a 1 h single run, and then a 3 h run.  These samples were not 
fractionated, they were only examined as single runs.   
For the CD14+ monocytes, 28 µl each sample was combined with 9 µl AcN and 3 µl 
TMT.  Following labelling, 2 µl of each sample was quenched and combined.  This was 
desalted using a StageTip (as above), dried down and resuspended in MS buffer for single 
shot analysis on the mass spectrometer.  Analysis of the single shot showed the percent 
of peptides labelled with a TMT was 89 %, slightly lower than expected.  As sufficient 
labelling is required to ensure the peptides can be assigned to the correct sample, greater 
than 90 % labelling is usually desired for PM samples, so the 38 µl of remaining samples 
was added to 3 µl TMT and again labelled for 1 h, then quenched with 5 % 
hydroxylamine.  3 µl of each sample was combined and processed as previously, and 
single shot analysis confirmed improved labelling.  Similar amounts of protein were 
quantified with each label, so there was not an excessive amount of electronic 
normalisation required.  25 % of the remaining sample was combined for a final single 
shot, and 75 % was combined in a 1:1:1:1:1:1:1:1:1:1 ratio and subjected to C18 solid 
phase extraction (SepPak, as above), prior to solid-phase cation exchange (SCX) 
fractionation.  
For the CD4+ T cells, a small amount of the samples from three donors were initially 
labelled and combined in a 6-plex for single shot analysis (protocol as described for THP-
1s and pan-monocytes).  When samples were collected from two additional donors, all 
samples were labelled and a small amount of each combined in equal volumes.  Single 
shot analysis was used to adjust for equal loading, and the remaining sample combined 
1:1:1:1:1:1:0.8:0.8, subjected to C18 solid-phase extraction with a SepPak (as above) and 
SCX fractionation. 
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Table 2.10 Sample labelling for PM proteomics samples 
Samples were labelled with TMT as indicated in the table.  Dx represents donor x. 
TMT Thp-1 
CD14+ 
Monocytes 
CD4+ T cells 
(6 plex) 
CD4+ T cells 
(10 plex) 
Pan 
Monocytes 
126 - D1 + IFN D6 + IFN D6 + IFN - 
127N - D1 D6 D6 - 
127C - D2 + IFN - D7 + IFN D11 + IFN 
128N - D2 D7 + IFN D7 - 
128C - D3 + IFN - D8 + IFN D11 
129N - D3 D7 D8 - 
129C Thp-1 + IFN D4 + IFN - D9 + IFN D12 + IFN 
130N - D4 D8 + IFN D9 - 
130C Thp-1 D5 + IFN - D10 + IFN D12 
131N - D5 D8 D10 - 
Whole Cell Protein Samples (VACV Screen) 
50 µg of protein was labelled, and made up to 35 µl with HEPES.  12 µl AcN was added, 
and 3 µl TMT.  Following labelling for 1 h, 1 µl of each sample (~1 µg) was added to 180 
µl 1 % FA and 1 µl 50 % FA.  The combined sample was desalted with a StageTip (as 
above), dried down in a speedvac and resuspended in 10 µl MS buffer for a single shot 
analysis.  This showed the amount of protein in each sample of the WCL1 time course 
was approximately equal, apart from sample one, in which ~20 % less total signal was 
detected.  Samples were therefore combined in a 1.2:1:1:1:1:1:1:1:1:1:1:1 ratio to avoid 
excessive digital normalisation.  For this reason, the single shot data was not later 
analysed with the fractionated data for this sample.  For time-courses WCL2 and WCL3, 
and the MG132 / C6 experiment, near equal amounts of protein where present with each 
label. Therefore, the remainder of the samples were quenched with 5 µl 5 % 
hydroxylamine and combined in a 1:1:1:1:1:1:1:1:1:1 ratio; the single shot and 
fractionation data were later analysed together for these samples.  The combined sample 
was dried down to < 100 µl, diluted in 1.5 ml 1 % FA and subjected to C18 solid-phase 
extraction with a SepPak (as above).   The eluted peptide was then dried down completely 
prior to offline high pH reversed-phase (HpRp) fractionation.  
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Table 2.11 Sample labelling for WCL proteomic samples 
TMT label 
WT VACV Time 
Course 1, 2 and 3 
wtVACV / vDC6 / 
MG132 
126 0h Mock Mock 
127N 2h VACV Mock + MG132 
127C 4h VACV wtVACV 1 
128N 6h Mock wtVACV 2 
128C 6h Mock + AraC wtVACV 3 
129N 6h VACV VACV ΔC6 1 
129C 6h VACV + AraC VACV ΔC6 2 
130N 8h VACV VACV ΔC6 3 
130C 12h VACV wtVACV + MG132 1 
131N 18h Mock wtVACV + MG132 2 
131C 18h VACV wtVACV + MG132 3 
 
2.9.3 Fractionation 
Offline Tip-Based SCX Fractionation for Plasma Membrane Samples (IFN Screen) 
SCX fractionation was based on a previous protocol (Dephoure & Gygi, 2011), in a 
modified form for small amounts of peptide.  A fritted tip was made by taking a p10 filter 
pipette tip, removing the filter and cutting it in half, then inserting this into the end of a 
p200 pipette tip.  10 mg of resin (polysulfoethyl A bulk material, Nest Group Inc) in 150 
µl 100 % AcN was loaded onto the tip under vacuum.   SCX buffer A and B were made 
as follows: 
Buffer A – 4 ml H2O, 168 µl 250 mM KH2PO4 pH 2.65 (final concentration of ~7mM), 
10 % H3PO4 (as required to reach a final pH of 2.6-3 as confirmed on a pH strip), and 1.8 
ml AcN (final concentration of 30 %).   
Buffer B – 1.9 ml H2O, 2.1 ml 1M KCl (final concentration of 350 mM), 168 µl 250 mM 
KH2PO4 pH 2.65 (final concentration of ~7mM), 10 % H3PO4 (as required to reach a final 
pH of 2.6-3 as confirmed on a pH strip), and 1.8 ml AcN (final concentration of 30 %).   
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The SCX material was conditioned with 2x 400 µl buffer A, then 400 µl buffer B and 
finally 4x 400 µl buffer A.  The dried peptides were resuspended in 400 µl buffer A and 
applied to the tip under vacuum, with a flow rate of ~150 µl/min.  It was then washed 
with 150 µl buffer A.  A series of 6x 150 µl washes were then performed with increasing 
concentrations of K+, starting at 10 mM (10 µl buffer B into 340 µl buffer A), through 
25, 40, 60, 90 to 150 mM KCl (150 µl buffer B into 200 µl buffer A).  The eluate from 
each was collected in a separate eppendorf, and the 6 fractions dried completely by 
vacuum centrifugation.  They were then resuspended in 200 µl 1 % FA, desalted using a 
StageTip (as above), dried again and resuspended in MS buffer for analysis.     
Offline HpRp Fractionation for Whole Cell Lysate Samples 
TMT-labelled tryptic peptides from WCL samples were subjected to HpRP fractionation; 
this was performed by Dr Colin Davies (Weekes Lab, Department of Medicine, 
University of Cambridge) using an Ultimate 3000 RSLC UHPLC system (Thermo Fisher 
Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm long, 1.7 µm particle 
Kinetix Evo C18 column (Phenomenex).  The mobile phase consisted of A: 3 % AcN, B: 
AcN and C: 200 mM ammonium formate pH 10. Isocratic conditions were 90 % A / 10 
% C, and C was maintained at 10 % throughout the gradient elution. Separations were 
conducted at 45 ºC. Samples were loaded at 200 µl/min for 5 min. The flow rate was then 
increased to 400 µl/min over 5 min, after which the gradient elution proceed as follows: 
0-19 % B over 10 min, 19-34 % B over 14.25 min, 34-50 % B over 8.75 min, followed 
by a 10 min wash at 90 % B. UV absorbance was monitored at 280 nm and 15 s fractions 
were collected into 96-well microplates using the integrated fraction collector. Fractions 
were recombined orthogonally in a checkerboard fashion, combining alternate wells from 
each column of the plate into a single fraction, and commencing combination of adjacent 
fractions in alternating rows (ie for fraction 1 combine column 1, row A, C, E etc, for 
fraction 2 combine column 2, row B, D, F etc).  This yielded 12 fractions.  The 
intermediate remaining wells were combined in the same manner to yield a second set of 
12 fractions.  Wells prior to the start or after the stop of the elution of peptide-rich 
fractions, as identified from the UV trace, were excluded. The first set of 12 fractions was 
dried by vacuum centrifugation and resuspended in 10 µl MS solvent prior to MS analysis.  
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2.9.4 LC-MS3 
MS data was acquired using an Orbitrap Fusion for all PM enriched experiments apart 
from the two initial monocyte single runs and the 10-plex CD4 single run, where an 
Orbitrap Fusion Lumos mass spectrometer was used instead (Thermo Fisher Scientific, 
San Jose, CA). The Orbitrap Fusion Lumos was also used for all the WCL proteomic 
studies.  Operation of the mass spectrometer was performed by Dr James Williamson 
(Department of Medicine, University of Cambridge) in the case of the Orbitrap Fusion, 
and Dr Robin Antrobus (Cambridge Institute for Medical Research, University of 
Cambridge) for the Orbitrap Fusion Lumos. 
In both cases, an Ultimate 3000 RSLC nano UHPLC equipped with a 300 µm ID x 5 mm 
Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 
µm particle Acclaim PepMap RSLC analytical column was used. 
Orbitrap Fusion Experiments 
Samples were loaded at 10 µl/min for 5 mins in loading solvent (0.1 % TFA) before 
beginning the analytical gradient which used solvents A (0.1 % FA) and B (80 % AcN + 
0.1 % FA). All separations were carried out at 55 ºC.  The following gradient was used: 
3-5.6 % B over 4 minutes, 5.6-32 % B over 162 minutes, followed by a 5 minute wash at 
80 % B and a 5 minute wash at 90 % B and equilibration at 3 % B for 5 minutes. For the 
analysis of the TMT samples, a MultiNotch MS3-based method  was used (Ting et al, 
2011; McAlister et al, 2014) with the following settings: MS1: 400-1400 thomson (Th), 
quadrupole isolation, 120,000 resolution, 2x105 automatic gain control (AGC) target, 50 
ms maximum injection time, ions injected for all parallisable time. MS2: Quadrupole 
isolation at an isolation width of m/z 0.7, CID fragmentation (normalised collision energy 
(NCE) 30) with ion trap scanning out in rapid mode from m/z 120, 1x104 AGC target, 70 
ms maximum injection time, ions accumulated for all parallisable time in centroid mode. 
MS3: in synchronous precursor selection mode the top 10 MS2 ions were selected for 
HCD fragmentation (NCE 65) and scanned in the Orbitrap at 50,000 resolution with an 
AGC target of 5x104 and a maximum accumulation time of 150 ms, ions were not 
accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 
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3 s. Dynamic exclusion was set to +/- 10 ppm for 90 s. MS2 fragmentation was trigged 
on precursors 5x103 counts and above. 
Orbitrap Fusion Lumos Experiments 
Samples were loaded at 5 ul/min for 5 mins in loading solvent (0.1 % FA) before 
beginning the analytical gradient which used solvents A (0.1 % FA) and B (80 % AcN + 
0.1 % FA). All separations were carried out at 55 ºC.  The following gradient was used: 
3-7 % B over 3 minutes, 7-37 % B over 173 minutes, followed by a 4 minute wash at 95 
% B and equilibration at 3 % B for 15 minutes. For the analysis of the TMT samples, a 
MultiNotch MS3-based method  was used (Ting et al, 2011; McAlister et al, 2014) with 
the following settings: MS1: 380-1500 Th, 120,000 resolution, 2x105 AGC target, 50 ms 
maximum injection time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, 
CID fragmentation (NCE 35) with ion trap scanning in turbo mode from m/z 120, 1.5x104 
AGC target, 120 ms maximum injection time. MS3: In synchronous precursor selection 
mode the top 6 MS2 ions were selected for HCD fragmentation (NCE 65) and scanned in 
the Orbitrap at 60,000 resolution with an AGC target of 1x105 and a maximum 
accumulation time of 150 ms. Ions were not accumulated for all parallelisable time. The 
entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclusion was set to +/- 10 
ppm for 70 s. MS2 fragmentation was trigged on precursors 5x103 counts and above. 
 
2.9.5 Data Processing 
Processing of Raw Proteomics Data 
Mass spectra were processed using ‘MassPike’ a Sequest-based software pipeline for 
quantitative proteomics, through a collaborative arrangement with Professor Steven 
Gygi’s laboratory (Harvard Medical School).  Within the MassPike platform is software 
for conversion of the spectra into mzXML format using an extractor modified from 
Thermo Fisher’s RAW File Reader library (version 4.0.26).    
The human UniProt database (26th January 2017) was combined with a database of 
common contaminants such as porcine trypsin and endoproteinase LysC.  For analysis of 
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the VACV infection samples, this was additionally combined with the VACV strain WR 
UniProt database (23rd February 2017). The combined database was concatenated with a 
reverse database composed of all protein sequences in reversed order.  Searches were 
performed using a 20 parts per million (ppm) precursor ion tolerance   (Haas et al, 2006) 
and product ion tolerance of 0.03 Th.  Static modifications were included for TMT on 
lysine residues and peptide N termini (229.162932 Da) and carbamidomethylation of 
cysteine residues (57.02146 Da), while oxidation of methionine residues (15.99492 Da) 
was set as a variable modification. 
A target-decoy strategy was employed to control the fraction of erroneous protein 
identifications (Elias & Gygi, 2007, 2010); this involves using intentionally incorrect 
‘decoy’ sequences (in this case the reversed protein sequences) in the database, in order 
to assess the number of matches to these and estimate a false discovery rate (FDR).  
Filtering of peptide spectral matches was to a FDR of 1 % at the peptide level, and 
subsequent filtering ensured an FDR of 1 % at the protein level (Kim et al, 2011a; Wu et 
al, 2011).  Filtering was performed using a linear discriminator analysis (Huttlin et al, 
2010), distinguishing correct from incorrect peptide identifications using an approach 
similar to the Percolator algorithm (Kall et al, 2007), though utilising a distinct machine 
learning algorithm.  These approaches set filters taking into account multiple parameters 
simultaneously; these include XCorr, ΔCn, missed cleavages, peptide length, charge state, 
and precursor mass accuracy.  Protein assembly was guided by principles of parsimony, 
generating the smallest set of proteins necessary to account for all observed peptides. 
MassPike software quantified proteins by summing TMT reporter ion counts across all 
matching peptide spectral matches for the given protein (McAlister et al, 2012, 2014).  A 
minimum of one unique or razor peptide per protein was used for quantitation. Briefly, a 
0.003 Th window around the theoretical m/z of each reporter ion (126, 127n, 127c, 128n, 
128c, 129n, 129c, 130n, 130c, 131n and 131c for 11-plex experiments) was scanned for 
reporter ions, and the maximum intensity nearest to the theoretical m/z was used. The 
number of TMT reporter ions in each MS3 spectrum is directly proportional to the signal-
to-noise (S:N) ratio for each ion, and is the primary determinant of the quality of 
quantitation (Makarov & Denisov, 2009).  Conservatively, each individual peptide used 
in quantitation was therefore required to contribute enough TMT reporter ions  (at least 
~1250 per spectrum) to ensure sufficient quality and a representative picture of relative 
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protein abundance (McAlister et al, 2012).  In order to minimise peptide co-isolation, an 
isolation specificity of 0.5 was employed (Ting et al, 2011).  Peptide-spectral matches 
with no MS3 spectra, or poor quality MS3 spectra (more than 9 TMT channels missing 
and/or a combined S:N ratio of less than 25 for each used channel up to a maximum of 
250 ie 100 total for a 4 plex, 150 for a 6 plex, 250 for a 10 or 11 plex) were excluded from 
quantitation.  All peptides that met the stated criteria for a given parent protein were then 
summed.  In effect, this weights the contribution of each peptide to the total S:N of the 
protein, according to the quantitation of the TMT reporter ions for that peptide.  Protein 
level quantitation values were exported to excel for further analysis. 
At this stage, proteins identified by matches to the reverse hits and common contaminants 
databases were removed.  The data was then normalised assuming an equal total amount 
of protein in every channel.  For this, a ratio was calculated between the total S:N in a 
given channel, and the total S:N in the first channel used; this ratio was used to scale all 
S:N values in that channel, providing a normalised S:N.  In all further investigations, S:N 
refers to this normalised S:N. 
 
2.9.6 Data Availability 
Unprocessed peptide data files for the VACV proteomic screen are available at 
doi:10.17632/wxk9gnw22r.1. These files include details of peptide sequence, 
redundancy, protein assignment, raw unprocessed TMT reporter intensities and isolation 
specificity. The MS proteomics data have been deposited to the ProteomeXchange 
Consortium (http://www.proteomexchange.org/) via the PRIDE partner repository with 
the dataset identifier PXD012785.  The IFN dataset will be made similarly available 
following publication. 
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2.10 Data Analysis and Statistics 
2.10.1 Chapter 3: IFN Screen 
The normalised S:N values, generated as describe above, were used for all further 
analysis, presentation and generation of plots.  Additionally, as it is challenging to 
confidently assign peptides to a specific human leukocyte antigen (HLA) alleles, and to 
account for different alleles being expressed in the different donors, the S:N values were 
summed to give a single value for HLA-A, HLA-B, HLA-C and HLA-DRB1.  
Additionally, all classical HLAs were excluded from the investigation of protein 
abundance. 
In the dot plot of IFN induced changes at the surface of THP-1s, p-values were estimated 
based on significance B (Cox & Mann, 2008), calculated using Perseus (Tyanova et al, 
2016).  Significance B assumes a normal distribution of fold changes (FCs) observed, but 
allows a different standard deviation (SD) for up- and down- regulated proteins.  
Additionally, proteins are grouped into bins according to their S:N; proteins with a higher 
S:N are more accurately quantified and therefore a smaller FC may still be significant.  
Abundance values for proteins were calculated based on the ‘iBaq’ methodology, adapted 
from the original description (Schwanhäusser et al, 2011).  The maximum MS1 precursor 
intensity for each peptide was determined, and a summed MS1 precursor intensity for 
each protein across all matching peptides was calculated.  This summed intensity was 
divided by the number of theoretical tryptic peptides for that protein between 7 and 30 
amino acid residues in length to give an estimated iBAQ value.   To determine the 
abundance of a protein at the surface of unstimulated cells, the summed intensity was 
adjusted in proportion to  the S:N values: (Donor 1 + Donor 2 + Donor 3 + Donor 4 + 
Donor 5 unstimulated) / ∑(all donors with/without IFN).  Colour coding for the 
comparison of the abundance of proteins at the surface of monocytes and T cells was 
based upon calculating the mean and SD of the log transformed ratios for all proteins 
quantified, and defining cut off ratios at one, two or three SDs away from the mean.  For 
donor-to-donor comparison, the intensity was adjusted in proportion to the unstimulated 
sample for that donor (eg Donor 1 unstimulated / ∑(all donors + / - IFN).   
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When examining IFN induced FC, in order to avoid artificial inflation of changes due to 
poor quantitation of a protein in one channel for a given donor, the data for a donor where 
either the stimulated or unstimulated channel contributed less than 2 % of the total S:N 
across the 10-plex for that proteins was removed.  This was only applied to the primary 
monocytes and T cells, where data for five donors was available.  Only proteins with data 
for three or more donors were examined.    
For identifying IFN regulated proteins, upregulated proteins met the ‘sensitive’ criteria 
by having an average FC > 1 SD away from the mean (calculated as described above for 
the abundance ratio), and a FC > 1 in all donors where quantified.  The SD away from the 
mean FC determined the colour of the average FC bar in the graphs.  The filter for being 
stringently upregulated employed an additional criteria of a Benjamini-Hochberg (BH)-
corrected p-value < 0.05, calculated using a paired, two-tailed student’s t-test on log 
transformed data.   Downregulated proteins were assessed identically.  This was all 
calculated using excel. 
R2 values for donor-to-donor comparisons were calculated using excel. 
 
2.10.2 Chapter 4: Vaccinia Virus Screen  
For analysis of the triplicate time course dataset, the S:N in each channel was analysed as 
a fraction of the total observed S:N for that protein across the 11 plex.   Considering the 
fractional TMT signal rather than the absolute normalised intensity effectively corrected 
for difference between the number of peptides quantified for each protein and between 
replicates.   
For analysis of proteomic changes in the host, proteins were defined as ‘sensitively’ 
upregulated if they had a FC > 2 at any infection time point compared to the 18 h mock, 
and to be stringently upregulated they were also required to have a BH-corrected p-value 
< 0.05 at that time point.  The same criteria were applied to downregulation.  A two-tailed 
Student’s t-test was used to estimate p-values for proteins quantified in all three replicates, 
comparing each time point with the 18 h mock, and these were BH-corrected.  These p-
values are also displayed in the dotplot and on graphs of expression profiles.  Expression 
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profiles display the mean abundance across all replicate time-courses where the protein 
was quantified, with error bars denoting the standard error of the mean (SEM).   
Hierarchical clustering was performed using Cluster 3.0 on the average of the three time-
courses, with the FC at each time point compared to the average of the three mock 
samples. 
For clustering of viral proteins, the AraC channels were removed, and the data normalised 
to the maximum signal for each protein.  XLStat (Addinsoft) was used for k-means 
clustering, and each cluster was then subjected to hierarchical clustering using cluster 3.0. 
The 11 plex incorporating the MG132 and C6 deletion mutant data encompassed triplicate 
samples for WT infection, WT + MG132, and infection with a C6 deletion mutant.  P-
values were estimated using a Students two-tailed t-tests on the normalised data 
comparing either WT + MG132 or the C6 deletion mutant to the triplicate WT infection, 
and these were BH-corrected. 
Viral replication assays were performed and analysed by Dr Yongxu Lu (Smith lab).  
Experiments were performed in triplicate, and the data displayed is the mean ± SEM.  P-
values were estimated using a two-tailed t-test. 
Pathway analysis for identification of enriched categories of proteins was performed 
using the Database for Annotation and Visualisation and Integrated Discovery (DAVID) 
version 6.8 (Huang et al, 2009a, 2009b).  The set of proteins indicated in the text was 
searched against a background of all human proteins quantified in that experiment.    
 
2.10.3 Chapter 5: Candidate Antiviral Restriction Factors 
Overlap between IFN stimulated proteins and virally downregulated proteins was 
performed using the sensitive criteria for IFN stimulation described above, and viral 
downregulation from multiple datasets as described in the text.   
For all ‘single colour’ HCMV restriction assays, data is presented as the mean ± SEM, if 
triplicate data is available.  If the data is duplicate, error bars indicate the range and this 
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is specified in the figure legend.  P-values were estimated using a two-tailed Student’s t-
test comparing the percent infection in the three test samples to the three control samples. 
For two colour restriction assays, the restriction ratio is calculated as described in the text.  
Bar plots display the mean restriction ratio ± SEM where triplicate data is available.  P-
values were estimated using a paired two-tailed Students t-test, with paired samples 
representing the percent infection of the iRFP cells compared to the mCherry cells in each 
of the three replicate wells. 
 
2.11 Software Used 
Table 2.12 Table of software used 
Software Source Use 
MassPike Prof Steven Gygi, Harvard  Processing of raw MS data 
Excel Microsoft 
Data analysis, graph generation 
and t-tests 
XLStat Addinsoft 
K-means clustering, Fischer’s 
exact test 
Cluster 3.0 
Stanford University & 
University of Tokyo 
Hierarchical clustering 
Java Treeview Stanford University Visualising clustering results 
Perseus 
Max Planck Institute 
(Tyanova et al, 2016) 
Significance B for dot plots 
DAVID (Huang et al, 2009a, 2009b) Pathway enrichment analysis 
R (R Core Team, 2018) Beeswarm plot of VACV proteins 
Inkscape 0.92.4 https://www.inkscape.org Drawing of some schematics 
Powerpoint Microsoft Production of figures 
Word Microsoft Writing of thesis 
FlowJo vX Becton Dickinson Analysis of flow cytometry data 
Image Studio Lite LiCor Analysis of immunoblots 
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CHAPTER 3:  INTERFERON SCREEN 
The Effect of Interferon at the Surface of Primary Leukocytes  
 
3.1 Introduction and Aims 
3.1.1  Introduction 
IFN Stimulation of Primary Leukocytes 
Several previous ‘omics studies characterising the effects of IFN on leukocytes have 
been conducted.  However, many are at the transcriptomic level, or were constrained by 
the available proteomic technology at the time (Rusinova et al, 2013; Smiljanovic et al, 
2012; Schlaak et al, 2002) (see Introduction 1.3.4).  In this chapter, a proteomic screen 
investigating the effects of IFN2a at the surface of primary leukocytes in multiple 
donors is described.  This was intended both for the characterisation of the IFN response 
in these cell types, an important component of innate immunity, and for examination 
alongside data on viral infection to identify candidate ARFs (see Chapter 5).    
The investigation of primary cells was particularly important for this research.  The 
proteomes of primary cells differ from their cell culture equivalents, and the HIV 
accessory proteins (Vif, Vpr, Vpu and Nef) are necessary for maintaining a high viral 
load in vivo, whilst being dispensable for replication in cultured cell lines.  This suggests 
a disparity in the cells responses to infection (Kestler  3rd et al, 1991; Malim & Emerman, 
2008).  Analysis of primary cells was previously challenging, as metabolic labelling 
requires the cells to be maintained in culture for some time prior to analysis.  The use of 
labelling with chemical tags, such as TMTs, subsequent to cell lysis now makes 
quantitative comparative analysis in these cell types straightforward.  Additionally, 
previous research observed vast donor-to-donor variation across IFN responses in 
primary T cells (Schlaak et al, 2002) (see Introduction 1.3.4).  It was therefore important 
to perform these experiments in primary cells from multiple donors.  Again, the use of 
TMTs for multiplexing samples was ideal for this purpose.  
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Being at the interface between cells and their environment, PM proteins are well situated 
to be components of signalling pathways, to interact with pathogens, or to act as ARFs.  
PM proteins are pharmacologically important, acting as the targets of many drugs, and 
are often under-represented in whole cell proteomic experiments (Savas et al, 2011; Kar 
et al, 2017). This investigation therefore uses PM profiling proteomics to focus on the 
effects of IFN at the cell surface. 
The analysis presented here therefore substantially expands on previous investigations as 
it provides an unbiased exploration of the effects of IFN, without needing to pre-
determine the genes of interest as in microarrays.  Additionally, analysis was at the 
proteomic rather than transcriptomic level, focused specifically on cell surface effects, 
and considered primary cells across multiple donors.   
Cell Surface Proteome of Primary Monocytes and T cells 
As well as investigating the effects of IFN, this approach can also be used to investigate 
the cell surface proteome of the leukocytes.  Previous investigation of the surface of 
primary T cells in the Cell Surface Protein Atlas identified 270 proteins in the CD4+ 
CD25- subset of cells (Bausch-Fluck et al, 2015).  Another ‘omic investigation of the 
naïve T cell surface identified 173 proteins using MS, and this was extended to 229 
proteins using flow cytometry, though this was not quantitative (Graessel et al, 2015).  
This was further extended using bioinformatic analysis of transcriptomic data to identify 
proteins that may be localised at the cell surface.  The investigation here quantified 
substantially more proteins than these previous studies, and can furthermore be used to 
compare the surface proteome of the two primary cell populations. 
 
3.1.2 Summary 
In this chapter, a proteomic screen exploring the effects of IFN2a stimulation on the cell 
surface of primary monocytes and CD4+ T cells is presented, examining five donors for 
each cell type.  The cells were stimulated overnight with IFN2a, samples were enriched 
for PM proteins, and then subjected to TMT-based MS3 analysis.  Ten-plex TMT allowed 
multiplexing of the unstimulated and IFN-stimulated samples from each of the five 
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donors, for analysis in a single experiment.   This resulted in the quantification of 607 
annotated PM proteins from monocytes and 485 PM proteins from T cells, as well as 
more limited data on the effects of IFN on THP-1s (a cultured monocyte cell line), and 
on pan-monocyte populations extracted from two additional donors.  This provides an 
interesting dataset for the examination of the cell surface proteomes, as well as IFN-
induced changes, and variation between donors.  Transmembrane protein 123 
(TMEM123) was identified as being IFN-stimulated in all cell types and donors 
examined, and some attempts were made to validate this observation.  
 
3.1.3 Aims 
1) Use a proteomic screen to investigate the effects of IFN2a at the surface of 
primary leukocytes in: 
a. CD14+ Monocytes 
b. CD4+ T cells 
2) Analyse the data to characterise the cell surface proteome of these leukocytes. 
3) Analyse the data to identify IFN-induced changes at the cell surface of these 
primary leukocytes. 
4) Consider donor-to-donor variation within the data. 
5) Validate IFN stimulation of selected hits. 
6) Overlap this data with corresponding data identifying virally-induced 
downregulation of cell surface proteins to identify candidate ARFs (chapter 5). 
 
3.2 Validation of the Workflow for the IFN Proteomic Screen 
3.2.1 Experimental Outline 
To investigate the effects of IFNα at the surface of primary leukocytes, multiplexed 
quantitative proteomics using TMT-based mass spectrometry (MS) was employed (see 
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Introduction 1.5.2).  At the time of performing this experiment, multiplexing up to 10 
samples was possible (though this has now been extended to 16-plex), therefore primary 
leukocytes were isolated from five donors for each cell type, enabling both IFN-
stimulated and unstimulated samples from each donor to be analysed together in a single 
experiment.  Primary CD4+ T cells and primary monocytes were examined.  To obtain 
these, peripheral blood mononuclear cells (PBMCs) were extracted from leukocyte cones 
from the NHS blood and transplant service (NHSBT) for monocytes, and from peripheral 
blood for T cells.  Leukocyte cones provide a far greater number of PBMCs than a 50 ml 
peripheral blood donation, and were therefore used for extraction of monocytes, as these 
are usually present at relatively low abundance in the blood.  The desired cells types were 
enriched from the PBMCs using negative isolation methods.  They were then cultured 
overnight in the presence or absence of IFNα2a, before biotinylation of the cell surface 
glycoproteins and subsequent enrichment using streptavidin beads (see Introduction 
1.5.3).  These PM proteins were digested with trypsin, the 10 samples labelled with TMTs 
and subjected to MS3 analysis.  In this way, relative quantitation of PM proteins in each 
sample was obtained (Figure 3.1).     
 
Figure 3.1 Experimental workflow for PM proteomic analysis of primary leukocytes 
PBMCs were extracted from either leukocyte cones (monocytes) or peripheral blood (T 
cells) from five donors for each cell type.  Primary monocytes or T cells were enriched 
from the PBMCs by negative isolation, and then cultured overnight in the presence of 
absence of IFN.  PM proteins were enriched by biotinylation of cell surface glycoproteins 
and a pull-down with streptavidin beads.  Proteins were digested into peptides using 
trypsin, labelled with TMT, and pooled for MS analysis. 
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3.2.2 Validation of the Workflow on THP-1s 
The protocol was initially trialled on THP-1s, a cultured monocyte cell line.  In most 
experiments presented, the MS sample was first analysed as a ‘single shot’ (one or three 
hour run on the mass spectrometer), which was examined to ensure adequate labelling 
with the TMTs, and roughly equal amounts of protein in each channel, to avoid excessive 
electronic normalisation.  Following this, most samples were fractionated, separating the 
peptides into multiple samples, each of which were subjected to a separate MS run, 
enabling deeper coverage.  In the case of the THP-1 sample, only the single shot was 
performed as this provided enough data to quantify positive controls and validate the 
approach.  This quantified 720 proteins; 570 of these had a GO annotation of ‘plasma 
membrane’, ‘cell surface’, ‘extracellular’ or ‘short GO’, and were therefore considered as 
annotated PM proteins (Table 3.2).  31 PM proteins were upregulated more than 1.5 fold, 
including several positive controls, giving confidence in this approach (Figure 3.2).   
 
 
Figure 3.2 Cell surface changes in THP-1 cells upon IFN stimulation 
Scatter plot of IFN induced changes in the 570 annotated PM proteins quantified in Thp-
1 cells.  Benjamini-Hochberg (BH)-corrected significance B was used to estimate p-
values.  The positive controls HLA and BST2 are highlighted in bold. 
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Multiple HLAs were upregulated, along with the IFN-stimulated HIV restricted factor, 
BST2 (Neil et al, 2008).  AXL, a receptor tyrosine kinase, was also upregulated; this was 
previously reported to be stimulated by IFNα in macrophages, acting to suppress TNFα 
production (Sharif et al, 2006).  A smaller subset of 13 proteins were downregulated 1.5 
fold by IFNα, including the IFNAR1 component of the IFN receptor.  Proteolytic 
downregulation of IFNAR1 after signalling provides negative regulation of the IFN 
response (Zheng et al, 2011).  
 
3.3 Enrichment of Primary Leukocytes 
3.3.1 Optimisation of Primary Monocyte Enrichment  
Having validated some technical aspects of the screen on THP-1s, it was also important 
to optimise enrichment of the primary cells.  Two kits for enrichment of primary 
monocytes were trialled, examining both the yield and purity.  A sufficient number of 
cells were required in order to obtain enough material for MS analysis following the 
enrichment for PM proteins.  PBMCs were enriched from leukocyte cones obtained from 
the NHSBT by density gradient centrifugation over Ficoll, and then subjected to negative 
selection for CD14+ monocytes using either the Dynabeads Untouched Human 
Monocytes kit or the MACS Monocyte Isolation Kit II.  Both protocols involved 
incubation of the PBMCs with an antibody cocktail designed to bind cells other than 
CD14+ monocytes, which could then be removed using magnetic beads.  The Dynabeads 
protocol employs a magnet to remove previously added magnetic beads, whilst MACS 
utilises a column of beads through which the cells are passed.  This leaves just the desired 
population of cells.  The MACS kit yielded improved viability (Figure 3.3A, B) and purity 
(Figure 3.3C, D) of cells compared to the Dynabeads kit, and was therefore used for all 
further experiments. 
An additional level of optimisation was then performed on the MACS enrichment 
protocol.  The MACS negative selection kit uses biotin conjugated antibodies to label 
cells, which are then removed by passing through a column of microbeads which have 
anti-biotin monoclonal antibodies conjugated to them.  The initial protocol tested for 
MACS enrichment involved passing the cells through the MACS ‘LS’ column of 
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microbeads.  An additional trial was performed with the inclusion of an ‘LD’ column.  
The LD column is intended to be more stringent, removing even weakly bound cells, due 
to having a slower flow rate.  Only a small improvement in purity (~0.5 %) was observed 
following this additional step, however this was accompanied by a substantial reduction 
in yield of > 50 %, and it was therefore decided to omit this for further experiments. 
 
Figure 3.3 Comparison of methods for enrichment of primary CD14+ Monocytes by 
flow cytometry 
(A) Viability of CD14+ monocytes following enrichment using the Dynabeads 
Untouched Human Monocytes kit was ~ 89 %. 
(B) Viability of CD14+ monocytes following enrichment using the MACS Monocyte 
Isolation Kit II was ~ 94 %. 
(C) Purity of CD14+ cells was ~91 % using the Dynabeads kit 
(D) Purity of CD14+ cells was ~97 % using the MACS kit 
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3.3.2 Purity of Enrichment 
PBMCs were isolated from NHSBT leukocyte cones, and enriched for primary 
monocytes using the MACS Monocyte Isolation Kit II, as described.  For primary CD4+ 
T cells, PBMCs were isolated from 50 ml peripheral blood, and T cells enriched using 
the Dynabeads Untouched Human CD4 T Cells kit.   Purity was confirmed by cell surface 
flow cytometry with antibodies detecting CD14 (Figure 3.4A, B) or CD4 (Figure 3.4C, 
D) for monocytes and T cells respectively, prior to overnight IFN stimulation.  In all 
cases, a purity of ≥90 % was confirmed (Table 3.1). 
 
 
Figure 3.4 Analysis of purity of primary monocytes and CD4+ T cells  
Purity of the primary cells was examined by cell surface flow cytometry: 
(A) Analysis of CD14 expression in PBMCs from donor 3 prior to enrichment. 
(B) Analysis of CD14 expression in monocyte enriched population from donor 3. 
(C) Analysis of CD4 expression in PBMCs from donor 8 prior to enrichment. 
(D) Analysis of CD4 expression in T cells enriched population from donor 8. 
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Table 3.1 Pre- and post- enrichment cell purity  
Cell purity assessed by flow cytometry for CD14 (monocytes, left) or CD4 (T cells, right). 
Monocyte 
donors 
Pre-
enrichment 
% CD14+ 
Post-
enrichment 
% CD14+ 
 
CD4+ T cell 
donors 
Pre-
enrichment 
% CD4+ 
Post-
enrichment 
% CD4+ 
Donor 1 18 91  Donor 6 30 96 
Donor 2 26 93  Donor 7 45 91 
Donor 3 20 93  Donor 8 46 96 
Donor 4 22 92  Donor 9 20 96 
Donor 5 28 90  Donor 10 25 97 
 
3.4 Mass Spectrometry Analysis 
Raw MS files were processed, and contaminating proteins and matches to the reverse 
database were removed.  Prior to analysis, the data was digitally normalised to ensure 
equal loading in all channels.  This was done by scaling the signal:noise (S:N) values so 
that the total intensity was the same in each channel.  Additionally, as multiple donors 
had been analysed, a variety of HLA alleles were quantified; identification of the true 
MHC allele a peptide is derived from by MS is challenging, as many peptides are 
redundant to multiple alleles.  The S:N values were therefore summed to give a single 
quantitation for HLA-A, HLA-B, HLA-C and HLA-DRB1.   In the monocytes, 607 PM 
proteins were quantified, and 485 in the T cells (Table 3.2).  In both cases PM annotated 
proteins comprised ~60 % of the proteins quantified.  
Table 3.2 Number of proteins quantified in each cell type 
The ‘total number’ column gives all proteins quantified in the given cell type (excluding 
reverse hits and contaminants), whilst ‘annotated PM proteins’ were filtered according to 
GO annotations as described in section 3.2.2. 
Cell type 
Total number of 
proteins 
quantified 
Number of annotated 
PM proteins 
quantified 
Thp-1 720 570 
Pan monocyte 716 582 
CD14+ monocyte 989 607 
CD4+ T cells 798 485 
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3.5 Quantitative Analysis of the Cell Surface Proteome 
In order to investigate the composition of the cell surface proteome, a method based on 
‘intensity based absolute quantification’ (iBAQ, (Schwanhäusser et al, 2011)) was used.  
The maximum precursor intensity for all peptides contributing to a given protein were 
summed, before dividing by the theoretical number of tryptic peptides between 7-30 
amino acids in length for that protein.  This therefore generated a measure of abundance 
of a protein, by comparing its observed signal to what would be expected based on its 
size.  As this abundance is given in terms of the whole 10-plex, the value was scaled 
according to the signal detected in the five unstimulated samples compared to the total 
signal for that protein, to give an estimate of the proteins expression at the surface of 
unstimulated cells.   Classical class I and II MHCs were excluded from all abundance 
analysis to eliminate bias introduced by differentially expressed alleles between donors.    
 
3.5.1 Monocyte and T cell Surface Proteomes 
Just 17 proteins were found to contribute more than 1 % each to the cell surface proteome 
of monocytes, with the summed contribution from all 17 totalling ~75 % (Figure 3.5A).  
DAVID enrichment analysis compared these proteins to the background of all the PM 
proteins quantified in each cell type, and revealed enrichment of a single cluster, with 
terms including ‘cell adhesion molecules’ and ‘leukocyte migration’.  Proteins 
contributing to this cluster included integrin alpha-L (ITGAL) and integrin beta-2 
(ITGB2), which form the leukocyte function-associated antigen-1 (LFA-1), and some of 
its ligands, intracellular adhesion molecule (ICAM)-1 and ICAM3.  Furthermore, the four 
most abundant proteins composed half of the proteome: CD44, solute carrier family 2, 
facilitated glucose transporter member 3 (SLC2A3), leukosialin (SPN) and basigin 
(BSG).  In CD4+ T cells, 22 proteins contributed more than 1 % of the cell surface 
proteome, with the summed contribution from all 22 totalling 67 % (Figure 3.5B).  No 
enriched classes of proteins were identified here, but SPN and CD44 were again some of 
the most abundant proteins.   
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Figure 3.5 Cell surface proteome of primary monocytes and T cells 
Abundance of proteins was calculated using an approach based on iBAQ methodology  
(Schwanhäusser et al, 2011), and pie charts display the relative contribution of individual 
proteins to the surface of the cells.  Proteins contributing <1 % of the surface proteome 
are grouped into ‘other’. Classical class I and II MHCs were excluded from all abundance 
analysis to eliminate bias introduced by differentially expressed alleles between donors. 
(A) Primary monocyte surface proteome. 
(B) Primary T cell surface proteome. 
 
3.5.2 Comparison of Surface Proteomes 
Comparison of the 281 PM proteins quantified in both monocytes and CD4+ T cells 
(excluding classical HLAs) showed a positive correlation in protein abundance, with 
CD44 and SPN being particularly abundant in both cell types (Figure 3.6).  Other proteins 
were expressed to a greater extent on just one cell type, for example the monocyte marker 
CD14 was 36 fold more abundant on monocytes (ratio calculated based on percent 
contribution to surface proteome of each cell type), and signal regulatory protein alpha 
(SIRPA), a myeloid membrane receptor which interacts with CD47, was 32 fold more 
abundant on monocytes.  SLC2A3 (also known as glucose transporter (GLUT)-3), was 
previously reported as being 8.4 times more predominant in monocytes compared to 
lymphocytes, whilst GLUT1 (SLC2A1) was more predominant in lymphocytes (Fu et al, 
2004), in keeping with the data presented here.  In T cells, CD5 was present at a greater 
abundance. 
This comparison only includes proteins quantified in both the monocyte and T cell 
dataset.  There were some proteins, such as leucine rich repeat-containing 25 (LRRC25) 
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and C-type lectin domain family 12 member A (CLEC12A), which are known to be 
predominantly expressed in monocytes, and were only detected in the monocyte samples 
(Liu et al, 2018; Marshall et al, 2004).  However, absence of a protein in the dataset of a 
particular cell type does not necessarily indicate it was not present.  It may simply not 
have been detected by chance, particularly if the protein was present at low abundance. 
Another caveat of this data is that the populations of cells were not completely pure, so 
contaminants from cell types other than those studied might have affected the proteins 
quantified, though these were likely to appear at low abundance.  Additionally, if the 
population was naturally heterogeneous, for example the CD4+ T cells encompass 
multiple subsets (Okada et al, 2008; Caza & Landas, 2015), profiles from these subsets 
will be averaged out.  Some proteins present in just one subset may therefore appear at 
very low overall abundance, or a protein that was highly abundant on just a subset of cells 
(either T cells or contaminants), may appear at high abundance. 
 
 
Figure 3.6 Comparison of monocyte and T cell surface proteomes 
Comparison of the contribution of different proteins to the cell surface of primary 
monocytes and T cells.  281 proteins were quantified in both cell types.  Classical class I 
and II MHCs were excluded from all abundance analysis to eliminate bias introduced by 
differentially expressed alleles between donors. 
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3.5.3 Variation between Donors 
Using multiplexed proteomics also enabled the comparison of protein abundance across 
the five donors to assess variability between individuals.  In this case, the abundance 
values were scaled according to the intensity in the unstimulated sample from each of the 
five donors separately, compared to the total signal.  Both monocytes and T cells revealed 
remarkably invariant cell surface composition, and a strong positive correlation was 
observed for all pairwise comparisons (Figure 3.7).  
  
 
 
Figure 3.7 Variation of cell surface proteomes between donors 
Pairwise comparison of the relative contribution of each protein to the cell surface in an 
individual donor. The iBAQ values for each protein was scaled according to the 
unstimulated S:N for each donor, and the % contribution to the cell surface proteome 
calculated.   Classical class I and II MHCs were excluded from this analysis.   
(A) Comparison of cell surface proteomes between monocyte donors.  
(B) Comparison of cell surface proteomes between T cell donors. 
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3.6 The Effects of IFN at the Surface of Primary Leukocytes 
Characterising the IFN response at the PM of these primary cells is important both in 
terms of developing our knowledge of IFN, crucial for its use in therapies, and to 
understand IFN related autoimmune diseases, as well as for identification of novel ARFs.  
To this end, the IFN induced changes in primary monocyte and T cells were examined. 
The data was filtered to only include donors for a given protein if it was likely to be 
accurately quantified in both the stimulated and unstimulated channel.  In some instances, 
the proteins were detected at the level of noise in one channel for a donor, giving a low 
intensity value.  This could result in an artificially inflated FC.  In order to avoid this, if 
a channel included less than 2 % of the total signal for that protein, that donor’s data was 
removed for the given protein.  As some proteins were now quantified in fewer donors, 
this dataset was then further filtered to remove any proteins that did not have data for at 
least three donors.  This resulted in a final dataset of 606 proteins in monocytes and 482 
in the T cells. 
 
3.6.1 Monocytes 
CD14+ Monocytes 
Initial criteria considered the average IFN induced FC across all donors where a protein 
was quantified.  The average FCs were taken for all proteins quantified in the monocytes, 
this data was log transformed and the mean calculated, giving the mean overall FC.  
Proteins with an average FC more than 1 SD away from this mean were considered 
upregulated.  In the primary monocytes, 57 proteins fulfilled this criteria (Figure 3.8A, 
Table 3.3).  
It was clear from visual inspection of this that in some instances, a particularly high FC 
in one or two donors meant a high enough average to pass the filtering in proteins which 
were not consistently IFN-stimulated.  Although donor-to-donor variation was expected, 
and proteins which were not induced by IFN in all five donors might still have been of 
interest, the most robust hits should be identified by filtering for consistency.  A second 
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criteria was therefore imposed, requiring the proteins to be IFN-stimulated to any extent 
(FC > 1) in all donors where quantified (Figure 3.8B).  Of the proteins with an IFN 
induced FC > 1 SD away from the mean, 72 % were consistently upregulated in all 
donors.  This is considered as the ‘sensitive’ criteria for IFN modulation, and used for all 
further analysis, however a more ‘stringent’ list could be obtained by considering only 
those proteins that also have a BH-corrected p-value < 0.05.  Equivalent criteria were 
applied to identify downregulated proteins (Figure 3.8C), and identified 55 proteins that 
were consistently downregulated (Table 3.3).     
 
Table 3.3 Proteins modulated by IFN in primary monocytes and T cells 
The number of up and down regulated proteins are given for primary monocytes and 
CD4+ T cells, according to the stated criteria.  Following application of the filtering 
described at the start of section 3.6, 606 proteins were examined for monocytes, and 482 
for T cells. 
 
CD14+ Monocytes CD4+ T cells 
 Upregulated Downregulated Upregulated Downregulated 
Average FC > 1 SD from mean 57 65 42 45 
Sensitive criteria  
(average FC > 1 SD from mean, 
and FC > 1 in all donors) 
41 55 13 14 
Stringent Criteria  
(Sensitive criteria, with BH-
corrected p-value < 0.05) 
21 30 0 0 
 
The sensitive criteria for upregulated proteins included several well characterised IFN-
stimulated proteins, such as BST2, multiple HLAs and ISG15 (Figure 3.8).  ISG15 is a 
known IFN-stimulated, ubiquitin-like protein involved in modulating the immune 
response, and inhibiting viral replication through a range of mechanisms (reviewed by 
Perng & Lenschow, 2018).  It can be conjugated to target proteins by ‘ISGylation’, which 
may result in modulation of protein abundance, cellular localisation or formation of 
protein complexes.  In the case of the influenza A virus non-structural protein 1 (NS1) 
protein, ISGylation disrupts its nuclear localisation and interaction with host proteins, 
limiting its ability to interfere with the antiviral response.  ISGylation of human 
96 Chapter 3 – INTERFERON SCREEN   
papillomavirus (HPV) and HCMV proteins also restricts viral infection, whilst 
ISGylation of host proteins required for viral egress restricts HIV infection.  ISG15 can 
also modulate the host immune response, for example unconjugated ISG15 stimulates 
IFN production, and the IFN response is further modulated by interaction with STAT1 
and USP18 (Perng & Lenschow, 2018).   
Sialic acid binding Ig-like lectin 1 (SIGLEC1) and CD69 were also identified by the 
sensitive criteria for IFN stimulation. SIGLEC1 provides negative feedback, controlling 
production of IFN.  This is via recruitment of the E3 ubiquitin ligase TRIM27, resulting 
in degradation of TBK1  (Zheng et al, 2015).  CD69 is known to act downstream of type 
I IFNs in order to inhibit egress of lymphocytes, so they are retained in the responding 
lymphoid organ during an immune response (Shiow et al, 2006).   
Although monocytes are usually differentiated into DCs in vitro using granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4/TNF, in a 
previous study, monocytes stimulated with GM-CSF and IFN also showed 
characteristics of DCs.  This included increased expression of CD11c (integrin alpha-X, 
ITGAX), CD86, HLA-DR and C-C chemokine receptor type 7 (CCR7), all of which were 
observed in this data.  The TNF derived DCs expressed higher levels of genes involved 
in phagocytosis and adhesion, whilst the IFN derived DCs expressed greater levels of 
genes associated with migration (Santini et al, 2000; Korthals et al, 2007).   
Upregulation of CD86 and CD83, DC maturation markers, was also observed in a 
previous study where monocytes were stimulated by IFN2a only (Gerlini et al, 2008), 
and this was seen in the data presented here.  In this study, they also observed an increase 
in adhesion molecules.  The IFN2a stimulated cells did not acquire a dendritic 
morphology or as potent an ability to induce naïve T cell proliferation as GM-CSF/IL-4 
induced DCs.  However, the cells were able to present antigen and activate memory T 
cells. Gerlini et al. suggested that the CD83+ CD14+ non-dendritic APCs may have a 
role in stimulating a memory immune response.  Interestingly, they could not identify any 
CD83+ CD14+ monocytes in PBMCs from patients undergoing IFNtherapy, but they 
could find them in varicella skin lesion, where recruitment of plasmacytoid DCs results 
in a high level of type I IFN.  A more comprehensive analysis of these markers and 
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examination of the monocyte morphology following IFN stimulation may therefore be 
interesting to investigate whether there is any differentiation of the cells.  
 
Figure 3.8 IFN-induced changes at the surface of primary monocytes 
(A) FC is shown for all proteins with an average IFN induced FC > 1SD away from 
the mean in primary monocytes.  Dots display the FC in each donor for the 
given protein, and the line is average FC.  Proteins which contributed less than 
2 % of the overall S:N in either the IFN-stimulated or unstimulated channel 
have been removed for the given donor.  Those that were not upregulated in all 
donors are shown in grey.  P-values were estimated using a BH-corrected paired 
two-tailed t-test on log transformed data; *p<0.05.  
(B) FC of proteins upregulated by IFN stimulation in primary monocytes.  As in 
(A) but with additional filtering to only show proteins consistently upregulated 
in all donors.   P-values were estimated using a BH-corrected paired two-tailed 
t-test on log transformed data; *p<0.05. 
(C) FC of proteins consistently downregulated by IFN in primary monocytes, 
filtered as in (A) and (B).  P-values were estimated using a BH-corrected paired 
two-tailed t-test on log transformed data; *p<0.05. 
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THP-1s 
Although the THP-1 sample (section 3.2.2) was not fractionated, so fewer proteins were 
quantified, an initial examination of this with the primary monocyte data could provide 
an interesting comparison between a primary cell type and its cultured equivalent.  
Previous research has shown that THP-1 cells express a lower level of CD14 than primary 
monocytes, and therefore show a reduced response to LPS, as measured by the production 
of IL-8.  Overexpression of CD14 in the THP-1s increased the level of IL-8 production 
in response to LPS, though did not entirely rescue it.  Additionally, whereas heparin 
enhances the LPS induced IL8 release in primary monocytes, it did not have the same 
effect in THP-1s (Bosshart & Heinzelmann, 2016).  This suggests that there are further 
differences in this pathway between the primary and cultured cells, and this may extend 
to other cellular responses.   
There were 357 proteins quantified in both the THP-1 and primary monocyte datasets 
(Figure 3.9).  Of these, 11 proteins were commonly upregulated (SIGLEC1, interleukin 
2 receptor subunit alpha (IL2RA), CD274, BST2, TMEM123, FAS and multiple HLAs), 
and 2 commonly downregulated (IFNAR1 and proto-oncogene KIT).  Several proteins 
showed changes in either THP-1s or primary monocytes, but not the other, though in 
some cases this may be due to the threshold applied (sensitive criteria for primary 
monocytes, 1.5 FC for THP-1s), or the requirement for consistency between the donors.  
There are however, many more proteins modulated in the primary cells.  CD59, a 
complement regulatory protein involved in inhibiting the membrane attack complex (Kim 
& Song, 2006), was the only protein to show conflicting regulation, being downregulated 
in the primary monocytes and upregulated in the THP-1s.   
Repetition of the THP-1 proteomic experiment presented here and perhaps more primary 
cell donors would be required, along with fractionation of the THP-1 sample, for a more 
thorough and meaningful comparison.  Additionally, it would be interesting to examine 
the primary cells alongside the cultured cells in the same multiplex experiment, to allow 
a more direct comparison of the relative abundance of different proteins.    
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Figure 3.9 IFN-induced changes in primary monocytes and cultured THP-1s 
Proteins were defined as being modulated by IFN in the primary monocytes if they met 
the ‘sensitive criteria’ (FC > 1 SD from the mean, and FC > 1 in all donors for 
upregulation), and were regulated in THP-1s if they had a FC > 1.5. 
 
Pan Monocytes 
In addition to the CD14+ monocytes from five donors, pan-monocyte populations were 
also examined from two more donors.  As with the THP-1s, this sample was not 
fractionated so does not provide a complete dataset, but is useful for comparison and 
validation of the larger dataset.  Whilst the MACS Monocytes Isolation Kit II extracted 
predominantly classical monocytes,  pan-monocyte populations were enriched using the 
MACS Pan Monocyte Isolation Kit, which isolated classical (CD14++, CD16-), 
intermediate (CD14++, CD16+) and non-classical (CD14+, CD16++) monocyte 
populations.  The same ‘sensitive’ filtering used previously was applied to the pan-
monocytes to identify IFN modulated proteins (>1SD away from the mean and 
upregulated in both donors).  As there were only two donors, no p-values were calculated 
and therefore ‘stringent’ filtering was not applicable.  Of the proteins quantified in both 
CD14+ and pan- monocyte populations, 80 % of the proteins consistently upregulated in 
the CD14+ monocyte samples were also upregulated in pan monocytes (Figure 3.10A), 
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providing confidence in the data.  Many of the proteins most dramatically downregulated 
by IFN in the CD14+ monocytes were also downregulated in the pan monocyte 
population, though often to a lesser extent (Figure 3.10B). 
  
 
Figure 3.10 IFN induced changes at the surface of primary pan-monocytes 
(A) IFN induced changes in pan-monocyte cells of proteins which were determined 
to be upregulated in the CD14+ monocytes (as in Figure 3.8B). 
(B) IFN induced changes in pan-monocyte cells of proteins which were determined 
to be downregulated in CD14+ monocytes (as in Figure 3.8C). 
 
Comparison to Transcriptomics 
The Interferome provides a database of the effects of IFN on various cell types, at the 
transcriptomic level (Rusinova et al, 2013).  Searching for previous datasets in the 
Interferome which investigated the effects of IFN on monocytes identified one 
transcriptomic study (ID 306)  (Smiljanovic et al, 2012).   This study used microarrays to 
examine the effects of IFN2a, IFN and TNF treatment for 1.5 h on primary monocytes 
from healthy donors, or patients with RA or SLE.  Smiljanovic et al. generated profiles 
of cytokine signatures so these could be compared to disease signatures.  As this is a 
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transcriptomic study at a much earlier time point, and does not have the same enrichment 
for proteins expressed at the cell surface, some differences would be expected.  However, 
this data was exported from the Interferome for a limited comparison.   
In the Interferome data, multiple FCs were given for a single gene (from different probes 
on the microarray).  An average was taken in these cases, to generate a single FC for each 
gene, and these were compared to the proteomic data generated here according to the gene 
name.  Proteomic data was determined as being up or down regulated based on the 
‘sensitive’ criteria described previously.  A gene was considered to be modulated by IFN 
in the transcriptomic data if it was > 2 fold up or down regulated; this is the default cut 
off for IFN modulation by the Interferome.  Note also, when searching the Interferome 
for a given gene, it only returns data where the difference in expression is significant at 
the FC searched for (p < 0.05).  Therefore, ‘no change’ here means a FC < 2, but the p-
value would still be significant; proteins, or some probes for given proteins, which truly 
showed ‘no change’ may therefore not show up in this comparison.  For a complete 
comparison the data would need to be reanalysed more carefully, but here an initial 
overview is presented. 
There were 250 proteins quantified in both datasets, the majority of which were not 
modulated by IFN in either study.  Of these, 12 were commonly upregulated, including 
ISG15, SIGLEC1 and CD274.  Two proteins were commonly downregulated, C5a 
anaphylatoxin chemotactic receptor 1 (C5AR1) and sodium/myo-inositol cotransporter 
(SLC5A3).  Additionally, there were four proteins which were downregulated in this 
study and upregulated in the transcriptomic data.  There were also a subset of proteins 
which were modulated by IFN in one study, but not the other.  Several HLA-DR proteins 
were upregulated in the proteomic data but not the transcriptomic data. IFN-induced 
upregulation of MHC class II has been previously observed in monocytes, though to a 
lesser extent than with IFN(Keskinen et al, 1997).  In some cases, the discrepancy may 
be due to the thresholds applied.  For example, BST2 is a known IFN-stimulated protein, 
and in this comparison does not appear as IFN-stimulated in the transcriptomic data, as it 
falls slightly below the two-fold cut off employed.  Additionally, some differences may 
be expected due to the comparison of transcript and protein levels, as well as different 
donors, and differences in the IFN concentration and time point.       
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Figure 3.11 Comparison of proteins modulated by IFN in transcriptomic and proteomic 
data 
Proteins from the proteomic data presented here were defined as up or downregulated 
according the sensitive criteria previously defined.  Transcriptomic data was from 
(Smiljanovic et al, 2012) and genes were considered to be up or downregulated if they 
had an average FC>2 (though genes with FC < 2 would still have p<0.05 to be included 
in dataset). 
 
3.6.2 CD4+ T Cells 
Applying the same ‘sensitive’ filtering used for the monocytes, a much smaller subset of 
proteins were consistently up or down regulated in CD4+ T cells (Figure 3.12, Table 3.3).  
Again, this included positive controls such as BST2 and HLAs.  Applying a BH-corrected 
paired two-tailed t-test did not identify any of the changes in T cells as being statistically 
significant, despite being consistent amongst the five donors.  This may be due to over 
stringency of the multiple testing correction in the context of this proteomic data 
(Pascovici et al, 2016).  It may also be partially due to heterogeneity in the population of 
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T cells.  Additionally, although consistent, the FCs were on a small scale of magnitude, 
and the majority of proteins do not show consistent changes in abundance upon IFN 
stimulation.  Despite this, identification of positive controls provides some confidence in 
the data.  
A small subset of proteins were downregulated by IFN, including the IL-6 receptor 
(IL6R).  This has previously been reported to be downregulated by IFNin myeloma 
cells, where it prevents IL6 induced growth (Schwabe et al, 1994).  Of the proteins 
identified as being upregulated by IFN, the IL-1 receptor antagonist (IL1RN) is also 
known to be regulated by IFN and is involved in modulating the inflammatory response 
(Arend et al, 1998; Liu et al, 1998), and C-type natriuretic peptide (CNP) is a known ISG 
involved in inhibiting HIV particle assembly (Wilson et al, 2012).   
Some of the upregulated proteins have less well characterised relationships with IFN.  
Potassium voltage-gated channel subfamily A member 3 (KCNA3) is a heavily 
glycosylated 64 kDa protein with 6 transmembrane domains, which forms a 
homotetrameric complex.  It is the major potassium channel responsible for regulation of 
the resting membrane potential and calcium signalling in T cells, with roles in T cell 
activation and proliferation, as well as IL-2 production (Spencer et al, 1997; Zhu et al, 
2012; Shah et al, 2003).  KCNA3 has previously been shown to be upregulated by JAK2, 
providing further evidence for its regulation by IFN (Hosseinzadeh et al, 2015).  Probable 
G-protein coupled receptor 171 (GPR171) was also IFN-stimulated in this data.  GPR171 
is part of a family of proteins activated by extracellular nucleotides; It is suggested to be 
a negative regulator of myeloid differentiation (Rossi et al, 2013), and was identified as 
the receptor for BigLEN, a neuropeptide involved in food intake and metabolism (Gomes 
et al, 2013).  GPR171 is also overexpressed in lung carcinoma tissues and thought to be 
involved in metastasis and migration (Dho et al, 2016).   
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Figure 3.12 IFN induced changes at the surface of primary CD4+ T cells 
FC of proteins up or downregulated in primary T cells.  All proteins displayed had a FC 
> 1 SD from the mean, and were up or downregulated in all donors where quantified.  A 
BH-corrected paired, two-tailed t-test did not identify any significantly modulated 
proteins. 
 
Comparison to Transcriptomics 
A previous investigation by Schlaak et al. (2002) used an array of 150 genes to investigate 
transcript level changes in expression of ISGs in various cells lines (fibrosarcoma 
HT1080, hepatoma HepG2 and HuH7, and T cell lymphoma Kit255), as well as primary 
T cells and DCs from several donors, upon stimulation with IFN2a.  There were 45 
genes stimulated in at least one of the T cell donors in the Schlaak et al data.  Of these, 
16 were annotated PM proteins, and 4 of those were quantified in the CD4+ T cell data 
presented here (BST2, ISG15, collagen alpha-2 (COL1A2), and complement C1r 
subcomponent (C1R)).  BST2 was upregulated in all donors in both datasets, and ISG15 
was upregulated in all five donors in the Schlaak data, and 3/5 in this dataset.  COL1A2 
was upregulated in 1/5 donors in the Schlaak data and 2/5 here, whilst C1R was 
upregulated in 2/5 donors in the Schlaak data and none here.  There are therefore several 
proteins showing concordant data between the proteomic and transcriptomic studies, with 
donor-dependent IFN stimulation.  However, there is not enough overlapping data for a 
large comparison.  
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3.6.3 Comparison of Monocytes and T cells 
The profile of IFN responses between monocytes and T cells appears quite different.  
There were 284 proteins quantified in both experiments, the majority of which were not 
IFN-stimulated in either cell type.  Applying the sensitive filtering criteria (FC > 1SD 
from the mean, and FC > 1 in all donors), 11 proteins were IFN-stimulated exclusively in 
monocytes, 4 only in T cells, and 5 were commonly IFN-stimulated.  These included the 
known HIV restriction factor BST2, HLA-C, E and F, and TMEM123 (Figure 3.13, Table 
3.4).  TMEM123 was also IFN-stimulated in samples from both pan-monocyte donors, 
and in the THP-1s.  This is discussed further in section 3.8.    
 
Figure 3.13 Overlap between IFN-stimulated proteins in monocytes and T cells 
The proteins upregulated by IFN in primary monocytes and T cell was compared amongst 
the 285 proteins which were quantified in both datasets.  Proteins were determined to be 
upregulated by IFN based on the sensitive criteria described previously and in Figure 
3.8B. 
 
Table 3.4 Proteins commonly modulated by IFN in monocytes and T cells 
The FC in abundance of commonly modulated proteins upon IFN stimulation (IFN-
stimulated / unstimulated) is given for each donor.  Note, BST2 was only quantified in 
three donors in the T cell sample.  D1 is donor 1, ‘-’ indicates the protein was not 
quantified. 
   CD14+ Monocytes FC upon IFN stimulation CD4+ T cells FC upon IFN stimulation 
  D1 D2 D3 D4 D5 Average D6 D7 D8 D9 D10 Average 
BST2 4.6 5.7 2.0 3.3 2.6 3.6 1.9 2.0 2.5 - - 2.2 
HLA-C 1.5 1.9 1.7 1.8 1.5 1.7 1.0 1.5 1.1 1.3 1.6 1.3 
HLA-E 1.6 2.4 1.6 1.9 1.5 1.8 1.1 1.3 1.2 1.1 1.6 1.3 
HLA-F 1.8 2.3 2.0 2.3 1.7 2.0 1.0 1.4 1.2 1.2 1.5 1.3 
TMEM123 2.3 2.8 1.7 2.1 1.4 2.1 1.1 1.8 2.7 1.9 2.5 2.0 
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Many more proteins changed in abundance in the monocytes compared to the T cells.  
This may be in part due to having quantified a greater number of proteins in the 
monocytes than in the T cells, however, 16 % of the proteins quantified in the monocytes 
were modulated by IFN, compared to 6 % of those in the T cells.  Therefore, it may also 
be a biologically relevant phenomenon.  A previous publication considered TNF pre-
treatment, followed by IFN stimulation of monocytes and T cells at the transcriptomic 
levels using microarrays.  Henig et al. also observed more proteins to be involved in the 
IFN response in monocytes than T cells (Henig et al, 2013).  Interestingly, they observed 
similar numbers of up and downregulated proteins in monocytes, whilst more were 
upregulated than down in T cells.  Here, similar numbers of proteins change in both 
directions in both cell types.  As this was a transcriptomic study, with a different subtype 
of IFN (and pre-treatment with TNF), not looking specifically at the cell surface, 
completely concordant results would not necessarily be expected. Encouragingly 
however, they also identified CD38 as a protein which was IFN-stimulated in monocytes 
but not T cells, and validated this by flow cytometry.   
Another study by Aso et al. combined transcriptomic data from multiple sources, 
examining stimulation with type I IFNs ( and ) on various HIV target cell types 
(monocytes, monocyte-derived macrophages and T cells) (Aso et al, 2019).  This 
included several RNA sequencing and microarray studies, including the previously 
discussed research by Smiljanovic et al.  They observed more proteins changing in 
abundance upon IFN stimulation of monocytes compared to T cells.  Examining the ISGs 
that were common to both cell types, they also saw a greater magnitude of FCs in the 
monocytes.  Aso et al. identified 1495 proteins which they defined as ISGs in at least one 
of the cell types, including 124 ISGs in T cells, 567 in monocytes and 1336 in monocyte-
derived macrophages.  Overlap between the proteomics data here and the meta-analysis 
by Aso et al. showed some commonly identified ISGs, and many commonly identified 
‘non-ISGs’ (Figure 3.14).  Encouragingly, Aso et al. identified TMEM123 as an IFN-
stimulated protein in monocytes and monocyte-derived macrophages, however they did 
not find it to be IFN-stimulated in T cells.   
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One reason for the limited overlap may be the way the data was combined from multiple 
studies for each cell type by Aso et al., incorporating primary and cultured cell lines, and 
various type I IFNs.  Somatostatin receptor type 2 (SSTR2) for example is designated as 
a non-ISG for monocytes, despite being 3.4 fold IFN-stimulated in primary monocytes 
by IFN (data in this meta-analysis from the Smiljanovic study), as it was not IFN-
stimulated in other studies incorporated in this analysis; however, these other studies used 
IFN or cultured monocyte cell lines.   IL1RN was designated a non-ISG in T cells for 
similar reasons.  Likewise, ISG15 was identified as an ISG in T cells by Aso et al., but 
has not be counted as one in T cells in this study, despite having an average FC of 3.5, 
due to  not being IFN-stimulated in two of the donors.  A more thorough future 
comparison could investigate the individual contributing datasets from the Aso et al. 
research, and less stringent criteria for IFN stimulation in this proteomics data. 
Nonetheless, the global conclusions regarding more IFN responsive genes in monocytes 
compared to T cells, and changes of greater magnitude, are interesting, and in keeping 
with the observations here.   
 
 
Figure 3.14 Comparison of proteomics data to transcriptomic meta-analysis 
The proteomic data presented here for monocytes and T cells was compared to data by 
Aso et al. (2019), which combined multiple RNA sequencing and microarray based 
studies to look at IFN stimulation of monocytes and T cells (both primary and cultured 
cells) with type I IFNs.  Proteins were considered as ISGs in this study if they met the 
sensitive criteria. 
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3.6.4 Variation between Donors 
Importantly, there did not appear to be a systematically greater effect of IFN in some 
donors than other, the pattern of IFN-induced FCs appeared random (Figure 3.15).  
However, unlike the relatively invariant cell surface proteome, the IFN induced changes 
appeared to be more variable between donors, with a particularly low correlation 
coefficient in T cells (Figure 3.16).    The particularly low correlation in the T cells may 
also be due, in part, to the majority of proteins not showing substantial changes in 
abundance upon IFN stimulation.  Therefore, many of the proteins have small fluctuations 
around zero.  Additionally, it could be influenced by different IFN responses of various 
T cell subsets.      
However, a high level of variability in the IFN response between donors has been reported 
previously in primary leukocytes (Schlaak et al, 2002).  In this instance, the cDNA array 
examined included 150 genes, composed of known ISGs and genes of interest.  Of the 
150 genes, 45 were induced >2 fold in at least one T cell donor, but only 10 were induced 
in all 5 donors.  DCs were examined from three donors, and were also variable, though 
slightly less so than the T cells.  Replicates of the cell line data however, were very 
reproducible, suggesting this is an effect of the donor variability, rather than the 
technique.  It is also well established that the side effects and efficacy of IFN-therapy for 
viral hepatitis and cancer treatment are highly variable, suggesting differences between 
individuals (Cornberg et al, 2010; Ji et al, 2003; Lens & Dawes, 2002).   Schlaak et al. 
suggest that variation between donors may be due to differential activation of STATs and 
IFN signalling pathways, or single nucleotide polymorphisms in the promotors or coding 
regions of IRFs, JAK or STAT proteins.  This suggests further examination of proteins 
upregulated in just a subset of donors may still be valuable.  Whilst just 13 proteins meet 
the sensitive criteria for consistent upregulation in T cells in this proteomic dataset, 112 
proteins were upregulated more than 1.5 fold in at least one donor.   
 
3.6 The Effects of IFN at the Surface of Primary Leukocytes 109 
 
Figure 3.15 IFN-induced changes in individual donors of modulated proteins 
(A) Proteins upregulated by IFN in monocytes, as in Figure 3.8A. 
(B) Proteins consistently upregulated by IFN in monocytes, as in Figure 3.8B. 
(C) Proteins consistently downregulated by IFN in monocytes, as in Figure 3.8C. 
(D) Pan-monocyte data on proteins upregulated in monocytes, as in Figure 3.10A. 
(E) Pan-monocyte data on proteins downregulated in monocytes, as Figure 3.10B. 
(F) Proteins up or downregulated in primary CD4+ T cells, as in Figure 3.12. 
110 Chapter 3 – INTERFERON SCREEN   
 
Figure 3.16 Variation in IFN induced changes between donors 
Comparison of the IFN induced changes of each protein between donors, applying the 
same filtering as described for Figure 3.8B, for monocytes and T cells. 
(A) Pairwise comparison of IFN induced proteomic changes between monocyte 
donors.  
(B) Pairwise comparison of IFN induced proteomic changes between T cell donors. 
 
3.7 Validation 
A subset of the proteins upregulated in primary monocytes, for which cell surface flow 
cytometry antibodies were readily available, were selected for validation (Figure 3.17A).  
The IFN stimulation of the well characterised ISG and HIV restriction factor BST2 was 
demonstrated by both the proteomic data and by flow cytometry (Figure 3.17B).  Other 
proteins were also validated by cell surface flow cytometry, including CD38 which is 
involved in cell adhesion, migration and calcium signalling (Frasca et al, 2006), and 
SIGLEC1 which provides negative feedback, controlling production of IFN (Zheng et al, 
2015) (Figure 3.17C).    
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Figure 3.17 Validation of proteomic data on IFN stimulation of primary leukocytes 
(A) Proteomic data on a subset of proteins that were IFN-stimulated in monocytes. 
(B) Flow cytometry analysis of BST2 expression at the surface of primary 
monocytes (top) and CD4+ T cells (bottom), indicating IFN stimulation. 
(C) Validation by flow cytometry of a selection of proteins stimulated by IFN from 
the proteomic data (as in A).  CD69, CD38, CD40, SIGLEC1 and CD274 were 
examined in primary monocytes from one donor, whilst SLAMF7 was from a 
second donor.   Red and blue lines show unstimulated and IFN-stimulated cells 
respectively.  For SLAMF7 the grey line represents a control stained with the 
secondary antibody only.  For all other samples, the antibody was conjugated 
to the fluorophore and the grey line represents the signal from an unstained 
sample. 
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3.8 TMEM123 
3.8.1 IFN Stimulation of TMEM123 
Aside from HLAs and the known HIV restriction factor BST2, TMEM123 was the only 
protein upregulated in both monocytes and T cells, in all donors where quantified (Figure 
3.13, Figure 3.18A).  It could therefore provide a pan-leukocyte marker for IFN 
stimulation, and may have as yet unrecognised roles in the immune response.  IFN 
stimulation was validated by RT-qPCR in THP-1 cells (Figure 3.18B). 
 
Figure 3.18 Validation of IFN stimulation of TMEM123 
(A) FC in abundance of TMEM123 upon IFN stimulation in each cell type 
examined by proteomics. 
(B) RT-qPCR validating IFN stimulation of TMEM123 in THP-1s. 
 
3.8.2 TMEM123 
Comparison of the IFN-stimulated proteins identified in monocytes and T cells revealed 
that the only protein upregulated in both cell types, aside from HLAs and the known HIV 
restriction factor BST2, was TMEM123.  This protein may therefore be of interest as a 
pan-leukocyte marker of IFN stimulation.  TMEM123 was originally identified by 
immunising mice with apoptotic jurkat cells and examining the antibodies raised.  It is a 
type I transmembrane protein of 189 amino acids, with a molecular mass of 19 kDa, 
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though the observed mass varies substantially due to having many glycosylation sites.  
TMEM123 is also known as Porimin, as the antibody was found to cause pore formation 
at the PM in jurkats, inducing oncotic cell death.  This particular form of cell death 
involves cell swelling and aggregation, formation of pores and membrane blebbing, but 
without DNA fragmentation or apoptotic bodies.  It is unclear what biological stimulus 
could lead to porimin induced oncotic cell death.  Cos7 and 293T cells transfected with 
porimin lost the ability to adhere to culture dishes, suggesting it may additionally be 
involved in cell adhesion, but these 293T cells did not undergo oncotic cell death 
following application of the anti-TMEM123 antibody (Zhang et al, 1998; Ma et al, 2001). 
   
3.8.3 Testing of TMEM123 Antibodies 
Since its identification in 1998, and cloning in 2001, TMEM123 has featured in very few 
publications.  It was originally characterised using an in-house antibody, and we were not 
able to gain access to this (Zhang et al, 1998; Ma et al, 2001).  Four different antibodies 
were tested (Table 3.5).  The R&D antibody was conjugated to AF647, so was only tested 
for flow cytometry, whilst the others were tested for flow cytometry and immunoblot.  
Six different TMEM123 shRNA knockdown cell lines were produced in THP-1 cells, and 
validated by qPCR, and two of these were selected for testing of the antibodies.  These 
had a 97 % and 83 % knockdown (Figure 3.19). 
 
Figure 3.19 shRNA knockdowns of TMEM123 
RT-qPCR validation of TMEM123 knockdown in two different shRNA THP-1 cell lines 
compared to a control shRNA.  Knockdown was 97 % in TMEM123_sh1 and 83 % in 
TMEM123_sh2. 
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Table 3.5 Table of antibodies trialled for detection of TMEM123 
Four antibodies were trialled for detection of TMEM123 by cell surface or intracellular 
flow cytometry and immunoblot.  Applications tested by supplier: flow cytometry (FCM), 
immunohistochemistry (IHC), western blot (WB), immunofluorescence (IF).  Residues 
were given in terms of: the 208 amino acid long isoform 1 (iso1), isoform 2 which is 
missing residues 34-52 (iso2), or an epitope within the stated region of mouse TMEM123 
for the Santa Cruz antibody (mouse). 
Supplier 
Product 
Code 
Species 
Polyclonal or 
Monoclonal? 
Residues 
Raised Against 
Applications 
Tested by 
Supplier 
R&D FAB3010R Mouse Monoclonal 27-149 (iso2) FCM 
Santa Cruz SC-377295 Mouse Monoclonal 81-113 (mouse) WB, IF 
Abcam ab81423 Rabbit Polyclonal 145-194 (iso1) WB 
Novus NB100-56371 Rabbit Polyclonal 173-188 (iso2) WB, IHC 
 
Cell Surface Flow Cytometry 
As the proteomic screen considered PM proteins, cell surface flow cytometry would be 
the ideal technique for validation and further experiments.  Unfortunately, in all cases, 
the signal in the knockdown was the same as that in the control (Figure 3.20).  Residues 
27-166 of TMEM123 are extracellular, equivalent to residues 27-147 of isoform 2, a 
splice variant where residues 34-52 are missing.  Therefore, the Novus antibody would 
not be expected to detect this extracellular region and work for cell surface flow 
cytometry.  Likewise many of the potential epitopes for the polyclonal Abcam antibody 
may not be extracellular. 
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Figure 3.20 Testing TMEM123 antibodies on shRNA knockdowns THP-1 cells by cell 
surface flow cytometry 
Four different primary antibodies were incubated with THP-1 cells expressing either a 
control shRNA or one targeting TMEM123.  For (B) - (D), unconjugated antibodies were 
used.  Although control samples were included where they were only stained with a 
secondary antibody, this was on IFN-stimulated cells, so the data is not shown, but good 
separation was observed.    
(A) R&D antibody for TMEM123.  This antibody was conjugated to AF647. 
(B) Santa Cruz antibody for TMEM123.  The sample was additionally stained with 
an anti-mouse secondary conjugated to AF647. 
(C) Abcam antibody for TMEM123.  The sample was additionally stained with an 
anti-rabbit secondary conjugated to AF647. 
(D) Novus antibody for TMEM123.  The sample was additionally stained with an 
anti-rabbit secondary conjugated to AF647. 
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Intracellular Flow Cytometry 
The antibodies were additionally all tested for intracellular flow cytometry.  The same 
signal was again observed for the shRNA knockdowns and the control THP-1s, 
suggesting the antibodies do not detect TMEM123 by flow cytometry. 
 
Figure 3.21 Testing TMEM123 antibodies on shRNA knockdown THP-1 cells by 
intracellular flow cytometry 
THP-1 cells expressing either a control shRNA or one targeting TMEM123 were fixed 
and permeabilised, before being stained with one of four different antibodies for 
TMEM123.      
(A) R&D antibody for TMEM123.  This antibody was conjugated to AF647. 
(B) Santa Cruz antibody for TMEM123.  The sample was additionally stained with 
an anti-mouse secondary conjugated to AF647. 
(C) Abcam antibody for TMEM123.  The sample was additionally stained with an 
anti-rabbit secondary conjugated to AF647. 
(D) Novus antibody for TMEM123.  The sample was additionally stained with an 
anti-rabbit secondary conjugated to AF647. 
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Immunoblot 
The Novus, Santa Cruz and Abcam antibodies were tested for detection of TMEM123 by 
immunoblot.  This was initially performed on lysates made using RIPA or 2 % SDS, with 
60 µg of protein being separated by gel electrophoresis, and transferred using a semi-dry 
system (Figure 3.22A).  There were no bands detected using the Santa Cruz antibody, and 
multiple bands were observed using the Novus and Abcam antibodies. 
On subsequent gels, 20 µg of protein was loaded in order to reduce noise.  Additionally, 
the standard protocol involved denaturation of the protein by boiling at 95 °C for 5 mins.  
In the case of membrane proteins this can lead to aggregation, so heating at 60 °C for 20 
mins or 37 °C for 30 mins was also tested.  This was initially attempted using the semi-
dry transfer system again, however the Novus antibody performed similarly, and Abcam 
and Santa Cruz staining did not show any bands.  As no bands were seen with the Santa 
Cruz antibody on either test, it was not used again. 
The same experiment was then performed using a wet transfer system (Figure 3.22B).  In 
this case, the Novus antibody again produced many bands, with none at the expected size 
described by the supplier (Figure 3.22C), or correlating to the expected control and 
knockdown expression levels.  The Abcam antibody provided some more promising 
results using RIPA lysates, with bands that seem to correlate to the control and 
knockdown.  However, these bands suggest a much larger protein than expected, and the 
results were not always recapitulated when repeating using other lysates.  
TMEM123 has a predicted molecular mass of ~19 kDa.  Both the Novus and Santa Cruz 
example immunoblots (from the websites) suggest bands are detected at a substantially 
higher molecular weight, whilst the Abcam example probes a placenta lysate and detects 
a protein ~25 kDa.  When TMEM123 was originally cloned, immunoblot analysis of 
transfected 293, Cos7 and HeLa cells found the molecular mass ranged from 55 kDa to 
80 kDa, and an endogenous molecular mass of 110 kDa was confirmed in Jurkat cells.  It 
was suggested that the differences were likely due to glycosylation (Ma et al, 2001).  It 
is therefore difficult to determine whether the band observed using the Abcam antibody, 
or any of the ones seen using the Novus antibody, are at the correct molecular mass to 
indicate detection of TMEM123 in THP-1s. 
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Figure 3.22 Testing TMEM123 Antibodies on shRNA knockdown THP-1 cells by 
Immunoblot 
(legend on next page) 
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Figure 3.22 Testing TMEM123 Antibodies on shRNA knockdown THP-1 cells by 
Immunoblot 
(A) An shRNA control cell line (control_sh3) and TMEM123 knockdown cell lines 
(TMEM123_sh1 and TMEM123_sh2), were lysed using either RIPA or 2 % 
SDS, and then boiled at 95 °C for 5 mins.  60 µg of protein from each lysate 
was separated by gel electrophoresis before transfer using a semi-dry transfer 
system.  One membrane was stained with Novus anti-TMEM123 (rabbit) and 
Santa Cruz anti-TMEM123 (mouse), whilst the other was stained with Abcam 
anti-TMEM123 (rabbit) and anti-GAPDH (mouse).  The dark line between the 
RIPA and SDS lysates indicates where superfluous lanes in the gel have been 
digitally removed. 
(B) Cells expressing a control shRNA (sh3) or TMEM123_sh1 were lysed using 
either RIPA or 2 % SDS, and then incubated at 95 °C for 5 mins, 60 °C for 20 
mins or 37 °C for 30 mins (as indicated).  20 µg of proteins from each lysate 
was separated by gel electrophoresis, and proteins were transferred to a 
membrane using a wet transfer system, prior to staining with the Novus or 
Abcam anti-TMEM123 antibodies and anti-GAPDH.  The dark line between 
sh5 at 60 °C and control at 95 °C indicates where superfluous lanes in the gel 
have been digitally removed. 
(C) Example immunoblots given on the website for the tested antibodies.  The 
Novus antibody probes HL60 cell lysates, the Santa Cruz one is trialled on 
HeLa cells (A), RAW 264.7 cells (B) and BYDP (C) whole cell lysates, and the 
Abcam antibody is depicted in an immunoblot of placenta lysate.   
 
3.9 Discussion 
This study represents the first systematic analysis of the effects of type I IFN at the cell 
surface of primary leukocytes.  Here, 607 and 485 cell surface proteins were quantified 
in primary monocytes and T cells respectively, providing a more comprehensive analysis 
of the cell surface proteome and the effects of IFN than was previously conducted.  The 
use of TMT technology enabled multiplexing of the samples in order to investigate five 
donors in parallel, allowing identification of the most consistent effects and the 
investigation of donor-to-donor variation. 
 
3.9.1 Cell Surface Proteome 
A previous investigation of the T cell surface proteome identified 173 proteins using MS 
(Graessel et al, 2015).  A thorough literature search by the authors suggested that 24 of 
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these proteins had not previously been associated with T cells. Nine of these were 
quantified in the PM data presented here: apolipoprotein C-III (APOC3), 
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1), transmembrane 
protein C16ORF54, ECE1, ecotropic viral integration site 2A protein homolog (EVI2A), 
cell surface A33 antigen (GPA33), neuroplastin (NPTN), ADP/ATP translocase 2 
(SLC25A5), Sodium bicarbonate cotransporter 3 (SLC4A7).  An additional four were 
found in the data presented here, if it was not filtered for PM annotated proteins: RING 
finger protein 149 (RNF149), suprabasin (SBSN), phosphate carrier protein 
mitochondrial (SLC25A3), transmembrane protein 2 (TMEM2).  This corroborates some 
of the findings in this data, as well as that of Graessel et al., and suggests that this 
proteomic data may be expanded further by not limiting the investigation to GO annotated 
PM proteins.   
Analysis of the dataset presented here revealed that CD44, SPN and PTPRC were some 
of the most abundant proteins at the surface of the monocytes and T cells.  CD44 is a 
highly glycosylated transmembrane protein, abundant at the surface of multiple 
leukocytes, and is involved in adhesion (Senbanjo & Chellaiah, 2017).  SPN (also known 
as CD43) is also involved in adhesion, as well as immune cell activation (Rosenstein et 
al, 1999; Kyoizumi et al, 2004), and receptor-type tyrosine-protein phosphatase C 
(PTPRC, CD45) is another highly abundant proteins, involved in T cell activation 
(Stanford et al, 2012).  Other proteins were more differentially expressed.  For example, 
previous examination of the differential distribution of the GLUT1 and GLUT3 
transporters was suggested to facilitate cellular function; GLUT3 has a higher affinity for 
glucose and its increased expression in monocytes may enhance its ability to combat 
infection in tissues with an impaired blood flow (Fu et al, 2004).    
 
3.9.2 The Effects of IFN 
Investigation of the IFN induced changes identified 41 consistently IFN-stimulated 
proteins in monocytes, and just 13 in T cells.  More proteins were modulated by IFN and 
showed larger FCs in monocytes compared to T cells, consistent with previous 
transcriptomic analyses (Aso et al, 2019; Henig et al, 2013).  These included multiple 
positive controls such as HLAs and BST2.  Characterisation of the IFN response has 
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important implications in multiple fields.  CD274 is also known as Programmed Death 
Ligand–1 (PD-L1), and was found to be upregulated in primary CD14+ and pan- 
monocytes as well as in THP-1s in this study.  CD274 has previously been found to be 
stimulated by IFNα in a variety of murine immune cells and human DCs.  Whilst many 
ISGs stimulated the immune response, CD274 is immunosuppressive, and this may have 
important implications for IFN based cancer therapies, with enhanced expression 
potentially contributing to tumour immune evasion (Bazhin et al, 2018). 
Variability between Donors 
TMEM123, BST2 and HLAs were some of the most consistently IFN-stimulated protein, 
both between cell types, but also between donors.  Whilst the cell surface proteomes were 
remarkably invariant, much greater variability was observed in the IFN responses, 
particularly in T cells.  One reason for the poor correlation may be that the majority of 
proteins were not IFN responsive.  Many FCs were therefore just small shifts that centre 
around zero.  Also, the CD4+ T cell population examined here is likely to be highly 
heterogeneous, and different between donors, possibly contributing to the different effects 
of IFN across donors.   The presence of CD44, CD62L (L-selectin, SELL) and CCR7 
suggest the majority were naïve or memory T cells.  Additionally, activated T cell markers 
include CD25 (IL2RA) and CD69, neither of which were quantified in the CD4+ T cell 
data (Sondel et al, 2003; Tan & Surh, 2006).  Although this does not definitively 
determine that CD25 and CD69 were not expressed, it gives a suggestion of the T cell 
populations present, and some confidence that the cells were not activated by the 
extraction and stimulation process.  There may naturally also be more variability between 
IFN responses in T cell donors, a phenomenon which has been reported previously 
(Schlaak et al, 2002).  The changes in monocytes showed a larger, more consistent IFN 
response between donors, though there was still a lot of variability.  This highlights the 
benefit of multiplexing samples for the examination of multiple donors.  An interesting 
follow up experiment would have been to examine the IFN responses of the same 
individuals on multiple occasions to see if it is consistent between replicates from the 
same donor.      
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TMEM123 
Other than HLAs and BST2, TMEM123 was the only protein upregulated in both primary 
monocytes and T cells by IFNα2a.  This may therefore provide a pan-leukocyte marker 
for IFN stimulation.  The protein was only quantified by a single peptide in T cells, and 
three peptides in monocytes.  It is possible that the peptides were misidentified and the 
observation requires validation.  Encouragingly however, the peptides sequences only 
aligned to the two isoforms of TMEM123, and were not redundant to any other proteins.  
Little is currently known about TMEM123.  Also known as Porimin,  it was originally 
identified due to the ability of anti-porimin to cause oncotic cell death in jurkats (Zhang 
et al, 1998; Ma et al, 2001).  Further characterisation of the protein would be interesting, 
though was unfortunately limited in this investigation by the lack of available reagents.  
Testing the antibodies was additionally complicated by not knowing the expected size of 
the protein in different cell lines.  It would therefore be beneficial to retest them on a cell 
line overexpressing a tagged version of the protein, so the expected size could be 
confirmed.  This process was started, however validation of the TMEM123 
overexpression by RT-qPCR failed and due to time constraints this has not yet been 
investigated further. 
Further Avenues for Analysis of the Data 
Further data from the screen may be gained by extending the analysis beyond proteins 
with PM related GO annotations.  Comparison to previous studies showed some proteins 
previously identified as PM were filtered out here (Graessel et al, 2015).  Only requiring 
a ‘membrane’ annotation would include a much broader range of proteins.  Many of these 
may not be specifically cell surface proteins, and may have been detected in the 
proteomics data as they were abundant intracellular contaminants, however incorporating 
them would reduce the chance of missing interesting proteins due to poor annotation.  
Additionally, only proteins meeting the described filtering criteria were analysed; 
reducing the stringency to incorporate more donor-to-donor variation may therefore 
provide further information.   
Studying IFN-stimulated proteins alongside viral infection data may also aid in 
identification of ARFs.  BST2 was upregulated in this data on monocytes and T cells.  It 
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is an extensively studied HIV restriction factor, which prevents HIV exit from the cell by 
tethering it to the cell surface, and is antagonised by the HIV protein Vpu (Neil et al, 
2008; Hammonds et al, 2010; Mitchell et al, 2009).  It was one of the only proteins 
upregulated in all the cell types examined in this study.  ECE1 was one of the most highly 
upregulated proteins quantified in all five T cell donors.  This theme is discussed further 
in chapter 5. 
This investigation provides a valuable characterisation of the effects of IFN in primary 
leukocytes across multiple donors, complementing and extending previous transcriptomic 
studies.  It captures a variety of effects of cell type and donors, crucial for a complete 
understanding of the IFN response, valuable in development of IFN related therapies and 
for identification of ARFs.  
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CHAPTER 4:  VACCINIA VIRUS SCREEN 
Quantitative Temporal Proteomic Analysis of Vaccinia 
Virus Infection 
 
The work in this chapter is adapted from the publication ‘Quantitative Temporal Proteomic 
Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an 
Interferon Antagonist’ published in Cell Reports, May 2019 (Soday et al, 2019).  Therefore 
many of the figures here resemble those in the manuscript.  This publication was produced in 
collaboration with the laboratory of Professor Geoffrey L. Smith, Department of Pathology 
(University of Cambridge).  I am joint first author on this paper, and was responsible for 
processing the samples for proteomic analysis, as well as the analysis of all proteomic data and 
production of related figures.  Dr Jonas Albarnaz (Smith Lab) performed the VACV infections 
and harvesting for proteomic experiments, as well as immunoblots for validation.  Dr Yongxu 
Lu (Smith Lab) conducted experiments relating to HDAC5.  Experiments performed by others 
are indicated throughout the text and figure legends in this chapter, as well as in the relevant 
methods. 
 
4.1 Introduction and Aims 
4.1.1 Introduction 
VACV and other members of the Poxviridae family have a multitude of mechanisms for 
manipulating host immunity, dedicating a considerable proportion of their coding 
capacity to this (Burshtyn, 2013).  Multiple VACV proteins are involved in inhibiting the 
IFN response, to which VACV is particular susceptible due to replicating in the 
cytoplasm.   Furthermore, several proteins are involved in antagonising ISGs, and others 
may act as ligands for NK cells;  for example the VACV protein N1 may limit NK cell 
activity, and A40 resembles a C-type lectin and some NK cell receptors, and contributes 
to virulence (Jacobs et al, 2008; Wilcock et al, 1999; Tscharke et al, 2002).   
One of the criteria defined for restriction factors is antagonism by a viral factor, and this 
may include downregulation of the protein.  Identifying proteins which are modulated by 
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viral infection may highlight those that are important in viral infection and immune 
evasion, as was previously demonstrated for HCMV (Weekes et al, 2014; Nightingale et 
al, 2018).  In VACV infection, IFITM3 is downregulated in order to evade restriction, 
though a mechanism for the modulation of IFITM3 by VACV, or how its restricts 
infection, has not been determined (Li et al, 2018).  A comprehensive analysis of the 
VACV proteome and which host proteins are modulated during infection could identify 
additional ways in which the virus evades the immune response.  To this end, a proteomic 
time-course was conducted, investigating the changes in protein abundance throughout 
infection.    
The time-course data can also be used to examine the kinetics of expression of viral 
proteins, which can assist in predicting their function, and defining host-virus 
interactions.  As VACV is a model for host-virus interactions, this could highlight 
potential therapeutic targets for antiviral treatments, as well as improving understanding 
of VACV biology; this is essential for its development as a vaccine, both in terms of 
safety and optimizing immunogenicity. 
The Western Reserve (WR) strain of VACV was used for infection of HFFF-TERTs in 
this investigation.  This is a commonly used lab strain which, unlike some of the more 
attenuated strains of the virus, can replicate efficiently in mammalian cells.  It is also 
considered to be one of the most virulent strains in animals, and can be used for in vivo 
experiments in mice.  This virulence has been correlated with increased modulation of 
the immune response compared to less virulent strains, so it may be particularly valuable 
for identifying facets of the immune response (de Freitas et al, 2018).  The HFFF-TERT 
cell line was chosen in order to be comparable with proteomic investigations of other 
virus (Weekes et al, 2014; Soh et al, 2019).  As many restriction factors are able to target 
multiple viruses (Table 1) comparison of this data can be used to identify proteins which 
may be important in infection.      
 
4.1.2 Summary 
In this chapter, a quantitative, multiplexed, proteomic screen over the whole time-course 
of VACV infection is described.  Around 9000 host proteins and ~80% of VACV proteins 
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were quantified, providing a comprehensive and dynamic view of proteomic changes 
during infection.  VACV downregulated 265 proteins more than two fold, and additional 
investigation using the proteasome inhibitor MG132 revealed that 69 % of these were 
specifically targeted for proteasomal degradation.  Many of these were cell surface 
proteins, and enrichment analysis revealed targeting of certain classes, in particular 
collagens, cadherins and innate immune proteins.  The viral proteins were also analysed, 
and four temporal classes identified, which correlate well with previous transcriptomic 
studies and known functions.  The data was used to predict an interaction between the 
early viral protein C6 and the host protein HDAC5.  C6 was found to target HDAC5 for 
degradation, and HDAC5 was demonstrated to restrict viral replication.     
 
4.1.3  Aims 
1) Perform an unbiased, systematic and quantitative analysis of proteomic changes 
in the host and virus across a single replication cycle of VACV infection. 
2) Determine which proteins may be of particular importance during infection by 
looking at enriched groups of proteins, overlap with other viruses, and 
examination of which proteins are being specifically targeted for proteasomal 
degradation. 
3) Classify viral proteins into temporal classes according to their kinetics. 
4) Examine how the data can be used to predict host-virus interactions.   
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4.2 Quantitative Temporal Analysis of VACV Infection 
4.2.1 Optimisation of the Infection Time Course 
In an initial experiment, Dr Jonas Albarnaz (Smith Lab, Department of Pathology, 
University of Cambridge) infected HFFF-TERTs with the WR strain of VACV at a high 
MOI (5.0), and harvested samples for whole cell protein analysis.  Mock samples were 
harvested at 0, 4 and 8 hpi, and VACV infected samples at 2, 4, 6, 8 and 12 hpi.  Mock 
and infected samples that were additionally treated with the DNA replication inhibitor 
AraC were harvested at 4 h.  From a single shot analysis, 1607 proteins were quantified 
including 48 viral proteins.   
The experiment technically appeared to work well; hierarchical clustering showed that 
mock and infected samples clustered together, and proteins that were modulated by 
infection largely changed in a linear fashion.  However, the fold downregulation of host 
proteins observed was modest and viral proteins expressed late during infection still 
appeared to be increasing in abundance by the end of the time-course.  It was therefore 
decided to improve the set up by considering up to 18 h of infection.   
Additionally, AraC was expected to limit expression of viral proteins dependent on viral 
DNA replication.  Comparison of the 4 hpi time point with and without AraC did not 
show much change, as these viral proteins were expressed later in infection and were 
therefore not expressed highly at 4 hpi.  The AraC treated samples were therefore included 
at a later time point in subsequent experiments.   
 
4.2.2 Experimental Outline 
Based on the initial experiment, the outline of the time-course was optimised, extending 
it to 18 hpi and investigating the effects of AraC at 6 hpi (Figure 4.1).  At this stage we 
were also fortunate to have access to an 11th TMT, allowing the 10-plex experiment to be 
expanded.  Mock infected samples were harvested at 3 time points (0, 6 and 18 h), and 6 
time points of VACV infection were now included, with samples harvested at 2, 4, 6, 8, 
12 and 18 hpi.  Mock and infected samples additionally treated with AraC were harvested 
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at 6 h.  Infection was again of HFFF-TERTs at a high MOI (5.0), and flow cytometry 
confirmed that > 95 % of cells were infected.  The time-course was conducted three times, 
with infections and harvesting performed by Dr Jonas Albarnaz.  The 11 samples for each 
time-course were given to me for further processing.  They were digested into peptides, 
labelled with TMT and subjected to MS3 analysis.  
The expression profiles of 8,991 human proteins and 172/216 viral proteins were 
quantified, with 7,316 human and 160 viral proteins quantified in all three replicates of 
the time-course (Table 4.1).  The FC of each protein compared to the average of the three 
mock samples was examined by hierarchical clustering, and as expected, mock, early and 
late viral infection time points all clustered separately (Figure 4.2).  Changes were largely 
linear with those of the greatest magnitude occurring late during infection.   
 
Figure 4.1 Schematic of workflow for proteomic analysis of VACV infection 
Cells were either mock treated or infected with VACV at an MOI of 5.  One mock and 
one infected sample at 6 h were treated with AraC, a viral DNA replication inhibitor.  The 
11 samples were labelled with TMT, pooled and analysed by MS3 analysis.  
 
Table 4.1 Table of peptides and proteins quantified in each proteomic experiment on 
VACV discussed in this chapter 
The time-course was repeated in triplicate harvesting samples at various time points 
throughout infection.  The MG / C6 data includes samples of WT infection with and 
without MG132, and also investigated the effects of deleting the viral protein C6.  For 
each experiment, the number of proteins quantified is given. 
 
Time 
Course 1 
Time 
Course 2 
Time 
Course 3 
Any Time 
Course 
All Time 
Courses 
MG / C6 
data 
Total peptides 120345 124779 112310   123980 
Human proteins 8229 8310 8076 8991 7316 8263 
Viral proteins 166 169 169 172 160 173 
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Figure 4.2 Hierarchical clustering of VACV infection time-course 
Hierarchical clustering of proteins quantified in all three biological replicates, with fold 
change compared to the average of the three mock samples.  Some subclusters are 
highlighted on the right, showing particularly up- (in red, top panel of viral proteins) or 
down- (in green, middle and bottom panels) regulated proteins.  
 
4.3 Modulation of Host Proteins by VACV Infection 
The three mock time points exhibited very similar profiles (Figure 4.3A).  Therefore in 
all further analyses of the triplicate time-course data in this chapter, FC of proteins was 
compared to the 18 h mock sample.   A mean FC for each time point was calculated by 
taking the FC at the given time point compared to the 18 h mock, and averaging this 
across all replicates where the protein was quantified.  The various plots of expression 
profiles in this chapter, as in Figure 4.3B, display this mean FC. 
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In order to examine which host proteins may be important in infection, the proteins 
downregulated during infection were examined.  For a comprehensive analysis of 
downregulated proteins, a ‘sensitive’ filter was applied, examining proteins that had a 
mean FC > 2 at any time point.  A shorter, ‘stringent’ list identified proteins which were 
quantified in all three replicates, had a mean FC >2 and a BH-corrected p-value <0.05 
(Table 4.2, Appendix Table 2, Appendix Table 3).  In practice, the proteins highlighted 
by the sensitive list were used for most analyses in order to encompass all changes, and 
to avoid exclusion of proteins because they were not quantified in all three time-courses.   
Applying the sensitive criteria, 265 human proteins were downregulated >2 fold, and 70 
human proteins were upregulated; these included cellular tumour antigen p53 (Tp53), 
proto-oncogene FOS and early growth response protein 1 (EGR1), proteins known to be 
modulated by VACV (de Magalhaes et al, 2001; Silva et al, 2006; Wali & Strayer, 1999; 
Yoo et al, 2008), Figure 4.3B).  The majority of changes could be seen by comparing the 
18 h VACV infected sample to the 18 h mock, as the greatest magnitude of change was 
observed at this latest time point in infection (Figure 4.3C).  Visual inspection of this 18 
h data on a dot plot highlights the downregulation of multiple collagens and IFIT proteins.  
The complete dataset is included in the supplemental excel workbook, Table S1, of the 
published manuscript (Soday et al, 2019).  The excel ‘plotter’ in this enables interactive 
generation of graphs displaying the relative abundance of all proteins quantified in the 
proteomic datasets presented in this chapter.  
 
Table 4.2 Number of host proteins modulated by VACV infection 
The number of proteins modulated by VACV infection according to ‘sensitive’ or 
‘stringent’ criteria is given.  
 
Sensitive Criteria 
(Mean FC > 2 at any        
time point) 
Stringent Criteria 
(Quantified in all 3 time 
courses;  mean FC > 2 and 
p <0.05 at any time point) 
Total Proteins 8991 7316 
Downregulated 265 142 
Upregulated 70 4 
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Figure 4.3 Quantitative temporal analysis of VACV infection 
(A) Correspondence between mock samples. Each graph shows log2(normalised 
S:N) for proteins quantified in all three biological replicates. 
(B) Expression profiles of proteins previously reported to be modulated by VACV.  
Data are represented as mean ± SEM; *p<0.05, **p<0.01. Error bars and 
statistics are not included on the plot for Fos as this protein was not quantified 
in all three replicates. 
(C) Scatterplot of proteins quantified in all three biological replicates at 18 hpi 
compared to the 18 h mock; each dot on the plot denotes an individual protein.  
The FC (on the x-axis) was determined by averaging the FC in each replicate.  
The y-axis displays the normalised S:N, indicating the accuracy of quantitation.  
P-values were estimated using a BH-corrected two-tailed t-test. 
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4.4 Downregulation of Cell Surface Proteins and Antiviral 
Factors 
Reasoning that proteins modulated by VACV may be of particular importance, several 
approaches were employed to perform a more systematic, unbiased exploration of 
proteins downregulated during infection. 
 
4.4.1 Enrichment Analysis of Downregulated Proteins 
DAVID enrichment analysis was used to identify enriched groups of proteins amongst 
those downregulated during infection according to the sensitive criteria (Huang et al, 
2009a, 2009b).  This examined protein annotations from various databases, including GO 
terms, Interpro domains and UniProt keywords, to find features enriched in the 
downregulated proteins compared to the total sample of proteins quantified.  
Interestingly, multiple clusters referred to downregulation of cell surface receptors and 
ligands, including terms such as ‘extracellular’, ‘cell attachment site’ and 
‘immunoglobulin’ (Figure 4.4A).  This suggests that the cell surface may be a key site for 
VACV modulation.  Enrichment analysis also highlighted terms relating to collagens, 
innate immunity and cadherins amongst others.  Some examples of the expression profiles 
of proteins identified in these clusters are shown (Figure 4.4B) and several of these were 
validated by immunoblot (Figure 4.6C, immunoblots performed by Dr Jonas Albarnaz).  
In total, 11 collagens and 3 related proteins were quantified in the collagen cluster, 13 
proteins were in the innate immunity cluster and the 4 protocadherins shown were 
identified in the cadherin cluster.  
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Figure 4.4 Downregulation of multiple collagens, protocadherins and innate immune 
mediators during VACV infection 
(A) DAVID functional enrichment analysis of all proteins downregulated by 
VACV (using sensitive criteria).  A background of all quantified human 
proteins was used.  Displayed are representative terms from each cluster with a 
BH corrected p < 0.05.  A similar analysis on upregulated proteins did not 
reveal any significantly enriched clusters.  
(B) Examples of proteins from the collagen, innate immunity and cadherin clusters.   
Data are represented as mean ± SEM (n=3); p-values compare the indicated 
time point to the 18 h mock using a two-tailed t-test, *p<0.05, **p<0.01.  Error 
bars and statistics are not included for protocadherins PCDHB8, PCDHGA6 
and PCDHGB4 as these proteins were not quantified in all three replicates. 
(C) Validation of expression profiles of some proteins shown in (B) by 
immunoblot.  HFFF-TERTs were infected with VACV at an MOI of 5, and the 
viral proteins D8 and C6 represent late and early viral gene expression 
respectively (experiments performed by Dr Jonas Albarnaz).  
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4.4.2 Overlap with HCMV 
Proteins of particular importance in defending the host against an infection may be 
targeted by multiple viruses (Schoggins et al, 2011; Schreiner & Wodrich, 2013).  This 
dataset on VACV infection was overlapped with previous data on the unrelated dsDNA 
virus, HCMV (Figure 4.5A).  The three VACV time-courses were included, with 
downregulated proteins defined as those fulfilling the sensitive criteria.  Two HCMV 
time-courses were analysed alongside this, WCL1 and WCL2 from Weekes et al. (2014).  
The set-up of these experiments was as discussed in the section 1.4.2).  For the HCMV 
data, the FC of proteins was calculated both compared to mock samples and also early 
time points of infection; this is because some IFN-induced proteins were initially 
upregulated, prior to being targeted by the virus.  Proteins were considered to be 
downregulated by HCMV in this comparison if they had a FC > 2 in both time-courses, 
or were downregulated in one time-course and not quantified in the other.     
The 7289 proteins that were quantified in at least one of the three VACV time-courses 
and one of the two HCMV time-courses were examined.  Of these, 85 proteins were 
commonly downregulated (Figure 4.4A).  DAVID enrichment analysis on these 85 
proteins, against a background of the 7289 proteins quantified in both studies, identified 
similar classes of proteins to those seen previously, again showing enrichment for cell 
surface proteins, as well as collagens and innate immunity (Figure 4.5B).   
The term proteoglycan highlighted the downregulation of multiple syndecans (SDC1, 
SDC2 and SDC4) by both viruses.  Interestingly, syndecans have varied roles in viral 
infection.  HSV-1 infection increases expression of SDC1 and 2, and knockdown of these 
reduces viral entry and plaque formation, suggesting they may be beneficial to the virus 
(Bacsa et al, 2011).  SDC1 is a receptor for HCV attachment (Shi et al, 2013).  VACV 
and HCMV appear to negatively regulate these proteins, so they may have alternative 
roles in infection with these viruses.    
The previous proteomic study of HCMV infection identified protocadherins as being 
downregulated by the virus and provided initial evidence that some members of this 
family are activating NK cell ligands.  Additionally, all of the 11 collagens downregulated 
by VACV were also downregulated by HCMV.  Certain collagens may be ligands for the 
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inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1), with ligand binding leading 
to inhibition of immune cell activation (Lebbink et al, 2006); collagen downregulation 
may therefore represent a cellular response to infection. 
Only 10 proteins were commonly upregulated by both viruses, and no terms were 
significantly enriched using DAVID analysis.   Interestingly however, one of these 
proteins was APOE which is known to have roles in HSV, HIV and HCV infection, 
potentially assisting cell entry (Tudorache et al, 2017). 
 
Figure 4.5 Co-regulation of proteins by VACV and HCMV 
(A) Overlap between VACV and HCMV WCL proteomic data (Weekes et al, 
2014).  Downregulation of proteins in the VACV dataset used the sensitive 
criteria, and downregulation of proteins in the HCMV time-course required the 
protein to have a FC > 2 compared to mock or an early infection time point in 
both time-courses, or in one with the protein not quantified in the other. 
(B) DAVID enrichment analysis of the 85 commonly downregulated proteins 
against a background of the 7,289 proteins quantified in both studies.  
Displayed are representative terms from each cluster and the associated BH-
corrected p-values. 
(C) Example profiles of proteins from enriched clusters.  For the VACV data, plots 
are represented as mean ± SEM (n=3); *p<0.05, **p<0.01.  For HCMV, plots 
are from the WCL2 experiment. 
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4.4.3 Downregulation of Innate Immune Proteins 
DAVID enrichment analysis highlighted that both VACV and HCMV target multiple 
molecules in the category ‘innate immunity’ (Figure 4.4, Figure 4.5), in particular IFITs, 
IFITMs and TRIM proteins.  Examination of these may identify additional mechanisms 
of immune evasion and assist identification of DNA virus restriction factors. 
Strikingly, VACV rapidly downregulated all four canonical IFITs 1, 2, 3 and 5 (Figure 
4.4B).  The IFITs are induced by IFN, and have homologues in multiple vertebrate 
species; they have previously been implicated in restricting diverse RNA viruses 
including Rift Valley fever virus, vesicular stomatitis virus, and influenza A (Vladimer et 
al, 2014).  IFITs restrict viral infection by inhibiting translation via binding of eukaryotic 
initiation factor 3 (eIF3), by recognition of RNA lacking 2’ O methylation of the 5’ 
guanosine cap, and of uncapped RNA with a 5’ triphosphate.  Direct interaction between 
IFITs and viral proteins may also be a mechanism of restriction; IFIT1 has been shown 
to directly inhibit DNA replication of HPV by binding and sequestering the viral protein 
E1 (Daffis et al, 2010; Pichlmair et al, 2011; Terenzi et al, 2008; Diamond & Farzan, 
2013).  Targeting of IFITs by both VACV and HCMV suggests that these proteins have 
additional mechanisms for restricting DNA viruses.  Subsequent to this research, the 
VACV protein C9 was demonstrated to be responsible for targeting multiple IFITs (Liu 
et al, 2019).   
Additionally, IFITM3 is downregulated by VACV in this study.  It has also recently been 
reported to be downregulated by VACV to avoid antiviral restriction (Li et al, 2018). 
Of the 29 TRIM proteins quantified, TRIM 5, 13, 25, 26 and 56 were downregulated 
during VACV infection.  TRIM5 was also downregulated by HCMV (Figure 4.5C), and 
is known to restrict retroviruses.  TRIM56 inhibits multiple RNA viruses (Liu et al, 2014; 
Rahm & Telenti, 2012).  It also induces mono-ubiquitination of the cytosolic DNA sensor 
cGAS, and mice deficient in TRIM56 exhibited impaired production of type I IFNs and 
increased susceptibility to lethal infection by HSV-1 (Seo et al, 2018).  Downregulation 
of TRIM56 by VACV may therefore represent a mechanism for immune evasion.  
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4.4.4 Modulation of Candidate Immunoreceptors 
Enrichment analysis highlighted the downregulation of multiple collagens and 
protocadherins by VACV, with these molecules potentially having roles as NK cell 
ligands (Figure 4.4, Figure 4.5).  Poxviruses have many mechanisms for manipulating 
host immunity, and regulates multiple ligands involved in modulating NK or T cell 
recognition (Burshtyn, 2013).  Analysis of this data revealed downregulation of multiple 
known NK and T cell ligands, such as HLA-A, B and C and TNF receptor superfamily 
member 10B (TNFRSF10B).  Nectin2, the ligand for activating NK receptor DNAX 
accessory molecule-1 (DNAM-1) was also downregulated, as were UL16 binding protein 
2 (ULBP2) and MHC class I polypeptide-related sequence A (MICA), ligands for the NK 
receptor, NKG2D (Vivier et al, 2008; Smith et al, 2013b) (Figure 4.6A).   
As many NK and T cell ligands belong to a small number of classes of proteins, candidate 
ligands were identified by considering proteins with associated InterPro functional 
domain annotations relating to immunoglobulins, C-type lectins, cadherins, TNF 
receptors, collagen, butyrophylin and MHC related molecules (Vivier et al, 2008; Hunter 
et al, 2012).  This approach was previously used in investigations of HCMV infection 
(Weekes et al, 2014).  Proteins identified which had these functional domains and were 
also modulated by VACV, are therefore potentially important.  This identified 37 proteins 
which were both 2 fold downregulated and had a relevant InterPro annotation (Table 4.3).  
All the collagens and cadherins quantified are displayed in Figure 4.6B and C, a number 
of these were downregulated > 2 fold meeting the previously described sensitive criteria, 
and many were downregulated to some lesser extent.   Other downregulated proteins 
included the tyrosine protein kinase receptor AXL, endosialin (CD248) and other 
molecules involved in adhesion, signalling and immunity (Figure 4.4, Figure 4.6). 
Further analysis of these candidate immunoreceptors and their possible functions was 
beyond the scope of the current project, however the Smith Lab are investigating this 
area.  An additional collaborative project with them is now focussing on changes at the 
PM of VACV infected cells.  This should be particularly interesting given the enrichment 
of cell surface related terms amongst proteins modulated by VACV, and this may shed 
light on additional candidate immunoreceptors and viral targets. 
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Figure 4.6 Modulation of known and putative immune ligands by VACV infection 
Data are represented as mean ± SEM; *p<0.05, **p<0.01. Error bars and statistics are not 
included on the plots for HLA-C, TNFRSF10B, ULBP2, COL10A1, COL15A1, 
CELSR3, FAT3, PCDHB8, PCDHGA6, PCDHGA10, PCDHGB4 as these proteins were 
not quantified in all three replicates. 
(A) Modulation of known NK or T cell ligands 
(B) All collagens quantified 
(C) All protocadherins quantified 
(D) Downregulation of AXL and CD248 
140 Chapter 4 – VACCINIA VIRUS SCREEN 
Table 4.3 Candidate immunoreceptors modulated by VACV infection 
Candidate immunoreceptors identified according to Interpro domains (Ig denotes the term 
immunoglobulin), and viral downregulation (‘Max FC’ gives maximal downregulation). 
InterPro Term Gene name Description Max FC 
Ig ADAMTSL3 ADAMTS-like protein 3 3.09 
MHC, Ig ALPK2 Alpha-protein kinase 2 2.05 
Ig AXL Tyrosine-protein kinase receptor UFO 2.48 
Collagen CCBE1 Collagen and calcium-binding EGF domain-containing protein 1 2.14 
C-type lectin CD248 Endosialin 2.18 
Cadherin CLSTN1 Calsyntenin-1 2.48 
Collagen COL11A1 Collagen alpha-1(XI) chain 2.70 
Collagen COL12A1 Collagen alpha-1(XII) chain 2.22 
Collagen COL1A1 Collagen alpha-1(I) chain 5.90 
Collagen COL1A2 Collagen alpha-2(I) chain 4.32 
Collagen COL2A1 Collagen alpha-1(II) chain 2.45 
Collagen COL3A1 Collagen alpha-1(III) chain 3.84 
Collagen COL5A1 Collagen alpha-1(V) chain 3.04 
Collagen COL5A2 Collagen alpha-2(V) chain 3.35 
Collagen COL5A3 Collagen alpha-3(V) chain 2.57 
Collagen COL6A1 Collagen alpha-1(VI) chain 2.11 
Collagen COL6A2 Collagen alpha-2(VI) chain 2.68 
Ig EBF1 Transcription factor COE1 2.34 
Ig F13A1 Coagulation factor XIII A chain 2.16 
Ig FGFR1 Isoform 21 of Fibroblast growth factor receptor 1 2.34 
Ig FLT1 Isoform 2 of Vascular endothelial growth factor receptor 1 2.22 
C-type lectin, Ig HAPLN3 Hyaluronan and proteoglycan link protein 3 2.35 
MHC, Ig HLA-C HLA class I histocompatibility antigen, Cw-4 alpha chain 2.78 
MHC, Ig HLA-C HLA class I histocompatibility antigen, Cw-12 alpha chain 2.22 
Ig IGFBP7 Insulin-like growth factor-binding protein 7 2.78 
Ig MXRA8 Matrix-remodeling-associated protein 8 3.29 
Ig NEO1 Neogenin 2.07 
Cadherin PCDHB8 Protocadherin beta-8 2.83 
Cadherin PCDHGA6 Protocadherin gamma-A6 2.78 
Cadherin PCDHGB4 Protocadherin gamma-B4 2.11 
Cadherin PCDHGB5 Protocadherin gamma-B5 2.06 
Ig PDGFRA Platelet-derived growth factor receptor alpha 2.16 
Ig PDGFRL Platelet-derived growth factor receptor-like protein 2.42 
C-type lectin SUSD5 Sushi domain-containing protein 5 2.37 
TNF TNFRSF1A Tumor necrosis factor receptor superfamily member 1A 2.61 
Butyrophylin TRIM5 Tripartite motif-containing protein 5 2.39 
Ig TXNIP Thioredoxin-interacting protein 2.42 
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4.5 Temporal Analysis of VACV Viral Protein Expression 
As well as quantifying nearly 9000 human proteins, the majority of the VACV proteins 
were also quantified over the whole course of infection, enabling a detailed temporal 
investigation of viral protein expression.  Previous classification of viral genes into 
temporal classes was predominantly based on RNA-sequencing (RNA-seq) analysis and 
very limited proteomic data. This investigation therefore complemented the previous 
studies, and enabled correlation between expression profiles of viral and cellular proteins, 
giving insights into host-virus interactions. 
 
4.5.1 There were Four Temporal Classes of Viral Protein Expression 
Around 80% of all predicted VACV proteins were quantified in this study, and the 
number of distinct classes determined using the k-means method.  The approach was 
trialled using 1-15 classes.  For each number of classes, all proteins were assigned to a 
class, and a ‘cluster centroid’ was calculated.  The distances of every protein from its 
cluster centroid was summed, and this was plotted against the number of classes.  This 
summed distance necessarily decreases as the number of classes increases, but this 
difference reduces with each added group.  When there are too many classes, the summed 
distances become minimal and simply represents overfitting of the data.  The point of 
inflection therefore indicates up to how many classes for which there is structure in the 
underlying data, estimating the true number of classes.  Using this approach, the point of 
inflection in this dataset fell between four and six classes, suggesting there were at least 
four distinct temporal classes (Figure 4.7A).   Plotting of the class centroid profiles 
displays the expression profile of the average protein in that class, from early Tp1 proteins 
(yellow) through to late Tp4 proteins (blue, Figure 4.7B).    
In order to provide additional confidence to the classification, viral expression at 6 hpi 
was examined in the presence of AraC.  Late viral genes were initially termed ‘post 
replicative’ (PR) in an early RNA-seq based classification system, due to the requirement 
of viral DNA replication for their expression (Yang et al, 2010).  As AraC is an inhibitor 
of viral DNA replication, this would be expected to limit expression of the later classes, 
without impacting proteins expressed early during infection.  The FC between protein 
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expression during VACV infection with or without AraC was calculated and examined 
in the context of each class (Figure 4.7C).  As expected, none of the Tp1 proteins were 
inhibited by AraC.  Conversely, more than 70 % of the latest class of proteins, Tp4, 
showed at least 1.5 fold downregulation with AraC.  However, a subset of proteins in Tp4 
were not inhibited by AraC.  This may be due to the somewhat arbitrary 1.5 fold cut off 
employed, or by the time point chosen.  Despite including this sample at a later time point 
than the 4 hpi used in the initial optimisation experiment, it may still be too early to see 
maximal effect; many of the late proteins were not yet highly expressed at 6 hpi, and a 
greater window for downregulation with AraC may exist at a later time point.  
Viral protein signals were normalised to the maximum expression across all time points, 
so expression was on a scale of 0 to 1.  Each class of proteins was then subjected to 
hierarchical clustering for visualisation on a heatmap.  A clear pattern of expression can 
be seen from the early to late classes (Figure 4.7D).  Examples of proteins from each class 
are shown underneath (Figure 4.7E).  No p-values are given on these profiles for viral 
proteins, as any signal observed in the mock samples was only at the level of noise, so 
comparing to the 18 h mock (as with the human proteins) would not give any meaningful 
information.  A list of all viral proteins detected and their assigned classes is given in 
Appendix Table 4. 
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Figure 4.7 Definition of temporal classes of VACV gene expression 
(A) The number of k-means classes is plotted against the summed distance of each 
protein from the class centroid, in order to determine the true number of classes.  
(B) Expression profiles of the class centroids. 
(C) Number of proteins per temporal class, and the number of proteins in each class 
whose expression was reduced > 1.5 fold at 6 hpi by the addition of AraC. 
(D) Hierarchical clustering of all proteins in each temporal class, as assigned by k-
means.  Expression was normalised to the maximum across the measured time 
points. 
(E) Expression profiles of example proteins, representative of each class.   Data 
shows the mean ± SEM (n=3). 
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4.5.2 Comparison of viral protein classes to previous studies 
Previous transcriptional studies have utilised microarrays (Assarsson et al, 2008), RNA-
seq (Yang et al, 2010, 2011) and a combination of RNA-seq with ribosome profiling 
(Yang et al, 2015).  There has additionally been a more limited proteomic investigation 
(Croft et al, 2015).   
RNA Sequencing Based Classifications 
RNA-seq studies were conducted on infected HeLa cells, harvested at 0 through to 4 hpi.  
This study defined three classes of viral proteins, ‘early’, separated into E1.1 and E1.2, 
and PR (Yang et al, 2010).  An extension of this study further dissected the PR category 
by utilising a virus with inducible expression of the late transcription factor G8 (Yang et 
al, 2011).  This yielded a classification systems of the four transcriptional classes: E1.1, 
E1.2, intermediate (I) and late (L).  Further RNA-seq data was included in the most recent 
ribosome profiling investigation, with samples up to 8 hpi (Yang et al, 2015). 
Comparison of protein level data to these RNA-seq based classifications showed a high 
level of similarity.  The RNA-seq data from the ribosome profiling publication provided 
expression data at 2, 4 and 8 hpi.  This was normalised to the maximum in the same way 
as the proteomics data so it could be included in the hierarchical clustering of each class.  
The heat map therefore shows the relative expression at each time point for a given protein 
in the RNA-seq data alongside its relative expression at each time point in the proteomic 
screen (Figure 4.8A).  Visual comparison suggests good concordance between the 
proteomic data and the RNA-seq.   
More extensive comparison identified that 18/18 Tp1 proteins were either E1.1 or E1.2 
transcripts, Tp2 proteins were also predominantly early transcripts, and 60/69 Tp4 
proteins were I or L transcripts (p < 0.0001, Fisher’s exact test; Figure 4.8B, Appendix 
Table 4).  This high level of correspondence between studies using different approaches 
suggests the temporal classes of VACV protein expression defined here were likely to be 
biologically relevant.  Additionally, as most class assignments were the same from 
proteomic and transcriptomic data, this suggests that regulation of expression was likely 
to be chiefly exerted at the level of transcription.   
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However, interesting differences were also highlighted.  Some early transcripts had their 
maximal expression at the protein level later during infection, and were defined here as 
Tp3 proteins (Figure 4.8A).  These included E4 and G5.5, which are subunits of the DNA-
dependent RNA polymerase, as well as G2, which has roles PR transcription elongation.  
There may therefore be additional mechanisms of temporal regulation of viral gene 
expression, in addition to that observed at the transcriptional level. 
Proteomic Studies Based Classifications 
A previous proteomic study examined infection of a murine bone marrow-derived 
dendritic-like cell line DC2.4 (Croft et al, 2015).  Two time-courses were conducted, the 
first from 0.5 – 9.5 hpi at 3 h intervals, and the second from 0.5 to 8.5 hpi at 2 h intervals.  
In total, 101 viral proteins were quantified, and 4 temporal classes defined.  There were 
47 proteins which showed concordant classification between the 2 time-courses, with the 
others being mismatched or only quantified in 1.  Comparison of the proteomic data 
presented here to these 47 proteins showed very similar classification, with 4/5 Tp1 
proteins assigned to temporal class 1 of the Croft et al data, and 19/20 Tp4 proteins 
classified as temporal class 3 or 4 (Figure 4.8C, Appendix Table 4). 
Viral Protein Class and Function 
A final comparison was between the assigned classes of viral proteins, and their functions.  
The functions were predominantly as summarised by Yang et al. (2010), with some 
updated functions added from other sources (literature reviewed and functions added by 
Dr Jonas Albarnaz, described in Appendix Table 4).  The majority of early expressed 
proteins were involved in ‘host interaction’, encompassing vaccinia growth factor and 
immune evasion proteins.  ‘DNA replication’ related largely to Tp2 proteins, including 
enzymes involved in nucleotide precursor synthesis, DNA replication and DNA 
processing.  The majority of Tp4 proteins were assigned to ‘virion association’, including 
virion structural proteins or those involved in virion morphogenesis (Figure 4.8D).  
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Figure 4.8 Comparison of viral protein temporal classes to previous studies 
(A) Comparison between temporal expression profiles of each protein from this 
study, and the equivalent expression profile in a transcriptional analysis (Yang 
et al, 2015).  Proteins were grouped according to assigned classes from this 
data, and expression was normalised to the maximum across the measured time 
points.  Each class of proteins was subjected to hierarchical clustering.  Full 
details of comparisons in this figure can be found in Appendix Table 4. 
(B) Comparison of viral protein classes (this study) and transcriptional classes 
(Yang et al, 2010, 2011).   
(C) Comparison of viral protein classes from this study, with those assigned in a 
previous proteomic study by (Croft et al, 2015).  As there were two datasets 
from the previous investigation, only the 47 viral proteins with concordant 
assignments in both experiments were included in the comparison.  
(D) Functional analysis of viral proteins in each class, based on information from 
(Yang et al, 2010) and other sources, as detailed in Appendix Table 4.  
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4.6 Systematic Analysis of Protein Degradation During VACV 
Infection 
4.6.1 Experimental Outline 
In order to examine the mechanism by which VACV led to downregulation of multiple 
classes of proteins, a multiplexed proteomic approach used the proteasome inhibitor, 
MG132, to investigate which proteins were subject to active degradation.  Cells were 
infected at an MOI of 5 in biological triplicate, for 12 h.  Infection was allowed to proceed 
for 2 h, as required to enable virus uncoating in the host cells, prior to the addition of 
MG132, or mock treatment with DMSO.  Uninfected samples were also either mock 
treated or treated with MG132; in this case just a single sample of each was harvested 
(Figure 4.9).  Infections and harvesting were performed by Dr Jonas Albarnaz.  
 
 
Figure 4.9 Schematic of MG132 experiment examining VACV induced protein 
degradation 
Cells were infected in the presence or absence of MG132 (10 µM added 2 h after 
infection), and harvested at 12 hpi for WCL proteomic analysis (in triplicate).  Mock 
treated cells were prepared similarly (single replicate). 
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4.6.2 Proteasomal Degradation of Human Proteins 
In this experiment, 8263 human proteins were quantified.  In each case, a BH-corrected 
p-value was estimated using a two-tailed t-test comparing the triplicate infected samples 
with or without MG132.  However, it was important to separate proteins which were 
proteasomally degraded from those that have a high baseline turnover and showed altered 
abundance during MG132 treatment of uninfected cells.  An MG132 ‘rescue ratio’ was 
therefore calculated by comparing protein abundance during VACV infection ± MG132 
(average of the three replicates) with the protein abundance during mock infection ± 
MG132 (Figure 4.10B).  A minimum value of one was used for the change in abundance 
of mock ± MG132 (‘a’ in the rescue ratio), in order to avoid artificial inflation of the 
rescue ratio for proteins where any decline was observed in the abundance.   
Of the proteins downregulated >2 fold in this experiment, 69 % had a rescue ratio > 1.5, 
p < 0.05 (Figure 4.10A).  This suggests that proteasomal degradation was one of the 
predominant mechanisms employed by VACV to modulate expression of host proteins.  
All of the IFITs, TRIMs and Ephrin receptors which were downregulated > 2 fold were 
rescued by MG132 (Figure 4.10B).  In contrast, some proteins were downregulated > 2 
fold, but not rescued by MG132; whilst isoforms 1 and 2 of collagen alpha-2(VI) chain 
(COL6A2) were rescued, a further six downregulated collagens did not meet the criteria.  
This suggests alternative mechanisms of downregulation were also acting.  The complete 
dataset of proteins quantified in this experiment, and their rescue ratios, is included in 
supplemental table S6 of the manuscript  (Soday et al, 2019). 
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Figure 4.10 Systematic analysis of proteasomal degradation of host proteins 
(A) Scatter Plot of all human proteins quantified in MG132 proteomic 
investigation.  Rescue ratio was calculated as:   (protein abundance during 
VACV infection with MG132 / abundance during infection without MG132) 
(b)    /   (protein abundance during mock infection with MG132 / abundance 
without MG132)  (a).  The denominator (a) was set a minimum of 1.   VACV 
infected samples (± MG132) were examined in triplicate, whilst mock samples 
(± MG132) were in single replicates, in order to fit the constraints of the 11-
plex experiment.  P-values were estimated for each protein using a BH-
corrected two-tailed t-test, comparing the triplicate infected samples with and 
without MG132.  Proteins highlighted in purple were downregulated > 2 fold, 
have a rescue ratio > 1.5 and p < 0.05. 
(B) Examples of proteins rescued by MG132.  Infected samples are displayed as 
the mean ± SEM. P-values were calculated as described in (A); *p < 0.01, **p 
< 0.0005. 
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4.6.3 Proteasomal Degradation of Viral Proteins 
MG132 inhibited expression of late but not early viral proteins, consistent with previous 
reports (Satheshkumar et al, 2009; Teale et al, 2009).  In this case, the rescue ratio does 
not take into account changes in mock infection, as any quantification of viral proteins 
here is only at the level of noise.  The viral rescue ratio was therefore calculated as mean 
expression (across the three replicates) during VACV infection in the presence or absence 
of MG132.  Distinct patterns of MG132 response were observed between the different 
classes of viral proteins (Figure 4.11).   
 
Figure 4.11 Effect of MG132 treatment on viral protein expression 
Effects of proteasome inhibition by MG132 on expression of viral proteins is displayed, 
with proteins separated according to their assigned temporal classes.  The viral rescue 
ratio was determined by the relative abundance during VACV infection with or without 
MG132, using the mean expression values from the three replicates.  The three proteins 
indicated in black were not quantified in the proteomic time-courses and therefore did not 
have an assigned class. 
 
Most Tp1 and some Tp2 proteins were upregulated by MG132, whilst Tp3 proteins were 
largely unaffected and Tp4 proteins were inhibited (Figure 4.11).  The increase in Tp1 
and Tp2 proteins may be a consequence of the inhibition of viral DNA replication and 
expression of PR genes, leading to accumulation of early viral mRNAs and their products.  
It may also be partially explained by enrichment for these classes of proteins in ‘host 
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interaction’ functions (Figure 4.8D); if the protein is usually co-degraded with a host 
factor, it will accumulate in the presence of MG132.   
Three viral proteins were detected in the MG132 experiment that were not quantified in 
the time-courses, and therefore did not have a class assigned.  They were A57, 
VACWR014 and VACWR012/VACWR207, and they had a viral rescue ratio of 6.9, 3.8 
and 1.4 respectively.  This suggests the first two were likely to be Tp1 or Tp2 early 
proteins, whilst the latter was most likely to be Tp2 or Tp3.  
 
4.7 Identification of Candidate Virus-Host Interactions: 
HDAC5 
HDAC5 was rapidly degraded during infection, with both VACV (Figure 4.12A) and also 
HCMV (Weekes et al, 2014) (Figure 4.12B).  In addition, it was one of the most 
substantially rescued proteins by MG132 (Figure 4.12C).  This suggests it may be 
important during infection with multiple viruses.   
 
Figure 4.12 HDAC5 expression during VACV infection 
(A) HDAC was downregulated during infection with VACV compared to mock.  
Data are represented as mean ± SEM (n=3); *p < 0.05. 
(B) HDAC5 was downregulated over 96 h of infection with HCMV (Weekes et al, 
2014). 
(C) HDAC5 was rescued by MG132.  Mock samples were single replicates, and 
infected samples were harvested in triplicate.  Infected samples are displayed 
as the mean ± SEM. P-values were estimated using a BH-corrected two-tailed 
t-test; **p < 0.0005. 
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4.7.1 HDAC5 was Targeted by VACV C6 Protein  
With more than 200 VACV proteins, identifying which viral factor is responsible for 
targeting a host protein can be challenging.  HDAC5 degradation was observed in the 
presence of AraC, suggesting the protein was likely to be from an early class.  An initial 
investigation was performed by considering the profile of HDAC5 degradation.  
Matching the inverse profile of HDAC5 to that of the central profiles of each temporal 
class indicated it was likely to be one of the 38 proteins from the Tp2 class (Figure 4.13A).   
More comprehensive investigation was used to match the profile of HDAC5 to Tp2 viral 
proteins known to have roles in innate immune signalling.  Along with additional data 
from the Weekes and Smith laboratories, investigating multiple mutant viruses 
(unpublished), C6 appeared to be a good candidate with matching kinetics (Figure 4.13B). 
In order to examine this further, an unbiased proteomic comparison of infection with WT 
VACV compared to a deletion mutant lacking the C6L gene which encodes the viral 
protein C6 (Unterholzner et al, 2011), vΔC6, was performed.  Cells were infected with 
WT and mutant virus in triplicate (by Dr Jonas Albarnaz), in order to assess which 
proteins were rescued by deletion of C6 and therefore were targeted by C6 for 
degradation.  This identified HDAC5 as the major target (Figure 4.13C).  Cerebellar 
degeneration-related protein 2 (CDR2) and the E3 ubiquitin ligase RING-finger protein 
114 (RNF114) were also rescued by deletion of C6, though to a lesser extent.  
Downregulation of HDAC5 during infection, and rescue by deletion of C6, was readily 
validated by immunoblot; additionally, there was no effect of infection on the control 
protein HDAC1, confirming the specific regulation of HDAC5 by C6 (Figure 4.13D, 
immunoblot by Dr Yongxu Lu, Smith Lab, Department of Pathology, University of 
Cambridge).  Deletion of C6 prevented the degradation of HDAC5, therefore C6 was 
necessary for its downregulation.  Additional experiments by Dr Yongxu Lu were able to 
demonstrate sufficiency of C6 for downregulation of HDAC5, using inducible expression 
of C6 and immunoblot analysis.  He was also able to validate that degradation was 
proteasome dependent, with an immunoblot confirming rescue by of HDAC5 by the 
addition of MG132 (data shown in Soday et al. 2019).  
4.7 Identification of Candidate Virus-Host Interactions: HDAC5 153 
 
Figure 4.13 HDAC5 was targeted by the VACV protein C6 
(A) Expression profiles of viral protein class centroids, alongside an inverted 
profile of HDAC5 scaled from 0 to 1. 
(B) Inverted and scaled profile of HDAC5 (as in (A)), alongside a selection of Tp2 
proteins with known roles in the regulation of IFN or ISGs. 
(C) HFFF-TERTs were infected in triplicate with WT VACV or a deletion mutant 
lacking the gene C6L (vΔC6), at an MOI of 5 for 12 h (Dr Jonas Albarnaz).  
The scatter plot shows all quantified proteins, with BH corrected p-values 
estimated using a two-tailed t-test. 
(D) Representative immunoblot (n=3) demonstrating that C6 specifically targeted 
HDAC5, and had no effect on HDAC1.  Infection was at an MOI of 5.  
Immunoblot by Dr Yongxu Lu. 
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4.7.2 HDAC5 Restricts VACV and HSV-1 Infection 
As HDAC5 was downregulated rapidly and early during infection by multiple large DNA 
viruses, it may have a role as an ARF.  In order to test this, Dr Yongxu Lu (Smith lab) 
generated various cell lines either overexpressing HDAC5 or with a HDAC5 knockout, 
and examined the effects on replication of VACV and HSV-1. 
He generated U2OS cell lines with inducible overexpression of HDAC5 (Figure 4.14B).  
The overexpression and control cells were infected with A5-GFP VACV at low MOI, and 
the supernatant harvested at two days post infection and titrated.  Overexpression of 
HDAC5 led to reduced viral titre.  The same experiment was performed using VP26-GFP 
HSV-1, in this case harvesting supernatants for titration at three days post infection, 
demonstrating HDAC5 restriction of HSV-1 replication (Figure 4.14A).  A similar 
experiment was performed on HDAC5 knockout populations in HeLa cells.  Knockouts 
were produced using the CRISPR/Cas9 system and single cell cloned to generate 
monoclonal populations.  CRISPR guides targeted exon 4 (HDA5 knockout (H5KO)-1) 
and exon 3 (H5KO2) of HDAC5 (Figure 4.14D).  Knockout of HDAC5 led to increased 
viral titre for both VACV and HSV-1, suggesting it was restricting viral replication 
(Figure 4.14C).  Reintroduction of HDAC5 into the CRISPR knockout cells restored this 
restriction, whereas transduction with an empty vector (EV) did not (Figure 4.14E).   Two 
further monoclonal population of HDAC5 knockouts (H5KO3, H5KO4, both targeting 
exon 4) were generated in HEK-293Ts (Figure 4.14H), and these also enhanced 
replication of both viruses (Figure 4.14G). 
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Figure 4.14 HDAC5 restricted infection with VACV and HSV-1 
All infections were performed at an MOI of 0.001, for two days with VACV, and three 
days with HSV-1.  Data are represented as mean ± SEM.  P-values were estimated using 
a two-tailed t-test (n=3) where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
Experiments were performed and figures produced by Dr Yongxu Lu. 
(legend on next page) 
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Figure 4.14 HDAC5 restricted infection with VACV and HSV-1 
(A) Replication of VACV and HSV-1 was reduced in U2OS cells inducibly 
expressing HDAC5-FLAG.  Induction was with 100 ng/ml doxycycline (Dox) 
overnight prior to infection. 
(B) Immunoblot of HDAC5-FLAG expression in U2OS cells used in (A) 
(C) Replication of VACV and HSV-1 was enhanced in HDAC5 CRISPR/Cas9 
knockout HeLa cells, compared to parental cell lines. 
(D) Immunoblot confirming knockout of HDAC5 in two HeLa monoclonal 
CRISPR populations, H5KO1 and H5KO2, as used in (C). 
(E) Reintroduction of HDAC5 in the CRISPR knockout HeLa cells restored 
restriction, whilst transduction with an empty vector (EV) did not. 
(F) Immunoblot confirming expression of HDAC5-Flag on reintroduction into 
H5KO1 knockout cell line, as used in (E). 
(G) Replication of VACV and HSV-1 was enhanced in HDAC5 CRISPR/Cas9 
knockout HEK-293T cells, compared to parental cell lines. 
(H) Immunoblot confirming knockout of HDAC5 in two HEK-293T monoclonal 
CRISPR populations, H5KO3 and H5KO4, as used in (G). 
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4.8 Discussion 
This study quantified ~9000 human proteins and ~80% of all VACV proteins over a single 
replication cycle.  This has greatly extended the findings from previous research, which 
were limited by the technology available (Bartel et al, 2011; Chou et al, 2012).  Here, the 
use of TMT-based MS3 analysis has provided a comprehensive and precise quantitative 
analysis of proteomic changes throughout infection, and therefore a valuable resource for 
researchers in the poxvirus and immunity fields. 
 
4.8.1 Downregulation of Host Proteins 
Global Host Shutoff  
Identifying host proteins which were downregulated by viral infection was a key part of 
this investigation; VACV has numerous strategies for modifying the immune response in 
order to enable its cytoplasmic replication, and therefore targeting of a protein by VACV 
may suggest important roles in immunity.  Global shutoff of host protein synthesis is a 
well documented phenomenon in VACV infection (Moss, 1968; Rice & Roberts, 1983).  
It is thought to reduce competition for the cellular machinery required for protein 
synthesis by host mRNAs and therefore direct resources to viral protein synthesis, as well 
as limiting expression of antiviral proteins.  Shutoff is achieved by viral proteins D9 and 
D10 removing the 5’ cap from host mRNAs leading to their degradation by 5'-3' 
exoribonuclease 1 (XRN1) (Parrish et al, 2007; Parrish & Moss, 2007), and through 
VACWR169 inhibiting translation initiation (Strnadova et al, 2015).  Global shutoff was 
not readily observed in this proteomic data.  This may be due to the experimental set up 
used here, which aimed to have an equal total amount of protein in each channel.  This 
was achieved by using a BCA to measure the amount of protein from each sample, and 
then electronic normalisation during data processing.  This normalisation may mask an 
overall reduction in the amount of host protein in a particular sample.  
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Specific Downregulation of Host Proteins 
In this study, just 265 proteins were downregulated; this was less than 3 % of the human 
proteins quantified.  Global shutoff is unlikely to account for changes only seen in such a 
small proportion of the proteins quantified, suggesting specific regulation of these 
proteins.  Further evidence of this comes from the rescue of ~69 % of proteins 
downregulated more than 2 fold by the addition of MG132.   
As MG132 is predominantly a proteasome inhibitor, rescue of many of these proteins will 
mean they were proteasomally degraded.  However, MG132 also has less potent effects 
as an inhibitor of calpains and lysosomal cathepsins, so these pathways may also be 
involved in the protein degradation (Kisselev et al, 2012).  A more specific proteasome 
inhibitor, such as bortezomib, could be used to confirm proteasomal degradation.  
Additionally, MG132 treatment has previously been shown to prevent formation of 
cytoplasmic viral factories, and expression of late viral genes (Teale et al, 2009); this is 
in concordance with the data presented here (Figure 4.11).  Therefore, proteins rescued 
by MG132 may also represent targets of late viral proteins.  It would be interesting to 
compare proteins which were rescued by MG132 with those rescued by AraC, an inhibitor 
of late viral gene expression, to delineate which host proteins may be targets of late viral 
proteins.  Although this investigation did include AraC treated samples, these were 
harvested at 6 hpi, whilst the MG132 treated samples were harvested at 12 hpi.  Not all 
the late viral proteins were highly expressed at 6 hpi, and most host proteins had not yet 
reached their maximal downregulation, therefore a later time point may be more suitable 
for this comparison.  
Overlap of Proteins Downregulated by VACV and HCMV 
It is interesting that so few proteins were specifically downregulated during VACV 
infection compared to during infection with HCMV.  Both are large dsDNA viruses with 
a similar number of canonical genes.  Many of the HCMV proteins are well characterised 
in targeting multiple host proteins.  Expression of HCMV US2 in THP-1 cells identified 
a multitude of proteins being downregulated, such as MHC molecules and integrins.  
Additionally, infection with a US2 deletion mutant rescued 21 proteins compared to WT 
HCMV infection, including multiple integrins and immunoglobulin superfamily 
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members; this suggests it has many targets (Hsu et al, 2015).  It is possible that each 
VACV protein has a more specific role and fewer targets, however examination of C6 
here shows it targets at least three proteins. Another possible explanation is the 
comparatively complex viral lifecycle of herpesviruses.  As they exhibit latent infection 
as well as lytic, and the life-cycle involves entry and exit of the nucleus, increased 
modulation of the infected cell may be required to achieve this.  
HDAC5 
Despite the vast difference in the number of modulated proteins, there were 85 proteins 
which were commonly downregulated by both VACV and HCMV.  With different 
viruses possessing varied mechanisms for regulating host immunity, convergence of these 
on downregulation of the same protein provides additional confidence that they may be 
of interest.  HDAC5, a class IIa histone deacetylase, was one such protein.  This class of 
proteins are transcriptional repressors, however one of their best documented roles is 
binding to and repressing the myocyte enhancer factor-2 (MEF2) transcription factors.  
MEF2 has varied roles in development, differentiation and cell survival (Verdin et al, 
2003; Lemercier et al, 2000).  Although HDAC5 has not previously been reported to 
restrict viral replication, it has been observed to interact with viral proteins.  The HSV-1 
immediate protein ICP0 is able to interact with HDAC5, preventing its repression of 
MEF2.  The function of this isn’t defined, but it may have roles in allowing MEF2 to aid 
neuronal cell survival during viral reactivation (Lomonte et al, 2004).  Additionally, 
HDACs may bind to the EBV protein EBNA2, preventing its transcriptional activation of 
the EBV oncoprotein latent membrane protein-1 (LMP1) (Portal et al, 2006).  HDACs 
have also been investigated in the context of EBV infection as MEF2 has binding sites in 
the promoter for its immediate early gene trans-activator BZLF1, expression of which 
leads to reactivation of the virus.  MEF2 binding is thought to recruit class IIa HDACs to 
the promoter, and maintain EBV in its latent state (Gruffat et al, 2002).       
In this investigation, HDAC5 was found to restrict both VACV and HSV-1 replication.  
These viruses replicate in distinct cellular compartments; VACV replicates in viral 
factories in the cytoplasm, whereas HSV-1 replicates in the nucleus.   The ability of 
HDAC5 to shuttle between these compartments may therefore be important for its 
function here.  The Smith Lab is currently investigating potential roles of HDAC5 in 
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VACV infection, it may involve inhibition of viral promoters, or modulating innate 
immune signalling pathways.  It would be interesting to determine whether this antiviral 
restriction is dependent on MEF2.  Histone deacetylase 4 (HDAC4) is also targeted by 
VACV protein C6, and limits replication; this is thought to be due to roles in promoting 
type I IFN signalling, through interaction with STAT2 (Lu et al, 2019).   
IFITs 
As well as HDAC5, multiple immune mediators were found to be degraded by VACV 
infection.  These included all canonical IFIT proteins, and some of the TRIM proteins.  
Following the publication of this data, the downregulation of IFIT proteins was attributed 
to the VACV protein C9  (Liu et al, 2019).  The C9 protein contains ankyrin repeats, 
usually involved in protein-protein interactions, and an F-box which forms part of the 
SCF complex, resulting in ubiquitination and proteasomal degradation of associated 
proteins.  Proteomic studies were used to investigate the effects of C9 expression in IFN-
stimulated cells.  The F-box was deleted in order to determine which proteins were 
associated with C9, by allowing them to accumulate rather than getting targeted for 
degradation.  This identified IFITs (1, 2, 3 and 5) as the primary targets for interaction 
with and degradation by C9.  This agrees well with the data presented here showing 
downregulation of the IFITs, and rescue with proteasome inhibition by MG132.   
Liu et al. investigated the role of IFITs in VACV infection, and confirmed that IFN 
sensitivity of a C9 deletion mutant was dependent on expression of IFIT1 and 3.  
Furthermore they found that IFN treatment during infection with a C9 deletion mutant 
inhibited synthesis of intermediate and late proteins.  An alternative VACV mutant with 
an inactivated ribose methyl-transferase is unable to convert the IFIT-sensitive 5’ mRNA 
cap to a form which is resistant to IFITs.  This mutant is unable to synthesise early as well 
as intermediate and late proteins, due to recognition of mRNAs by IFITs.  Expression of 
C9 and therefore degradation of IFITs rescued this mutant.  However, expression of 
additional methyl transferase was not able to rescue viral protein synthesis in the C9 
mutant, suggesting the IFITs have additional mechanisms, later in viral replication, 
beyond those involving the 5’ cap.  They suggested that as the expression of intermediate 
and late genes is dependent on viral DNA replication the IFITs may be inhibiting VACV 
at this stage.  This may be in a similar manner to the role of IFITs in restricting HPV 
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infection by binding the E1 protein, but no mechanism was identified (Liu et al, 2019).  
It could be interesting to overlap the list of downregulated proteins from this study with 
the proteomic investigations of C9 to see if any additional targets are identified. 
Collagens 
Although more than two thirds of the downregulated proteins were rescued by proteasome 
inhibition with MG132, such as HDAC5 and the IFITs, some proteins were not rescued.  
A major group of these was the collagens.  In the MG132 experiment, there were 8 
collagens downregulated more than 2 fold, and 11 more than 1.5 fold.  However, just the 
two quantified isoforms of COL6A2 were rescued by MG132.  In the recent analysis by 
the Weekes lab of proteins degradation in HCMV infection, 10 of the 11 collagens 
downregulated by HCMV were transcriptionally regulated, rather than proteasomally 
(Nightingale et al, 2018).  Transcriptional regulation during VACV infection is also a 
possibility, and RNA samples harvested alongside the proteomics ones could be used to 
confirm this.   If this is the mechanism, it remains unclear whether the two viruses regulate 
the collagens in a similar manner, or whether this is a cellular response to infection.      
  
4.8.2 Temporal Regulation of Viral Proteins 
VACV orchestrates a careful cascade of temporally controlled viral protein expression.  
The DNA-dependent RNA polymerase and transcription factors for early genes are 
packaged within the virion.  Stage specific transcription factors then recognise promoters 
of different temporal classes of viral proteins, to regulate their expression.  Additionally, 
expression of intermediate and late genes relies on DNA replication (Baldick  Jr. et al, 
1993; Broyles & Fesler, 1990; Yang et al, 2013; Moss & Salzman, 1968; Keck et al, 
1990).  In this study, quantification of ~80 %  of the viral proteins allowed k-means 
clustering into temporal classes, and identified 4 distinct profiles of expression, Tp1-Tp4.  
These correlated well with RNA-seq based assignments into the E1.1, E1.2, I and L 
classes (Yang et al, 2010, 2011, 2015), and with a previous, more limited, proteomic 
study (Croft et al, 2015).  Additionally, it fitted well with the expected cascade of 
functions at various points during infection, with the earliest class of proteins functioning 
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largely in host interaction, moving through to viral replication and transcription, and 
finally virion associated proteins.   
The rapid changes in the viral proteins present may be assisted by turnover of the mRNAs, 
and proteasomal degradation.  Inhibition of the proteasome led to accumulation of early 
viral proteins, and limited expression of late ones.  The proteasome is known to be 
required for VACV DNA replication, and therefore for the expression of intermediate and 
late viral proteins which is dependent on this (Satheshkumar et al, 2009; Teale et al, 2009; 
Mercer et al, 2012).  Mercer et al. identified that the proteasome is required for viral 
uncoating (hence the addition of MG132 at 2 hpi in this investigation).  However they 
also suggested that a second mechanism is involved in inhibiting viral DNA replication.  
They found that Cullin 3 (Cul3) and RING-box protein 1 (Rbx1), two components of an 
E3 ubiquitin ligase complex, were required for late viral gene expression and for normal 
levels of viral replication.  A mechanism for the involvement of the proteasome in viral 
DNA replication has not yet been elucidated.  The data presented here was consistent with 
these findings, showing early viral proteins accumulate with MG132 treatment, whilst the 
majority of intermediate proteins and all late viral protein expression was reduced with 
MG132.  The reasons for dependence on the proteasome is unclear, it may be necessary 
for degradation of host antiviral factors such as the HDACs and IFITs discussed 
previously, in order to allow viral replication. 
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CHAPTER 5:  CANDIDATE ANTIVIRAL 
RESTRICTION FACTORS 
 
This chapter presents follow up work exploring results from the proteomic screens.  Some of the 
cell lines produced, and restriction assays utilised, where developed by other members of the 
Weekes lab (in particular Dr Katie Nightingale, Dr Luis Nobre and Alice Fletcher-Etherington,, 
University of Cambridge), as indicated in the text, figure legends and methods. 
 
5.1 Introduction and Aims 
5.1.1 Identifying Candidate Antiviral Restriction Factors 
Various characteristics of restriction factors were defined by Duggal et al (2012) (see 
Introduction 1.2.1), and two key features are used here to identify candidate ARFs: (1) 
stimulation by IFN (2) downregulation by viral factor. (Duggal & Emerman, 2012) From 
the work so far presented in this thesis, proteomic data is available on IFN stimulation at 
the surface of primary leukocytes, and on VACV infection in HFFF-TERTs.  As well as 
this, proteomic studies previously published by the Weekes lab and others provide data 
on additional viral infections, in particular WCL and PM data on HCMV infection 
(Weekes et al, 2014) and HIV infection (Matheson et al, 2015; Greenwood et al, 2016).  
Overlap of the IFN screen with these viral datasets was performed to identify candidate 
antiviral restriction factors, and Endothelin Converting Enzyme 1 (ECE1) was identified 
as the major target.  ECE1 is introduced further in section 5.3. 
 
5.1.2 Aims 
1) Identify candidate ARFs through the overlap of IFN and viral infection datasets. 
2) Once a candidate restriction factor has been identified examine: 
a. How the virus downregulates the protein. 
b. Whether the protein acts to restrict viral infection, and if so, how. 
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5.2 Identifying Candidate Antiviral Restriction Factors 
5.2.1 Overlap of IFN Simulation and Viral Infection Data 
Overlap of the IFN stimulation with the VACV infection proteomic screens presented 
here, along with proteomic data on other viral infections, provided a basis for identifying 
candidate restriction factors (Table 5.1, Table 5.2).  IFN stimulated proteins in both 
monocytes and T cells were examined (‘sensitive’ criteria, requiring the protein to have 
an IFN-induced FC > 1SD from the mean and a FC > 1 in all donors, as described in 
Chapter 3).  Alongside this, infection with HCMV, VACV and HIV was analysed.  For 
each virus, the maximal downregulation of each protein is given, and this was determined 
by considering FC at each time point examined by proteomics, and taking the minimum: 
1. HCMV WCL and PM (Weekes et al, 2014): For WCL1 and PM1, the average 
expression at each time point was compared to the average mock and to 24 hpi.  
For WCL2 and PM2, the expression at each time point was compared to the 
average mock, 12 hpi and 18 hpi.  Comparison to early infection time points 
was in order to account for proteins that were initially induced by IFN and then 
downregulated by the virus.    
2. VACV WCL (Soday et al, 2019): Expression at 18 hpi was compared to the 18 
h mock. 
3. HIV WCL (Greenwood et al, 2016), HIV PM (Matheson et al, 2015): 
Expression at each time point was compared to an uninfected 0 h sample. 
It is important to note that the data from the IFN and viral proteomic screens were matched 
on the basis of the gene symbol, and therefore may represent data on different isoforms 
of the protein.  Blank spaces in the table indicate that the protein was not quantified in the 
given screen.  Additionally, whilst the IFN data is in primary monocytes and CD4+ T 
cells, the HCMV and VACV proteomic time courses were performed in HFFF-TERTs, 
and the HIV one in CEM-T4s, a cultured T cell line. 
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Table 5.1 Effect of viral infection on proteins which were IFN stimulated in monocytes 
IFN and viral induced FCs were calculated as explained in the text above.  Blank spaces 
indicate that the protein was not quantified in the given screen.  Viral data from (Weekes 
et al, 2014; Soday et al, 2019; Matheson et al, 2015; Greenwood et al, 2016).  
Gene 
Symbol 
FC on IFN 
Stimulation 
HCMV VACV HIV 
WCL1 WCL2 PM1 PM2 WCL1 WCL2 WCL3 WCL PM 
SSTR2 7.62                   
CD69 4.29                 0.93 
SLAMF7 4.06                   
CD38 3.88     0.89         0.87 0.64 
FFAR2 3.69                   
BST2 3.64     0.52 1.02       0.48 0.11 
ISG15 3.30 1.03 0.32 0.93 1.20 0.99 0.73 0.85 0.98   
CD40 2.55   1.29 1.26 2.54 0.78 0.92 0.84     
SEMA4A 2.53                 0.19 
HLA-DRB4 2.45                   
LILRB4 2.43               0.74   
SIGLEC1 2.41                   
SLAMF1 2.41                   
IL2RA 2.40                   
CD83 2.29                 0.20 
LILRB4 2.23               0.74   
CD274 2.21   0.77 0.92 1.64   1.26 0.97     
HSPA6 2.14   1.44 0.70 3.43 1.03 1.26 1.29     
HLA-A 2.10 0.43 0.22 0.45 0.53 0.94 0.71 0.73 0.63 0.13 
HLA-B 2.07         0.81 0.72 0.78     
CCR7 2.07                 0.15 
TMEM123 2.05     0.48 0.50           
HLA-F 2.02   0.36   0.77 0.57 0.80 0.65     
HLA-DRB1 1.92                   
CALU 1.90 0.79 1.03 0.71 2.95 1.01 1.03 1.08 0.95 0.95 
HLA-DRA 1.87                   
HLA-E 1.82 0.49 0.68 1.12 2.42 1.27 0.74 0.48 1.16   
LILRA6 1.81                   
HLA-DRB3 1.79                   
SLC39A8 1.76     0.96 12.6       1.13 0.45 
CD22 1.76                   
CCR5 1.70                 0.39 
HLA-C 1.68     0.56 0.36 0.66 0.47 0.40 0.99 0.64 
DMKN 1.65                 0.67 
BMPR2 1.64   0.89 1.25 1.38 0.87 1.19 0.70   0.85 
GPR84 1.63                 0.40 
FAS 1.58 0.25 0.29 0.67 0.49 0.83 0.70 0.81 1.08 0.60 
CD86 1.56                   
HLA-DPB1 1.56                   
CYBB 1.53                   
LILRB2 1.52                   
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Table 5.2 Effect of viral infection on proteins which were IFN stimulated in T cells 
IFN and viral induced FCs were calculated as explained in the text above.  Blank spaces 
indicate that the protein was not quantified in the given screen.  Viral data from (Weekes 
et al, 2014; Soday et al, 2019; Matheson et al, 2015; Greenwood et al, 2016). 
Gene 
Symbol 
Fold 
Change on 
IFN 
Stimulation 
CMV VACV HIV 
WCL1 WCL2 PM1 PM2 WCL1 WCL2 WCL3 WCL PM 
IL1RN 2.35   0.22               
ECE1 2.30 0.42 0.24 0.51 0.31 0.66 0.80 0.69 0.78 0.60 
BST2 2.16     0.52 1.02       0.48 0.11 
TMEM123 2.01     0.48 0.50           
CNP 1.46 0.99 0.88 0.80 0.98 0.79 0.80 0.83 0.64 0.74 
KCNA3 1.45                   
GPR171 1.37                   
XRCC5 1.33 0.92 0.81 0.64 0.39 1.01 1.02 1.11 0.98 0.61 
HLA C 1.32     0.56 0.36 0.66 0.47 0.40 0.99 0.64 
PKP1 1.29   0.22             0.78 
HLA F 1.26   0.36   0.77 0.57 0.80 0.65     
HLA E 1.26 0.49 0.68 1.12 2.42 1.27 0.74 0.48 1.16   
ORM1 1.22                   
 
5.2.2 Candidate Antiviral Restriction Factors 
Monocytes 
BST2 (tetherin) is a well characterised, IFN-stimulated restriction factor for HIV (Perez-
Caballero et al, 2009; Hammonds et al, 2010); the overlap shows it was both upregulated 
by IFN and also downregulated during HIV infection as has been previously observed 
(Neil et al, 2008; Van Damme et al, 2008).  It is interesting that there were several proteins 
in the monocyte dataset which were quantified exclusively in the PM HIV data, and not 
the other viral time-courses.  This is likely due to the enrichment for PM proteins, and 
because the HIV infection was of CEM-T4 cells rather than fibroblasts, and some of the 
proteins quantified are expressed predominantly in leukocytes.  CCR7 was stimulated by 
IFN in primary monocytes and downregulated at the cell surface in HIV infection; it is 
thought to be downregulated by the HIV protein Vpu in order to limit migration to lymph 
nodes (Ramirez et al, 2014).  However, not all of the proteins that fall into this overlap 
are known to have antiviral activity; they may be important in infection or immunity for 
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other reasons.  C-C chemokine receptor type 5 (CCR5), for example, is known to act as 
the HIV coreceptor.  Rather than being antiviral,  upregulation by IFN may in fact result 
in an expanded cell tropism for HIV (Stoddart et al, 2010).  Downregulation of CCR5 is 
by the HIV protein Nef, and may be in order to prevent superinfection (Michel et al, 
2005).  FAS was upregulated by IFN in primary monocytes, and downregulated by 
multiple viruses.  It was previously observed to be downregulated at the cell surface 
during both adenovirus and HCMV infection, in order to evade Fas induced apoptosis 
(Shisler et al, 1997; Seirafian et al, 2014). 
T cells 
Fewer proteins were consistently upregulated by IFN in primary CD4+ T cells.  IL1RN 
competes with IL-1 for binding to its receptor, preventing its pro-inflammatory functions 
(Arend et al, 1998).  IL1RN was quantified in three of the five donors, and upregulated 
by IFN in all of these.  It also appears to be downregulated by HCMV infection, although 
it should be noted that it was only quantified here with a single peptide, and has a complex 
and variable effect during infection with multiple viruses (Kline et al, 1994; Hill-Batorski 
et al, 2015; Yoon et al, 1999).  X-ray repair cross-complementing protein 5 (XRCC5), 
also known as Ku80, was upregulated by IFN and downregulated to some extent at the 
cell surface by infection with HCMV or HIV; examination of the individual datasets 
showed these effects were modest.  Ku80 forms part of the DNA-PK complex, which has 
been associated with DNA sensing and innate immune functions (Ferguson et al, 2012; 
Morchikh et al, 2017).  However, it also has roles at the cell surface in cell-cell 
interactions and adhesion (Monferran et al, 2004).  CNP was also downregulated to some 
extent by HIV, and is a known ISG which restricts HIV infection (Wilson et al, 2012).    
Candidate ARFs targeted by HCMV presented the most tractable targets, due to the 
establishment of HCMV restriction assays within the Weekes lab.  Although TMEM123 
may be an interesting candidate for follow up studies, the lack of prior literature and 
reagents limited this (see chapter 3.8).  ECE1 was upregulated in all five donors in 
primary T cells, and downregulated during HCMV infection, and to some extent by the 
other viruses; it was therefore chosen for further investigation.  
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5.3 Endothelin Converting Enzyme 1 (ECE1) 
ECE1 is a zinc metallopeptidase and type II integral membrane protein.  It was first 
identified as a 758 amino acid polypeptide, expressed abundantly in epithelial cells and 
responsible for the production of the vasoactive molecule Endothelin (ET), by cleavage 
of an inactive intermediate.  It shows sequence similarity to the peptidase Neprilysin and 
the human Kell blood group protein (Xu et al, 1994).  There are four isoforms, with some 
localised to the cell surface where they are present as homodimers, and some intracellular. 
ECE1 has also been shown to be shed from endothelial cells (Kuruppu et al, 2007). 
 
5.3.1 Isoforms  
The four isoforms of ECE1 are all generated from different promoters in a single gene.  
They share a common, large C terminal domain containing the HEXXH zinc binding 
motif and have differing N terminal cytoplasmic tails (Figure 5.1).  They are all thought 
to cleave ET with equal efficiency, but they vary in their subcellular localisation, and 
expression across different tissues (Valdenaire et al, 1999; Schweizer et al, 1997). 
The first three isoforms of ECE1 discovered were ECE-1a, 1b and 1c. ECE-1a is the most 
highly expressed at the cell surface, followed by ECE-1c.  ECE-1b is found at intracellular 
compartments (Schweizer et al, 1997; Barnes et al, 1998). ECE-1d was identified later, 
and found to have an intermediate distribution, present both at the PM and intracellularly 
in endosomal structures (Valdenaire et al, 1999).  Finer definition of their intracellular 
localisations showed that ECE-1b concentrates in late endosomes/multivesicular bodies, 
whilst ECE-1d is in recycling endosomes.  However, the isoforms may heterodimerize, 
in which case the localisation of ECE-1b acts as the dominant regulatory signal, resulting 
in intracellular localisation of other isoforms (Muller et al, 2003).  ECE-1a may also be 
targeted to the nucleus (Jafri & Ergul, 2003).  The tissue distribution of each isoform also 
differs; ECE-1a for example has a high level of expression in endothelial cells, but not 
smooth muscle cells (Valdenaire et al, 1999).   
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Figure 5.1 Isoforms of ECE1 and gene organisation 
The organisation of the 5’ end of the ECE1 gene is shown, and how the four exons 
contribute to each isoform (based on Valdenaire et al, 1999).  Exons 4-19, which are 
common to all isoforms and constitute the extracellular domain, have been omitted.  
Transcription is driven from the promoters (P) upstream of the four exons, and these 
transcripts are spliced to generate the isoforms.  The length of each isoform in amino 
acids is given, along with the predominant localisation (sources of this information given 
in text).    
 
5.3.2 Function 
Endothelin 
The main function of ECE1 is to cleave the inactive precursor big-ET into its mature 
vasoactive form.  There are three isoforms of ET, with ET-1 being cleaved at Trp21-
Val22  (Létourneau et al, 2000).   ET-1 is usually produced by endothelial cells, but can 
also be produced by other cells including macrophages (Ehrenreich et al, 1990, 1993). 
Endothelin acts via the ETA and ETB receptors, with the exact function depending on the 
localisation and type of the receptor, but the overall effect is of ET-1 as a potent 
vasoconstrictor and pro-inflammatory peptide (Houde et al, 2016).  It is also known to 
induce expression of monocyte chemotactic protein-1 (MCP1) and IL-8 (Helset et al, 
1994), and the endothelin system involving ECE1, ETB and ET-1 is involved in monocyte 
diapedesis of the brain endothelial cell barrier (Reijerkerk et al, 2012). 
Figure of ECE1 isoforms and gene organisation removed for copyright reasons.  
Copyright holder is John Wiley and Sons. 
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Cleavage of other peptides 
Analysis of a purified, recombinant soluble form of ECE1 showed it is also able to cleave 
other biologically active peptides, including Bradykinin (Pro7-Phe8), angiotensin I 
(predominantly pro7-phe8 but also some other residues), neurotensin (pro10-tyr11, leu2-
tyr3) and substance P (SP, gln6-phe7, gly9-leu10), as well as having various cleavage 
sites in other peptides.  The study demonstrated that ECE1 cleavage sites are usually 
found on the amino side of hydrophobic residues. Substrates smaller than hexapeptides 
were not efficiently hydrolysed (Johnson et al, 1999).  The cleavage of substrates by 
ECE1 is pH dependent, with hydrolysis of big ET-1 being most efficient at a neutral pH, 
but smaller substrates being cleaved at an acidic pH (Fahnoe et al, 2000). 
Receptor Recycling and Resensitisation  
ECE1 regulates receptor recycling and resensitisation through metabolism of peptide 
ligands in endosomes (Figure 5.2).  SP binds the neurokinin 1 receptor (Nk1R) at the PM, 
leading to activation of NF-B and proinflammatory cytokines.  Translocation of 
arrestin to the membrane triggers receptor desensitisation and internalisation, and then 
recruitment of proto-oncogene tyrosine-protein kinase Src, dual specificity MAPK-kinase 
(MEK) and extracellular signal-regulated protein kinase 1/2 (ERK1/2), leading to MAPK 
signalling.   ECE1 is able to degrade SP in the early endosomes, terminating this signal 
and allowing recycling of Nk1R (Roosterman et al, 2007).  Inhibiting ECE1 therefore 
leads to increased signalling through ERK1/2, which triggers phosphorylation of the 
nuclear death receptor, nuclear receptor subfamily 4 group A member 1 (Nur77) and cell 
death (Cottrell et al, 2009).  It also attenuates inflammation by preventing the recycling 
and resensitisation of the receptor (Cattaruzza et al, 2013).  ECE1 is also involved in 
recycling of other receptors, degrading calcitonin gene related peptide (CGRP) to 
promote calcitonin receptor-like receptor / receptor activity-modifying protein 
1 (CLR/RAMP) recycling (Padilla et al, 2007), and degrading glucagon-like peptide 1 
(GLP-1) to recycle and resensitise the GLP-1 receptor (Lu & Willars, 2019).  ECE1 has 
also been implicated in the cleavage and recycling of TLR9 in endosomes, regulating 
TLR9 mediated cytokine release (Julian et al, 2013).  
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Other functions and homologues 
Finally, ECE1 may have other functions.  It has been implicated in many diseases, and 
homologues may also suggest additional roles.  The homologue M13 is found in 
invertebrates.  This suggests that the enzyme is evolutionarily conserved, and as 
invertebrates do not have a closed circulatory system emphasises roles outside of blood 
pressure regulation (Macours et al, 2004).   
 
Figure 5.2 ECE1 involvement in substance P degradation and receptor recycling 
Substance P activates NK1R, inducing phosphorylation of the receptor and translocation 
of    -arrestin to the membrane.  This triggers receptor desensitisation and endocytosis, 
as well as recruitment of the components of a MAPK signalling module (Src, MEK, 
ERK1/2).  In the acidified endosome, ECE1 degrades substance P, causing the complex 
to disassemble, and dephosphorylation of NK1R.  The receptor is recycled to the PM, 
mediating resensitisation.  In the absence of ECE1, sustained signalling through ERK 
leads to phosphorylation and activation of Nur77, leading to cell death.  Mechanism of 
ECE1 regulation of SP-stimulated ERK activation and cell death proposed by (Cottrell et 
al, 2009), and figure reproduced based on this research originally published in the Journal 
of Biological Chemistry © American Society for Biochemistry and Molecular Biology. 
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5.3.3 Regulation 
Expression 
Previous research has implicated a variety of factors in regulating ECE1 expression, 
which may vary dependent on context and cell type.  It is upregulated in endothelial cells 
by the cell surface TNF-like weak inducer of apoptosis (TWEAK), through the 
modulation of AP-1 and NF-b transcription factors (Martínez-Miguel et al, 2017).     In 
addition, expression of ECE1 in human umbilical vein endothelial cells could be induced 
by some chemokines; MCP1 was the most potent stimulator, but macrophage 
inflammatory protein 1 and 1, IL-8, and RANTES (regulated on activation, normal T 
cell expressed and secreted) all stimulated ECE1, as did a mixture of cytokines (IL-1, 
TNF-, IFN-) (Molet et al, 2000).  A study in mice found that poly(I:C) transfection led 
to increased ECE1 mRNA in skin, and that this effect could be blocked by knockout of 
TLR3, but not the IFN receptor (Farina et al, 2011).  This suggests that ECE1 is 
upregulated by the TLR3 pathway and this is independent of IFN.  ECE1 is also 
upregulated by shear stress, hyperochesterolemia, during statin therapy and due to high 
glucose levels.  It is downregulated by the influx of calcium triggered by ETB receptor 
activation, acting as a negative feedback loop when ET-1 concentrations are high 
(Kuruppu & Smith, 2012).  There are therefore many interacting factors and a great deal 
of complexity in the regulation of ECE1 expression.  
Localisation  
In CHO cells, PKC mediated phosphorylation triggers ECE-1a and ECE-1b 
internalisation.  PKA mediated phosphorylation only led to ECE-1b internalisation as 
ECE-1a does not have this phosphorylation site.  Conversely, PMA mediated 
phosphorylation or high glucose concentrations, lead to trafficking of ECE-1c to the cell 
surface (Kuruppu & Smith, 2012; Kuruppu et al, 2012).  In the AtT-20 neuroendocrine 
cells, ECE-1a and 1c are at the PM, and 1b and 1d in the endosomal system.  Formation 
of heterodimers with ECE-1b was able to regulate localisation of other isoforms (Muller 
et al, 2003).  
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5.3.4 ECE1 in Disease and Infection 
Levels of ECE1 or of ET have been linked to viral myocarditis in a murine model, with 
increasing levels of ECE1 in murine heart tissue following infection with 
encephalomyocarditis virus (Ono et al, 1999).  Increased levels of ECE1 and ET in the 
placenta are also observed in infection associated pre-term birth (Olgun et al, 2010; Wang 
et al, 2010), and in chronic rhinitis (Furukawa et al, 1996).  The HIV proteins gp120 and 
trans-activator of transcription (TAT) have been reported to upregulate ET-1, and this 
may be related to HIV-associated pulmonary hypertension, though the role of ECE1 here 
has not been investigated (Ehrenreich et al, 1993; Chauhan et al, 2007).   ECE1 has also 
been linked to cell invasion in multiple cancers, including prostate cancer (Lambert et al, 
2008; Hong et al, 2011), breast cancer (Smollich et al, 2007) and colorectal cancer (Pérez-
Moreno et al, 2019) amongst others, with the different isoforms having different effects 
(Tapia & Niechi, 2019).  ECE1 also has a role in Alzheimers (Eckman et al, 2003), and 
cardiovascular disease (Martínez-Miguel et al, 2009), as well as an inactivating mutation 
of ECE1 being associated with Hirschsprung disease (Hallett et al, 1992).   
 
5.3.5 Potential Roles as a Restriction Factor 
Based on its known functions, there are several ways that ECE1 might be predicted to 
restrict viral infection.  As ECE1 is able to cleave peptides, a potential mechanism could 
involve hydrolysis of peptides necessary for viral replication, or potentially even of the 
virus itself at the cell surface or in endosomes.  Alternatively, ECE1 may be involved in 
the recycling and resensitisation of immune receptors.  A major role of ECE1 is in 
cleavage of big-ET to its mature form, so another possibility is that it is the increased 
level of ET that is important.  If a role in infection was established, there would therefore 
be several interesting avenues for exploration.   
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5.4 ECE1: A Candidate Antiviral Restriction Factor 
5.4.1 Validation of IFN Stimulation 
Upon IFN stimulation, ECE1 was upregulated more than 1.5 fold in all five donors 
(Figure 5.3A).  The average FC with IFN stimulation was greater than that observed for 
BST2, a known restriction factor.  This proteomic data was validated by RT-qPCR in 
primary CD4+ T cells (Figure 5.3B), and by immunoblot in two cultured T cell lines, 
Jurkats and SUPT1s (Figure 5.3C).  Identification of a suitable antibody for this is 
discussed in section 5.5. 
 
Figure 5.3 Validation of IFN stimulation of ECE1 
(A) FC of ECE1 upon IFN stimulation in each cell type examined by proteomics. 
(B) RT-qPCR validating IFN stimulation of ECE1 in primary CD4+ T cells. 
(C) Immunoblot validating IFN stimulation of ECE1 in two cultured T cell lines, 
Jurkats and SUPT1s. 
 
5.4.2 How Does HCMV Downregulate ECE1? 
In addition to being stimulated by IFN, ECE1 was highlighted as a candidate restriction 
factor due to also being downregulated by viral infection.  Over 96 h of infection of 
fibroblasts with HCMV, ECE1 was substantially downregulated at both the whole cell 
and PM level (Weekes et al, 2014) (Figure 5.4).   
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Figure 5.4 ECE1 is downregulated during infection with HCMV 
Data from Weekes et al., 2014. 
(A) Downregulation of ECE1 at the whole cell level during HCMV infection 
(B) Downregulation of ECE1 at the cell surface during HCMV infection 
 
Further data was examined to investigate how HCMV might downregulate ECE1.  Dr 
Katie Nightingale (Weekes Lab, Department of Medicine, University of Cambridge) in 
collaboration with Dr Richard Stanton (Cardiff University) performed a proteomic screen 
whereby HFFF-TERTs were infected with HCMV mutants, each with a different block 
of genes deleted (Nightingale et al, 2018).  Deletion of the US1-US11 block led to 
increased expression of ECE1 compared to WT infection or other mutants (Figure 5.5A).  
This suggests that a gene in this block is responsible for downregulation of ECE1 during 
infection.  Furthermore, a proteomic examination of the HCMV protein US2 was 
previously published (Hsu et al, 2015).  In this, fibroblasts were infected with WT HCMV 
or a US2 deletion mutant, and examined by MS.  A host of proteins were rescued by 
deletion of US2, including multiple integrin family members, and ECE1 (Figure 5.5B).  
US2 is therefore necessary for ECE1 downregulation.  An immunoblot of fibroblasts 
expressing US2 demonstrated that US2 was also sufficient for degradation of ECE1 
(Figure 5.5).  The US2 expressing cell line was kindly provided by Dr Luis Nobre 
(Weekes Lab, Department of Medicine, University of Cambridge).   
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Figure 5.5 The HCMV proteins US2 is necessary and sufficient for degradation of 
ECE1 
(A) HFFF-TERTs were infected with either WT HCMV or various mutant viruses 
with different blocks of genes deleted, before WCL analysis by TMT-based 
proteomics.  Deletion of the US1-11 gene block resulted in increased 
expression of ECE1 compared to infection with the WT virus (data from 
Nightingale et al, 2018). 
(B) ECE1 expression is increased during infection with a US2 deletion mutant 
compared to infection with WT HCMV, demonstrating that US2 is necessary 
for downregulation of ECE1 during infection (data from Hsu et al, 2015). 
(C) Immunoblot of WT fibroblasts or cells expressing the viral protein US2, 
demonstrating that US2 alone was sufficient for downregulation of ECE1. 
 
 
5.5 ECE1:  Reagents 
5.5.1 ECE1 Antibodies 
Several different unconjugated antibodies were trialled for detection of ECE1 (Table 5.3).  
Ideally, the PM proteomic data would be validated by cell surface flow cytometry, 
however intracellular flow cytometry and immunoblot were also tested.       
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Table 5.3 Table of antibodies trialled for ECE1 detection 
Four antibodies were trialled for detection of ECE1 by cell surface or intracellular flow 
cytometry and immunoblot.  Applications tested by supplier: flow cytometry (FCM), 
immunohistochemistry (IHC), western blot (WB).  The Proteintech antibody was still 
undergoing quality control checks, so some information was not available.  
Supplier 
Product 
Code 
Species 
Polyclonal or 
Monoclonal? 
Residues 
Raised 
Against 
Applications 
Tested by Supplier 
Invitrogen PA5-24563 Rabbit Polyclonal 528-556 FCM, IHC, WB 
Abcam ab71829 Rabbit Polyclonal 700-770 WB 
R&D MAB17841 Rat Monoclonal 90-770 FCM 
Proteintech N/A Rabbit - - - 
 
 
5.5.2 Testing ECE1 Antibodies by Flow Cytometry 
Cell Surface Flow Cytometry 
As the proteomic data on IFN stimulation of ECE1 was from PM samples, cell surface 
flow cytometry would be the ideal technique for validation and further investigation.  The 
Invitrogen, Abcam and R&D antibodies were tested for this application.  ECE1 is a 770 
amino acid single pass type II membrane protein, with residues 90-770 being 
extracellular, and all antibodies were raised against extracellular epitopes (Table 5.3).    
Unfortunately, none of the antibodies showed substantial separation in signal compared 
to unstained samples or those stained with only a secondary antibody (Figure 5.6A).  
Furthermore, the signal from CRISPR/Cas9 ECE1 knockout cells was the same as that 
observed in ECE1 overexpressing and control cells (Figure 5.6B, cell lines discussed in 
section 5.6.2 and 5.6.4).  Multiple concentrations of the antibodies were tested and similar 
results were observed.  One caveat to this data is however, that the ECE1 overexpressing 
cell line was later determined to be isoform ECE-1b, which is predominantly intracellular.  
Additionally, it can heterodimerise with other isoforms and is the dominant protein in 
determining their location.         
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Figure 5.6 Testing ECE1 antibodies for cell surface flow cytometry on HFFF-TERTs 
(A) Cells expressing the GAW control pHAGE-PSFFV plasmid were analysed by 
cell surface flow cytometry.  They were either unstained (light grey), stained 
with only the relevant AF647-conjugated secondary antibody (rabbit for 
Invitrogen and Abcam, rat for R&D; dark grey), or stained with both primary 
and secondary antibodies (red). 
(B) Overlay of signal from staining of GAW control cells (red) compared to 
CRISPR knockout polyclonal populations (blue, ECE1_g2, ECE1_g4) and 
cells overexpressing ECE1-Flag (orange), using the stated antibodies. 
 
Intracellular Flow Cytometry 
The same antibodies were additionally tested for intracellular flow cytometry.  In this 
case, the HFFF-TERTs were fixed using 4% paraformaldehyde and then permeabilised 
using methanol, prior to antibody staining.  Despite all three antibodies showing a more 
promising distinction between the stained samples and those incubated with just the 
secondary antibody (Figure 5.7A), none showed consistent correlation between the level 
of ECE1 expected in the CRISPR and overexpression cell lines, and the signal detected 
by flow cytometry (Figure 5.7B).  As an antibody had been validated for immunoblot (see 
section 5.5.3), and no promising results were obtained for cell surface flow cytometry, no 
further examination of antibodies for detection of ECE1 by flow cytometry was 
conducted. 
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Figure 5.7 Testing ECE1 antibodies for intracellular flow cytometry on HFFF-TERTS 
(A) Cells expressing the GAW control pHAGE-PSFFV plasmid were analysed by 
intracellular flow cytometry.  They were either unstained (light grey), stained 
with only the relevant AF647-conjugated secondary antibody (rabbit for 
Invitrogen and Abcam, rat for R&D; dark grey), or stained with both primary 
and secondary antibodies (red). 
(B) Overlay of signal from staining of GAW control cells (red) compared to 
CRISPR knockout polyclonal populations (blue, ECE1_g1, ECE1_g4) and 
cells overexpressing ECE1-Flag (orange), using the stated antibodies. 
 
5.5.3 Testing ECE1 Antibodies by Immunoblot 
The four antibodies described in Table 5.3 were trialled on three different cancer cell lines 
for detection of ECE1 by immunoblot.  DLD1 and SW48 cells are both colorectal cancer 
cell lines (kindly gifted by Dr Matthew Hoare, Cancer Research UK, Cambridge) and in 
proteomic data available in the Weekes lab, DLD1 cells were shown to have higher 
expression of ECE1 than SW48 cells (Weekes and Gygi et al, unpublished).  In a separate 
experiment, MDA-MB-231 cells showed high expression of ECE1 relative to other breast 
cancer cell lines (Weekes and Gygi et al, unpublished), and ECE1 should therefore be 
readily detectable in this cell line (kindly gifted by Proffessor Paul Lehner).     
All four antibodies were trialled for detection of ECE1 by immunoblot (Figure 5.8A).  
Using the R&D antibody, no bands were observed.  As it was not advertised by the 
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supplier as being suitable for readout by immunoblot, no further optimisation was 
performed with the R&D antibody.  The Proteintech antibody resulted in many bands; as 
it had not yet passed quality control, further testing with this was also abandoned.  The 
Invitrogen and Abcam antibodies both gave promising results, and as the Abcam antibody 
produced bands of the expected size this was used for all further experiments (Figure 
5.8B).  Immunoblot analysis of the subsequently produced overexpressing and knockout 
cell lines provided additional confidence on detection of ECE1 by the Abcam antibody 
(eg Figure 5.10, Figure 5.15). 
 
Figure 5.8 Immunoblot analysis of ECE1 antibodies 
(A) Immunoblot of indicated anti-ECE1 antibodies on various cancer cell lines. 
(B) Example immunoblots given on the manufacturer’s website for ECE1 from the 
Invitrogen and Abcam anti-ECE1 antibodies.  The Invitrogen antibody was 
tested on A2058 cell lysates, whilst the Abcam antibody probed HUVEC (L1), 
MEF1 (L2) and NIH-3T3 (L3) lysates. 
 
5.6 ECE1: Does it Restrict HCMV Infection? 
5.6.1 Restriction Assay Methodology 
In order to examine the possibility of ECE1 being a novel ARF, restriction assays were 
performed to assess the effects of ECE1 expression on HCMV infection.  All cell lines 
were produced in HFFF-TERTs as these are permissive to infection with the Merlin strain 
of HCMV, and previous data demonstrated that the virus targets ECE1 in this cell line.  
ECE1 overexpression cells were produced, as well as knockdowns using either shRNAs 
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or the CRISPR/cas9 system.  For the restriction assay with overexpression cell lines, 
gateway (GAW) control cells and cells overexpressing ECE1 were seeded in triplicate for 
each MOI to be analysed.  The cells were infected with HCMV in which the immediate-
early protein UL36 was fused to GFP at the C terminus with a self-cleaving P2A peptide, 
so GFP would be released on translation.  UL36 was chosen for these assays as it was one 
of the most abundantly expressed viral proteins early in infection, and the fusion of GFP 
did not disturb function (Nightingale et al, 2018).  After 24 h the samples were harvested 
and fixed for analysis by flow cytometry (Figure 5.9).  If ECE1 is a restriction factor, a 
reduced percentage of GFP positive cells would be expected to be observed in the 
overexpressing cells compared to controls.  The opposite would be true of the knockdown 
cells, where an increased percent infection would be expected if the protein were a 
restriction factor.     
 
Figure 5.9 Schematic of HCMV restriction assay 
Control, knockdown or overexpression cells were infected at low MOI with HCMV, 
where the immediate-early viral protein UL36 was fused to GFP.  After 24 h the cells 
were harvested and analysed by flow cytometry.  If the protein were a restriction factor, 
you would expect to see decreased infection of the overexpressing cells compared to 
controls, and therefore a reduced percent of GFP positive cells.  Conversely, increased 
infection would be expected in the knockdown cells compared to the control, and 
therefore a higher percentage of GFP positive cells would be observed. 
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Low MOIs have traditionally been used for restriction assays (Adler et al, 2011; 
Nightingale et al, 2018).  There is some previous evidence that restriction may be 
saturated or overcome at higher MOIs (Griffin & Goff, 2015; Nightingale et al, 2018; 
Tavalai et al, 2011).  Therefore, a range of low MOIs were used for each infection.   
The read out from these assays was detection of fluorescence from the GFP tagged 
immediate-early UL36 protein, by flow cytometry.  Detection of GFP therefore suggests 
the virus has successfully entered the cells and begun expression of immediate-early viral 
genes.  The assay therefore does not examine the efficiency of viral assembly or exit.   
This assay was adapted from one developed by (Tavalai et al, 2011), examining the effect 
of Sp100 on HCMV infection.  Positive controls used for these assays were the previously 
identified restriction factors, Sp100 and Daxx, both of which are components of ND10 
bodies (Kim et al, 2011b; Adler et al, 2011; Woodhall et al, 2006). 
 
5.6.2 Overexpression 
Lentiviral transduction was used to produce cell lines overexpressing FLAG tagged 
ECE1.  This was expressed from the pHAGE-PSFFV plasmid, which had been generated 
using the gateway system to transfer the ECE1 sequence from a donor plasmid to the 
expression vector (see Methods 2.4.1).  The control cells were transduced with the GAW 
control plasmid (GAW).   Overexpression of ECE1 was validated by immunoblot (Figure 
5.10).  Some caution should be exerted in interpreting these results as the plasmid was 
overexpressing ECE-1b, a predominantly intracellular isoform of ECE1, and therefore 
possibly not the one detected in the PM proteomics.  
 
Figure 5.10 Immunoblot confirming overexpression of ECE1 in HFFF-TERTs 
HFFF-TERTs expressing the GAW control plasmid or ECE1-Flag.  Unfortunately, the 
gel was over-exposed on imaging resulting in the blue band, but still shows clear 
overexpression. 
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The restriction assay was performed as described in Figure 5.9.  The assay was repeated 
four times on a range of low MOIs (Figure 5.11).  Sp100 and Daxx were included as 
positive controls in three of the experiments.  In almost all cases, overexpression of Sp100 
and Daxx resulted in a significantly reduced percent infection compared to GAW control 
cells (p< 0.05); however, this reduction was much more dramatic with Daxx than Sp100.  
Overexpression of ECE1 also resulted in a clear reduction in HCMV infection, though 
more similar in extent to Sp100 than Daxx.  This provided some initial support for ECE1 
acting to restrict early stages of HCMV infection. 
 
Figure 5.11 HCMV restriction assay on HFFF-TERTs overexpressing ECE1 
(A-D)   In all cases, cells were infected with UL36-GFP HCMV for 24 h before harvesting 
and analysis of the percent infection by flow cytometry.  The control cell line was 
transduced with the GAW control plasmid.  Sp100 and Daxx were included as positive 
controls for restriction factors.  Overexpression of ECE1-Flag led to reduced percent 
infection in all cases, similar to that observed with Sp100 but to a much lesser extent 
than with Daxx.  Data is represented as the mean of triplicate data ± SEM.  P-values 
were estimated using a two-tailed t-test, with each sample compared to the GAW 
control cells; * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
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5.6.3 shRNA knockdown 
A complementary approach to the overexpression restriction assay examined two 
knockdown cell lines, Sh1 and Sh2.  These were produced in HFFF-TERTs, each using 
an shRNA targeting a different sequence which was common to all isoforms of ECE1.  
As an antibody had not yet been identified for immunoblot at this stage, RT-qPCR was 
used to confirm a knockdown of 3.3 and 4.3 fold in ECE1 Sh1 and Sh2 cells respectively 
(Figure 5.12).   Sp100 knockdown cells were produced by Dr Katie Nightingale (Weekes 
Lab) and validated by immunoblot (Nightingale et al, 2018). 
 
Figure 5.12 Validation of ECE1 knockdown in HFFF-TERTs by RT-qPCR 
RT-qPCR was used to confirm the knockdown of  ECE1 in HFFF-TERTs by shRNA.  
The two different shRNAs resulted in 3.3 and 4.3 fold knockdowns compared to the cell 
line expressing a control shRNA. 
 
Restriction assays were performed as depicted in Figure 5.9.  A range of low MOIs were 
used, and results from a subset of these in three different experiments are shown in Figure 
5.13.  Results here were inconclusive.  The percent infection observed in the ECE1 
shRNA knockdown cells was variable, with Figure 5.13C showing a clear restrictive 
effect of ECE1, and more variable results in Figure 5.13A and B, particularly with 
ECE1_sh1.  Additionally, despite using the same Sp100_sh1 positive control cell line as 
was previously used in restriction assays (Nightingale et al, 2018), a reliable increase in 
the percent infection compared to the control cells was not observed.  It was therefore 
difficult to draw definitive conclusions from this data.   
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Figure 5.13 HCMV restriction assay on ECE1 shRNA knockdown HFFF-TERTs 
In all cases, control shRNA or ECE1 knockdown cells were infected with UL36-GFP 
HCMV for 24 h before harvesting.  The percent infection was assessed by flow cytometry.  
Sp100 was included as a positive control for a restriction factor.   
(A) Bars represent the mean of duplicate data, and error bars display the range 
(except for the Sp100 data at an MOI of 0.003 where only one data point was 
available). 
(B) Bars represent the mean of duplicate data, and error bars display the range.  
(C) Bars represent mean of triplicate data ± SEM.  P-values were estimated using 
a two-tailed t-test, with each samples compared to control_sh1; * p < 0.05, ** 
p < 0.01, *** p < 0.001, ns = not significant. 
 
There was some concern that the shRNA knockdown of ECE1 was being lost over time, 
resulting in variable effects depending on how long the cells had been passaged for prior 
to the assay.  Following these restriction assays, an antibody had been identified for 
detection of ECE1.  This was used to test the original lysates, and some lysates made from 
cells which had been passaged several times (passage ~5 following selection).  It did 
appear that the level of knockdown was reduced, particularly in the sh2 cells, even after 
a low number of passages (Figure 5.14).  This suggests either unreliable determination of 
the knockdown from the first set of lysates made immediately following selection, or the 
possibility that the knockdown might be lost completely following more time in culture, 
despite cells stably expressing the shRNA.  Research forums suggest this is not an 
uncommon problem, and it has been reported before (Salazar et al, 2014).  One possible 
reason for this phenomenon is that depending on where the shRNA integrates, it may not 
be highly expressed, or could later be silenced.  It may also be possible that the cells were 
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not selected for long enough or should have been maintained in antibiotic selection to 
ensure only those expressing the shRNA survived.  Although anecdotal evidence, other 
researchers on forums have seen maintenance of antibiotic resistance with loss of the 
shRNA knockdown.  A possible explanation for this, is that the level of knockdown in 
different cells within the population was variable and those with a lower level of 
knockdown may have outcompeted the others over time (Sigma).  It may therefore be 
important in future studies to only use very early passage cells, and to re-confirm the 
knockdown prior to experiments.  
 
Figure 5.14 ECE1 knockdown in HFFF-TERTs was diminished following passaging 
Immunoblot of lysates produced when the shRNA cells were originally made (no 
antibody available at the time) being probed for ECE1, alongside lysates produced from 
cells frozen after ~5 passages (‘retest’).      
 
5.6.4 CRISPR knockdown 
In order to improve the level of the knockdown and eliminate the concern regarding loss 
of the knockdown over passages, CRISPR/Cas9 was employed to generate knockout cell 
lines.  The CRISPR/Cas9 technology has become commonly used in molecular biology.  
It relies on the Cas9 endonuclease being targeted to specific DNA sequences according 
to complementarity to a guide RNA (gRNA).  Cas9 then generates double strand breaks, 
which when repaired by the error prone non-homologous end joining DNA repair 
mechanism, will often result in an insertion or deletion mutation (Sander & Joung, 2014; 
Sanjana et al, 2014; Shalem et al, 2014).  Cells constitutively expressing Cas9 were 
transduced with lentiviruses expressing the gRNAs.  Multiple cell lines were produced, 
expressing guides targeting different sequences in the gene of interest, or non-targeting 
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control sequences, and these were used in the restriction assay described previously 
(Figure 5.9). 
Restriction assay with polyclonal CRISPR population 
Polyclonal CRISPR populations were produced by transducing HFFF-TERTs 
constitutively expressing Cas9 with the gRNAs targeting ECE1, Sp100 or control guides.  
All the cell lines were made both in the presence or absence of raltegravir, which inhibited 
integration in order to limit off target effects.  Five different guides were used for ECE1, 
and the level of knockdown was assessed by immunoblot (Figure 5.15).  The control and 
Sp100 cells were produced together with Dr Katie Nightingale and Dr Ben Ravenhill 
(Weekes Lab), and knockout of Sp100 was also assessed by immunoblot (Nightingale et 
al, 2018).   
 
Figure 5.15 Immunoblot showing knockdown in polyclonal ECE1 CRISPR 
populations  
Immunoblot of polyclonal ECE1 CRISPR cell populations using each of the five guides 
is shown for both the raltegravir treated and the untreated, integrated, cell lines.  Guides 
2 and 4 from the raltegravir treated cell lines were chosen for single cell cloning.  This 
immunoblot was performed by Dr Ben Ravenhill (Weekes Lab). 
 
All five of the integrated cell lines were tested in a restriction assay (Figure 5.16A).  
Guides 2 and 4, which showed the best knockdown in the polyclonal populations, also 
resulted in the greatest increase in infection.  These were therefore used in a second 
restriction assay with the raltegravir treated cell lines, and subsequently for single cell 
cloning (Figure 5.16).  In the restriction assay on the raltegravir treated cell lines, ECE1 
appeared to restrict infection compared to the control_g1 cell line, however this showed 
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a significantly different percent infection to control_g2, so it was difficult to draw 
conclusions.     
    
 
Figure 5.16 HCMV restriction assay on ECE1 polyclonal CRISPR populations 
Five ECE1 CRISPR/Cas9 knockout cell lines, along with Sp100 knockout cell lines, were 
infected with UL36-GFP HCMV at an MOI of 0.01 and 0.03 for 24 h, and the percent 
infection measured by flow cytometry.  Data is represented as the mean of triplicate data 
± SEM.  P- values were estimated using a two-tailed t-test, with each sample compared 
to control_g1; * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
(A) Five different ECE1 knockout cell lines, along with two Sp100 knockout cell 
lines were examined.  Cells were generated in the absence of raltegravir. 
(B) All cell lines were produced in the presence of raltegarvir, to prevent 
integration.  Two ECE1 knockout cell lines (sg2, sg4) and two Sp100 knockout 
cell lines were examined. 
 
Restriction Assay on Monoclonal CRISPR Populations 
The raltegravir treated (not integrated) CRISPR cell lines with guides 2 and 4 were chosen 
for single cell cloning, due to having the greatest knockdown and largest effect on percent 
infection in the restriction assay.  The cells were seeded at a density of 0.5 cells/well in a 
96-well plate, so monoclonal populations could grow from a single cell.  The resulting 
monoclonal populations were examined by immunoblot to identify those with an ECE1 
knockout (Figure 5.17A) and five cell lines were selected (Figure 5.17B).  Interestingly, 
four of these retained a band just under the expected ECE1 band, whilst ECE1_g4_G9 
was missing this band.   
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Figure 5.17 Immunoblot for ECE1 in monoclonal CRISPR populations  
(A) Immunoblot of monoclonal CRISPR populations expressing ECE1 guides 2 
and 4, compared to HFFF-TERT-Cas9 cell lines prior to the transduction of the 
gRNAs. 
(B) Immunoblot of selected ECE1 knockout monoclonal cell lines from (A) 
compared to monoclonal populations transduced with control CRISPR guides. 
 
Restriction assays were performed on the monoclonal cell lines identified in Figure 
5.17B.   The percent infection was most substantially increased in the ECE1_g4_G9, with 
mixed results from the other guides (Figure 5.18).  It is interesting that G9 was the only 
monoclonal cell line where all bands on the immunoblot for ECE1 appear to be missing, 
and it would therefore be important for further investigation to determine what is being 
detected in the two bands.  Furthermore, the two monoclonal control cell lines resulted in 
significant differences in infection in two of the three assays.  It was therefore not possible 
to know what the expected level of infection should be, and what the ECE1 knockouts 
should be compared to. 
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Figure 5.18 HCMV restriction assay on monoclonal ECE1 CRISPR populations 
Monoclonal populations were produced from Control_g1, Sp100_g1, ECE1_g2 and 
ECE1_g4 polyclonal cell lines, all of which were transduced in the presence of raltegravir 
to prevent integration.  They were infected with UL36-GFP HCMV at an MOI of 0.01 
and 0.03 for 24 h, and the percent infection measured by flow cytometry.  Data is 
represented as the mean of triplicate data ± SEM.  P-values were estimated using a two-
tailed t-test, with each sample compared to control_g1_E1; * p < 0.05, ** p < 0.01, *** 
p < 0.001, ns = not significant. 
(A) The two control cell lines were compared to Sp100_g1_E7, ECE1_g2_B5 and 
D1, and ECE1_g4_F4 and G9. 
(B) The two control cell lines were compared to the two Sp100 and five ECE1 
CRISPR knockout cell lines described. 
(C) The two control cell lines were compared to the two Sp100 CRISPR cell lines, 
ECE1 sg2_B5 and D1, and ECE1 sg4_F4 and G9. 
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Comparison of Monoclonal CRISPR Control Cell Lines 
As the percent infection differed between the control cell lines, further investigation was 
necessary to determine whether the variability was reproduced in other controls.  Multiple 
monoclonal populations expressing the control CRISPR guides were therefore tested in a 
restriction assay (Figure 5.19).  Four monoclonal cell lines were established from the 
single cell cloning of both the control_g1 and control_g3 populations, and a range of 
levels of infection were observed for these in the HCMV restriction assay (Figure 5.19A).  
In each case, the bar displays the mean of triplicate data for the given cell line, and error 
bars show the SEM.  Each cell line was trypsinised, counted and seeded from a single 
flask.  
To ensure there was no effect of inconsistent cell confluency due to differential counting 
and seeding, a repeat of the experiment included duplicates of some of the cell lines 
(Figure 5.19B).    In these case three wells were seeded from each of two flasks of the 
stated cell line, which had been counted and seeded separately.  In this way, the duplicate 
flasks were effectively treated as if they were for two different monoclonal control 
populations, so any effect of seeding could be examined.  The percent infection observed 
between these pairs was very similar, suggesting the differences in infection were not 
simply due to seeding.  This does not however, rule out difference in confluency due to 
different growth patterns.  Additionally, the pattern of infection was similar between the 
two experiments, with control_g3_C9 resulting in the greatest level of infection, and 
control_g1_H3 and control_g1_H10 giving the least infection.  A WT HFFF-TERT 
sample was also included in the second experiment, and gave a percent infection roughly 
in the middle of the various CRISPR cells.  It is possible that off target effects of the 
control CRISPR guide may lead to knockouts of important antiviral genes, or that changes 
in growth patterns lead to differences in cell seeding between cell lines.  As it was not 
possible to determine with confidence which of the control cell lines the ECE1 knockouts 
should be compared to, this approach was not used further. 
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Figure 5.19 HCMV restriction assay comparing percent infection between different 
monoclonal CRISPR control guide populations 
Monoclonal populations were produced from control_g1 and control_g2 polyclonal cell 
lines, all of which were transduced in the presence of raltegravir to prevent integration.  
They were infected with UL36-GFP HCMV at an MOI of 0.05 and 0.1 for 24 h, and the 
percentage infection measured by flow cytometry.   
(A) Bars represent the average of triplicate data ± SEM. 
(B) Bars represent the average of duplicate data, and the error bars display the 
range.  Some cell lines have been included twice, counted and seeded 
separately each time, to examine the effects of cell seeding. 
 
5.6.5 Two Colour Restriction Assays 
The Two Colour Restriction Assay Methodology 
Although the morphology and growth of the knockdown and overexpression cells did not 
obviously differ from control cells, there was some concern that cell seeding or small 
differences in growth of the different cell lines could affect the way the cells settle down 
in the well and their confluency prior to infection.  Identical cell seeding is required 
between the control and test cells to ensure equal infection.  Minor changes could affect 
the results of assays, both due to differences in the effective MOI if the same amount of 
virus is applied, and because cells are less readily infected at higher confluency.   
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In order to circumvent this potential issue, a ‘two colour’ restriction assay was developed.  
This system was developed and validated predominantly by Alice Fletcher-Etherington 
(Weekes Lab).  She first produced HFFF-TERTs expressing either mCherry or iRFP.  The 
mCherry cells were subsequently transduced with the control plasmid (control sh or 
GAW), whilst iRFP cells were transduced with an shRNA or overexpression plasmid for 
the protein of interest (ECE1, Sp100 or Daxx).  The appropriate mCherry and iRFP cells 
were mixed in a 1:1 ratio and seeded in triplicate for each MOI.  The cells were then 
infected for 24 h with UL36-GFP HCMV before harvesting and analysis by flow 
cytometry, as with the previous restriction assay.   Each well therefore contained a mixed 
population of cells, and flow cytometry could determine the percent of GFP positive (and 
therefore infected) cells within both the mCherry and iRFP positive populations in each 
well.  A ‘restriction ratio’ could then be calculated, comparing the percent infection in 
each population (Figure 5.20).   
 
 
Figure 5.20 Schematic of two colour restriction assay for shRNA knockdown cells 
Control cells expressing mCherry and a control shRNA were mixed in a 1:1 ratio with 
iRFP cells co-expressing the target shRNA.  The mixed population was seeded in 
triplicate for each cell type, and infected with UL36-GFP HCMV, and infection 
proceeded for 24 h.  The cells were then harvested and the % GFP+ cells in the mCherry 
population and in the iRFP population in each well was measured by flow cytometry. 
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Cell Lines 
Cells expressing mCherry and iRFP were kindly provided by Alice Fletcher-Etherington 
(Weekes Lab).  The plasmids for expression of mCherry and iRFP included a blasticidin 
resistance gene, enabling selection of cells expressing each fluorescent marker.  They 
could then be transduced with constructs encoding an shRNA for the protein of interest 
or an overexpression plasmid, and subjected to a second round of antibiotic selection 
using hygromycin or puromycin respectively.  Knockdown and overexpression of ECE1 
was confirmed by immunoblot (Figure 5.21).  Sp100 and Daxx cells were produced by 
Dr Katie Nightingale (Weekes Lab) and validated by immunoblot. 
shRNAs were employed for production of knockdown cells due to the concerns regarding 
different levels of infection in the CRISPR control cells, as well as the technical 
difficulties of generating single cell CRISPR clones within this two colour system.  Use 
of early passage cells ensured there would not be a loss of the knockdown affecting the 
results of the assays.   
 
Figure 5.21 ECE1 cell lines for HCMV restriction assay in two colour system 
Immunoblot confirming ECE1 knockdown and overexpression in iRFP cells compared 
to mCherry control cells expressing a control Sh or GAW plasmid.   
 
Two Colour Restriction Assay: shRNA Knockdown 
Four restriction assays were performed on the ECE1 knockdown cells using the two 
colour system (Figure 5.22).  A restriction ratio greater than one (represented by the 
dotted line) would indicate increased infection with HCMV and therefore restrictive 
effects.  Unlike in the previous shRNA based restriction assay, the Sp100_sh1 did work 
as a reliable positive control in all instances, showing restriction to various degrees.  
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Substantial restriction by ECE1 was observed in Figure 5.22C and D, similar in level to 
that observed with the Sp100_sh1 positive control; some of the lowest MOIs were 
included in these two assays.   Restriction was also observed to a lesser extent in Figure 
5.22B, however it was not seen in the first assay.  The iRFP only control was included in 
Figure 5.22D to ensure that there was no difference in infection as a result of the cells 
expressing iRFP rather than mCherry.  There was not much of a difference, though 
possibly a slight reduction in infection with the iRFP only cells, suggesting restrictive 
effects may be slightly compressed. 
Two Colour Restriction Assay: Overexpression  
Three assays were performed considering the effect of ECE1 overexpression, including 
Daxx as a positive control (Figure 5.23).  In this case, a restriction ratio of less than one 
(represented by the dotted line) would indicate restriction, as overexpression of an ARF 
should reduce infection.  ECE1 did not show any restrictive effects in these assays, in 
contrast to the results observed in the single colour overexpression restriction assays 
(Figure 5.11).  In these two colour restriction assays, overexpression of ECE1 actually 
led to increased HCMV infection.  The assay appears to technically work as Daxx shows 
a high level of restriction.  However, the iRFP only control in Figure 5.23C also led to 
increased infection, to a similar extent to that seen with ECE1.  The iRFP cells should 
show the same infection as mCherry control cells (expressing GAW); this result suggests 
there may be a difference between the mCherry and iRFP expressing cells in this instance, 
or an effect of the GAW plasmid.   
 
198 Chapter 5 – CANDIDATE ANTIVIRAL RESTRICTION FACTORS 
 
Figure 5.22 Two colour restriction assays on ECE1 shRNA knockdown cells 
ECE1 restriction was examined using the two colours restriction assay.  HFFF-TERTs 
expressing mCherry and control_sh1 were mixed in a 1:1 ratio with cells expressing iRFP 
and an shRNA targeting ECE1 or Sp100.  The cells were infected with HCMV UL36-
GFP for 24 h at the indicated MOI (0.01 - 0.1), and then the percent of GFP positive cells 
in both the mCherry and iRFP population in each well was measured by flow cytometry.  
A restriction ratio was calculated as described in Figure 5.20.  Cell types were examined 
in triplicate except where specified, and the bars display the mean of the restriction ratios 
in the three wells ± SEM.  The dotted line marks a restriction ratio of 1, equivalent to 
observing the same percent infection in the control and knockdown cells, and therefore 
no restriction; a restriction ratio > 1 indicates restriction.  P-values were estimated using 
a paired two-tailed t-test, comparing the percent GFP+ cells in the iRFP population to the 
percent GFP+ cells in the mCherry population for each cell type. *p < 0.05, ** p < 0.01, 
*** p < 0.001, ns = not significant. 
(A) Bars represent the mean of triplicate data ± SEM in all cases. 
(B) Bars represent the mean of triplicate data ± SEM, with the exception of Sp100 
at an MOI of 0.02, for which there were only two data points.  For this sample, 
error bars display the range, and no p-value was determined. 
(C) Bars represent the mean of triplicate data ± SEM in all cases. 
(D) Bars represent the mean of triplicate data ± SEM in all cases.  An additional 
‘iRFP only’ sample was included, where the cells did not express any shRNA, 
to investigate effects of mCherry compared to iRFP expression. 
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Figure 5.23 Two colour restriction assay on ECE1 overexpressing cells 
(A-C) Each iRFP cell type (overexpressing ECE1 or Daxx) was mixed in a 1:1 ratio with 
mCherry GAW control cells and seeded in triplicate.  Cells were infected for 24 h with 
HCMV UL36-GFP, and the percent of infection in the iRFP and mCherry cells in each 
well measured by flow cytometry.  Data is represented as the mean restriction ratio 
(n=3) ± SEM.  The dotted line marks a restriction ratio of 1, equivalent to observing 
the same percent infection in the control and overexpression cells, and therefore no 
restriction; a restriction ratio < 1 indicates restriction.  P-values were estimated using 
a paired two tailed t-test comparing the percent GFP+ cells in the iRFP and mCherry 
population for each cell type.  *p < 0.05, ** p < 0.01, *** p < 0.001, ns = not 
significant. 
 
5.6.6 HCMV Assays in Novel ECE1 shRNA Cell Lines 
Cell Lines 
As the results from previous restriction assays were inconclusive, a final experiment was 
performed on a new set of cell lines.  As the previously employed shRNA contstructs did 
not provide a reliable knockdown, four new shRNAs targeting ECE1 were used.  
Additionally, transductions for the controls, positive controls and ECE1 cell lines were 
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all performed in parallel on the same population of HFFF-TERTs.  Immunoblot showed 
that of the four new shRNA expressing cell lines, ECE1_sh4, ECE1_sh5 and ECE1_sh6 
all displayed a good level of knockdown.  Additionally, control_sh1 seemed to have lower 
expression of ECE1 than control_sh2 or control_sh3 (Figure 5.24A).  For this reason, 
ECE1_sh4, sh5 and sh6, and control_sh2 and sh3, were used in the shRNA based 
restriction and plaque assays.  The Sp100 knockdown (Figure 5.24B) and overexpression 
of ECE1 and Daxx worked well (Figure 5.24A, C).  These restriction assays used the 
‘single colour’ system for simplicity and were only repeated once, in parallel with a 
plaque assay. 
 
 
Figure 5.24 Immunoblot of shRNA and overexpressing cell lines 
(A) WT HFFF-TERTs were transduced with control shRNAs or a GAW plasmid 
to generate control cells.  Four different ECE1 shRNAs were transduced, with 
sh4, sh5 and sh6 producing the best knockdown.  An ECE1 overexpressing line 
showed increased levels of ECE1 compared to GAW. 
(B) WT HFFF-TERTs were transduced with either control shRNAs or an shRNA 
targeting Sp100, and knockdown was confirmed by immunoblot. 
(C) WT HFFF-TERTs were transduced with a control GAW plasmid, or one 
overexpressing Daxx, and overexpression was confirmed by immunoblot. 
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shRNA Restriction Assay 
The infections at an MOI of 0.01 resulted in generally greater infection in the ECE1 
knockdown cells compared to the controls.  However, all infections other than that of the 
Sp100 knockdown cells resulted in less than 0.15 % infection; therefore, there were too 
few infected cells to draw any substantial conclusions.    The 0.03 MOI resulted in 0.8 
and 1.3 % infection in control cells, whilst ECE1 knockdowns had between 1.0 and 2.2 
% infection.  ECE1 sh5 and sh6 showed 2 fold and 1.6 fold more infection in the 
knockdown compared to the sh3 control (and a greater FC than this when compared to 
the sh1 control).  This does suggest some level of restriction, however it was far less than 
observed with Sp100, which worked as a strong positive control in this assay (Figure 
5.25). 
 
Figure 5.25 Repeat HCMV restriction assay on shRNA cell lines 
A new set of control, Sp100 and ECE1 shRNA cell lines were produced.  They were 
infected with UL36-GFP HCMV for 24 h prior to harvesting, and the percent infection 
was assessed by flow cytometry.  Data is presented as the mean ± SEM (n=3).  P-values 
were estimated using a two-tailed t-test, and were compared to the percent infection in 
the control_sh2 cell line; *p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
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Overexpression Restriction Assay 
The overexpression restriction assay showed no significant effect of ECE1 
overexpression.  Although it should be noted that Daxx had a far smaller effect in this 
assay compared to the previous overexpression experiments, though still significant 
(Figure 5.26). 
 
Figure 5.26 Repeat HCMV restriction assay on overexpression cell lines 
A new set of control, Daxx and ECE1 overexpressing cell lines were produced.  They 
were infected with UL36-GFP HCMV for 24 h prior to harvesting and analysis by flow 
cytometry.  Data is presented as the mean ± SEM (n=3).  P-values were estimated using 
a two-tailed t-test, and were compared to the percent infection in the control GAW cell 
line; *p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant. 
 
Plaque Assay 
A plaque assay was also performed in parallel with the restriction assays.  The UL36-
GFP restriction assay only considers any restriction of the virus in the first stages of a 
single round of infection.  In contrast, the plaque assay examines any effect over multiple 
replication cycles and on cell-to-cell spread.  The number of plaques and the size of the 
plaques can be observed.   
At 24 h after seeding, the cells were infected with AD169-GFP HCMV.  This strain of 
the virus was used as infection with the Merlin strain of HCMV (as used in the restriction 
assays) does not form plaques that are clearly distinct and easy to count.  Cells were 
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infected with virus at multiple dilutions in order to obtain wells with a suitable number of 
plaques to count.  Infection was allowed to proceed on a rocker for 2 h at 37ºC, and then 
the inoculum was replaced with a 1:1 mix of 2x DMEM culture media, and Avicel.  After 
two weeks at 37ºC, the Avicel was removed, the wells fixed, and the fluorescent plaques 
examined and counted under the microscope.  Of the four MOIs tested, an MOI of 0.02 
and 0.06 resulted in too many plaques to allow accurate counting, but an MOI of 0.002 
or 0.006 generated between 5-100 plaques/well. 
The plaque assay examining ECE1 and Daxx overexpressing cells provided remarkably 
similar results to the restriction assay on the same cells (Figure 5.26, Figure 5.27B).  
Again, Daxx significantly reduced the number of plaques observed, and ECE1 had some 
effect though to a much lesser extent.   
The plaque assay on the shRNA cells showed quite different results (Figure 5.27A).    
There was a significant difference between the number of plaques in the two control cell 
lines, and the Sp100 and ECE1 knockdowns led to fewer plaques than the control_sh2.  
This is the opposite of what would be expected for a restriction factor, which was 
particularly surprising for the positive control Sp100, and is in contrast to previously 
published data (Adler et al, 2011).   It is possible that the control_sh3 is a better baseline, 
showing a more similar number of plaques to the GAW control.  However, even if the 
other cell lines are compared to this control, not much change was detected apart from a 
large reduction in the number of plaques with ECE1_sh4.  Without any replicates of the 
experiment it is not possible to determine if these effects are reproducible, or indeed an 
effect of differences in cell seeding.  As the cells remained in culture for two weeks, this 
could have a substantial impact.  
Another interesting aspect of the plaque assay data could be the size of the plaques, 
indicating a difference in viral spread.  In this instance there was no obvious difference 
in plaque size by eye, therefore the plaques were not imaged and measured.  By eye, the 
plaques formed by the Sp100 knockdown cells appeared slightly smaller than others.  This 
was again the opposite of what might be expected, though has previously been observed 
by other members of the Weekes lab.  Along with no increase in the number of plaques, 
this may indicate an artefactual effect of the cell line employed and therefore represents 
a significant caveat in this experiment. 
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Figure 5.27 Plaque assay on ECE1 shRNA and overexpression cells 
Cells were infected with AD169-GFP for 2 h, prior to replacing the inoculum with 1:1 
media and Avicel.  Plaques were counted after two weeks.  Data is presented as the mean 
± SEM (n=3).  P-values were estimated using a two-tailed t-test; *p < 0.05, ** p < 0.01, 
*** p < 0.001, ns = not significant. 
(A) ECE1 shRNA cells were infected, along with control and Sp100 cell lines.  T-
tests compared each cell line to control_sh2. 
(B) ECE1 overexpressing cells were infected, along with the GAW control and 
Daxx cell lines.  T-tests compared each cell line to GAW cells. 
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5.7 Summary of ECE1 Results 
Table 5.4 Table summarising results of ECE1 restriction and plaque assays 
Experiment 
ECE1 
restriction? 
Summary of Results Effectiveness of Controls 
Overexpression  Yes 
All assays showed some level 
of restriction by ECE1, though 
to a lesser extent than Daxx 
Worked well.  Greater effect of 
Daxx than Sp100 
shRNA 
Knockdown 
Mixed 
results 
One of the three assays 
showed ECE1 restricting 
infection 
Sp100 did not work as an 
effective control 
CRISPR 
Polyclonal 
Population  
Mixed 
Results 
The two polyclonal 
populations with the best 
knockdown showed restriction 
in integrated cell lines, but not 
the raltegravir treated ones 
One of the Sp100 guides 
worked well 
CRISPR 
Monoclonal 
Population  
Yes? 
Restriction by some cell lines, 
(particularly in ‘cleanest’ 
knockout) but interpretation 
of this depends on what is 
detected in the two bands on 
the immunoblot 
Sp100 control worked well, 
however significant 
differences in the percent 
infection was observed 
between control cell lines 
shRNA 
Knockdown  
Two Colour  
Yes 
ECE1 knockdown led to a small 
increase in infection 
Sp100 control worked well 
Overpxression 
Two Colour 
No 
ECE1 overexpression led to a 
small increase in infection, not 
decrease as expected 
Daxx control worked well.  
‘iRFP only’ led to a small 
increase in infection 
shRNA 
Knockdown  
Repeat sh4-6 
Small effect 
ECE1 knockdown led to a small 
increase in infection, though 
much less than Sp100 
Sp100 control worked very 
well 
Overexpression 
Repeat 
No 
ECE1 overexpression led to a 
small, not significant decrease 
in infection 
Daxx control worked, though 
less substantial effect than 
seen previously 
shRNA Plaque 
Assay 
No 
ECE1 knockdown led to 
reduced percent infection 
Sp100 knockdown also led to 
reduced percent infection 
Overexpression 
Plaque Assay 
No 
ECE1 led to a small, not 
significant decrease in 
infection 
Daxx control worked well 
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5.8 Discussion 
A proteomic screen was used to identify changes at the surface of primary monocytes and 
T cells upon IFN stimulation.  The resulting data was overlapped with proteomic analyses 
of viral infection, in order to identify candidate restriction factors which were both 
stimulated by IFN and downregulated by viral factors.  TMEM123 may present an 
interesting candidate for a restriction factor.  If it does have a role in triggering oncotic 
cell death (Ma et al, 2001), it may be beneficial for the virus to inhibit this.  However, 
due to a lack of reagents this was not further investigated.  ECE1 was identified as a 
candidate restriction factor.   
 
5.8.1 How Does HCMV Downregulate ECE1? 
ECE1 was IFN stimulated at the surface of primary T cells in all five donors, and was 
also downregulated by HCMV and to a lesser extent HIV.  Fortunately, previous literature 
was available to demonstrate specific downregulation of ECE1 by the HCMV US2 
protein, answering the first question about how the virus targets ECE1.  Infection with a 
HCMV US2 deletion mutant demonstrated that US2 is necessary for the downregulation 
of ECE1.  Other US2 targets include MHC molecules, integrins and members of the 
immunoglobulin superfamily.  Targeting of the integrins as well as some other US2 
targets was found to be dependent on the cellular E3 ligase TRC8, with shRNA 
knockdown of TRC8 diminishing the downregulation.  HCMV US2 recruits TRC8 to 
these proteins, resulting in their ubiquitination and proteasomal degradation (Hsu et al, 
2015).  Immunoblot demonstrated that single-gene expression of US2 was also sufficient 
to induce the downregulation of ECE1.  It would be interesting to examine the expression 
of ECE1 during infection of TRC8 knockout cells to determine if the same mechanism is 
responsible here. 
 
5.8.2 Does ECE1 Restrict Viral Infection? 
Despite fulfilling the criteria for a candidate restriction factor, it proved challenging to 
obtain a conclusive result on the role, if any, of ECE1 in HCMV infection (Table 5.4).  
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Whilst shRNA knockdown of ECE1 led to a significant increase in infection in many of 
the restriction assays, the effect was not consistent.  Overexpression of ECE1 limited 
infection in the WT HFFF-TERTs providing initially promising results, but did not show 
this in the two colour system.  In the additional repeat of the restriction assay on newly 
generated cells, ECE1 overexpression did not show a substantial effect.  Caution should 
be exercised in interpreting the results of the overexpression assays, as overexpression 
was of ECE-1b, a predominantly intracellular isoform.  ECE1 can also form heterodimers, 
and in this case the localisation is dominated by isoform B.  As there were no antibodies 
which definitely worked for cell surface flow cytometry, overexpression of ECE1 at the 
cell surface was not tested, but would be important to know for drawing more definitive 
conclusions from this data.   
Some of the initial shRNA knockdown experiments showed an increase in infection with 
the ECE1 shRNA cell lines, and three of the four two colour shRNA assays showed 
equivalent restriction by ECE1 and Sp100, though the effect of Sp100 was not as big as 
might be expected of an ARF.  However, there was no effect seen in some of the other 
experiments, and it varied between the two shRNA cell lines.  In the initial experiments, 
this may have been due to a reduced level of knockdown from passaging of the cells.  
However, subsequently produced knockdowns for the final experiment presented were 
frozen when the lysates were produced, and used rapidly after thawing, so should not 
have had this complication.   
Unfortunately no reliable results could be obtained from the monoclonal CRISPR system 
due to differences in the percent infection between control cell lines, however 
ECE1_g4_G9 and in some cases ECE1_g4_F4 did show increased infection.  If further 
experiment were to be performed, it may be beneficial to increase the number of control 
cell lines used.  The monoclonal CRISPR assay and the final restriction and plaque assays 
presented included multiple controls, and showed there were often differences in the 
infection of these cells.  This was a particularly obvious effect in the CRISPR cells.  This 
could be the result of different off-target effects between the monoclonal populations.  
CRISPR is known to result in some off-target effects, with up to five mismatches being 
tolerated in order to generate a double strand break (Fu et al, 2013).  Another possibility 
is that because the HFFF-TERTs transduced with Cas9 were not single cell cloned prior 
to transduction with the guides, the parent population of cells was not homogeneous, and 
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may have resulted in differential effects of the CRISPR guides.  Perhaps proteomics 
experiments could be used to investigate any substantial differences between the cells that 
give the highest and lowest rates of infection, though most likely there will be many 
differences and discerning the important proteomic changes could be challenging.   
Despite this variation however, when the positive controls worked effectively, a seven 
fold increase in infection was seen with the Sp100 knockout (Figure 5.25), and a > 10 
fold decrease was seen with Daxx (Figure 5.11).  ECE1 did not reliably show effects of 
this magnitude, and had it done so, some variation in the controls would have been less 
critical.  This is not to say it has no role in infection, but it is unlikely to be a major 
restriction factor acting early during HCMV infection, or if it is it may act in concert with 
other proteins.  To establish a more conclusive result from these restriction assays, another 
possible experiment would be to complement the CRISPR knockouts with ECE1, in 
particular the ECE1_g4_G9 clone.  This clone showed the cleanest knockout by 
immunoblot, and a substantial increase in infection in two of the three experiments.  The 
Abcam antibody for ECE1 often detected two bands, and this was the only clone for 
which both were missing.  The two bands have been seen previously with a different 
antibody (Lambert et al, 2008).  In the Lambert et al study, a targeting siRNA only 
appears to reduce the upper band.  However, overexpression of ECE1 also increased the 
signal in the lower band, as was observed in experiments here (Figure 5.21, Figure 5.24).   
It would therefore be important to sequence the clones to determine the effect of the 
CRISPR knockouts, and perhaps screen additional monoclonal populations for more 
complete knockout cell lines.   
It may be valuable to repeat these assays with a HCMV US2 deletion mutant, which is 
unable to degrade ECE1; in the current assays, infection with wild type virus may result 
in a comparable level of ECE1 in the knockdown and control cells.  The deletion mutant 
would therefore increase the window for observing a restrictive effect.  It is also possible 
that ECE1 acts at a later point in infection than would be detected with the UL36-GFP 
restriction assay.  The HCMV tegument protein UL32 is expressed later during infection, 
and a UL32-GFP virus is also available, so a restriction assay with this may be more 
informative if ECE1 acts later during infection.  The results of the plaque assay would 
cover more of the viral replication cycle, and also did not show an obvious phenotype 
relating to a restricting effect.  However, this was a single replicate of the experiment, 
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and Sp100 did not work as an effective positive control.  To fully establish that there was 
no effect in the plaque assay, it would be necessary to repeat it and identify more 
consistent control cell lines.  In both the restriction assay and the plaque assay, ECE1_sh4 
showed a reduced percent infection and number of plaques, whilst this was increased with 
ECE1_sh5.  The consistency between the two different types of assay, and the different 
viruses (UL36-GFP Merlin Strain HCMV and AD169-GFP) may be interesting, however 
this could also be an artefact of cell seeding, as cells for both assays were seeded together.     
As well as downregulation by HCMV, ECE1 was also downregulated to a lesser extent 
at the surface of HIV infected cells (Matheson et al, 2015).  With CD4+ T cells being 
both a major site of HIV infection, and the cell type ECE1 IFN stimulation was observed 
in, a HIV restriction assay may be relevant.  Assays to investigate this could involve 
infecting cells with Env-GFP-HIV and using flow cytometry to assess the percent 
infection, as with HCMV.  This would examine any restrictive effects preventing viral 
entry or integration.  Additionally, the supernatants can be harvested and the amount of 
p24, a HIV capsid protein, measured by enzyme-linked immunosorbent assay (ELIZA).  
  
5.8.3 Other Considerations from the Data 
Although ECE1 was selected for follow up, other proteins in the dataset may be candidate 
restriction factors.  One limitation of the current overlap between the IFN and viral data, 
is that many of the proteins identified in the primary monocytes were not quantified in 
the viral datasets.  Of the 41 IFN-stimulated proteins, just 15 were quantified in any of 
the HCMV infection datasets, as these were in fibroblast cell lines.  In addition to the 
experiments presented in this thesis, I have been using multiplexed proteomics to examine 
HCMV infection of primary DCs in collaboration with Dr Richard Stanton (Cardiff 
University), both at the whole cell and PM level.  This dataset may provide a better 
comparator for the monocyte data, particularly if there are leukocyte specific proteins 
restricting infection.  Additionally, the investigation presented here shortlisted IFN-
stimulated proteins based on reasonably stringent criteria, requiring the proteins to be 
upregulated in all five donors, despite evidence that differences between donors may be 
expected.  Therefore, some interesting candidate restriction factors may have been filtered 
out.   
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CHAPTER 6:  DISCUSSION AND FUTURE 
DIRECTIONS 
  
6.1 IFN Screen 
6.1.1 Summary 
Multiplexed quantitated proteomics was used to investigate the effects of IFN2a 
stimulation on the cell surface of primary CD14+ monocytes and CD4+ T cells, across 
five donors.  This was complemented with the study of a cultured monocyte cell line, 
THP-1s, and pan-monocyte populations from two further donors.    This resulted in the 
quantification of 607 PM proteins in monocytes, and 584 in T cells, which could be used 
to examine the cell surface proteome, and to investigate the IFN-induced changes.   
Methodology based on iBAQ was used to determine the abundance of different proteins 
at the cell surface.  In both monocytes and T cells, a large proportion of the surface 
proteome consisted of a relatively small number of proteins, with some commonalities 
between the cell types.  Additionally, the cell surface proteomes were highly similar 
between donors.   
To examine IFN stimulation, criteria were determined for identifying proteins that were 
consistently IFN stimulated across multiple donors.  In the monocytes, 41 proteins met 
these criteria, and the observation of similar proteomic changes in the pan-monocyte 
populations provided confidence in the findings.  Just 13 proteins were consistently IFN 
stimulated in T cells.  There was also a large amount of variability in the IFN response 
between donors, as has been observed in the literature.  Comparison of the IFN stimulated 
genes in both cell types identified TMEM123 as the only protein upregulated in all cell 
types, other than HLAs and the known restriction factor tetherin.  IFN stimulation of 
TMEM123 was validated in THP-1 cells by RT-qPCR, but unfortunately no antibodies 
have yet been identified for validation at the proteomic level or for further investigations.  
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6.1.2 Discussion and Future Directions 
This is a large dataset, with many potential avenues for further investigation.  The focus 
in this thesis has been on identifying the most consistent results, in order to be able to 
provide some validation, and to identify candidate ARFs.  However, there are a variety 
of ways in which this investigation could be extended, some of which are summarised 
here: 
1) Comparison of the primary and cultured cell data – It would be interesting to 
perform a comprehensive analysis of differences in the cell surface proteome and 
IFN response of the primary monocytes compared to the cultured THP-1s, 
determining the validity of this cell line as a model for primary cells in research.  
The THP-1 data is currently only from a ‘single shot’ analysis, used for validation 
of the workflow and a very brief comparison.  Upon fractionation, and repetition 
of the THP-1 experiment to ensure reliability, it may be valuable to do a more 
thorough comparison.  Cultured cell lines thought to represent their equivalent 
primary cells are routinely used in laboratory research, despite observations of 
differences in their proteome and cytokine response (Bosshart & Heinzelmann, 
2016).  This approach provides a method for systematic analysis of the proteome 
and IFN response in these cells.  Investigation of equivalent T cell lines such as 
Jurkats, CEM-T4 or SUPT1s in the same way would be similarly interesting.  
Additionally, it would assist in choosing appropriate cell lines for testing 
antibodies and validation of the data.         
2) Investigating proteins which are IFN stimulated in a subset of donors - This 
investigation only considered proteins as IFN stimulated if they were upregulated 
to some extent in all five donors, filtering for the most consistent results.  Given 
the variability between donors, it may be interesting to consider proteins which 
were only upregulated in a subset of donors, as these may still be true IFN 
responsive proteins.  The extent of variability in the IFN response between donors 
was initially surprising, though upon investigation had been observed previously 
at the transcriptomic level (Schlaak et al, 2002).  In order to identify true IFN 
stimulated proteins which are not observed in all donors, it may be necessary to 
have a bigger sample.  It would also be challenging to validate with orthogonal 
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techniques, requiring assessment of multiple donors.  For the purposes of this 
investigation, interest was predominantly in the most consistently IFN stimulated 
proteins, so this was not necessary, but it is worth noting that some important 
results may have been overlooked.   A follow up experiment could involve 
repeating the IFN stimulation multiple times for a single donor to see if the same 
level of variability is observed.  This would however, be challenging in the context 
of the monocytes, as these samples were obtained from anonymous donors through 
the NHSBT, so it would not be possible to obtain repeated donations.  It would 
additionally be beneficial to repeat the experiment on the cultured cell line to 
ensure none of the inconsistency is generated from the experimental workflow, 
and does represent true variation between donors.   
3) Investigating proteins which are not annotated as being at the PM - This dataset 
was filtered for proteins with PM related annotations.  It is highly likely that this 
has led to removal of some genuine cell surface proteins from the data due to poor 
annotation, leading to more potentially interesting data being bypassed.   
In this investigation, the data was filtered for annotated PM proteins which were 
consistently modulated, in order to identify the highest confidence targets.  These points 
are therefore all given as suggestions for expanding the results rather than necessities.  
Another consideration with this data, is that post-translational modifications were not 
examined.  As PTMs apart from oxidation of methionine were not included in the 
database when searching the proteomic data, peptides modified upon IFN stimulation 
would not have been quantified in these samples.  In the specific scenario where a protein 
was only quantified by a small number of peptides, the majority of which were modified, 
and the modified version of the protein accounted for a substantial portion of the protein 
pool, then the protein would appear downregulated.  This may be relevant here as several 
components of the IFN response pathway, including the IFN receptor, are known to be 
phosphorylated upon signalling (Zheng et al., 2011). However, it is likely that only a 
minority of the peptides from any given protein would be modified, so this should not 
affect quantitation too greatly.  It would be interesting to do further proteomic 
investigations with prior enrichment for post-translationally modified proteins, 
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particularly as this may modify localisation of proteins as in the case of ECE1 (Kuruppu 
and Smith, 2012), and this may alter abundance at the plasma membrane. 
TMEM123 was the only protein other than the positive controls which was IFN 
stimulated in all cell types examined.  It may represent a pan-leukocyte marker of IFN 
stimulation, and have as yet uncharacterised roles in immunity.  Little is currently known 
about this protein, aside from its ability to induce oncotic cell death upon the application 
of an antibody.  It may even represent another candidate restriction factor, as it is 
downregulated by HCMV.   Unfortunately, reagents were not yet identified for validation 
at the proteomic level, or for further investigation of TMEM123.  A first step in 
continuing this process would be to generate a cell line overexpressing tagged 
TMEM123, so the size of it could be determined, as this is variable between cell lines.  
This would help to identify a suitable antibody for validation and further studies.  A 
proteomic experiment considering overexpression and knockdown of TMEM123 could 
yield information on its function. 
 
6.2 VACV Screen 
6.2.1 Summary 
A quantitative temporal proteomic analysis of a single round of VACV infection was 
conducted.  Samples were harvested at three mock time points, and six infection time 
points up to 18 hpi.  The experiment was performed in triplicate, and provided robust and 
interesting data.  The majority of changes occurred linearly, with the greatest modulation 
of the host proteome at 18 hpi.  During infection, 265 proteins were downregulated by 
VACV, and these were enriched for cell surface proteins, innate immune proteins, 
collagens and cadherins amongst other classes; this was highly similar to classes of 
proteins modulated by HCMV.  A further proteomic investigation examined the addition 
of MG132 during infection, a proteasome inhibitor, identifying that around two thirds of 
the downregulated proteins were specifically targeted for proteasomal degradation.  This 
included all the canonical IFITs.  From this data, HDAC5 was identified as being 
downregulated by both VACV and HCMV, and was proteasomally targeted by VACV 
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C6; this was validated by proteomics and immunoblot using a C6 deletion mutant.  
Further examination showed that overexpression of HDAC5 reduced viral titre, whilst 
knockdown resulted in increased infection with both VACV and HSV-1, suggesting 
HDAC5 acts to restrict viral infection. 
 
6.2.2 Discussion and Future Directions 
This dataset has provided a comprehensive and valuable resource for the poxvirus field, 
and has already been used to identify HDAC5 as a novel restriction factor for VACV and 
HSV-1, as well as C6 as its viral antagonist.  It is also informative in terms of guiding 
future investigations.  Of the 265 proteins downregulated by VACV, the majority were 
rescued by proteasomal inhibition.  However a subset of these, including most of the 
collagens, were not.  Samples were harvested for RNA sequencing alongside those 
harvested for proteomic analysis.  It would therefore be interesting to determine if the 
collagens and other proteins not proteasomally degraded are modulated at the 
transcriptional level. 
Enrichment analysis on the downregulated proteins highlighted terms referencing the cell 
surface, such as extracellular, cell attachment site and immunoglobulin.  This suggests 
that the cell surface is a key site of modulation for VACV.  Further experiments are now 
being conducted using PM enrichment of infected cells, so the effects on the cell surface 
can be more thoroughly analysed.  This may highlight additional candidate restriction 
factors, as well as an improved dataset for identification of immune ligands.  It is also 
being used for investigation of viral proteins present at the cell surface. 
In this experiment, C6 was validated as the viral protein responsible for targeting HDAC5 
for degradation.  The Smith lab has a variety of deletion mutant viruses available, and 
further proteomic experiments have been commenced to assess the role of other viral 
proteins in infection.  In these experiments, multiplexed proteomics has been used to 
analyse a series of mutants, so the host proteins targeted by each can be determined.  This 
will complement the current dataset well in terms of identifying additional host-virus 
interactions. 
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6.3 ECE1 
Overlap of the IFN screen with the VACV, HCMV and HIV proteomic screens led to the 
identification of ECE1 as a candidate restriction factor.  The effect in HCMV infection 
are as yet inconclusive, with mixed results from the various restriction assays, and 
challenges ensuring appropriate controls.  It would be interesting to investigate this 
further using overexpression of an isoform of ECE1 known to be localised at the cell 
surface.  Some additional single cell CRISPR lines have been screened, and it would be 
useful to examine any others that have a complete knockout.  There is substantial data to 
suggest there may be some effect of ECE1 on HCMV infection, however this was not 
completely reproducible, and is unlikely to be a particularly large effect.  It would also be 
extremely interesting to investigate ECE1 in the context of HIV infection, with CD4+ T 
cells being the primary targets of viral infection and the cells in which IFN stimulation 
was observed.  Some cell lines have been prepared for this, however the experiments have 
not yet been performed.       
 
6.4 Identification of ARFs 
The data regarding IFN stimulation was overlapped with various datasets on viral 
infection to identify candidate ARFs which were both upregulated by IFN and 
downregulated by viral infection.  There are several ways in which this analysis could be 
expanded to identify more potential ARFs. 
The current comparison of data to identify candidate restriction factors utilised the 
relatively stringent criteria that the protein should be IFN stimulated in all five donors.  
More candidates may have been identified if a lower threshold was employed.  For 
example, epherin receptor B2 (EPHB2) did not fulfil this criteria, however it was 
upregulated in four monocyte donors and was upregulated 2.4 fold on average.  It was 
additionally upregulated more than 2 fold in both pan-monocyte samples, and 1.9 fold in 
THP-1s.  It was downregulated at the WCL and PM level during HCMV infection, and 
also by VACV.  EPHB2 is a receptor tyrosine kinase which forms heterotetrameric 
receptor-ligand complexes with Ephrin ligands, and triggers bidirectional signalling, with 
6.4 Identification of ARFs 217 
roles in cell migration and development (Park & Lee, 2015; Bryson & Bhandoola, 2015).  
The family of Epherin receptors and ligands has various roles in immunity, and have been 
previously identified as viral entry receptors for KSHV and EBV (Darling & Lamb, 
2019). 
Additionally, overlap with the IFN and VACV data so far only included WCL data for 
viral infection.  As the IFN data focusses on the cell surface, it will be interesting to see 
if more of the proteins quantified in the IFN data are identified in the PM VACV dataset.  
Another limitation of this so far, is that many of the viral infections were in fibroblasts, 
so a number of the proteins identified in the primary leukocytes were not quantified in 
the viral data.  Some additional proteins were seen in the CEMT4 HIV infection dataset.  
Additional experiments are currently being performed in collaboration with Dr Richard 
Stanton (Cardiff University), investigating the effect of HCMV infection of primary DCs.  
This will be especially interesting for overlap with the IFN data, as there are likely to be 
more commonly quantified proteins.    
This project attempted to identify restriction factors on the basis of IFN stimulation and 
viral downregulation.  Another approach discussed briefly in this thesis was the overlap 
of data from multiple viruses to identify proteins which are commonly targeted and 
therefore likely to be important in infection.  In this investigation, the HCMV and VACV 
infection datasets were overlapped to identify 85 commonly downregulated proteins.  
HDAC5 was one such protein, and was later found to restrict VACV and HSV-1 
infection.  I previously performed a similar comparison between HCMV and EBV 
infection to identify commonly downregulated proteins (Ersing et al, 2017).  This 
highlighted multiple poly(A) RNA binding proteins, and several proteins involved in 
synapse organisation including three neuroligins.  It is of course not always the case that 
a restriction factor is able to limit infection with all viruses.  BST2 for example is a potent 
HIV restriction factor, but HCMV may actually co-opt it, using a ‘reverse tethering’ 
mechanism to facilitate entry (Viswanathan et al, 2011).  However, a comprehensive 
overlap of the accumulating datasets in the Weekes lab, investigating different viral 
infections, would be interesting.  
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6.5 Concluding Remarks 
This work used proteomic screens exploring two characteristic features of ARFs: 
stimulation by IFN and downregulation by viral infection.  As well as providing a basis 
for identifying candidate ARFs, these screens have both provided interesting and 
expansive datasets in their own right, which are useful resources in the field and a basis 
for many further investigations.   
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 Appendix Table 1. Oligonucleotides for generation of cell lines 
 
  
Name Target sequence 
Oligonucleotides 
  Forward Reverse 
shRNA 
Knockdown 
 Control_sh1 GTTATAGGCTCGCAAAAGG gatccGTTATAGGCTCGCAAAAGGTTCAAGAGACCTTTTGCGAGCCTATAACTTTTTTg aattcAAAAAAGTTATAGGCTCGCAAAAGGTCTCTTGAACCTTTTGCGAGCCTATAACg 
 Control_sh2 GGCATATAACTATTTAGGTAT gatccGGCATATAACTATTTAGGTATTTCAAGAGAATACCTAAATAGTTATATGCCTTTTTTg aattcAAAAAAGGCATATAACTATTTAGGTATTCTCTTGAAATACCTAAATAGTTATATGCCg 
 Control_sh3 CGTGATCTTCACCGACAAGAT gatccCGTGATCTTCACCGACAAGATTTCAAGAGAATCTTGTCGGTGAAGATCACGTTTTTTg aattcAAAAAACGTGATCTTCACCGACAAGATTCTCTTGAAATCTTGTCGGTGAAGATCACGg 
 Sp100_sh1 CGCTAGGAAGCCAACAAACAA gatccCGCTAGGAAGCCAACAAACAATTCAAGAGATTGTTTGTTGGCTTCCTAGCGTTTTTTg aattcAAAAAACGCTAGGAAGCCAACAAACAATCTCTTGAATTGTTTGTTGGCTTCCTAGCGg 
 TMEM123_sh1 CCACACAACTCCAGTGCTAAC gatccCCACACAACTCCAGTGCTAACTTCAAGAGAGTTAGCACTGGAGTTGTGTGGTTTTTTg aattcAAAAAACCACACAACTCCAGTGCTAACTCTCTTGAAGTTAGCACTGGAGTTGTGTGGg 
 TMEM123_sh2 GGGATGGTCTCAACAAATATG gatccGGGATGGTCTCAACAAATATGTTCAAGAGACATATTTGTTGAGACCATCCCTTTTTTg aattcAAAAAAGGGATGGTCTCAACAAATATGTCTCTTGAACATATTTGTTGAGACCATCCCg 
 ECE1_sh1 GCAGTTCCAGACCTCTACTTT gatccGCAGTTCCAGACCTCTACTTTTTCAAGAGAAAAGTAGAGGTCTGGAACTGCTTTTTTg aattcAAAAAAGCAGTTCCAGACCTCTACTTTTCTCTTGAAAAAGTAGAGGTCTGGAACTGCg 
 ECE1_sh2 GCCGATGAGAAGTTCATGGAA gatccGCCGATGAGAAGTTCATGGAATTCAAGAGATTCCATGAACTTCTCATCGGCTTTTTTg aattcAAAAAAGCCGATGAGAAGTTCATGGAATCTCTTGAATTCCATGAACTTCTCATCGGCg 
 ECE1_sh3 CTTCCACAGCCCCCGGAGT gatccCTTCCACAGCCCCCGGAGTTTCAAGAGAACTCCGGGGGCTGTGGAAGTTTTTTg aattcAAAAAACTTCCACAGCCCCCGGAGTTCTCTTGAAACTCCGGGGGCTGTGGAAGg 
 ECE1_sh4 GCCTTAAACTTTGGTGGCATA gatccGCCTTAAACTTTGGTGGCATATTCAAGAGATATGCCACCAAAGTTTAAGGCTTTTTTg aattcAAAAAAGCCTTAAACTTTGGTGGCATATCTCTTGAATATGCCACCAAAGTTTAAGGCg 
 ECE1_sh5 TGTCTATGTCAGTGCCGATTC gatccTGTCTATGTCAGTGCCGATTCTTCAAGAGAGAATCGGCACTGACATAGACATTTTTTg aattcAAAAAATGTCTATGTCAGTGCCGATTCTCTCTTGAAGAATCGGCACTGACATAGACAg 
 ECE1_sh6 GATCAATGAATCCGAGCCTAT gatccGATCAATGAATCCGAGCCTATTTCAAGAGAATAGGCTCGGATTCATTGATCTTTTTTg aattcAAAAAAGATCAATGAATCCGAGCCTATTCTCTTGAAATAGGCTCGGATTCATTGATCg 
CRISPR 
knockout 
 Control_g1 GTACAGCTAAGTTAAACTCG caccgGTACAGCTAAGTTAAACTCG aaacCGAGTTTAACTTAGCTGTACc 
 Control_g2 GATGTCCGTTGTAGTCCTCG caccgGATGTCCGTTGTAGTCCTCG aaacCGAGGACTACAACGGACATCc 
 Sp100_g1 GCAGCCTGTCATCTACACCC caccgGCAGCCTGTCATCTACACCC aaacGGGTGTAGATGACAGGCTGCc 
 Sp100_g2 TGAGATGGGGAACCCGAAGG caccgTGAGATGGGGAACCCGAAGG aaacCCTTCGGGTTCCCCATCTCAc 
 ECE1_g1 GGAAACCCGAAAATCAGCCA caccgGGAAACCCGAAAATCAGCCA aaacTGGCTGATTTTCGGGTTTCCc 
 ECE1_g2 GAACTGGGTGAAGAAGAACG caccgGAACTGGGTGAAGAAGAACG aaacCGTTCTTCTTCACCCAGTTCc 
 ECE1_g3 CATGGAGCTCAAGATGGAGC caccgCATGGAGCTCAAGATGGAGC aaacGCTCCATCTTGAGCTCCATGc 
 ECE1_g4 GAGCTCCATGGACCCCACAG caccgGAGCTCCATGGACCCCACAG aaacCTGTGGGGTCCATGGAGCTCc 
 ECE1_g5 CTGGGGAAGCTGCTGGGCGG caccgCTGGGGAAGCTGCTGGGCGG aaacCCGCCCAGCAGCTTCCCCAGc 
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Appendix Table 2. Proteins downregulated during VACV infection 
The 265 proteins which met the ‘sensitive’ criteria for downregulation are given.  This 
requires them to be downregulated > 2 fold on average across the three replicates, at any 
time point compared to the 18 h mock (‘sensitive’ criteria).  P-values are given for 
proteins that additionally met the ‘stringent’ criteria of being quantified in all three 
replicates of the time-course, and p < 0.05 at the point of maximal downregulation 
(estimated using a BH-corrected two-tailed t-test).  
Gene 
Symbol 
Description 
Maximal fold 
downregulation 
P-value for 
stringently 
downregulated 
proteins 
PTOV1 Prostate tumor-overexpressed gene 1 protein 0.04 
 
MID1IP1 Mid1-interacting protein 1 0.10 
 
FBXO22 F-box only protein 22 0.12 0.008 
CITED2 Cbp/p300-interacting transactivator 2 0.13 
 
CNTLN Isoform 2 of Centlein 0.13 
 
CST3 Cystatin-C 0.15 
 
ZFAND3 AN1-type zinc finger protein 3 0.17 0.009 
COL1A1 Collagen alpha-1(I) chain 0.17 0.034 
CREB3L2 Cyclic AMP-responsive element-binding protein 3-like 
protein 2 
0.17 0.008 
IFIT5 Interferon-induced protein with tetratricopeptide 
repeats 5 
0.17 0.010 
SCD Acyl-CoA desaturase 0.18 
 
TWIST2 Twist-related protein 2 0.19 0.005 
NDFIP1 NEDD4 family-interacting protein 1 0.20 
 
SCAND1 SCAN domain-containing protein 1 0.22 0.006 
SULF2 Extracellular sulfatase Sulf-2 0.22 
 
FRMD6 FERM domain-containing protein 6 0.22 0.006 
TP53 Cellular tumor antigen p53 0.23 0.009 
EPB41L5 Band 4.1-like protein 5 0.23 0.011 
COL1A2 Collagen alpha-2(I) chain 0.23 0.030 
PPDPF Pancreatic progenitor cell differentiation and 
proliferation factor 
0.23 0.032 
AR Androgen receptor 0.23 0.050 
DAZAP2 DAZ-associated protein 2 0.23 0.009 
SPARC SPARC 0.24 0.009 
TMEM59 Transmembrane protein 59 0.25 0.018 
CDC25B Isoform 4 of M-phase inducer phosphatase 2 0.25 
 
TIMP1 Metalloproteinase inhibitor 1 0.25 0.011 
FBLN1 Isoform C of Fibulin-1 0.26 
 
COL3A1 Collagen alpha-1(III) chain 0.26 0.030 
ZNF703 Zinc finger protein 703 0.27 0.023 
CDKN1A Cyclin-dependent kinase inhibitor 1 0.27 
 
SOX4 Transcription factor SOX-4 0.23 
 
FAM127A Protein FAM127A 0.28 0.028 
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Symbol 
Description 
Maximal fold 
downregulation 
P-value for 
stringently 
downregulated 
proteins 
PRRX1 Isoform 2 of Paired mesoderm homeobox protein 1 0.28 
 
CYBA Cytochrome b-245 light chain 0.29 
 
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 
2 
0.29 0.013 
HMGCR Isoform 3 of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase 
0.22 
 
COL5A2 Collagen alpha-2(V) chain 0.30 0.013 
IFIT2 Interferon-induced protein with tetratricopeptide 
repeats 2 
0.30 0.023 
ITM2C Integral membrane protein 2C 0.30 0.021 
LUM Lumican 0.30 0.031 
MXRA8 Matrix-remodeling-associated protein 8 0.30 0.008 
TUSC1 Tumor suppressor candidate gene 1 protein 0.30 
 
LDB2 LIM domain-binding protein 2 0.31 
 
CKS1B Cyclin-dependent kinases regulatory subunit 1 0.31 0.012 
GPC1 Glypican-1 0.31 0.017 
MT1X Metallothionein-1X 0.31 
 
APP Amyloid beta A4 protein 0.31 0.012 
IGFBP4 Insulin-like growth factor-binding protein 4 0.31 0.027 
GINM1 Glycoprotein integral membrane protein 1 0.31 0.008 
IFIT1 Interferon-induced protein with tetratricopeptide 
repeats 1 
0.31 0.030 
RHOBTB3 Rho-related BTB domain-containing protein 3 0.32 
 
RARA Retinoic acid receptor alpha 0.32 
 
CKS2 Cyclin-dependent kinases regulatory subunit 2 0.32 
 
ZER1 Protein zer-1 homolog 0.32 0.016 
MASP1 Isoform 2 of Mannan-binding lectin serine protease 1 0.32 0.015 
MMADHC Methylmalonic aciduria and homocystinuria type D 
protein, mitochondrial 
0.32 
 
CXXC5 CXXC-type zinc finger protein 5 0.32 0.008 
MRFAP1 MORF4 family-associated protein 1 0.32 0.025 
ADAMTSL3 ADAMTS-like protein 3 0.32 
 
COL5A1 Collagen alpha-1(V) chain 0.33 0.016 
SERF2 Small EDRK-rich factor 2 0.33 0.017 
FSTL1 Follistatin-related protein 1 0.33 0.008 
HDAC5 Isoform 3 of Histone deacetylase 5 0.33 0.013 
TRPC4AP Short transient receptor potential channel 4-
associated protein 
0.33 
 
TERT Telomerase reverse transcriptase 0.33 0.043 
COA5 Cytochrome c oxidase assembly factor 5 0.34 0.029 
TPGS2 Tubulin polyglutamylase complex subunit 2 0.34 
 
CREB3L1 Cyclic AMP-responsive element-binding protein 3-like 
protein 1 
0.32 0.023 
LRP11 Low-density lipoprotein receptor-related protein 11 0.34 
 
EPHA4 Ephrin type-A receptor 4 0.34 0.008 
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Maximal fold 
downregulation 
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stringently 
downregulated 
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MAGED1 Isoform 2 of Melanoma-associated antigen D1 0.34 0.008 
DKK3 Dickkopf-related protein 3 0.35 
 
AHR Aryl hydrocarbon receptor 0.35 0.009 
EFR3B Protein EFR3 homolog B 0.31 
 
CDC42EP3 Cdc42 effector protein 3 0.35 0.008 
IFITM3 Interferon-induced transmembrane protein 3 0.35 0.017 
RNF4 E3 ubiquitin-protein ligase RNF4 0.26 
 
PCDHB8 Protocadherin beta-8 0.35 
 
SEMA5A Semaphorin-5A 0.36 
 
PCDHGA6 Protocadherin gamma-A6 0.36 
 
HLA-C HLA class I histocompatibility antigen, Cw-4 alpha 
chain 
0.36 
 
IGFBP7 Insulin-like growth factor-binding protein 7 0.36 0.024 
TCF4 Isoform SEF2-1D of Transcription factor 4 0.36 0.017 
LAPTM4A Lysosomal-associated transmembrane protein 4A 0.36 
 
TCP11L2 T-complex protein 11-like protein 2 0.36 
 
ITM2B Integral membrane protein 2B 0.36 0.026 
IFFO1 Isoform 5 of Intermediate filament family orphan 1 0.36 0.026 
TRIM13 Isoform 3 of E3 ubiquitin-protein ligase TRIM13 0.36 
 
OLFML3 Olfactomedin-like protein 3 0.36 0.011 
FAM168B Myelin-associated neurite-outgrowth inhibitor 0.37 0.050 
COL11A1 Collagen alpha-1(XI) chain 0.37 0.013 
FADS2 Fatty acid desaturase 2 0.37 0.046 
TCF4 Transcription factor 4 0.36 
 
XPA DNA repair protein complementing XP-A cells 0.37 0.009 
SCRIB Isoform 3 of Protein scribble homolog 0.37 0.009 
COL6A2 Collagen alpha-2(VI) chain 0.37 0.011 
CDKN3 Cyclin-dependent kinase inhibitor 3 0.37 
 
CALCOCO2 Isoform 4 of Calcium-binding and coiled-coil domain-
containing protein 2 
0.38 0.009 
DNAJC15 DnaJ homolog subfamily C member 15 0.38 
 
SDC4 Syndecan-4 0.38 0.009 
GAS1 Growth arrest-specific protein 1 0.38 0.009 
ECM1 Isoform 4 of Extracellular matrix protein 1 0.38 0.033 
TNFRSF1A Tumor necrosis factor receptor superfamily member 
1A 
0.38 0.029 
IFFO2 Intermediate filament family orphan 2 0.37 0.033 
PCOLCE Procollagen C-endopeptidase enhancer 1 0.38 0.048 
CHCHD2 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 2 
0.39 0.009 
HERPUD1 Homocysteine-responsive endoplasmic reticulum-
resident ubiquitin-like domain member 1 protein 
0.39 0.028 
COL5A3 Collagen alpha-3(V) chain 0.39 
 
TCHP Trichoplein keratin filament-binding protein 0.39 0.014 
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RFWD3 E3 ubiquitin-protein ligase RFWD3 0.39 
 
NR3C1 Isoform Alpha-2 of Glucocorticoid receptor 0.40 0.008 
STC2 Stanniocalcin-2 0.40 0.017 
TNRC18 Trinucleotide repeat-containing gene 18 protein 0.38 0.010 
RASA2 Ras GTPase-activating protein 2 0.40 0.008 
AXL Tyrosine-protein kinase receptor UFO 0.40 0.026 
CLSTN1 Calsyntenin-1 0.40 
 
ZFAND5 AN1-type zinc finger protein 5 0.41 
 
DCN Decorin 0.41 0.024 
EPHB4 Ephrin type-B receptor 4 0.41 0.012 
SIX2 Homeobox protein SIX2 0.41 
 
SIPA1L2 Signal-induced proliferation-associated 1-like protein 2 0.41 
 
COL2A1 Collagen alpha-1(II) chain 0.41 
 
DENND4C DENN domain-containing protein 4C 0.37 
 
LOXL1 Lysyl oxidase homolog 1 0.41 0.020 
EPHB2 Ephrin type-B receptor 2 0.41 0.017 
TXNIP Thioredoxin-interacting protein 0.41 0.015 
PDGFRL Platelet-derived growth factor receptor-like protein 0.41 
 
PJA2 E3 ubiquitin-protein ligase Praja-2 0.41 0.021 
KIAA0922 Isoform 4 of Transmembrane protein 131-like 0.41 0.032 
COL6A2 Isoform 2C2A of Collagen alpha-2(VI) chain 0.42 0.032 
HSD17B14 17-beta-hydroxysteroid dehydrogenase 14 0.26 
 
PJA1 E3 ubiquitin-protein ligase Praja-1 0.42 
 
TRAIP E3 ubiquitin-protein ligase TRAIP 0.42 
 
TRIM5 Tripartite motif-containing protein 5 0.42 0.018 
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 
1 
0.42 0.009 
TMEM248 Transmembrane protein 248 0.42 
 
TCEAL7 Transcription elongation factor A protein-like 7 0.42 0.030 
PRRX1 Paired mesoderm homeobox protein 1 0.42 0.013 
KRCC1 Lysine-rich coiled-coil protein 1 0.42 
 
SUSD5 Sushi domain-containing protein 5 0.42 0.011 
HAPLN3 Hyaluronan and proteoglycan link protein 3 0.43 
 
EBF1 Transcription factor COE1 0.43 
 
CDR2 Cerebellar degeneration-related protein 2 0.43 0.008 
HDAC4 Histone deacetylase 4 0.43 0.016 
FGFR1 Isoform 21 of Fibroblast growth factor receptor 1 0.43 0.027 
RTFDC1 Protein RTF2 homolog 0.43 0.009 
BCAT1 Branched-chain-amino-acid aminotransferase, 
cytosolic 
0.43 
 
PSAP Isoform Sap-mu-6 of Prosaposin 0.43 
 
CDCA7 Isoform 2 of Cell division cycle-associated protein 7 0.43 
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AHRR Isoform 2 of Aryl hydrocarbon receptor repressor 0.43 
 
IGFBP6 Insulin-like growth factor-binding protein 6 0.43 0.009 
SDHAF2 Succinate dehydrogenase assembly factor 2, 
mitochondrial 
0.43 
 
THBS2 Thrombospondin-2 0.44 0.011 
TSC22D3 Isoform 2 of TSC22 domain family protein 3 0.44 0.035 
PHLDA3 Pleckstrin homology-like domain family A member 3 0.44 0.041 
TSEN34 tRNA-splicing endonuclease subunit Sen34 0.44 0.025 
NLGN1 Neuroligin-1 0.44 
 
ZNFX1 NFX1-type zinc finger-containing protein 1 0.44 0.019 
RNF114 E3 ubiquitin-protein ligase RNF114 0.44 0.040 
CRIM1 Cysteine-rich motor neuron 1 protein 0.44 0.012 
SPOCK1 Testican-1 0.44 0.028 
JDP2 Isoform 2 of Jun dimerization protein 2 0.44 
 
ARL6IP4 Isoform 3 of ADP-ribosylation factor-like protein 6-
interacting protein 4 
0.44 
 
LONP2 Lon protease homolog 2, peroxisomal 0.45 0.011 
MLF2 Myeloid leukemia factor 2 0.45 
 
CCDC28B Coiled-coil domain-containing protein 28B 0.45 
 
ATP6AP2 Renin receptor 0.45 0.046 
CSF1 Macrophage colony-stimulating factor 1 0.45 
 
HLA-C HLA class I histocompatibility antigen, Cw-12 alpha 
chain 
0.45 0.024 
COL12A1 Collagen alpha-1(XII) chain 0.45 0.021 
FLT1 Isoform 2 of Vascular endothelial growth factor 
receptor 1 
0.45 0.015 
TWIST1 Twist-related protein 1 0.45 
 
EPHB3 Ephrin type-B receptor 3 0.45 0.009 
PIAS3 E3 SUMO-protein ligase PIAS3 0.45 
 
ARID5B AT-rich interactive domain-containing protein 5B 0.45 0.042 
TCF3 Isoform 3 of Transcription factor E2-alpha 0.45 0.026 
C15orf39 Uncharacterized protein C15orf39 0.45 
 
SOGA1 Isoform 2 of Protein SOGA1 0.46 0.016 
FER Tyrosine-protein kinase Fer 0.46 0.016 
CTSL Cathepsin L1 0.46 0.026 
TMEM168 Transmembrane protein 168 0.46 0.031 
FOXP1 Forkhead box protein P1 0.46 0.009 
CD248 Endosialin 0.46 0.008 
LOX Protein-lysine 6-oxidase 0.46 
 
ID1 DNA-binding protein inhibitor ID-1 0.46 
 
PPP2R3C Serine/threonine-protein phosphatase 2A regulatory 
subunit B'' subunit gamma 
0.46 
 
PEG10 Retrotransposon-derived protein PEG10 0.46 
 
LRRC42 Leucine-rich repeat-containing protein 42 0.46 0.046 
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PDGFRA Platelet-derived growth factor receptor alpha 0.46 0.013 
RNF216 Isoform 2 of E3 ubiquitin-protein ligase RNF216 0.46 
 
TBKBP1 TANK-binding kinase 1-binding protein 1 0.46 
 
TSPYL4 Testis-specific Y-encoded-like protein 4 0.46 0.008 
TCF7L1 Transcription factor 7-like 1 0.46 0.015 
MKX Homeobox protein Mohawk 0.47 
 
CCBE1 Collagen and calcium-binding EGF domain-containing 
protein 1 
0.47 
 
IFIT3 Interferon-induced protein with tetratricopeptide 
repeats 3 
0.47 0.039 
SOX6 Transcription factor SOX-6 0.47 0.016 
ZBED6 Zinc finger BED domain-containing protein 6 0.47 
 
SDC2 Syndecan-2 0.47 0.026 
ZC3HAV1 Isoform 3 of Zinc finger CCCH-type antiviral protein 1 0.47 
 
TSPAN5 Tetraspanin-5 0.47 
 
CCDC85B Coiled-coil domain-containing protein 85B 0.47 0.042 
TMEM184B Transmembrane protein 184B 0.47 
 
FOXF1 Forkhead box protein F1 0.47 
 
UBE2C Ubiquitin-conjugating enzyme E2 C 0.47 
 
VANGL1 Vang-like protein 1 0.47 0.011 
SDC1 Syndecan-1 0.47 0.038 
CSNK1A1 Isoform 3 of Casein kinase I isoform alpha 0.47 
 
PCDHGB4 Protocadherin gamma-B4 0.47 
 
COL6A1 Collagen alpha-1(VI) chain 0.47 0.009 
S100PBP S100P-binding protein 0.48 
 
APCDD1 Protein APCDD1 0.48 
 
FAM168A Protein FAM168A 0.48 
 
ANAPC11 Anaphase-promoting complex subunit 11 0.48 
 
FBXO18 Isoform 2 of F-box DNA helicase 1 0.48 0.009 
C1S Complement C1s subcomponent 0.48 
 
HIF1A Isoform 3 of Hypoxia-inducible factor 1-alpha 0.44 
 
SLIT3 Isoform 4 of Slit homolog 3 protein 0.48 0.045 
TCEAL9 Transcription elongation factor A protein-like 9 0.36 
 
APLP2 Amyloid-like protein 2 0.48 0.025 
USP1 Ubiquitin carboxyl-terminal hydrolase 1 0.48 
 
NEO1 Neogenin 0.48 0.013 
ADAMTS5 A disintegrin and metalloproteinase with 
thrombospondin motifs 5 
0.48 
 
QSOX1 Sulfhydryl oxidase 1 0.48 
 
SQLE Squalene monooxygenase 0.48 
 
PCDHGB5 Protocadherin gamma-B5 0.49 0.009 
SLIT2 Slit homolog 2 protein 0.49 0.046 
ZNF503 Zinc finger protein 503 0.48 
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LAMB2 Laminin subunit beta-2 0.49 0.026 
PPRC1 Peroxisome proliferator-activated receptor gamma 
coactivator-related protein 1 
0.48 
 
ALPK2 Alpha-protein kinase 2 0.49 0.011 
MEX3B RNA-binding protein MEX3B 0.49 
 
DENND6A Protein DENND6A 0.49 
 
PRELP Prolargin 0.49 
 
NBPF19 Neuroblastoma breakpoint family member 19 0.49 
 
TMEM132A Isoform 2 of Transmembrane protein 132A 0.49 
 
RNF5 E3 ubiquitin-protein ligase RNF5 0.49 
 
CFLAR CASP8 and FADD-like apoptosis regulator 0.46 
 
PRNP Major prion protein 0.49 0.048 
FLT1 Vascular endothelial growth factor receptor 1 0.49 0.012 
LRRC17 Leucine-rich repeat-containing protein 17 0.45 0.028 
OLFM2 Noelin-2 0.46 
 
FST Follistatin 0.49 0.012 
LAMA4 Laminin subunit alpha-4 0.49 0.038 
PHLDA2 Pleckstrin homology-like domain family A member 2 0.49 0.033 
MORF4L1 Mortality factor 4-like protein 1 0.49 0.030 
ADM ADM 0.49 
 
CDCA7L Cell division cycle-associated 7-like protein 0.49 
 
IL6ST Interleukin-6 receptor subunit beta 0.50 0.008 
SPATA13 Isoform 6 of Spermatogenesis-associated protein 13 0.50 
 
PNMA1 Paraneoplastic antigen Ma1 0.49 
 
CXCL12 Isoform Delta of Stromal cell-derived factor 1 0.50 0.014 
HBP1 HMG box-containing protein 1 0.37 
 
PDGFC Platelet-derived growth factor C 0.46 
 
VWF von Willebrand factor 0.40 
 
CDC7 Cell division cycle 7-related protein kinase 0.47 
 
OLFML2A Olfactomedin-like protein 2A 0.48 
 
TMSB4X Thymosin beta-4 0.49 
 
F13A1 Coagulation factor XIII A chain 0.46 
 
ESPL1 Separin 0.49 
 
ZNF282 Zinc finger protein 282 0.46 
 
TOB2 Protein Tob2 0.49 
 
CDK10 Cyclin-dependent kinase 10 0.50 
 
NFE2L2 Nuclear factor erythroid 2-related factor 2 0.44 
 
THBS3 Thrombospondin-3 0.42 
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Appendix Table 3. Proteins upregulated during VACV infection 
The 265 proteins which met the ‘sensitive’ criteria for upregulation are given.  This 
requires them to be upregulated > 2 fold on average across the three replicates, at any 
time point compared to the 18h mock (‘sensitive’ criteria).  P-values are given for proteins 
that additionally met the ‘stringent’ criteria of being quantified in all three replicates of 
the time-course, and p < 0.05 at the point of maximal upregulation (estimated using a BH-
corrected two-tailed t-test).  
Gene 
Symbol 
Description 
Maximal fold 
upregulation 
P-value for 
stringently 
upregulated 
proteins 
ZMYND19 Zinc finger MYND domain-containing protein 19 57.19 
 
IGKC Ig kappa chain C region 38.99 
 
PER1 Period circadian protein homolog 1 33.13 
 
ZFP64 Zinc finger protein 64 homolog, isoforms 3 and 4 30.57 
 
NR4A1 Isoform 2 of Nuclear receptor subfamily 4 group A member 1 26.56 
 
NRIP1 Nuclear receptor-interacting protein 1 25.55 
 
ABLIM1 Actin-binding LIM protein 1 13.36 
 
TMEM26 Transmembrane protein 26 13.32 
 
ATXN7L3 Isoform 2 of Ataxin-7-like protein 3 10.97 
 
ZNF195 Zinc finger protein 195 9.38 
 
CD58 Lymphocyte function-associated antigen 3 7.65 
 
EXOC3L4 Exocyst complex component 3-like protein 4 6.98 
 
DNAH10 Dynein heavy chain 10, axonemal 5.94 
 
TBC1D32 Isoform 2 of Protein broad-minded 5.28 
 
EGR1 Early growth response protein 1 5.24 0.036 
MDM4 Protein Mdm4 4.93 
 
PSTPIP2 Proline-serine-threonine phosphatase-interacting protein 2 4.59 
 
B9D1 B9 domain-containing protein 1 4.51 
 
IL1R1 Interleukin-1 receptor type 1 4.48 
 
ALG13 Putative bifunctional UDP-N-acetylglucosamine transferase 
and deubiquitinase ALG13 
4.42 
 
NFKBIL1 NF-kappa-B inhibitor-like protein 1 4.34 
 
FOS Proto-oncogene c-Fos 4.15 
 
RANGRF Ran guanine nucleotide release factor 3.97 
 
STAB1 Stabilin-1 3.85 
 
ZDHHC18 Palmitoyltransferase ZDHHC18 3.84 
 
ELOVL4 Elongation of very long chain fatty acids protein 4 3.80 
 
APOE Apolipoprotein E 3.72 0.015 
SVBP Small vasohibin-binding protein 3.44 
 
FSIP2 Fibrous sheath-interacting protein 2 3.25 
 
C2CD2L Isoform 2 of C2 domain-containing protein 2-like 3.03 
 
MAFK Transcription factor MafK 2.99 
 
DISC1 Disrupted in schizophrenia 1 protein 2.93 
 
DUSP1 Dual specificity protein phosphatase 1 2.93 
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Gene 
Symbol 
Description 
Maximal fold 
upregulation 
P-value for 
stringently 
upregulated 
proteins 
WNT2B Protein Wnt-2b 2.91 
 
PTGS2 Prostaglandin G/H synthase 2 2.90 
 
MSI1 RNA-binding protein Musashi homolog 1 2.80 
 
TNFRSF10D Tumor necrosis factor receptor superfamily member 10D 2.79 0.060 
CLK1 Isoform 3 of Dual specificity protein kinase CLK1 2.76 0.026 
ID1 DNA-binding protein inhibitor ID-1 2.75 
 
TAGLN3 Transgelin-3 2.71 
 
F13A1 Coagulation factor XIII A chain 2.69 
 
TNC Isoform 6 of Tenascin 2.69 
 
A2M Alpha-2-macroglobulin 2.69 
 
LMBRD2 LMBR1 domain-containing protein 2 2.64 
 
PARP12 Poly [ADP-ribose] polymerase 12 2.55 
 
CSAD Isoform 3 of Cysteine sulfinic acid decarboxylase 2.53 
 
APOA4 Apolipoprotein A-IV 2.51 
 
PLIN2 Perilipin-2 2.50 
 
LOXL1 Lysyl oxidase homolog 1 2.47 
 
ID3 DNA-binding protein inhibitor ID-3 2.46 
 
BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 2.44 
 
CDC45 Isoform 3 of Cell division control protein 45 homolog 2.43 
 
PTTG1 Securin 2.43 
 
SDC3 Syndecan-3 2.34 
 
VRK3 Inactive serine/threonine-protein kinase VRK3 2.18 
 
CTGF Connective tissue growth factor 2.16 
 
CBX2 Chromobox protein homolog 2 2.16 
 
EVC Ellis-van Creveld syndrome protein 2.16 
 
ETS2 Protein C-ets-2 2.15 
 
RASSF1 Isoform C of Ras association domain-containing protein 1 2.12 
 
FGB Fibrinogen beta chain 2.12 
 
GSTT1 Glutathione S-transferase theta-1 2.11 
 
PLG Plasminogen 2.10 
 
HMCN1 Hemicentin-1 2.10 
 
PZP Pregnancy zone protein 2.09 
 
ZSCAN20 Zinc finger and SCAN domain-containing protein 20 2.08 
 
STC1 Stanniocalcin-1 2.08 
 
COQ10B Coenzyme Q-binding protein COQ10 homolog B, 
mitochondrial 
2.07 
 
AKAP13 Isoform 3 of A-kinase anchor protein 13 2.06 
 
TPGS1 Tubulin polyglutamylase complex subunit 1 2.01 
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Appendix Table 4. Proteomic and transcriptional assignment of VACV protein classes 
The proteomic data was compared to previously assigned transcriptional classes (Yang et 
al, 2010, 2011, 2015), and proteomic classes (Croft et al, 2015).  Croft et al. analysed 
VACV infection in two independent time-courses, with one from 0.5–9.5 hpi, sampled at 
3 h intervals and a second time-course from 0.5–8.5 hpi sampled at 2 h intervals, with 
each generating four temporal classes of viral proteins.  As in some cases the two 
classifications were not identical, the dataset presented here was compared to the 47 
proteins that produced concordant temporal classes in the two time-courses. 
Viral Gene 
Temporal 
class from 
this 
proteomic 
study 
Previously 
assigned 
transcriptional 
class 
Fold 
Change    
with 
AraC  
(6 hpi) 
Functional 
Category 
Reference for  
function 
Croft et al 
consensus 
A35 1 E1.1 0.88 Host interaction Yang et al. (2010) 
 
A37 1 E1.1 0.95 Unknown Yang et al. (2010) 
 
A48 1 E1.1 1.35 DNA replication Yang et al. (2010) 1 
B8 1 E1.1 1.43 Host interaction Yang et al. (2010) 
 
C11 1 E1.1 1.52 Host interaction Yang et al. (2010) 1 
E5 1 E1.1 1.08 Unknown Yang et al. (2010) 
 
F11 1 E1.1 0.99 Host interaction Yang et al. (2010) 1 
F15 1 E1.1 0.71 Unknown Yang et al. (2010) 
 
K1 1 E1.1 0.84 Host interaction Yang et al. (2010) 1 
N2 1 E1.1 1.12 Host interaction Ferguson et al. (2013) 
 
VACWR018 1 E1.1 1.50 Unknown Yang et al. (2010) 
 
A41 1 E1.2 1.58 Host interaction Yang et al. (2010) 
 
A47 1 E1.2 0.91 Unknown Yang et al. (2010) 
 
A52 1 E1.2 1.15 Host interaction Yang et al. (2010) 
 
B11 1 E1.2 0.76 Unknown Yang et al. (2010) 
 
B15 1 E1.2 0.90 Host interaction Chen et al. (2008) 4 
F3 1 E1.2 1.11 Host interaction Yang et al. (2010) 
 
M2 1 E1.2 1.32 Host interaction Yang et al. (2010) 
 
A46 2 E1.1 1.25 Host interaction Yang et al. (2010) 1 
A51 2 E1.1 1.09 Unknown Yang et al. (2010) 1 
A8 2 E1.1 0.98 Transcription Yang et al. (2010) 
 
B12 2 E1.1 1.06 Unknown Yang et al. (2010) 
 
B13 2 E1.1 1.07 Host interaction Yang et al. (2010) 2 
B19 2 E1.1 1.10 Host interaction Yang et al. (2010) 
 
C1 2 E1.1 1.20 Unknown Yang et al. (2010) 
 
C6 2 E1.1 1.10 Host interaction Unterholzner et al. 
(2011) 
2 
D9 2 E1.1 0.70 Host interaction Yang et al. (2010) 
 
K7 2 E1.1 0.76 Host interaction Yang et al. (2010) 
 
O1 2 E1.1 1.01 Host interaction Schweneker et al. 
(2012) 
1 
A20 2 E1.2 1.05 DNA replication Yang et al. (2010) 
 
A23 2 E1.2 0.92 Transcription Yang et al. (2010) 
 
A31 2 E1.2 0.98 Unknown Yang et al. (2010) 2 
A40 2 E1.2 1.23 Host interaction Yang et al. (2010) 2 
A44 2 E1.2 0.93 Host interaction Yang et al. (2010) 
 
B18 2 E1.2 0.89 Host interaction Colamonici et al. (1995) 
 
B6 2 E1.2 1.11 Unknown Yang et al. (2010) 
 
C4 2 E1.2 1.11 Host interaction Ember et al. (2012) 
 
C5 2 E1.2 1.14 DNA replication Liu et al. (2018) 1 
C7 2 E1.2 0.93 Host interaction Yang et al. (2010) 
 
C9 2 E1.2 1.16 Host interaction Liu & Moss (2018) 
 
D4 2 E1.2 1.17 DNA replication Yang et al. (2010) 
 
F1 2 E1.2 0.53 Host interaction Yang et al. (2010) 
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Viral Gene 
Temporal 
class from 
this 
proteomic 
study 
Previously 
assigned 
transcriptional 
class 
Fold 
Change    
with 
AraC  
(6 hpi) 
Functional 
Category 
Reference for  
function 
Croft et al 
consensus 
F12 2 E1.2 1.03 Virion association Yang et al. (2010) 
 
F16 2 E1.2 1.14 Unknown Yang et al. (2010) 
 
F4 2 E1.2 1.14 DNA replication Yang et al. (2010) 1 
F7 2 E1.2 0.88 Unknown Yang et al. (2010) 
 
G5 2 E1.2 1.07 DNA replication Yang et al. (2010) 
 
I4 2 E1.2 1.09 DNA replication Yang et al. (2010) 
 
J2 2 E1.2 1.17 DNA replication Yang et al. (2010) 
 
M1 2 E1.2 1.03 Host interaction Ryerson et al. (2017) 1 
VACWR011/ 
VACWR208 
2 E1.2 1.16 Truncated Yang et al. (2010) 
 
VACWR169 2 E1.2 1.14 Host interaction Strnadova et al. (2015) 
 
A2 2 I 0.11 Transcription Yang et al. (2010) 
 
A43 2 I 0.28 Host interaction Yang et al. (2010) 
 
C13 2 I 0.19 Unknown Yang et al. (2010) 
 
D10 2 I 0.31 Host interaction Yang et al. (2010) 
 
A36 3 E1.1 0.83 Virion association Yang et al. (2010) 
 
C23/B29 3 E1.1 1.05 Host interaction Yang et al. (2010) 
 
E3 3 E1.1 1.19 Host interaction Yang et al. (2010) 2 
E4 3 E1.1 1.12 Transcription Yang et al. (2010) 
 
H5 3 E1.1 0.96 Transcription Yang et al. (2010) 
 
I3 3 E1.1 1.19 DNA replication Yang et al. (2010) 
 
K3 3 E1.1 0.51 Host interaction Yang et al. (2010) 
 
A18 3 E1.2 0.32 Transcription Yang et al. (2010) 
 
A24 3 E1.2 0.66 Transcription Yang et al. (2010) 2 
A29 3 E1.2 0.95 Transcription Yang et al. (2010) 
 
A49 3 E1.2 0.78 Host interaction Mansur et al. (2013) 
 
A5 3 E1.2 0.83 Transcription Yang et al. (2010) 
 
A50 3 E1.2 0.82 DNA replication Yang et al. (2010) 
 
A55 3 E1.2 0.87 Host interaction Yang et al. (2010) 
 
B1 3 E1.2 0.97 DNA replication Yang et al. (2010) 
 
B17 3 E1.2 0.88 Unknown Yang et al. (2010) 
 
B2 3 E1.2 1.07 Host interaction Eaglesham et al. (2019) 
 
C12 3 E1.2 0.93 Host interaction Yang et al. (2010) 
 
C2 3 E1.2 0.94 Host interaction Yang et al. (2010) 
 
D1 3 E1.2 1.05 Transcription Yang et al. (2010) 2 
D12 3 E1.2 1.09 Transcription Yang et al. (2010) 
 
D5 3 E1.2 0.86 DNA replication Yang et al. (2010) 
 
D7 3 E1.2 0.98 Transcription Yang et al. (2010) 
 
E1 3 E1.2 0.82 Transcription Yang et al. (2010) 
 
E9 3 E1.2 1.12 DNA replication Yang et al. (2010) 2 
F2 3 E1.2 1.15 DNA replication Yang et al. (2010) 
 
F6 3 E1.2 0.52 Unknown Yang et al. (2010) 
 
G2 3 E1.2 0.55 Transcription Yang et al. (2010) 
 
G5.5 3 E1.2 0.96 Transcription Yang et al. (2010) 
 
J3 3 E1.2 1.03 Transcription Yang et al. (2010) 
 
J4 3 E1.2 0.93 Transcription Yang et al. (2010) 2 
J6 3 E1.2 0.74 Transcription Yang et al. (2010) 2 
N1 3 E1.2 0.52 Host interaction Yang et al. (2010) 
 
VACWR013 3 E1.2 1.54 Host interaction Yang et al. (2010) 
 
A1 3 I 0.17 Transcription Yang et al. (2010) 
 
A12 3 I 0.35 Virion association Yang et al. (2010) 3 
A30.5 3 I 0.58 Virion association Maruri-Avidal et al. 
(2013) 
 
A6 3 I 0.19 Virion association Yang et al. (2010) 3 
E7 3 I 0.25 Unknown Yang et al. (2010) 3 
G8 3 I 0.19 Transcription Yang et al. (2010) 
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Viral Gene 
Temporal 
class from 
this 
proteomic 
study 
Previously 
assigned 
transcriptional 
class 
Fold 
Change    
with 
AraC  
(6 hpi) 
Functional 
Category 
Reference for  
function 
Croft et al 
consensus 
H7 3 I 0.14 Virion association Yang et al. (2010) 
 
I6 3 I 0.37 Virion association Yang et al. (2010) 
 
K2 3 I 0.42 Host interaction Yang et al. (2010) 
 
K4 3 I 0.29 DNA replication Yang et al. (2010) 
 
A26 3 L 0.80 Virion association Yang et al. (2010) 
 
C3 3 L 0.31 Host interaction Yang et al. (2010) 4 
C8 3 L 0.43 Unknown Yang et al. (2010) 4 
A33 4 E1.1 0.82 Virion association Yang et al. (2010) 
 
A4 4 E1.2 0.82 Virion association Yang et al. (2010) 
 
A56 4 E1.2 0.62 Virion association Yang et al. (2010) 4 
B5 4 E1.2 0.63 Virion association Yang et al. (2010) 
 
C10 4 E1.2 0.96 Host interaction Yang et al. (2010) 2 
C22/B28 4 E1.2 0.55 Truncated Yang et al. (2010) 
 
E2 4 E1.2 0.80 Virion association Yang et al. (2010) 
 
F5 4 E1.2 0.78 Unknown Yang et al. (2010) 4 
F8 4 E1.2 0.66 Unknown Yang et al. (2010) 
 
A15 4 I 0.65 Virion association Yang et al. (2010) 
 
A16 4 I 0.67 Virion association Yang et al. (2010) 
 
A19 4 I 0.36 Virion association Satheshkumar et al. 
(2013) 
3 
A22 4 I 0.80 DNA replication Yang et al. (2010) 
 
A25 4 I 0.68 Virion association 
(truncated) 
Yang et al. (2010) 
 
A27 4 I 0.76 Virion association Yang et al. (2010) 
 
A3 4 I 0.72 Virion association Yang et al. (2010) 3 
A30 4 I 0.54 Virion association Yang et al. (2010) 
 
A32 4 I 0.33 Virion association Yang et al. (2010) 
 
A34 4 I 0.41 Virion association Yang et al. (2010) 
 
A38 4 I 0.16 Virion association Yang et al. (2010) 
 
A42 4 I 0.54 Virion association Yang et al. (2010) 
 
B16 4 I 0.35 Host interaction Yang et al. (2010) 
 
D11 4 I 0.46 Transcription Yang et al. (2010) 
 
D13 4 I 0.33 Virion association Yang et al. (2010) 
 
D6 4 I 0.44 Transcription Yang et al. (2010) 
 
D8 4 I 0.53 Virion association Yang et al. (2010) 4 
E11 4 I 0.35 Virion association Yang et al. (2010) 
 
E6 4 I 0.38 Virion association Yang et al. (2010) 3 
E8 4 I 0.40 Virion association Yang et al. (2010) 
 
F13 4 I 0.47 Virion association Yang et al. (2010) 4 
G4 4 I 0.29 Virion association Yang et al. (2010) 4 
H1 4 I 0.48 Transcription Yang et al. (2010) 3 
H3 4 I 0.68 Virion association Yang et al. (2010) 4 
I1 4 I 0.19 Virion association Yang et al. (2010) 
 
I8 4 I 0.62 Transcription Yang et al. (2010) 
 
J1 4 I 0.42 Virion association Yang et al. (2010) 3 
L4 4 I 0.67 Transcription Yang et al. (2010) 3 
O2 4 I 0.56 Unknown Yang et al. (2010) 
 
A10 4 L 0.74 Virion association Yang et al. (2010) 3 
A11 4 L 0.53 Virion association Yang et al. (2010) 4 
A13 4 L 0.51 Virion association Yang et al. (2010) 
 
A17 4 L 0.55 Virion association Yang et al. (2010) 3 
A2.5 4 L 0.65 Virion association Yang et al. (2010) 
 
A21 4 L 0.74 Virion association Yang et al. (2010) 
 
A28 4 L 0.84 Virion association Yang et al. (2010) 
 
A39 4 L 0.41 Truncated Yang et al. (2010) 
 
A45 4 L 0.63 Virion association Yang et al. (2010) 
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Viral Gene 
Temporal 
class from 
this 
proteomic 
study 
Previously 
assigned 
transcriptional 
class 
Fold 
Change    
with 
AraC  
(6 hpi) 
Functional 
Category 
Reference for  
function 
Croft et al 
consensus 
A7 4 L 0.47 Transcription Yang et al. (2010) 
 
A9 4 L 0.58 Virion association Yang et al. (2010) 
 
B7 4 L 0.50 Host interaction Yang et al. (2010) 4 
D2 4 L 0.56 Virion association Yang et al. (2010) 
 
D3 4 L 0.69 Virion association Yang et al. (2010) 
 
E10 4 L 0.56 Virion association Yang et al. (2010) 4 
F10 4 L 0.65 Virion association Yang et al. (2010) 
 
F17 4 L 0.61 Virion association Yang et al. (2010) 3 
F9 4 L 0.72 Virion association Yang et al. (2010) 
 
G1 4 L 0.52 Virion association Yang et al. (2010) 
 
G3 4 L 0.85 Virion association Yang et al. (2010) 
 
G6 4 L 0.63 Host interaction Yang et al. (2010) 
 
G7 4 L 0.55 Virion association Yang et al. (2010) 
 
G9 4 L 0.53 Virion association Yang et al. (2010) 
 
H2 4 L 0.59 Virion association Yang et al. (2010) 
 
H4 4 L 0.49 Transcription Yang et al. (2010) 3 
H6 4 L 0.64 Transcription Yang et al. (2010) 
 
I7 4 L 0.54 Virion association Yang et al. (2010) 
 
J5 4 L 0.62 Virion association Yang et al. (2010) 
 
L1 4 L 0.81 Virion association Yang et al. (2010) 
 
L3 4 L 0.65 Transcription Yang et al. (2010) 
 
L5 4 L 0.81 Virion association Yang et al. (2010) 
 
 
 
 
 
